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Summary 
Psoriasis is a chronic and recurrent skin disease that affects 1-5% of the population in 
various countries. The cause of psoriasis is not fully understood but the disease is thought to 
be a T-cell mediated inflammatory disorder. Conventional medical treatments can control the 
symptoms associated with psoriasis but can have significant side effects. There is, as yet, no 
curative regimen for the clinical management of psoriasis. Around half of psoriasis patients 
use some forms of complementary and alternative medicine including herbal medicine (HM) 
used topically and orally. In China, Chinese HM is frequently used by psoriasis patients and 
may be prescribed by dermatologists in combination with pharmaceutical medicines.  
A number of clinical trials of HMs for psoriasis have been conducted but many different 
HMs have been used and trials have been diverse in their design, duration and in the 
outcome measures used. Consequently, the clinical efficacy of these HMs has yet to be 
systematically evaluated.  
The project aimed to evaluate the clinical efficacy and safety of HM for psoriasis, identify 
the herbs for which the clinical evidence is strongest, investigate the anti-psoriatic actions of 
the most promising herbs, and develop an in silico method for investigating the targets of 
these herbs.  
The first component of the project was to systematically evaluate the clinical evidence using 
systematic reviews. This involved comprehensive searches of the literature followed by 
assessments of the quality of published clinical trials on psoriasis and meta-analyses of 
outcome measures to determine the best available clinical trial evidence. This component 
used the methods developed by the Cochrane collaboration and extended the methods used 
for meta-analysis to address the particular issues raised by the use of multi-ingredient 
formulations. 
This first component was divided into two parts. The first part analysed clinical trials of HMs 
used internally and the second part included HMs used as topical preparations. Due to the 
xx 
diversity in the use of topical HMs, the second part was further divided into three sections 
based on the type of topical HM intervention: single herb, multi-ingredient herbal formula, 
and HM plus anti-psoriatic pharmacotherapy (APP).  
Based on the results of the systematic reviews and meta-analyses of 39 studies a short-list of 
12 herbs was selected as showing promise for the internal and/or external treatment of 
psoriasis: Oldenlandia diffusa, Rehmannia glutinosa, Salvia miltiorrhiza, Aloe vera, Indigo 
naturalis, Camptotheca acuminata, Mahonia aquifolium, Sophora flavescens, Lithospermum 
erythrorhizon, Cnidium monnieri, Dictamnus dasycarpus and borneol. 
The second component of the study focussed on the likely mechanisms of action of the herbs 
identified in the first component. It was possible that the actions identified were the result of 
single or multiple compounds contained in the herbs. Also, it was possible that the herbs 
acted on single or multiple targets. The investigation of how these herbs might act in the 
management of psoriasis involved a series of steps.  
Firstly, for each of the main herbs, the in vivo and in vitro evidence for biological activity of 
relevance to psoriasis therapy was reviewed. This is evidence for anti-inflammatory, 
anti-proliferative, anti-angiogenic, wound healing/skin repair and/or anti-pruritic actions for 
extracts of the plants and/or their bioactive constituents. 
In the second part, the compounds contained in the short-listed herbs and their associated 
species were identified using Encyclopaedia of TCM and other sources. This identified 482 
compounds. The targets of these compounds were identified for each herb using the database 
HIT resulting in 350 biological targets.  
The main therapeutic targets of relevance to anti-psoriatic therapy were identified using the 
DrugBank database to search for the targets of 20 drugs with known anti-psoriatic effects 
(APPs) that had received FDA approval for psoriasis. The search located 70 targets with 
known actions including Glucocorticoid receptor (NR3C1), Prostaglandin G/H synthase 1 & 
2 (COX 1 & 2), Retinoic acid receptor (RAR) alpha, beta & gamma-1, RXR-alpha & 
RXR-beta, T-cell surface antigen CD2 (CD2), Tumor necrosis factor (TNF) and Vitamin D3 
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receptor (VDR). 
Next, the targets of each of the compounds contained in the short-listed herbs were filtered 
based on the targets of the APPs. Ten targets were common to the APPs and the herbs. This 
enabled the identification of 11 herbs which shared at least one target with at least one of the 
APPs. Since some of these targets were enzymes from the Cytochrome p450 family, these 
were filtered out leaving the 9 herbs as follows: Dan shen (Salvia miltiorrhiza, S. sinica), Di 
huang (Rehmannia glutinosa), Bai hua she she cao (Oldenlandia diffusa), Lu hui (Aloe vera, 
A. ferox), Qing dai (Indigo naturalis), Xi shu (Camptotheca acuminata), Gong lao mu 
(Mahonia spp), Ku shen (Sophora flavescens) and Zi cao (Lithospermum erythrorhizon, 
Arnebia spp). These were considered the herbs most likely to have APP-like actions.  
Although these herbs had targets that were of known or likely relevance to psoriasis therapy, 
the herbs typically contained multiple compounds and some of the targets of these 
compounds which were not known targets of the APPs may also be of relevance to psoriasis. 
In order to explore how the multiple compounds in the herbs might be affecting biological 
processes, the database PANTHER was used to identify which biological processes and 
which pathways could be involved in the actions of these herbs.  
Since it was impractical to analyse all the 350 targets of the HMs, the following four herbs 
were selected for analysis using PANTHER: Dan shen, Di huang, Qing dai and Xi shu.  
Each herb had targets that were involved in between 48 and 59 pathways. The main 
pathways in which these targets were involved were identified as: Apoptosis signalling 
pathway, Angiogenesis, Gonadotropin releasing hormone receptor pathway, Inflammation 
mediated by chemokine and cytokine signalling pathway, and Interleukin signalling pathway. 
These pathways are primarily related to inflammation, proliferation and angiogenesis.  
The approach used in the second component was proposed as a more general method for 
adding value to the results of systematic reviews of herbal medicines and as an approach to 
identifying directions for clinical trials and drug discovery. The limitations of this approach 
and the implications for further research were discussed.
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Chapter 1: Introduction 
This chapter describes the types and features of psoriasis as well as discusses the 
epidemiology and economic impact of this disease. A brief review of the literature on the 
clinical management of psoriasis available at the time of writing is also provided. The 
chapter concludes with a statement of the aims of this study and specific research questions.  
1.1 Overview of the disease 
Psoriasis is a chronic inflammatory disease characterised by clearly delimited erythaematous 
plaques with large silvery scales and/or mild itching. It is often accompanied by ‘Auspitz 
sign’ (expanded blood vessels underneath the plaque), ‘tache de bougie’ (waxy appearance 
induced by scratching the involved skin) or Koebner phenomenon (psoriasis at the site of 
scars and minor skin injuries). Furthermore, 5%–10% of psoriasis patients have psoriatic 
arthritis (PsA), which mainly affects the distal interphalangeal joints and 
metacarpophalangeal joints (1).  
Psoriasis presentation patterns vary in appearance and location. The common types are 
plaque psoriasis, guttate psoriasis, scalp psoriasis, nail psoriasis, flexural psoriasis and 
psoriasis of palms and soles. Less common patterns include napkin psoriasis in infants, acute 
generalised pustular psoriasis and erythrodermic psoriasis. The plaque pattern (psoriasis 
vulgaris) is the most common type (2). 
Psoriasis is also categorised as Type 1 or Type 2 depending on the type of human leukocyte 
antigen (HLA) present. Type 1 is characterised by early onset and mostly affects the skin, 
whereas Type 2 usually appears at later stages in life and can affect the nails and joints (3).  
Till date, there is no uniform therapeutic regimen for the clinical management of psoriasis (4) 
despite the existence of several guidelines developed by various institutions that have been 
recommended by the relevant authorities (2, 5). The treatment of psoriasis and management 
of psoriasis patients varies widely throughout the world (6).  
2 
Research on inflammatory mechanisms of psoriasis at the genetic, molecular and cellular 
levels, undertaken over the last 20 years, has improved our understanding of this disease. 
New treatments have been developed and have markedly improved the clinical efficacy of 
psoriasis management (4). Current conventional approaches include a range of topical 
medications, phototherapy and systemic therapies using pharmaceutical and biological 
agents (2, 7). Nevertheless, there is no single effective treatment for psoriasis; more research 
and development are required to improve the efficacy and safety of future therapies for 
psoriasis.  
1.2 Epidemiology of psoriasis 
1.2.1 Incidence 
Studies have investigated the incidence of psoriasis in specific populations; however, there 
are no definitive data on its global incidence (8-10).  
The first study on the incidence of psoriasis was conducted in Olmstead County Minnesota, 
USA during 1980–1983. The study used medical records of the local population and 
involved 132 newly diagnosed psoriasis patients. The overall average annual incidence rate 
was 57.6 per 100,000 person-years (54.4 per 100,000 person-years for males and 60.2 per 
100,000 person-years for females). The overall rate of incidence peaked in the 60–69-year 
age group at 112.6 per 100,000 person-years. For females, the rate increased until 69 years of 
age, whereas for males, the rate increased with age. Because 58% of subjects were 
categorised as mild (<10% body surface area), they may not have considered the condition to 
be severe enough to visit their doctors; therefore, the real incidence of psoriasis may have 
been underestimated (8). 
In 1998, a survey involving 8,045 Norwegian twins aged 19–31 years (4,602 females and 
3,443 males) found that the incidence rates peaked in the 24–27-year age group for males 
and in the 16–19-year age group for females. The rates were 300 per 100,000 person-years 
for males and 290 for females. The mean age at the onset of the disease was much lower for 
females (14.8 years) than for males (17.3 years). The study also showed a definite linear 
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increase in incidence rates, although they peaked at different age intervals: the mid-twenties 
for males and late teens for females (10).  
The incidence rates are very different in the 2 abovementioned studies. This could be 
attributed to differences in methodology and populations. The Minnesota study was limited 
to patients diagnosed with psoriasis at a hospital clinic, whereas the Norwegian study used a 
population-based method. In the first study, mild cases may have been omitted and the 
incidence of psoriasis could have been underestimated. The populations studied were also 
considerably different. The Norwegian study was limited to twins aged 19–31 years with 
Type 1 psoriasis, whereas the Minnesota study included all psoriasis types and all ages (8, 
10). 
1.2.2 Prevalence in the world, Australia and China 
Psoriasis is found throughout the world; however, there is a wide variation in its reported 
prevalence. The prevalence of psoriasis in the US is estimated to be approximately 2% (3). 
However, only a few epidemiological studies of psoriasis have been population-based, and 
almost all data have been derived from references to other types of studies (11).  Because 
patient ethnicity may affect the prevalence of psoriasis, studies that do not use 
population-based methods can produce biased results, can differ between countries, regions 
and areas and the validity of the findings might be limited. For psoriasis, population-based 
factors are as significant as genetic and environmental factors. However, it is also important 
to differentiate between various subpopulations and their individual healthcare needs (12).  
The factors that affect the reported prevalence include the country investigated, definition of 
prevalence (point, period or lifetime), sampling method and methods used to diagnose the 
disease (e.g. disease reported by a patient with/without confirmation by a practitioner) (12). 
Among the abovementioned factors, the definition of prevalence should be clarified first. It 
is ‘the proportion of individuals in the population who have the disease of interest in a 
specified time period’ (p 1538), and it could refer to the lifetime prevalence of the disease 
(13).  
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Some studies conducted using appropriate approaches that allowed making reasonable 
inferences have been the subject of a recent review. Cimmino (2007) estimated the average 
global prevalence of psoriasis to be 3%–4%, without evident differences between the 
genders. Furthermore, Cimmino estimated that the prevalence of PsA should be 0.5%–1%; 
this estimate is based on the fact that although the percentage of psoriasis is 3%, 
approximately 15%–30% of the patients also have PsA. The prevalence of psoriasis is 
probably underestimated because the disease is mainly reported by patients themselves. This 
approach may miss undiagnosed mild psoriasis, and the lack of precise classification criteria 
and the elusive nature of skin diseases in general may result in the disease being undiagnosed 
(14). For example, the National Health and Nutrition Examination Survey (NHANES) 2003–
2004 in USA showed that the prevalence of undiagnosed active psoriasis, based on a 
conservative definition and a broader definition, was 0.4% and 2.28%, respectively, of the 
US population aged 20–59 years. These percentages accounted for approximately 600,000 
and 3.6 million US adults, respectively. These results are almost comparable with the 
number of adults diagnosed with psoriasis during the same period (over 5 million; 
prevalence of 3.15%) (15).  
In a review of the prevalence of psoriasis in different countries and populations, Cimmino 
(14) reports a large variation. However, few of the epidemiological studies reviewed were 
population based, and there was a considerable variation in the methods used. The 
prevalence of psoriasis varied from 0% in the Samoan Islands to 11.8% in Kasach’ye on the 
Arctic Circle (16). Mali and Nigeria had a low prevalence of psoriasis (0.05% and 0.08%–
0.4%, respectively). In addition, Angola had a low prevalence (0.3%). East Africa had 0.7% 
prevalence, which was the same level as that in the African–American population in the 
USA. However, higher prevalence rates were found in Uganda (2.8%), Tanzania (3%) and 
Kenya (3.5%), with the highest rate being found in South Africa (4.5%). 
The prevalence of psoriasis in India has been estimated to be 0.7%, whereas that in Malaysia 
has reached 4%–5.5%. Approximately 0.3%–1.2% of the Japanese population was affected 
by the condition; however, its prevalence in the Henan Province of China was only 0.4%. 
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The only data available for the Middle East were for Kuwait; the prevalence rate was 3.1%, 
it was similar to that in Egypt (3%).  
In Europe, the prevalence of psoriasis in Norway, Croatia, UK and Former USSR was low at 
1.45%, 1.55%, 1.6% and 2%, respectively. The prevalence of psoriasis in Spain was high at 
3.7%, and even higher rates were found in Scotland (4.8%) and Ireland (5.5%). The highest 
rate in Europe was found in Germany (6.5%) (14).  
Data for America showed the lowest prevalence rate in Brazil (1.3%), followed by 
Venezuela (2%), and the highest prevalence rate in the Caribbean (6.5%). Approximately 4.6% 
of the population of the USA was affected by psoriasis, while 4.2% prevalence was found 
among Paraguayans and 4.7% among Canadians. Interestingly, the prevalence in some 
countries showed a large variation depending on the origin of the population. For instance, 
the prevalence among Caucasians in Australia was 2.6%, whereas that among the aboriginals 
was 0%. Similarly, the overall prevalence in the USA was 4.6%; however it was only 0.7% 
in African Americans and 0% in Native Americans and Alaskan natives. In general, it seems 
that psoriasis tends to occur at higher rates in Europe and among white populations (14).  
The Australian prevalence of psoriasis has been estimated to be 2.6% (14). According to 
Psoriasis Australia, there are approximately 350,000 Australian patients with plaque 
psoriasis, and 10% of these can be categorised as cases of severe chronic plaque psoriasis 
(17). An epidemiological study of skin conditions, including psoriasis, using a random 
population-based survey method was implemented from August 1997 to February 1998 in 
central Victoria, Australia. The study found a 6.6% [95% confidence interval (CI), 5.4%–
7.9%] prevalence that varied with age and sex (18). The rate for males differed from that for 
females; it was 8.9% (95% CI, 6.8%–11.0%) versus 4.5% (95% CI, 3.2%–6.3%), giving a 
gender rate ratio of 2.0 (95% CI, 1.3–3.2) However, the study found that the prevalence of 
psoriasis was not likely to be related to age. The percentages of individuals suffering from 
mild, moderate and severe psoriasis were 81.1%, 16.1% and 2.8%, respectively; however, 
the severity was not associated with sex or age. Only 41 of the 99 respondents who were 
found to have psoriasis mentioned psoriasis in their disease history questionnaire. The 
6 
authors believe that the the current prevalence rate may be higher than the previously 
reported rate because of the use of a specialist clinician, which resulted in greater sensitivity 
in detecting the disease. When the authors removed 80% of cases classified as mild, the 
prevalence fell to 1.8% in males and 0.6% in females, which was closer to the earlier 
estimates of prevalence rates. However, this also resulted in a higher male-to-female 
prevalence ratio of 3.0 (18).  
From 1976 to 2008, a series of surveys on psoriatic prevalence were conducted in China. 
They are listed in Table 1.1 in chronological order (19-24). 
Table 1.1 Prevalence Surveys of Psoriasis in China 
 
Year Area Method Prevalence (%) Sample Size (n) 
1976–
1977 
Xinjiang 
autonomous region 
Not stated 0.18% 18,498 
1984 
23 provinces & 
municipalities 
Clue filtering 0.12% 5,742,066 
1987 
Inner Mongolia 
autonomous region 
Clue filtering 0.22% 108,975 
1993–
1994 
Xuzhou 
Prefecture-level 
city, Jiangsu 
Province 
Stratified & overall random 
sampling and single blinding 
0.11% 98,642 
2001 
Suzhou Prefecture, 
Anhui Province 
Stratified & overall random 
sampling 
0.11% 92,857 
2008 
6 provinces & 
municipalities 
Overall sampling 0.47% 17,345 
The survey of 23 provinces and municipalities (21) conducted in 1984 by the National 
Survey Group of Psoriasis Prevalence was the most comprehensive. It was the largest and 
the most extensive survey in the field of epidemiology of psoriasis in China; it sampled 
6,617,917 people, covering 53 sites in 24 provinces and municipalities, and recorded data for 
5,742,066 respondents at 49 sites in 23 provinces and municipalities. Apart from a 0.12% 
general prevalence rate of psoriasis, the study also found other significant differences in 
prevalence, as described below.  
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a) Difference between the northern and southern regions: With a latitude of 35 degrees north 
as the boundary, the standardised prevalence rate was 0.200% in 12 northern cities versus 
0.140% in 14 southern cities and 0.180% in 6 northern villages versus 0.065% in 14 southern 
villages. In particular, the highest rates were 0.439% in Dehui County, the Jilin Province in 
northeast China, and 0.442% in the Capital Steel Corporation in Beijing, while the lowest 
rate was 0.006%–0.008% in the Guangdong Province, southern China. 
b) Differences between urban and rural areas: The prevalence rate was 0.176% in the former 
and 0.100% in the latter. This was also evident in similar geographical environments. For 
instance, it was 0.259%, 0.141% and 0.082% in Nanjing, a highly industrialised municipality; 
Taizhou, a small city and a village in Yangzhou, respectively. 
c) Differences between males and females: The corresponding rates were 0.168% versus 
0.124%. In addition, the study revealed that the patients of aged 20–54 years constituted 78% 
of the total patients; young and middle-aged adults formed the largest group of psoriasis 
sufferers. In total, 75% of patients had their first occurrence by the age of 34 years. The most 
frequent onset age bracket for males was 20–24 years (17.22%), whereas that for females 
was 15–19 years (18.46%). The survey revealed that most patients were diagnosed with 
psoriasis vulgaris (97.9%) and the remaining patients had psoriasis of the erythrodermic 
(0.58%), pustular (0.69%), erythaema (0.04%) or arthritic type (0.69%). The majority of 
patients were classified as mild psoriasis sufferers (62.81%), whereas moderate and severe 
groups constituted 29.47% and 7.71% of the total, respectively. The study also showed a 
remarkable positive association with family history (32%).  
1.3 The cost of prevention & treatment 
The economic burden (25) for psoriasis patients includes a wide range of aspects such as 
medical visits and prescriptions, hospitalisation, medication costs and over-the-counter (OTC) 
products for skin care. It can also include additional therapies, travel expenses, loss of work 
and a negative effect on professional opportunities because of the long-term duration of the 
disease. The disease also affects the overall healthcare budget. Therefore, we should evaluate 
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the relevant expenses involved in the management and treatment of psoriasis. In general, the 
costs of the disease can be divided into 3 types: 
a) Direct costs: the direct expense of the therapy; 
b) Indirect costs: the investment from a societal point of view and  
c) Intangible costs: the burden to patients and their families, which may not be easy to 
estimate. 
1.3.1 Total cost of psoriasis management 
The total cost of psoriasis management, particularly in cases of moderate-to-severe psoriasis, 
usually treated with phototherapy or systemic agents (26), arises from a series of 
expenditures throughout the consultation, examination, diagnosis and treatment that a patient 
with psoriasis may undergo (and may be reimbursed by a third-party), for example: 
a) Office visit: level 3 return, nursing visit; 
b) Laboratory work: complete blood count, complete blood count with differential, 
liver function test, lipid panel, basic metabolic profile, complete metabolic profile, 
magnesium, T-cell CD4 count, tuberculosis PPD;  
c) Radiological studies: chest X-ray; 
d) Procedures: liver biopsy; 
e) Infusion: 1-h or >1-h infusion and 
f) Treatment: ultraviolet B (UVB), psoralen and ultraviolet A (PUVA). 
In addition, the drug acquisition costs can be estimated on the basis of their average 
wholesale price. 
In the USA, the direct costs of adult psoriasis (including PsA) were studied in 1997 (27). The 
study revealed that the main direct medical costs were hospitalisation, inpatient physician 
services, outpatient physician visits and prescription medications. In addition, OTC costs 
were estimated by referring to the changes in the number of psoriasis patients, the consumer 
price index (CPI) and the OTC drug index [series SEMB – Non-prescription Drugs and 
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Medical Supplies (28)]. Because certain expenses such as emergency department services, 
diagnostic radiology and laboratory services and nursing home or home healthcare services 
were weighted lower, they were not included in the analysis. The study revealed that the total 
direct medical expenses for approximately 1.4 million psoriasis patients were US$ 649.6 
million (M) per year. This included hospitalisations ($ 30.5 M); outpatient physician visits 
($ 86.6 M); photochemotherapy ($ 27.4 M); dermatological prescription drugs ($ 147.9 M) 
and OTC drugs ($ 357.2 M). The authors noted that the overall cost was smaller lesser than 
that in a 1979 study; they attributed this to a fall in the hospitalisation rate since 1979 and 
differences in the methods used to cost medical services. 
For patients with moderate-to-severe chronic psoriasis vulgaris, a study (29) has been 
conducted in 17 centres in Germany to determine the mean annual cost and expenditure and 
cost per flare in out-patients and office-based care. The data were obtained from 192 of 227 
enrolled patients and consisted of direct costs to patient and from third-party payers (TPP) 
and indirect costs from the patient. In general, the cost per patient was €2,866 (including 
€864 reimbursed by a TPP and €1,440 of indirect costs) per year. However, for systemic 
therapy, the total cost rose to €4,985, compared with €1,173 for topical and/or phototherapy. 
In 2002, Jenner et al. published the first longitudinal study of morbidity and cost of psoriasis 
(30). This was a prospective cohort study conducted in Melbourne, Australia from 1997 to 
1999. It included an initial interview and 8 subsequent 3-monthly follow-ups. Complete 
diary data were provided by 46 of 83 originally recruited participants. This included the cost 
of medical products (i.e. prescription medications, OTC treatments and household items) and 
costs of medical consultations, including (a) cost of consultation with a bulk-billing general 
practitioner, (b) cost of consultation with a general practitioner paid by the participant, (c) 
out-of-pocket cost for specialist fees and (d) cost of photochemotherapy with PUVA and 
UVB. The study reported that the average annual cost of psoriasis products for each 
participant was AUD$ 254.25; however, the individual cost over the 2-year period could 
vary from zero for a mild psoriasis patient to AUD$ 2000 for a severe psoriasis patient. In 
fact, the average OTC product cost was more than the average out-of-pocket cost for 
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prescription products. Medical consultation costs ranged from AUD$ 128 to approximately 
$ 1206 p.a., with a mean of AUD$ 473. In addition, there was an average of AUD$ 185.28 in 
out-of-pocket costs in consultation fees to other healthcare providers. The authors noted that 
the use of Psoriasis Area and Severity Index (PASI) may not provide an accurate assessment 
of the severity of the disease over time and that patient’s self-assessment may not agree with 
the dermatologist’s assessment. 
A Chinese study, conducted from March 2001 to October 2003 investigated the cost of 
long-term psoriasis therapy using a specific questionnaire (31). In total, 132 patients who had 
suffered from psoriasis for 10 or more years participated in the study. They were variously 
employed as labourers, agricultural workers, management staff, self-employed, and others. 
The total amounts spent by the respondents on their psoriasis treatment varied considerably, 
from RMB¥ 1000 to RMB¥ 150,000. The total long-term costs were categorised into 4 
groups: ≤RMB¥ 5000; RMB¥ 5000–20,000; RMB¥ 20,000–50,000 and >RMB¥ 50,000.  
Patients in different occupations reported significantly different costs of treatment; 
management staff and self-employed patients bore higher expenses than patients with other 
professions (χ2 = 38.44, P < 0.01). The total cost of treatment also varied with the severity of 
psoriasis (divided into 4 groups on the basis of the latest relapse); the differences were highly 
significant (χ2 = 78.88, P < 0.01). The individuals with a higher severity of psoriasis had 
spent more than those with a milder form of the disease. The majority of participants in 
cost-groups I and II (94% and 87.18%, respectively) had psoriasis of ‘mild’ to ‘middle’ 
severity. In cost-group IV (i.e. the highest expenditure), a large proportion of patients 
suffered from ‘medium-severe’ and ‘severe’ psoriasis (37.5% and 43.75%, respectively).  
According to China Labour Statistical Yearbook 2004, the average annual wages of the 
office staff and manual workers were RMB¥ 9,774 and RMB¥ 11,001 for Manufacturing 
Industry in 2001 and 2002, respectively, and RMB¥ 12,142 and RMB¥ 13,975 for 
Government Agencies, Party Agencies & Social Organisations in 2001 and 2002, 
respectively (32). The cost of psoriasis treatment mainly fell into cost-groups I and II; the 
amounts spent were between 41.18% and 205.90% of the annual income in 2001 and 
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between 45.45% and 181.80% of the annual income in 2002. 
1.3.2 Cost of specific interventions 
1.3.2.1 Topical therapy 
Because psoriasis is a persistent and progressive disease with a tendency to relapse after 
remissions, lifelong expenses accompany lifelong care (33). The first-line intervention for 
psoriasis is the use of topical agents, including steroids (i.e. fluocinonide), retinoids, 
calcipotriol (calcipotriene in US) and tazarotene. These remedies play substantial roles in the 
management of psoriasis. A US study investigated the cost-effectiveness of each topical 
therapy. In the study, pharmacoeconomic decision–analysis model was developed and 
validated. Data on the clinical efficacy (including clearance and relapse rates) of calcipotriol, 
tazarotene and fluocinonide were obtained from clinical trials and analysed via meta-analysis. 
The costs of medical consultation, treatment preparation, laboratory testing and treatment for 
potential side effects were taken into account in the decision model. The expected costs of a 
condition-free day were the basis of cost-effectiveness analysis. The study revealed that 0.1% 
tazarotene was 16.74% more cost-effective than 0.05% tazarotene, 143.75% more 
cost-effective than calcipotriol and 85.46% more cost-effective than fluocinonide. The 
anticipated expense of a condition-free day was $ 49.46 for 0.1% tazarotene, $ 57.74 for 0.05% 
tazarotene, $ 91.73 for fluocinonide and $ 120.56 for calcipotriene. The study recommended 
the use of tazarotene for patients with mild-to-moderate stable plaque psoriasis as the most 
cost-effective topical therapy.  
1.3.2.2 Systemic, phototherapy and biological therapy 
In 2003, Feldman analysed the annual cost of treatment for severe psoriasis with a focus on 
comparison between established systemic treatments and the newly introduced biological 
agents alefacept, etanercept and infliximab (26). The annual cost of treatment with 
methotrexate, UVB, PUVA, acitretin, cyclosporine, etanercept, alefacept or infliximab 
varied from US $ 3,600 to 34,600. Methotrexate treatment was the cheapest, at US$ 1,600 
per year. The second lowest cost was for phototherapy, namely US$ 3,600 for UVB and 
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US$ 4,600 for PUVA. Cyclosporin was more expensive than acitretin at US$ 6,500–10,000 
versus US$ 5,200 per annum. Alefacept, etanercept and infliximab were all considerably 
more expensive than the abovementioned interventions; however, the cost depended on the 
individual dose. For example, the cost of a 25 mg dose of etanercept twice a week (the 
standard dose also used in rheumatoid arthritis) was US$ 16,900, whereas that for a 50 mg 
dose was US$ 33,000. Similarly, the annual cost of alefacept treatment based on an average 
of 1.5 × 12-week courses was US$ 16 000–20 000, which included the cost of the drug, drug 
administration, laboratory testing and travel. However, the annual direct costs for alefacept, 
etanercept and infliximab were similar. In terms of cost per treatment success, the most 
expensive were etanercept (25 mg twice a week, US$ 35,900) and intravenous alefacept 
(US$ 40,600), followed by infliximab at 5 mg/kg (US$ 22,500). Methotrexate was the 
cheapest drug at US$ 5,400, while the costs of UVB (US$ 5,100) and PUVA (US$ 5,700) 
were comparable. Cyclosporin was considerably more costly at US$ 14,200, and acitretin 
monotherapy was the most expensive of the established treatments (US$ 17,300); however, 
acitretin is more commonly used in low doses in combination with phototherapy. The 
authors of the study concluded that UVB is one of the least costly and safest therapies but it 
is not very convenient. Although methotrexate is a cost-effective second-line treatment, its 
risks limit its long-term use. Similarly, skin cancer risks of PUVA therapy limit its long-term 
use. The new biologicals carry a lower risk-to-benefit ratio but have the disadvantage of a 
high cost.  
1.4 Research background 
The causes of psoriasis are still unclear, and the current conventional therapies are mainly 
used to control the symptoms and/or signs (34, 35). Although there have been some advances 
in psoriasis symptom management, the efficacy of the available treatments remains limited. 
The conventional treatments are also associated with significant side effects, including the 
various side effects of corticosteroids; skin cancer risks of PUVA; teratogenic effects of the 
oral retinoid acitretin; myelosuppression and liver fibrosis due to methotrexate; toxicity and 
gastrointestinal intolerance of fumaric acid; reactivation of latent tuberculosis, hepatotoxicity, 
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lymphoma and congestive heart failure due to the agents blocking T-cell activation and 
tumour necrosis factor (TNF)-α and renal damage caused by cyclosporine (35). These side 
effects limit the application of certain therapies, particularly in long-term treatment.  
The costs of conventional psoriasis therapy are considerable, particularly for the new 
systemic drugs used during prolonged periods. The recalcitrant nature of this disease, the 
limitations of conventional therapies, their associated cost and the problems caused by their 
side effects are the issues that concern patients, dermatologists and government health 
agencies. It is necessary to seek new clinical approaches for psoriasis management.  
Man has long struggled against the obstinate diseases using traditional medicine systems. 
Traditional approaches have now been included within complementary and alternative 
medicine (CAM) and are often regarded as safe and economical. They also tend to 
incorporate prevention and rehabilitation in addition to the treatment of psoriasis symptoms. 
Chinese medicine (CM) is a well-known CAM system. Smith et al. (2009) reviewed a 
number of clinical studies and found that 43%–69% of psoriasis patients utilise some form of 
CAM, often in combination with conventional treatments (36). They also showed some 
evidence for the efficacy of certain CAM therapies.  
Some methods of controlling of psoriasis symptoms have been recorded in both the classical 
and modern clinical CM literature. Although the prevalence of psoriasis in pre-modern China 
is unknown, diseases that are likely to have been psoriasis have been described in classical 
texts under a number of different names. For example, a disease that appears to have been 
psoriasis (named Ganxian) was described in the ‘General Treatise on the Causes and 
Symptoms of Diseases’ written by Chao Yuanfang in A.D. 610. A disease termed Baichuang 
was also described in the ‘Comprehensive Summary of External Medicine’ by Qi Kun (1665) 
(37). However, within the scope of these disease descriptions, classical CM texts may have 
also included diseases that would not fit the contemporary definition of psoriasis. Therefore, 
these issues require some careful analysis and clarification. The records of psoriasis 
treatment in the pre-modern/classical CM literature may provide useful leads for the 
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development of new psoriasis treatments; however, no systematic compilation or evaluation 
of these records is available. 
The current approaches to finding new leads for drug development include high-throughput 
screening, data mining of database entries and systematic mining of old herbalist texts, 
including those from China (38, 39). Experimental studies of the anti-psoriatic effects of 
Chinese herbs are also in progress (40); however, no studies have integrated the clinical and 
experimental evidence for individual herbs. This study will provide a comprehensive 
evaluation of the CM literature and experimental evidence to help identify specific CMs, 
which may warrant further clinical and experimental investigation. 
1.5 Reviews on herbal medicine (HM) for psoriasis 
There were several review articles related to the field of HM and psoriasis that has been 
published when this study began. Most of these were either general reviews of HM or CAM 
for skin disorders, including psoriasis, or reviews of specific HMs, and some focused on 
experimental studies. There were 3 reviews on the medical uses of Aloe vera and one on 
shark cartilage (41-44). There was one review is on the use of acitretin in combination with 
Chinese herbs (45), another on Chinese experimental studies investigating the use of 
traditional remedies in psoriasis (40), while a third review was on the methodology for 
evaluating trials of traditional CMs for psoriasis (46).  
Four articles had analysed a broader range of HM and/or CAM interventions (36, 47-49). 
Two of these were general reviews of skin disorders (36, 47). The remaining 2 focused on 
psoriasis; however, the article by Steele et al. (48) was mainly regarding the top 15 plants in 
common use, and the article by Tse (49) focused on the individual Chinese herbs commonly 
used in clinical trials.  
In reviews of the use of Chinese Herbal Medicine for skin disorders, Koo et al (50, 51) 
provided comparisons between the Western and Chinese Medicine treatments for psoriasis 
which discussed the use of CHMs topically, orally and in conjunction with ultraviolet (UV) 
radiation treatment. This approach is similar to that of Western medicine and the reviews 
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noted that a number of the herbs included in topical HMs that were combined with UV 
contained photosensitising compounds. Although such similarities are evident, points of 
difference included the use of multiple HMs in many CHM formulations, the use of 
syndrome differentiation in the selection of HMs appropriate to an individual case, and the 
modification of multi-herbal formulae according to the needs of each patient. In a discussion 
of the Chinese and Western medicine treatments of psoriasis, the expert on psoriasis Ouyang 
Heng mentioned similar points regarding the Chinese medicine approaches to diagnosis and 
therapy and also noted that psoriasis can require life-long therapy in Chinese medicine as it 
does in Western medicine. He made the point that in modern Chinese medicine the diagnosis 
of psoriasis is based on the same principles as in Western medicine but Chinese medicine 
adds syndrome differentiation and the approach to treatment varies according to the 
syndrome and stage of the disease (52). 
These reviews were essentially descriptive and did not provide information on selection and 
exclusion criteria, methodological assessment or meta-analyses. A Cochrane protocol for a 
comprehensive systematic review of psoriasis treatment with Chinese HMs was published in 
2009 (53). However, at the commencement of this study no systematic review on topical or 
systemic HM for psoriasis was identified.  
1.6 Significance of the research 
Studies in Europe have revealed that approximately 43% of psoriasis patients utilise some 
form of CAM, often in combination with conventional treatments (36, 54). In China, HM is 
extensively used by psoriasis patients. Dermatologists may intentionally use combined 
conventional and HM treatments to enhance the overall therapeutic effect or reduce the 
dosage of conventional medications (52, 55). Some methods for controlling psoriasis 
symptoms have been recorded in both the classical and modern clinical CM literature. 
Certain CM treatment approaches have attracted the attention of clinical researchers, and a 
number of clinical trials have been published. However, the quality of these trials appears 
variable, and there has been no systematic clinical evaluation of CMs for the treatment of 
psoriasis. 
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For further development of the clinical management of psoriasis using CM, the clinical 
efficacy of the various approaches needs to be evaluated in a systematic manner and the 
results need to be presented in an easily accessible form. Providing an objective scientific 
evaluation of the best available evidence may lead to the increased adoption of the 
evidence-based practice by CM practitioners and encourage the adoption of CM methods by 
other relevant professionals, including dermatologists, researchers and administrators of 
healthcare services.  
A systematic exploration of the results obtained in experimental studies of the individual 
herbal remedies used in the clinical management of psoriasis should provide useful leads for 
the development of new psoriasis treatments. 
1.7 Aims of the research  
The present study evaluates the effectiveness/efficacy and safety of psoriasis treatments 
using Chinese HMs. The first component of the project is a systematic review of the modern 
clinical research literature in English and Chinese and quality evaluation of published 
clinical trials of psoriasis remedies to find the best available clinical trial evidence. This 
stage of the study will also identify which herbs and formulae, used topically and 
systemically, are the best candidates for further clinical and/or experimental research. The 
second component of the present study is an examination of the experimental evidence for 
the anti-psoriatic effects of herbs identified in the first 2 stages of the study as promising for 
the topical and/or systemic treatment of psoriasis.  
The objectives of this research are as follows: 
1) Systematically review the results of modern clinical research published in English and 
Chinese on the topical use of CM for psoriasis. 
2) Systematically review the modern clinical research published in English and Chinese on 
the oral/systemic use of CM for psoriasis. 
3) Identify the best available evidence for the clinical efficacy of CMs topically and orally 
used in the treatment of psoriasis. 
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4) Select the herbs and herbal formulae that show the most promising clinical efficacy. 
5) Examine the existing experimental evidence in vivo and in vitro for the anti-psoriatic 
effects of the individual herbs identified as having the greatest therapeutic potential in the 
treatment and/or management of the symptoms of psoriasis.  
6) Identify the possible mechanisms of action of the most promising herbs. 
1.8 Research questions 
To realise these research aims within the stated time frame, the following list of research 
questions was proposed.  
The principal research questions are as follows: 
1) What is the current state of the clinical evidence for the efficacy and safety of herbal 
medicine for psoriasis? 
2) Which herbs and/or formulas have the best evidence of efficacy in the management of 
psoriasis? 
3) Which herbs show the best evidence of anti-psoriatic activity based on the combination 
of clinical and experimental studies? 
4) What are the likely mechanisms of action of the most promising herbs and/or their 
constituents? 
5) What are the implications of the clinical and research evidence for the clinical 
management of psoriasis and for on-going research? 
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Chapter 2: The characteristics of psoriasis and related disorders 
2.1 Pathophysiology of psoriasis 
2.1.1 Genetics of psoriasis  
A study of psoriasis in Australian twins has estimated that its level of heritability is 
approximately 80% (56). Among psoriasis or psoriatic arthritis (PsA) patients, the family 
history includes these conditions in 52% and 41% of cases, respectively (57). With 1 parent 
suffering from the disease, the child has a 16% chance of contracting it; this chance increases 
to 50% if both parents are affected (2).  
Lowes et al. (2007) have summarised the genetic background associated with psoriasis (58). 
As many as 10–20 chromosome regions have been considered to be harbouring candidate 
psoriasis genes. However, only a small proportion of these have been confirmed. Several 
potential psoriasis susceptibility loci (PSORS1 to PSORS12) have been mapped to different 
chromosomal regions. The class I region of the major histocompatibility complex (MHC) 
locus cluster has been strongly associated with psoriasis; however, its low penetrance of 
approximately 10% suggests that other factors may also be involved. It is now accepted that 
the main susceptibility locus PSORS1 (psoriasis susceptibility 1) is contained within MHC, 
on chromosome 6p21. Associations between psoriasis and human leukocyte antigen 
(HLA)-Cw6 have been reported in many different populations. This supports the proposal 
that a psoriasis susceptibility gene is located in the MHC cluster. Moreover, changes in the 
HLA-C activity are likely to affect psoriasis susceptibility because HLA-C is involved in the 
process of immune self-recognition. 
The exact function of PSORS1 is still to be confirmed; it is not even clear whether PSORS1 
is a classical MHC allele or a regulatory variant. The immune system and keratinocyte 
differentiation may be adjusted by some predisposing polygenes. Immune synapse regulation 
can be affected by common variants in the SLC9A3R1/NAT9 region, loss of a potential 
RUNX binding site and variants of the lymphoid phosphatase PTPN22. At least 4 other 
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autoimmune diseases are also affected by R620W polymorphism of PTPN22. Associations 
with genes encoding other immune system components, IL-12, IL-19/20 and IRF2, have also 
been reported. Chromosome 17q25 has been associated with a family history of psoriasis. 
Patients suffering from psoriasis present with autosomal-dominant seborrhoea-like dermatitis 
and psoriasiform expression caused by alterations in zinc finger protein 750 (ZNF750). 
Because the alteration generally occurs in keratinocytes rather than in fibroblasts (it is even 
rare in CD4 lymphocytes), keratinocytes should be the main site of the defect (58). 
2.1.2 Psoriasis-precipitating factors 
a) Trauma: 
Koebner phenomenon can be triggered by some physical traumas, chemical injuries and 
inflammation, abrasions, excoriations, laceration, scarification, rubbing, incision, surgery 
wounds, and others. This phenomenon is characteristic in psoriasis patients; new psoriasis 
lesions form at the site of injury in previously unaffected areas. While the disease is active, 
the phenomenon tends to aggravate. The incidence of Koebner phenomenon among psoriasis 
patients is approximately 5%–50%. In patients with an early onset, this tendency seems to be 
stronger; relapses are frequent and have to be controlled with multiple therapies (59). 
A reverse Koebner phenomenon can be caused by similar skin injuries; the original psoriatic 
lesions may clear after skin stimulation. In a 24-patient study, in response to standard skin 
injuries to psoriasis-affected and unaffected areas, 67% of subjects displayed a reverse 
Koebner reaction and the proportion of positive Koebner reactions was 25%. The Koebner 
reaction in psoriasis was found to be of an ‘all-or-none’ type, i.e. if the reaction occurs at 1 
injury site, all the injured sites will react in the same manner. Similarly, psoriasis did not 
develop in the unaffected area after its disappearance from the traumatised area. In terms of 
the relationship between the disease activity and the Koebner reaction, the former cannot 
predict the latter but the latter can predict the former (60). 
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b) Infection: 
The incidence of psoriasis linked to bacterial or viral infection ranges from 15% to 76%. 
Tonsillitis and upper respiratory infections are clearly associated with acute guttate psoriasis. 
A strong association has been found between streptococcal infections and HLA B13 
positivity in patients, which may be caused by insufficient levels of anti-streptolysin-O. 
Throat infection with beta-haemolytic streptococci can induce and aggravate plaque psoriasis. 
The human 50-kDa keratin type 1 protein shows a substantial homology with the 
streptococcal protein M6. A certain degree of cross-reactivity with anti-streptococcal 
antibodies may be caused by this similarity; this may be linked to the pathogenesis of 
post-streptococcal psoriasis. During the activation of T cells, keratinocytes may present 
determinants, which will be identified by T cells as epitopes on beta-haemolytic streptococci. 
In cases of local skin infections, psoriasis may also be aggravated by superantigens secreted 
from Staphylococcus aureus or Candida albicans (59). 
A linkage between severe psoriasis and human immunodeficiency virus (HIV) infection has 
been considered because HIV-1 infection often exacerbates existing psoriasis or triggers the 
onset of this disease. However, the mechanism underlying this phenomenon seems to be 
related to comprehensive immunodeficiency of patients rather than their immune reaction to 
HIV. Psoriasis is considered to be a T-cell-mediated disease. However, CD4+ T cells can 
still be recruited into the lesional skin in psoriatic patients without acquired 
immunodeficiency syndrome (AIDS). Besides, T cells may be activated by HIV that acts as a 
superantigen (59). Some studies and case reports substantiate a close association between the 
2 diseases. Psoriasis may be worsened by AIDS (61) but can also regress during terminal 
AIDS (62). 
c) Smoking: 
Cigarette smoke contains a complex mixture of substances, including nicotine and carbon 
monoxide. Gender, genetic background, nicotine dose and concentration may affect the 
impact of smoking on psoriasis. A case-control study with 560 psoriatic patients analysed the 
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association between the onset of psoriasis and smoking habits. The overall odds ratio (OR) 
for psoriasis was higher for current and former smokers [OR, 1.7; 95% confidence interval 
(CI), 1.1–3.0 and OR, 1.9; 95% CI, 1.3–2.7, respectively] than for non-smokers. Among 
former smokers, males were at a higher risk of psoriasis (OR, 2.1; 95% CI, 1.3–3.5) than 
females (OR, 1.2; 95% CI, 0.6–2.2). In contrast, the risk in the current female smokers was 
higher than that in the current male smokers. There was no significant difference between 
different types of cigarettes, consumption or smoking styles. A clear association has been 
established between smoking and pustular psoriasis (OR, 5.3; 95% CI, 2.1–13.0) (63).  
d) Drinking: 
There is no confirmed direct association between alcohol consumption and psoriasis, despite 
a potential connection between alcohol abuse or alcoholism and psoriasis. The morbidity of 
psoriasis may be affected by alcoholism; alcohol misuse increases a risk of liver disease and 
unfavourable drug interactions (59). 
e) Exposure to sunlight: 
Sunlight improves the lesions of most psoriasis patients; however, the condition of 10% of 
patients may worsen (2).  
f) Endocrine factors: 
The condition of women with psoriasis frequently improves during pregnancy and relapses 
postpartum. Psoriasis has also been associated with hypocalcaemia and hypoparathyroidism 
(2).  
g) Drug effects: 
Some psoriasis patients react against non-steroidal anti-inflammatory drugs (NSAIDs). 
When the application of systemic steroids, potent topical steroids or efalizumab is 
discontinued, a ‘rebound’ phenomenon may occur. The severity of psoriasis can also be 
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increased by some drugs such as antimalarials, beta-blockers, interferon (IFN-α) and lithium 
(2)  
h) Emotional factors: 
Stress is likely to lead to deterioration in some psoriatic patients (2).  
2.1.3 Main mechanism of psoriasis 
The main mechanism of psoriasis is likely to be related to epidermal hyperproliferation, 
abnormal differentiation of keratinocytes, inflammation and angiogenesis (64). Psoriasis is 
now considered to be an autoimmune disease rather than just an epidermal condition. T cells 
play a crucial role in the pathophysiology of this disease (65). After bone marrow 
transplantation from a donor without the disease, psoriasis in the recipient can clear (66) and 
it can be transmitted as a result of bone marrow transplantation from a patient with psoriasis 
(64, 67). Psoriasis patients respond well to DAB389IL-2, a drug directed at T cells bearing 
interleukin 2 receptors, without any effect on keratinocytes, indicating that T cells play a 
major role in the induction of psoriasis. Similarly, ciclosporin, which mainly inhibits the 
activation of T cells, is used as a highly effective systemic treatment for psoriasis (65).  
Lebwohl (65) has proposed an immunological and inflammatory mechanism in which T-cell 
response is centralised (Fig. 2.1). Unidentified antigens can initiate this response by 
maturation of Langerhans cells, the antigen-presenting cells in the epidermis. The cells then 
move to regional lymph nodes where naïve T cells are activated by the interaction with the 
previous antigen-presenting cells. The activation of T cells is based on at least 2 pathway 
signals. When a T-cell receptor encounters an antigen presented by MHC, the first signal 
starts the induction. The second signal can control message delivery from antigen-presenting 
cells to T cells by co-stimulatory signal induction on the surface of the resting T cell. This 
occurs when lymphocyte functional antigen (LFA)-3 stimulates CDs, B7 stimulates CD28 or 
intercellular adhesion molecule -1 (ICAM-1) stimulates LFA-1 (Fig. 2.1). After T-cell 
interaction with the antigen-presenting cells, T cells proliferate and memory T cells are 
formed. These cells join the blood circulation and finally infiltrate the endothelium of the 
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inflamed areas. LFA-1 on T cells interacts with ICAM-1 in the endothelium, which is 
necessary for the adherence of T cells to the affected area. At the same time, T lymphocytes 
can encounter the initiating antigen and secrete type-1 cytokines (Th1), mainly including 
interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumour necrosis factor alpha (TNF-α), 
which can lead to the proliferation and parakeratosis of keratinocytes and appropriate 
angiogenesis. Other cells and molecules may also affect the condition. Some chemokines 
may guide T cells towards the inflamed skin. When they encounter antigen-presenting cells, 
CD8+ T cells can mature, proliferate, join the blood circulation, return to the affected skin 
where the initiating antigen remains and secrete IFN-γ (65).  
 
Fig. 2.1 Activation of T cells (adapted from Lebwohl, 2003) 
The subsequently accelerated proliferation of keratinocytes decreases the epidermal transit 
time from approximately 23 days in the normal skin to only 3–5 days in psoriasis patients. 
This alters the natural process of the proliferation of keratinocytes in which they just slowly 
travel towards the surface, where they predominate, following their growth at the bottom 
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(basal) layer. The differentiation of keratinocytes is also disturbed because they cannot lose 
their nuclei in a normal manner. Therefore, the 2 main epidermal features of psoriasis are 
formed: scaling (thickened skin) and parakeratosis (abnormal differentiation) (1).  
T-cell cytokines activate epidermal keratinocytes, which can promote angiogenesis (vascular 
proliferation) (68). Keratinocytes, activated T cells and endothelial cells also synthesise 
vascular endothelial growth factor (VEGF), which is likely to be a key factor in angiogenesis 
during psoriasis (69). VEGF and its receptors are overexpressed in human psoriatic lesional 
and non-lesional epidermis. VEGF levels reflect psoriasis activity, severity and joint 
involvement. The typical manifestations of psoriasis, such as vascular changes (increased 
dermal vascularity), epidermis alterations and inflammatory infiltrates can be affected by 
VEGF in vivo. VEGF inhibitors can reverse or inhibit some of these processes (68). 
2.1.4 Histopathological changes 
There are several characteristic changes associated with psoriasis. For example, Lowes et al. 
(2007) stated five features on the histopathological aspect: 
a) Substantial thickening of the epidermis: This is caused by the accelerated proliferation of 
keratinocytes; epidermal rete ridges lengthen to form projections that are long, thin and 
downward-oriented to adapt to the downward undulations of the epidermis. 
b) Differentiation of keratinocytes with regenerative maturation: Keratinocytes switch from 
the normal growth program to regenerative maturation, normally only required during wound 
healing.  
c) Abnormal terminal differentiation of keratinocytes: Terminal differentiation begins in the 
granular layer of the epidermis; however, in the absence of this layer in psoriatic lesions, 
hyperproliferation and abnormal differentiation of keratinocytes results in surface scale 
formation. 
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d) Parakeratosis: Keratinocytes still have cell nuclei after shaping the stratum corneum 
because their differentiation is incomplete. Psoriatic corneocytes (terminally differentiated 
keratinocytes) cannot stack normally, release lipids or adhere effectively, which leads to 
scaling and causes further damage to the protective barrier. 
e) Presence of neutrophils and marked infiltration of mononuclear leukocytes: They are 
found in small foci of the stratum corneum and in the epidermis. In particular, the 
mononuclear leukocytes [T cells and dendritic cells (DCs)] may lengthen, and multiple 
microvessels form in epidermal rete. These vessels greatly dilate, causing the redness 
observed in the psoriatic lesions. Large numbers of numerous lymphocytes and monocytes 
adhere to endothelial cells to be recruited by high endothelial venules (58).  
2.2 Diagnosis 
2.2.1 Clinical features 
In general, psoriasis can be diagnosed on the basis of its clinical features. Illustrations of the 
symptoms and signs and the types of psoriasis can be found in the books by Buxton and 
Morris-Jones (1) and Weller et al (2). The clinical morphology of psoriasis lesions is so 
characteristic that the diagnosis is not difficult. Only in special cases such as psoriatic 
erythroderma, Sèzary syndrome and erythrodermic eczema, a biopsy may be required (11).  
Psoriasis is a papulosquamous issue on the body surface. The lesions can be easily 
distinguished from other papulosquamous diseases such as tinea infections, pityriasis rosea 
and lichen planus. Psoriasis lesions are well delimited, circular red papules or plaques. On 
the basis of the diameter of the raised lesions, the papulosquamous lesions can be categorised 
as scaling papules (<1 cm) and plaques (>1 cm) (3). Plaque psoriasis is the most common 
type, constituting 90% of all the cases. The plaques activate at the edge of lesions and 
surround the fast progressing lesions; the normal skin is visible in the lesion centre (70). 
Some non-coherent scales with dry, grey or silvery–white appearance cover the lesions, and 
shiny erythaema is visible under the scales (3, 71). Removal of the scales can lead to 
26 
pinpoint bleeding (Auspitz sign) (71). In 20% of psoriasis patients, the lesions may appear in 
non-lesional areas after local stimulation or trauma (Koebner phenomenon) (3, 71).  
The lesions are often symmetrically distributed and tend to occur on the scalp, umbilicus, 
lumbosacral area, extensor aspects of elbows and knees and body folds (3, 11). 
Nail abnormalities may occur in psoriasis patients, particularly in PsA (3, 71). These changes 
may evolve from small pits to substantial deformities, including onychodystrophy, which can 
make the entire nail yellow and keratinous (71). 
As a papulosquamous skin disorder, psoriasis varies widely with regard to the manifestation 
of lesions, their form, size, number, location and severity. Small tear-shaped papules can be 
found in guttate psoriasis patients, and pustules may occur in pustular psoriasis patients. 
Erythrodermic psoriasis may manifest itself as generalised erythaema and scaling. From a 
chronic and stable condition, the disease may progress to an acute status, covering wide areas 
and developing serious symptoms (3). 
2.2.2 Diagnosis and assessment tools 
The Committee on Guidelines of Care and the Task Force on Psoriasis of the American 
Academy of Dermatology defined the disease as ‘A chronic skin disease that is classically 
characterised by thickened, red areas of skin covered with silvery scales’ (72). Psoriasis 
Diagnosis and Management of Psoriasis and Psoriatic Arthritis in Adults, a national clinical 
guideline created in Scotland, pointed out that the diagnosis of psoriasis may be easily 
confirmed on the basis of its clinical appearance. As the commonest presentation of the 
disease, psoriasis vulgaris (chronic plaque psoriasis) manifests itself as characteristic grey or 
silvery–white scales and well-delimited shiny red plaques. The lesions are symmetrically 
distributed; they usually affect the scalp and extensor surfaces of limbs, although any part of 
the body surface can be involved. However, scaling rarely occurs on the genital area, in body 
folds or on the palmoplantar skin (4).  
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In general, the severity of psoriasis can be categorised into 3 levels on the basis of the 
affected body surface area (BSA) (73):  
a) Mild psoriasis: less than 5% of the skin area; 
b) Moderate psoriasis: from 5% to 15% of the skin area and 
c) Severe psoriasis: more than 15%–20% of the skin area 
The abovementioned clinical diagnosis may be not very precise or reproducible in terms of 
severity measures (74). The known biomarkers that may trace or predict psoriasis activity, 
such as C-reactive protein, soluble adhesion molecules and soluble cytokine receptors, are 
often not available or are unreliable (70). The use of easily available, practical assessment 
tools could assist in precise evaluation of the condition.  
There are numerous tools for assessing the clinical severity of the disease and its effect on 
the daily quality of life (QoL). The tools for severity assessment are mainly used to establish 
the activity of psoriasis rather than the validity of management, and Psoriasis Area and 
Severity Index (PASI) is the most frequently used measure. The tools for QoL evaluation are 
often applied in the form of a QoL questionnaire, and Dermatology Life Quality Index 
(DLQI) is the most used instrument (4). The correlation between PASI and DLQI is rather 
poor, and DLQI can alter with the improvement of PASI. Both PASI and DLQI are applied 
in clinical practice to characterise the 2 aspects of the disease (3). 
2.2.3 Types of psoriasis 
Psoriasis can be classified into 2 types: common pattern and less common pattern. The 
former includes plaque psoriasis (psoriasis vulgaris), guttate psoriasis, scalp psoriasis, nail 
psoriasis, flexure psoriasis and palm and sole psoriasis, while the latter includes napkin 
psoriasis, acute generalised pustular psoriasis and erythrodermic psoriasis (2). 
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Plaque psoriasis (psoriasis vulgaris: 
Plaque psoriasis, also known as psoriasis vulgaris, is the most frequent type that is diagnosed 
in 90% of the cases (75). In general, this type of psoriasis expresses circular, oval or 
nummular (coin-sized) plaques with well-circumscribed lesions. The lesions may develop 
from some early flat erythaematous macules (less than 1 cm in diameter) and later form 
coalesced plaques (over 1 cm in diameter). Woronoff’s ring (a white blanching ring) may 
appear to be circling the affected sites (3). 
Plaque psoriasis frequently occurs on the trunk, limbs and elbows, particularly on the 
extensor surfaces such as the lower back and extensor surfaces of the knees. This type of 
psoriasis can also appear on flanks and the umbilicus. Lesions of this type are likely to show 
a seborrheic distribution, appearing in areas such as eyebrows, cheeks and nasolabial folds as 
well as on the scalp and scalp line. Breasts or scapular areas are also often involved. In 
comparison with the classical form, these types of lesions are thinner (<0.75 mm) and their 
scales look more ‘waxy’ (75).  
The plaques may gradually evolve into several different forms as follows (3): 
a) Psoriasis gyrata: Most plaques form bent linear patterns. 
b) Annular psoriasis: Circular lesions arise after central clearing.  
c) Psoriasis follicularis: Some tiny plaques with scales appear at the openings of 
pilosebaceous follicles. (See reference 1 & 2 for illustration(s)) 
Guttate psoriasis: 
The term ‘guttate’ is derived from the Greek word gutta that means ‘drop’ (3), which reflects 
the manifestation of guttate psoriasis: numerous tear-shaped small plaques (<1cm) with 
scales (75). In guttate psoriasis, the trunk is typically affected; this type is prevalent among 
children. It often follows an acute infection by group B haemolytic streptococci. The number 
of lesions often increases to 5–10 and sometimes can even reach over 100 (3). The salmon 
pink lesions persist during a 3-month period. They suddenly appear in the first month, 
remain during the second month and finally clear in the third (75). Guttate psoriasis usually 
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appears in children, whereas chronic plaque psoriasis develops in adults. Approximately, 
one-third of guttate psoriasis patients develop a chronic plaque disease later in life (3). 
However, some plaque psoriasis patients develop guttate psoriasis after a streptococcal 
infection (75). (See reference 2 for illustration(s)) 
Scalp psoriasis: 
The scalp is frequently affected, and scalp psoriasis is often the earliest sign of this disease 
(75). The scaling area is often crisscrossed by the normal skin. Sometimes, palpating the 
lesions supplies better evidence than visual examination (2). In this type, the lesions are not 
symmetrical as observed in other types of psoriasis. The lesions rarely overflow the scalp 
line but tend to locate in the posterior auricular area; they vary from localised to diffuse and 
from thick to thin. The hair-bearing skin can also be affected (75). (See reference 1 & 2 for 
illustration(s)) 
Nail psoriasis: 
The nails are affected in approximately 50% of psoriasis patients; they are more frequent in 
PsA patients. There are several types of nail lesions (70): 
a) Pitting: the commonest form that can be seen in oblique light; 
b) Onycholysis: the separation between the nail bed and plate;  
c) Oil spots: orange–yellow stains located in the sub-ungual area and 
d) Dystrophy: phenomenon similar to pitting. (See reference 1 & 2 for illustration(s)) 
Flexure psoriasis: 
In comparison with other types, flexure psoriasis presents as thin lesions with fewer scales 
and more erythaema. The affected areas are the folds in the body surface, such as the axillae, 
infra-mammary region, inguinal folds and gluteal cleft. Physical or biological factors, for 
example, friction or candidiasis, may aggravate the condition (75). (See reference 1 & 2 for 
illustration(s)) 
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Palm and sole psoriasis: 
This type of psoriasis causes yellow, sterile pustules within areas of the erythaema, with 
scaling on the palms and/or soles. Dark brown colouration and scale/crust may develop when 
the pustules become tender and fade (3). Among patients with this psoriasis type, 25% also 
suffer from chronic plaque psoriasis. This type is still categorised as a subtype of psoriasis in 
many specialist textbooks. However, genetic factors involved in this type of psoriasis are 
different from those involved in psoriasis vulgaris. Furthermore, these 2 types have different 
demographics. Plaque psoriasis patients tend to be female (9:1 ratio of female to male 
patients) and smokers, and the condition develops between 30 and 40 or 40 and 50 years of 
age. Therefore, palm and sole psoriasis should be considered to be a comorbidity rather than 
a subtype of psoriasis (70). (See reference 2 for illustration(s)) 
Napkin psoriasis: 
This condition occurs at the napkin (nappy/diaper) area in an infant and provides the first 
clue of psoriatic susceptibility of the baby. In general, this condition is short-lived. However, 
it reveals an increased risk of contracting psoriasis later in life (2). (See reference 1 & 2 for 
illustration(s)) 
Acute generalised pustular psoriasis:  
This type of psoriasis, also known as von Zumbusch psoriasis, is rare; however, it is an 
active and unstable form of the disease. The patients usually have to be hospitalised. The 
condition may be triggered by the withdrawal of systemic or potent topical corticosteroids or 
by infections. The patients have fever and red, painful flare sites with monomorphic and 
sterile pustules that may fuse to form sheets (3). (See reference 1 & 2 for illustration(s)) 
Erythrodermic psoriasis: 
This type of psoriasis is also rare and often occurs suddenly; it can be triggered by several 
factors such as irritation by tar or dithranol, drug eruption or withdrawal of potent 
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external/internal steroids. It often affects most of the body surface, resulting in a fiery red, 
peeling skin. Patients often shiver, and their skin feels hot and uncomfortable (2). It is likely 
that the thermoregulatory function of the skin is affected. The pathological changes can be 
life-threatening because pneumonia or congestive heart failure may develop (3). (See 
reference 1 & 2 for illustration(s)) 
2.2.4 Differential diagnosis: 
In general, cases of classic psoriasis are unlikely to be confused with other diseases. 
However, sometimes, psoriatic symptoms are atypical, and the diagnosis becomes uncertain. 
It may be necessary to apply additional measures to ensure correct diagnosis. A detailed skin 
examination, skin biopsy and other tests may be required for asymptomatic patients and for 
examining disease evolution (76). Differential diagnosis of psoriasis involves the assessment 
of several inflammatory, infectious or neoplastic conditions (75): 
Atopic dermatitis: It appears on the flexural surfaces of the body with ‘weeping’ lesions and 
a type of erythaema but without scales. Patients complain of severe itching and have slight 
nail abnormalities. Their personal and/or family history may support the diagnosis. 
Dyshidrotic eczema: Vesicles may arise at the sides of fingers, toes and webs, with 
tapioca-like fluid. Patients complain of severe itching. 
Nummular eczema: It frequently occurs at distal leg areas. The lesions are small, 
coin-shaped (nummular) or oval. The scaling is less silvery than that in psoriasis.  
Pityriasis rubra pilaris: Its scaly plaques resemble psoriasis. Pityriasis rubra pilaris shows 
acral distribution of ‘islands of sparing’, which are patches of the unaffected skin. Changes 
in the nails appear in narrow bands. This condition also causes characteristic changes in 
follicular orientation and lesion colour. 
Pityriasis rosea: It usually begins with a single ‘herald patch’ lesion on the trunk, which is a 
salmon red plaque approximately 2–10 cm size, followed by smaller patches 1 or 2 weeks 
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later. This disease can last for 2–3 months. With its ‘Christmas tree’ distribution and 
collarette scale, it is easily distinguished from guttate psoriasis. 
Tinea capitis: This is an adenopathy caused by a fungal infection; hair shafts are broken and 
alopecia occurs. 
Tinea corporis/tinea cruris: The lesions are not symmetrical. There is unaffected skin in the 
centre of the lesion; however, the border displays active scaling. 
Tinea paedis: Some forms affect the toe-web spaces, causing chronic scaling, fissuring and 
maceration; other types of this infection may attack the soles and sides of the foot. A 
papulosquamous (‘moccasin-like’) pattern of scaling may develop. 
Tinea unguium: This disease affects toenails without causing pitting. The distribution is not 
symmetrical. 
Candidiasis and genital candidiasis (‘balanitis’): Candida forms peripheral pustules, known 
as ‘satellite’ pustules. Crural areas and finger webs may be affected and appear moist and 
whitish. In genital candidiasis, pustules with erosion and fissures arise on the genitalia. 
Spread erythaema can also be observed. 
Secondary syphilis: The patients have a history of chancre. During 2–6 months after the 
initial infection, the disorder will develop. First, it presents as erythaematous exanthaema, 
followed by a guttate-like papular eruption. Following this, copper-coloured papules develop 
around the trunk and limbs. Finally, the palms and soles are affected. Mucosal lesions and 
condyloma lata commonly appear on the mouth and genitalia. This condition can be 
identified with a treponemal antibody test. 
Squamous cell carcinoma in situ (Bowen’s disease): As observed in psoriasis, separate 
erythaematous plaques are well-circumscribed and covered with scale. The lesions arise on 
the sun-exposed areas such as the ears, scalp, lower lip, upper chest, back and hands. The 
disease can be suspected when a prolonged treatment fails and/or evolves into an invasive 
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disease. Fewer scales and a dull appearance of erythaema can distinguish this condition from 
psoriasis. It can occur on any part of the body, although the lower legs are most commonly 
affected.  
Cutaneous T-cell lymphoma (CTCL): This group of disorders includes mycosis fungoides, 
lymphoma cutis and Sézary syndrome. Erythaematous patches may develop into plaques and 
further into nodules or tumours. Sometimes, erythaematous shapes may be formed. In the 
‘patch’ stage, it is easily confused with psoriasis and is often not identified correctly in 
biopsy specimens. With disease progression, identification may be easier using a series of 
biopsies and some specific techniques such as T-cell receptor gene rearrangement and flow 
cytometry. When topical drug administration has no effect on the isolated psoriasiform 
plaques, this disorder should be suspected. The specific tests should be performed, including 
a complete blood count with a peripheral smear.  
2.2.5 Comorbidities associated with psoriasis  
PsA: This may be an early example of associated diseases in dermatology. In 1818, Alibert 
observed the symptoms and called the disease ‘psoriasis arthritic’ (11). PsA often presents as 
symmetric polyarthritis or asymmetric oligoarthritis (<5 joints), with symmetric polyarthritis 
being the most common. This disease has variants such as distal arthritis, spondyloarthritis 
(sacroilitis and spondylitis) and arthritis mutilans. PsA also includes enthesitis, dactylitis and 
tenosynovitis. Patients whose back pain lasts for more than 3 months should be screened 
using the Assessment of SpondyloArthritis International Society (ASAS) criteria. The 
criteria are age of onset less than 40 years, insidious onset, pain relief by exercise but not by 
resting and occurrence of pain at night. The diagnosis can be reached when at least 4 of these 
5 criteria are fulfilled (4). 
Systemic disorders: The associated conditions may be cardiovascular disease, type 2 diabetes 
mellitus (DM), metabolic syndrome, Crohn’s disease and cancer. Psychological issues such 
as depression may also follow the clinical appearances of psoriasis (70). In particular, severe 
psoriasis or PsA is associated with a high risk of cardiovascular disease and diabetes. The 
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patients should be assessed on the basis of body mass index (BMI), DM screening, blood 
pressure measurement and lipid profile (4). 
2.3 Therapy 
In general, the management of psoriasis includes 4 types of treatment: external/topical 
treatments, phototherapy, systemic medication and biological therapies. While deciding on 
the appropriate management, many physical and psychosocial factors should be taken into 
account. Some of the most important factors are the number of lesions, affected BSA, 
phenotypical characteristics and QoL of the patient (75). Therefore, psoriatic treatment 
should be individualised. This may be subject to the condition, location, impact, comorbidity 
and risk factors of the disease as well as patient compliance with the treatment (6). 
2.3.1 Topical treatment 
Topical treatment is still the most frequently used method of treating most psoriasis patients, 
particularly when the condition is limited. Individual lesions can be treated separately. 
However, this type of management is time-consuming and may cause lack of patient 
compliance. It should be individualised and simplified as far as possible. The applications of 
different preparations such as creams, lotions, foams, sprays, ointments and gels should also 
be considered (6). 
Numerous textbooks and many reviews have been written on the topic. Recommended 
treatments include topical glucocorticoids (GCs), vitamin A derivatives (tazarotene), vitamin 
D derivatives (calcipotriol, calcitriol, paricalcitol and tacalcitol), tar preparations and 
anthralin. The literature in this field also contains many relevant indications and 
contraindications, application instructions and descriptions of side effects (77). 
Topical corticosteroids 
The types of corticosteroids used depend on the location of the affected region. Ointments 
are suitable for thicker skin, such as the skin on the elbows and knees, whereas creams are 
suitable for thinner skin. For the scalp, foams, gels and shampoos are available. In general, 
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corticosteroids can be divided into 4 groups according to their clinical efficacy and 
vasoconstriction subsequence (75):  
Class 1(very potent): ≤600 times more potent than hydrocortisone; 
Class 2 (potent): 100–150 times more potent than hydrocortisone; 
Class 3 (moderate): 2–25 times more potent than hydrocortisone and 
Class 4 (mild): 0.5%–2.5% of the potency of hydrocortisone. 
Because the efficacy of corticosteroids appears to be inversely proportional to their toxicity, 
it is often recommended that they should be applied less than 3 times per day, for up to 2 
consecutive weeks (no more than 50 g a week). Corticosteroids should not be used on the 
face or in flexures. New innovative products have been developed, which can be applied 
only during weekends to minimise complications. The treatment can also be combined with 
non-steroidal medications. After the lesions respond to the initial intervention, the 
medication can be changed to one of the less potent types (6).  
GCs, which are used in the treatment of psoriasis, include prednisone/prednisolone, 
methyl-prednisolone and fluorinated GCs (i.e. dexamethasone and betamethasone). As main 
immunosuppressive and anti-inflammatory drugs, GCs are applied widely and show high 
efficacy. The effect may be associated with genomic (sequential interaction with cytosolic 
GC receptors and the genome) or non-genomic aspects (interaction with cellular membranes). 
The former manner of action is more likely to affect the efficacy. It often involves 
transrepression and transactivation, which inhibit and activate the synthesis of regulatory 
proteins, respectively. Furthermore, transrepression appears more relevant to the 
anti-inflammatory effects because it inhibits the synthesis of proinflammatory cytokines or 
cyclooxygenase. The selective GC receptor agonists (SEGRAs) regulate their efficacies via 
the desired transrepression effect rather the than transactivation activity exerted by 
conventional GCs (78). 
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Vitamin D3 derivatives 
Three Vitamin D3 derivatives are available as the current first-line intervention for plaque 
psoriasis: calcitriol, tacalcitol and calcipotriol. These vitamin D3 derivatives can be used as 
monotherapy but are often combined with topical steroids in ointment, cream or solution. 
The common application frequency is once or twice a day. There are several commonly 
available products, which are safe in if used within a maximum recommended dose (6): 
Table 2.1 Common Vitamin D3 analogues for psoriasis 
Specification Form Weekly maximum recommended dose 
Calcitriol 3 μg/g Ointment 210 g 
Tacalcitol 4 μg/g Ointment 70 g 
Calcipotriol 50 μg/g‡ Cream, ointment, 
Scalp solution 
100 g of cream or ointment, 
60 mL of scalp solution 
Calcipotriol 50 μg/g + 
betamethasone 
dipropionate 0.5 mg/g 
Ointment 100 g 
 ‡Generic name calcipotriene in USA. 
Ortonne et al. have found that calcitriol ointment is superior to calcipotriol ointment in its 
efficacy and is better tolerated on sensitive areas such as the face, hairline, retroauricular 
areas and flexural skin (79). With its once-daily application, tacalcitol is regarded as better 
than calcipotriol (6). However, the efficacy of calcipotriol is slightly higher than that of 
calcitriol or tacalcitol and is comparable with the efficacy of potent topical corticosteroids 
(80).  
In combination therapy, the use of Vitamin D3 analogues can reduce the required dose and 
duration of treatment with other topical drugs, which improves the risk:benefit ratio of 
management. In particular, vitamin D3 analogues in combination with topical corticosteroids 
have shown high efficacy in numerous interventions. This strategy has enabled physicians to 
reduce the frequency of primary topical interventions in plaque psoriasis (e.g. once-daily 
applications) and/or minimised the impact of side effects (6).  
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Vitamin D (calcitriol) can be used to synthesise calcipotriol, tacalcitol and paricalcitol. Their 
biologically active forms act as agonists of the vitamin D receptor (VDR), which can change 
the conformation of VDR and affect gene transcription. This may improve cell 
differentiation, proliferation, immunomodulation and mineral homeostasis (77).  
Calcineurin inhibitors 
Tacrolimus and pimecrolimus are the 2 agents available for treating psoriasis. These drugs, 
with immune-modulating and anti-inflammatory properties, do not cause skin atrophy. They 
can be safely applied to all sensitive skin surfaces, including the head, face, neck, around the 
eyes and intertriginous areas (6). 
Tazarotene 
Tazarotene, a retinoid derived from vitamin A, is used once a day in the management of 
psoriasis vulgaris. It can be applied as a gel or cream. Tazarotene is not very efficacious on 
its own and is often used in combination with other drugs. In comparison with calcipotriol, 
tazarotene appears less effective and causes more local irritation. It should not be used by 
pregnant women as it carries a risk of teratogenicity. For lactating women, its use is 
restricted to localised lesions (6).  
The recommended indication of tazarotene is chronic stable plaque psoriasis that involves no 
more than 20% of the skin surface and appears on the trunk and limbs. It is sparingly used 
only once a day, usually at night, for a period of up to 12 weeks. Preparations of 0.05% and 
0.2% tazarotene are available. If irritation arises, only the weaker form should be used; if the 
problem still persists, it should be applied every 2 days in combination with a topical steroid. 
Tazarotene can control emissions, induration, scaling and redness of the lesions. Its efficacy 
is associated with its selective affinity for retinoic acid receptors (RAR) that affect 
keratinocyte proliferation, differentiation and infiltration of dermal inflammatory cells (2). 
Coal tar and dithranol (anthralin)  
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Coal tar and dithranol (anthralin) have been used in the management of psoriasis for a long 
time. In 1921, Goeckerman introduced the combined treatment using tar and phototherapy. 
In 1948, Ingram introduced another treatment using dithranol and phototherapy. Both the 
drugs are available in a series of different vehicles as ointments, pastes, shampoos and 
solutions. Because dithranol often stains clothes and irritates the skin, it is only applied for a 
short time (≤1 h) and then removed. This is called a ‘short-contact’ treatment. Although tar 
preparations in shampoo have been used for scalp problems, few studies have reported 
long-term remissions. Therefore, these treatments do not seem very competitive, particularly 
after the launch of vitamin D3 derivatives. Vitamin D3 derivatives show a greater efficacy 
and lower irritation incidence than coal tar and dithranol treatment (2). 
2.3.2 Phototherapy and photochemotherapy 
Phototherapy and photochemotherapy use ultraviolet light at 200–400 nm. The treatment can 
be categorised into 3 types: 
Ultraviolet light C (200–290 nm): it has germicidal properties, 
Ultraviolet light B (290–320 nm): this wavelength range is used most often in the 
management of psoriasis, particularly its 311–313 nm (narrowband UVB) variant, which is 
most effective, and 
Ultraviolet light A (320–400 nm): also called UVA, used for psoriasis in combination with 
photosensitisers such as methoxsalen (8-methoxypsoralen) (75).  
Radiophysical effects and therapeutic mechanisms 
The efficacy of UV irradiation in clearing psoriasis depends on the wavelength of the light 
used during this treatment. The most effective wavelength seems to be 304–313 nm, the 
UVB range. Shorter wavelengths (less than 300 nm) are associated with more side effects 
such as erythaema and burns. Therefore, the minimal erythaema dose (MED), defined as the 
threshold dose that may produce burns, should be referred to when calculating the daily dose 
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of UV. In principle, daily MED becomes the customary dosage in the treatment of psoriasis. 
The most effective lamps are UVB lamps with a strict UVC filter and UVA lamps. Phillips 
UV-B TL01 lamp (Philips, Germany) is the preferred instrument for treating psoriasis (81). 
UV irradiation can supress lymphoproliferation and the activity of peripheral natural killer 
cells. It also has a direct effect on cytokine production in both Th1 and Th2 T-cell 
populations. UV irradiation can affect transcription factor binding to DNA. Cis-urocanic acid, 
formed after UV-B exposure, has been implicated in regulating the activity of epidermal 
antigen-presenting cells. The suppression of cell-mediated immune function has been shown 
to be advantageous in treating psoriasis (82). UV radiation has both immediate and delayed 
effects. The immediate effects include the damage of cell membranes and DNA, induction of 
cytoplasmic transcription factors and isomerisation of chromophores, which result in 
substantial cytopathic changes, growth arrest and/or apoptosis. The delayed effects cause 
alterations in the psoriasis microarchitecture, involving immune response based on Th-1 
(81). 
Phototherapy (broadband and narrowband UVB) 
Although broadband UVB sources were the first to be introduced in the management of 
psoriasis, they are not much used in current practice. They are less effective than narrowband 
UVB or psoralen and UVA (PUVA). Broadband UVB treatment exposes patients to 
substantial doses of low wavelength spectra (<300 nm). This results in a higher risk of 
non-melanoma skin cancer than that caused by the combination therapy with UVB of 311 
nm. The dose starts at 0.7 of the patient’s individual MED and increases by 20% of MED per 
session. The frequency of weekly sessions is set between 3 and 5. Narrowband UVB has 
better efficacy than broadband UVB and causes fewer side effects. Consequently, the use of 
broadband UVB has been recently discouraged, and narrowband treatment is now preferred. 
(81).  
The traditional broadband UVA treatment has been almost replaced by narrowband UVB 
intervention. Narrowband UVB irradiation was first successfully applied in Europe using 
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Phillips TL01 lamp. UVB-311 nm phototherapy has long been regarded as an appropriate 
approach because of its high tolerance and acceptable safety. However, there is no single 
optimal irradiation solution. Regimens can vary depending on the starting dose, irradiation 
frequency and dose increments. The starting dose should be individually calculated taking 
into account the allowed MED. Doses of 0.5–1 of MED are recommended, and 0.7 of MED 
appears to be the most frequently used. Normally, it is necessary to conduct 3 sessions per 
week. It is not clear whether more than 3 sessions per week would provide better results. 
With regard to the increment scheme, it is important to limit the damage to only a mild 
perceptible erythaema with minimal burns. Various increment schemes have been proposed, 
e.g. 10%–20% per day or 30%–40% per week. As an alternative, 0.01 to 0.05 J·cm−2·d−1 
increment has been set. It would be useful to achieve a global consensus on this issue (81). 
At present, UVB plus tazarotene, vitamin D3 derivatives or systemic agents are the most 
frequently used combined phototherapies. Interestingly, a 25-year follow-up study using UV 
radiation plus topical crude coal tar conducted at the Mayo Clinic (Rochester, Minnesota, US) 
showed the incidence of skin cancer to be similar to the expected incidence (83). 
PUVA photochemotherapy 
PUVA photochemotherapy is a therapy combining UVA radiation with psoralen. First, 
patients take a photosensitive drug, 8-methoxypsoralen or 5-methoxypsoralen, in the oral or 
topical form. Then, they are exposed to UVA light in the wavelength range from 320 nm to 
400 nm (6, 69).  
Oral PUVA therapy should be continued until the lesions become imperceptible and scaling 
and intrinsic erythaema disappear. No further maintenance therapy is required. Psoralen can 
cause the accumulation of insoluble proteins on the lens, which increases the risks of 
cataracts and retinal damage. Eye protection is necessary during this therapy and for at least 
12 h after irradiation (81). Because it carries a cumulative risk of cutaneous malignancy, 
PUVA has been limited to 150 applications in a lifetime. The increased risk of skin cancer 
can persist for at least 15 years after the treatment and becomes greater after using 
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ciclosporin (69). A topical application variant of PUVA photochemotherapy, bath PUVA 
therapy, has many benefits in comparison with the oral administration method. It has a lower 
gastrointestinal and hepatic impact and does not require eye protection. Moreover, oral 
PUVA therapy is not more effective than bath PUVA therapy (81). 
In summary, PUVA therapy can be used for most psoriasis types and achieves a complete or 
partial remission in 70%–90% of cases. The efficacy of PUVA therapy can be increased by 
the application of topical remedies. Combined PUVA therapy, e.g. with added retinoid 
treatment, provides even better results than either of the 2 abovementioned interventions. 
However, PUVA therapy is not suitable for patients with some specific conditions (69): 
1) Patients with photosensitivity, skin cancer or aphakia; 
2) patients undergoing immunosuppressive intervention; 
3) women during pregnancy or breastfeeding; and  
4) children.  
2.3.3 Systemic and biological treatments 
In 1971, methotrexate (MTX) was approved to be launched in the US. Since then, traditional 
systemic therapy has been used for psoriasis and has become the primary treatment for 
moderate-to-severe conditions. It is also used for patients not responding to topical 
treatments or phototherapy. It is also suitable for patients with low QoL or physical 
restrictions. To decide on a treatment, it is necessary to evaluate each patient carefully. The 
availability of drugs and individual issues such as the HIV status and disease history (e.g. 
hepatitis, systemic cancers) should be examined. If traditional treatments are not available or 
badly tolerated, biological therapy can be offered as an alternative scheme (6). Biological 
therapies can be categorised into into T-cell-targeted treatments (alefacept, efalizumab) and 
TNF-α antagonist treatments (infliximab, etanercept and adalimumab). Traditional systemic 
agents include MTX, ciclosporin, acitretin and fumaric acid esters (69).  
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MTX 
MTX is available for psoriasis patients in the US and Europe. Its main mechanism of action 
is immunosuppression by specific modulation of cytokine production by T cells. The dose 
should be as low as possible and individually adjusted to minimise the toxicity during 
therapy (84). 
In general, the starting dose is 2.5–25 mg in a single weekly oral, intramuscular or 
intravenous administration for a normal-weight adult patient. The dose can be gradually 
increased until the symptoms are controlled. The total dose should not exceed 30 mg per 
week (84). To ensure high efficacy, bioavailability and low hepatic toxicity, the oral method 
is not recommended for the first 6 months. Instead, intramuscular or subcutaneous 
administration should be used. Tablets may be used later if the treatment is effective and the 
patient adapts to the regimen well. One weekly dose of tablets can cause problems such as 
low absorption and digestive disturbances; the tablets are usually administered in 2 or 3 
separate doses. For example, the tablets could be administered at 8 pm on Friday, 8 am on 
Saturday and 8 pm on Saturday. Folic acid (5 mg q.n.) can also effectively improve MTX 
tolerance (85). Because hepatic toxicity is a primary issue in MTX treatment, liver biopsy 
should be considered before treatment. Patients on a long-term course of MTX should also 
be considered for biopsy if their liver function becomes abnormal or the total cumulative 
dose reaches 1.5 g. MTX can interact with some other drugs such as systemic steroids, 
trimethoprim/sulphonamides and non-steroidal anti-inflammatories. These drugs should not 
be prescribed with MTX (86).  
MTX provides an affordable, gold-standard regimen for recalcitrant conditions. It is still 
widely used even after the introduction of new regimens (6). 
Ciclosporin (cyclosporin) 
In 1979, ciclosporin (cyclosporin) was first applied for treating psoriasis. Today, it has 
become the first choice among systemic treatments; however, it is often used only for short 
periods (≤3 months or 4 months). The main limitation of ciclosporin is its renal toxicity; it 
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can also cause hypertension (85). Therefore, full renal function tests should be considered 
before the treatment. A series of tests should be conducted: blood pressure, serum creatinine, 
urea and 2-h creatinine clearance. The first 3 items need to be tested monthly and the last 
item needs be measured every 3–6 months. When creatinine is above 25% of the baseline 
data and/or the diastolic blood pressure is higher than 95 mm Hg, ciclosporin administration 
should be reduced or discontinued (86). The normal starting oral dose is 2.5 mg/kg per day, 
which can be administered as 1.25 mg/kg b.i.d. The dose is gradually increased by 0.5–1.0 
mg/kg per day every 2–4 weeks. A dose of 5 mg/kg per day is regarded as the maximum. 
The duration of a short course is usually 12 weeks. For young patients, the duration of 
treatment should not exceed 4 months and the dose should gradually be reduced during the 
last 2 months (87, 88). 
Retinoids 
Retinoids are derivatives of vitamin A; etretinate and acitretin are the 2 main substances of 
this type developed for medical purposes (87). At present, only acitretin is licensed for use in 
the US and Europe. Its mechanism of action has not been not confirmed till date; it may be 
associated with immunosuppression, anti-inflammatory effects and modulation of 
proliferation and differentiation in the epidermis (84).  
The initial dose is often 10 mg/day, administered with meals. The daily dose can be 
increased every 2 or 4 weeks, till the tolerated dose peaks. When the expected tolerance 
under the maximum dose lasts for 3 months, efficacy can be evaluated. The adjustable dose 
resulting in a lack of efficacy or intolerance is often as low as 5 mg (87). The main 
disadvantage of retinoids is their teratogeny and long-term accumulation in the body. 
Women should not become pregnant before 2 years after discontinuation of the drug (86).  
Fumaric acid esters 
This treatment has been frequently applied in Germany since 1995. It is a combination 
therapy using dimethylfumarate and monoethylfumarate. The mechanism of action may be 
associated with the suppression of hyperproliferation of epidermal cells and T-cell activity. 
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The initial daily dose is usually 1 or 2 tablets containing 30 mg of dimethylfumarate and 75 
mg of monoethylfumarate. The dose can be raised to a maximum of 6 tablets containing 120 
mg of dimethylfumarate and 95 mg of monoethylfumarate, divided into 2 daily doses. The 
use of these drugs in monotherapy of a 3-month duration or combination therapy with topical 
drugs can result in significant improvements (75). 
Infliximab 
Infliximab is a monoclonal antibody against TNF-α. This biological agent can achieve 
significant improvements in the condition of patients (89). Infliximab is often administered 
by an intravenous drip, usually of least 2-h duration. The dose varies depending on the 
condition treated. No optimised solution, frequency or dose of infusions has been established 
till date. However, a recommended starting dose is 5 mg/kg on weeks 0, 2 and 6; this is 
repeated after 8–12-week intervals (90). Once the efficacy of infliximab reduces, the 
frequency of infusions should be increased (89). 
Etanercept 
Etanercept is a recombinant TNF-α receptor fusion protein. It targets human IgG1 via its 2 
extracellular ligand-binding domains. The drug has been approved for treating rheumatoid 
arthritis; its applications in PsA have been fairly successful. Among PsA patients, 87% of 
cases respond well to etanercept. Approximately 50%–70% of patients improve their PASI 
after etanercept treatment; it has been reported that 56% of patients using etanercept show a 
75% reduction in the PASI score after a 24-week course (65). It is subcutaneously infused, 
and the recommended starting dose is 50 mg per week for 12 weeks, followed by the same 
maintenance dosing. This regime offers the optimal balance between cost and effectiveness 
for 1-year therapy. Combining it with NB-UVB, acitretin or MTX may strengthen its 
therapeutic action. If etanercept has no or little effect, it can be replaced with infliximab, 
adalimumab or efalizumab (89). 
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Adalimumab 
Adalimumab is a monoclonal antibody against TNF-α. It can be subcutaneously 
administered by patients themselves. The dose is 40 mg per fortnight. It has been reported 
that 54% of patients using adalimumab for 24 weeks can effectively alleviate their condition 
on joints and skin, achieving PASI 75. This efficacy ranges between that of infliximab and 
etanercept. After 60-week therapy, 58% of patients achieve PASI 75. The treatment can be 
combined with other anti-TNF-α drugs. This treatment can prevent radiographic signs of 
joint destruction or arrest the development of disability. Adalimumab is a good option for 
psoriasis patients, resulting in considerable improvements in their QoL (6). 
Alefacept 
Alefacept is a fusion protein targeting IgG1. With its Fc receptors, alefacept can trigger the 
apoptosis of CD45RO+ T cells by affecting macrophages and natural killer (NK) cells. CD2 
expression in CD45RO+ memory T cells is associated with the psoriasis status. Alefacept 
suppresses T-cell activation via CD2. Interestingly, neither primary nor acquired immune 
responses in the patients using alefacept are likely to be affected. A weekly dose, 
administered by intravenous boluses for 12 weeks, should be 0.025–0.150 mg/kg. A dose of 
0.075–0.15 mg/kg can cause 53% reduction in PASI scores. The drug can also be 
administered by intramuscular injection at a dose of 15 mg/week for 12 weeks. After 
subsequent 12-week observation, a second 12-week therapy can be implemented. Psoriasis 
responds well to alefacept administered using either of the 2 methods (65). 
Efalizumab 
Efalizumab is used for moderate-to-severe conditions. It is a recombinant humanised 
monoclonal IgG1 antibody that can block T-cell-dependent functions; it suppresses the 
responses mediated by T cells. Efalizumab can effectively control T-cell diapaedesis towards 
the lesional skin. PASI 75 can be achieved by 29.5% of patients using efalizumab for 12 
weeks. Furthermore, a 75% reduction in the PASI score can be reached after a 27-month 
course of weekly injections. Efalizumab is effective in the treatment of plaque psoriasis and 
the palmoplantar form of psoriasis (75).
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Chapter 3: Traditional Chinese Medicine for psoriasis 
3.1 Introduction 
Psoriasis has been treated in China since ancient times and the accumulated clinical 
experiences of generations of practitioners have been recorded and systematized into the 
approaches to the clinical management of psoriasis now used in traditional Chinese medicine. 
Chinese Herbal Medicine (CHM) is one of the most frequent types of intervention and has 
played a critical role in the management of psoriasis since ancient times. This chapter 
examines the history of Chinese medicine and the treatment of psoriasis, the theories 
regarding the disease, and the schools of thought in its treatment. This is followed by a 
discussion of the etiology, pathology, diagnosis, and treatment of psoriasis in contemporary 
traditional Chinese medicine.  
3.2 Background of Chinese Herbal Medicine (CHM) 
Chinese Medicine (CM) can be traced back as early as around 5,000 years ago. 
Archaeological findings during the 1970s suggest that medical stone needles were made as 
early as Neolithic period (91). Chinese Herbal Medicine (CHM), one form of the most 
frequent and important CM treatments, can be traced to the Xiayu Period (c. 2100-1600 BC 
夏禹时代 ) when medicinal liquors and fermented preparations were applied. In the 
Shangtang Period (c. 1600-1100 BC 商汤时期), Yi Yin is reputed to have invented 
decoctions and wrote the Tang Ye Jing (汤液经), the first monograph on formulae and 
preparation (92).  
The first medical classic in China, The Yellow Emperor’s Classic of Internal Medicine 
(Huang Di Nei Jing, 黄帝内经) which probably originated in the Warring States Period (c. 
770-221 BC) discussed the use of acupuncture and the principles for the organisation of 
herbal formula (92). The Formulae for 52 diseases (Wu Shi Er Bing Fang, 五十二病方) 
which was discovered in the Ma Wang Dui Tomb which was sealed in 168 BC during the 
Western Han dynasty (206-24 BC)  is the oldest existing medical book that provides herbal 
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treatments for a wide variety of diseases (93). Shennong’s Classic of Materia Medica (Shen 
Nong Ben Cao Jing, 神农本草经) completed in Eastern Han Period (东汉) (25 - 220 AD) is 
the earliest surviving compendium of materia medica. Based on the individual herb’s effect 
and toxicity, it divided Chinese medicinal herbs into three grades: high, medium and low. It 
not only founded the basis of the classification of herbal medicines but also developed the 
medical thought of The Yellow Emperor’s Classic of Internal Medicine (Huang Di Nei Jing, 
黄帝内经). Furthermore, both these classics in combination with The Classic of Medical 
Problems (Nan Jing, 难经) established TCM’s theoretical system and provided a standard 
for clinical practice (93, 94).  
Zhang Zhongjing, a renowned TCM expert in Eastern Han Period (东汉), established a 
methods for the composition and application of multi-ingredient herbal formulae in his 
Treatise on Cold Damage and Miscellaneous Diseases (Shang Han Za Bing Lun, 伤寒杂病
论) (93). Numerous topical preparations and their applications where described by Ge Hong 
(281-341 AD) in his Handbook of Prescriptions for Emergencies (Zhou Hou Bei Ji Fang, 肘
后备急方). Lei Xiao (420-477 AD) wrote the first work on the methods for the preparation 
and processing of medicinal materials: Lei’s Treatise on Processing of Drugs (Lei Gong Pao 
Zhi Lun, 雷公炮炙论) (95).  
In 659 AD, the Newly Revised Materia Medica (Xin Xiu Ben Cao, 新修本草) which was 
edited by officials of Tang Dynasty Government was issued. It included 850 herbs in 54 
volumes, and has been regarded as the first official pharmacopoeia in the world. In the same 
era, Sun Simiao wrote two large compendia on medical theory and practice: Essential 
Prescriptions Worth a Thousand Gold for Emergencies (Bei Ji Qian Jing Yao Fang, 备急千
金要方) and Supplement to the Essential Prescriptions Worth a Thousand Gold (Qian Jing 
Yi Fang, 千金翼方), which included about 5,300 and 2,000 formulae respectively. During 
the Song dynasty (960-1279), there were major developments in CHM (92, 93). In 1076 AD, 
the Song government established the first manufacturer of standardised medicines whose 
roles including manufacture, preparation, audit and inspection of medicinal materials. Its 
compendium of standard prepared formulae, Prescriptions from the Great Peace Imperial 
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Grace Pharmacy (Tai Ping Hui Min He Ji Ju Fang, 太平惠民和剂局方), was the first 
Chinese pharmaceutical preparation standard (96).  
Compendia of Chinese medicinal formulae expanded greatly during the Ming (1368-1644) 
and Qing (1644-1911) Dynasties. Prescriptions for Universal Relief (Pu Ji Fang, 普济方) 
was the largest of the TCM formula treatises with 61,739 formulae including topical 
preparations such as ointments, pills and medicinal liquors. The most well-known book of 
this period is the Compendium of Materia Medica (Ben Cao Gang Mu, 本草纲目) which 
was written by Li Shizhen in the Ming Dynasty. It systematically reviewed the study of 
Materia Medica up until the 16th century and included 1,892 herbs, about 1,300 formulae and 
over 1,100 illustrations. It is widely recognized as a masterpiece of pharmacology with its 
great contributions to the study of formulae and pharmaceutical preparation. In the Qing 
dynasty, Zhao Xuemin’s Supplement to the Compendium of Materia Medica (Ben Cao Gang 
Mu Shi Yi, 本草纲目拾遗) supplemented the previous work with an additional 716 new 
herbs (92, 93).  
After Western Medicine (WM) was introduced into China in the early 19th century, many 
traditional medical practices were gradually replaced by WM as contemporary hospitals that 
offered surgery and other WM services increasingly became part of the Chinese healthcare 
mainstream. During this time there were efforts to combine TCM and WM. For example, 
Zhang Xichun (1860-1933) wrote Integrating Chinese and Western Medicine (Yi Xue Zhong 
Zhong Can Xi Lu, 医学衷中参西录) which was published in 1918 is thought to be the first 
treatise on this topic. Efforts to modernise TCM including CHM have progressed 
significantly in the last 60 years. Since the 1963 version of the Chinese Pharmacopoeia (中
国药典), the uses of Chinese traditional medicines and their methods of preparation have 
been regularly collected and supplemented. These developments have been further shaped 
into statutory forms as regulatory acts and codes, for example the Drug Administration Act of 
the People's Republic of China (中华人民共和国药品管理法), New Drug Examination 
Code (新药审批办法), and Good Agricultural Practice of Medical Plants and Animals (中
药材生产质量管理规范 ). Through these processes CHM has been developed as a 
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standardised, legally regulated medical system (92, 97).  
Since late 19th century, TCM including CHM has spread widely in the world. Especially 
since the 1970s, it has been gradually acknowledged by more clinicians and researchers as 
the body of research evidence grows and drug discoveries such as in the field of malaria 
receive international attention. 
3.3 The TCM terms for psoriasis 
In contemporary TCM psoriasis is known as Yin xie bing (银屑病), Niu pi xuan (牛皮癣) or 
Bai Bi (白疕). However, in the traditional literature this disease has been known under a 
variety of other terms, each of which may also have included other diseases, including: Gan 
xuan (干癣 ‘dry scale’), She shi (蛇虱 ‘snake lesion’), Bai ke chuang (白壳疮 ‘white shell 
sore’), Song pi xuan (松皮癣 ‘pine bark scale’), Ying qian feng (银钱疯 ‘silver coin 
lesion’). The features and descriptions of these disorders are summarised below. 
3.3.1 Gan xuan (干癣) 
The disorder was first documented by Chao Yuanfang in his Treatise on the Pathogenesis 
and Manifestations of All Diseases (Zhu Bin Yuan Hou Lun, 诸病源候论) written in the Sui 
Dynasty (581-618 AD). It presented as white scales which after scratching the skin became 
dry and itchy. This disease resulted from Wind, Cold and Damp which led to disharmony of 
qi and blood. Complete Record of Sacred Benevolence (Sheng Ji Zong Lu, 圣济总录) of the 
Song dynasty included a similar description (98). In Prescriptions for Universal Relief (Pu Ji 
Fang普济方) of the Ming dynasty, the pathogens in Gan xuan were mainly thought to be 
Wind together with Damp and Heat. It was also referred to by the Golden Mirror of 
Medicine (Yi Zong Jin Jian, 医宗金鉴), which summarized the condition as basically due to 
Wind, Damp and Heat (99). 
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3.3.2 She shi (蛇虱) 
In the Ming Dynasty, Wang Kentang included the term She shi in his Standards of 
Pattern/Syndrome Identification and Treatment (Zheng Zhi Zhun Sheng, 证治准绳). It had 
white scales after being scratched which were painless but itchy (99).  
3.3.3 Bai bi (白疕) 
Bai bi (白疕) was firstly described in Complete Compendium of Surgery (Wai Ke Da Cheng, 
外科大成) by Qi Kun in the Qing dynasty. It has become the current standard TCM term for 
psoriasis. It was caused by Wind invading the skin and the blood being too dry to nourish the 
skin (100). It was described as like a scab that was white and itching, and could develop to 
white scales after being scratched. Also it was often called She shi (蛇虱) (99). 
3.3.4 Bai ke chuang (白壳疮) 
In the Ming Dynasty, Sheng Douyuan included this disorder in his Disclosure of External 
Medicine Mystique (Wai Ke Qi Xuan, 外科启玄). It spread over the full body and was white, 
painless and itching. The Dong Tian Ao Zhi (洞天奥旨) also described its clinical 
manifestation as being mainly on both upper limbs, or on the trunk when it called Wan xuan 
(Stubborn psoriasis, 顽癣) (99). 
3.3.5 Song pi xuan (松皮癣) 
This disorder was so named as the scales frequently itched and showed red/white spots 
mixed like in pine bark. There were similar descriptions of these symptoms in Golden 
Mirror of Medicine (Yi Zong Jin Jian, 医宗金鉴), In this book, the condition was thought to 
be mostly related to Wind and also partially to Dry blood (98). Both Song pi xuan and Bai bi 
are regarded as the disease descriptions most similar to psoriasis by most contemporary 
TCM practitioners (100). 
3.3.6 Ying qian feng (银钱疯) 
The name was recorded in Completed Works at Feng Meng (Feng Meng Quan Shu, 疯门全
书) by Xiao Xiaoting in the Qing Dynasty. The lesion was like a coin, red on the inside while 
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white on the outside. If you pierce it there is no blood but it is white like silver, first it is on 
the body and then on the face (99). 
3.4 The TCM etiology of psoriasis 
In terms of the etiology of psoriasis in TCM thought, there has been a progressive change in 
the way the disease has been viewed. Prior to the Sui-Tang period, the emphasis was on 
external pathogens such as Wind, Cold, Dampness, Heat, etc. (see Maciocia (101) for an 
explanation of the meanings of these terms in TCM). During the Ming-Qing era, internal 
damage was considered to be an important aspect of the condition, and there was a focus on 
the involvement of blood (xue fen). The following is a brief outline of the etiology of 
psoriasis according to TCM. 
3.4.1 External pathogens 
Wind-dampness located at the level of the skin and flesh can induce psoriasis. In addition, 
Cold-dampness can stagnate the flow of qi and blood, which can result in the disease. This 
viewpoint that these external pathogens contributed to psoriasis was stated in Treatise on the 
Pathogenesis and Manifestations of All Diseases (Zhu Bin Yuan Hou Lun, 诸病源候论), 
and was followed by many medical books in the Tang dynasty and Song dynasty (99, 100). 
Since Fire (Heat) came to be regarded as the primary pathogen during the Jin dynasty and 
Yuan dynasty (1115-1368), this pathogen was thought to relate to psoriasis. In this view, 
Heat toxin invading the lung can result in the disease. This point was made in Yan Yong He’s 
Comprehensive Medical Book (Yan Yong He Yi Xue Quan Shu, 严用和医学全书) (100).  
3.4.2 Internal damage 
Disorders of blood such as Blood-dryness and Blood-heat can facilitate the invasion of 
external pathogens such as wind pathogen into the body. The lung channel and spleen 
channel adversely affected by Blood-dryness and Wind-toxin, and this can eventually lead to 
psoriasis. Orthodox Manual of External Medicine (Wai Ke Zheng Zong, 外科正宗) was the 
first text to state that psoriasis is closely related to disorders of the lung channel and spleen 
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channel (100).  
Long-term Blood-deficiency can induce internal wind which when combined with external 
dryness adversely impacts the nourishment of the skin and flesh. As a result, psoriasis could 
occur in the coming autumn. This school of thought was presented in Complete Works of 
Pattern/Syndrome Identification and Treatment (Wai Ke Zheng Zhi Quan Shu, 外科证治全
书) (99).  
In summary, the main external pathogen is Wind, which together with the pathogens of Cold, 
Dampness, Dryness and Fire toxin can result in psoriasis. In general, psoriasis is closely 
related to the condition of the blood. Blood-dryness, Blood-heat, and Blood-deficiency form 
the basic underlying causes of psoriasis. Blood-heat or Blood-dryness may lead to 
Blood-stasis. Blood-stasis is a condition that usually lingers inside the body for long term, 
and this is the main factor that leads to the protracted nature of psoriasis (99).  
3.5 The TCM physiology and pathology of psoriasis  
In the physiology and pathology of psoriasis, the functions of the internal organs as well as 
the regulation of qi and blood are involved. In short, psoriasis mainly depends on the 
physical functions of the lung, heart, liver and blood. 
3.5.1 The physiology and pathology of lung in TCM 
According to the concept that the ‘lung regulates the skin and (body) hair’, the skin is closely 
related to the lung. The essence of water and food is distributed to the body by the lung and 
this essence nourishes the skin and (body) hair to keep it shiny. In addition, the Defense qi 
(wei qi) is also diffused outward to the skin by the lung. Defense qi can fulfill the three 
physical functions: skin warming, helping the skin prevent the invasion of external 
pathogens, and controlling the opening and closing of the pores. When there is lung 
deficiency and non-diffusion of defense qi, external pathogens easily invade the body. When 
the lung channel is affected, there can be wheals, papules, erythema, scaly dry skin, itching, 
dry nose and throat, or dry cough without phlegm (102).  
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3.5.2 Physiology and pathology of heart in TCM 
Fire and Heat can induce all pain, itch, sores and ulcers. The heart regulates Fire, so the 
above conditions are related to the heart. When there is Heat in the heart the colour of the 
network vessels (i.e. fine blood vessels) changes to red. Also wind can enter the network 
vessels, and as a result there is erythema. In addition, when there is Heat in the blood this 
induces Wind which intensifies leading to Dryness and the production of the white scales 
(103). 
3.5.3 Physiology and pathology of liver in TCM 
Liver regulates free coursing of the qi and the storing of the blood. When its function of free 
coursing is normal, there is fluent movement of qi and blood as well as normal emotional 
states. However, when there is abnormal emotion without free coursing, this may lead to an 
abnormal qi dynamic. When liver fails in its free coursing function Fire can be generated. 
Lesions can be induced or aggravated when fire it produced in this way. In addition, Lung 
yin can be impacted by the Fire reducing fluid, which results in a dry throat. Liver fire can 
lead to dysfunction of the lung defense system producing abnormal opening and closing of 
the pores. Therefore so psoriasis patients become prone to catching colds. Furthermore, Cold 
can also inhibit the liver function of free coursing. Therefore, upper respiratory tract 
infections and psychological factors constitute the main inducements to relapses or 
aggravations in psoriasis (104). 
3.5.4 Physiology and pathology of blood in TCM 
The skin is an important organ in maintaining the close relationship between the flow of qi 
and blood throughout the body. Also, the growth and metabolism of the skin depend on the 
function of qi, blood, and body fluids (jin ye) (102). For psoriasis, TCM considers that the 
principal factor is blood while the secondary aspects are Wind, Heat and Dryness. In general, 
this disease starts as Blood heat which is followed by Blood deficiency, then Blood dryness 
and Blood cold. Blood toxin appears when there are abnormal developments of the disease. 
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Blood stasis is present throughout the entire progress. Therefore, the methods of Quickening 
the blood and Dispelling stasis are applied in the all the types of psoriasis (105). 
3.5.5 The pathogenesis of psoriasis in TCM  
Chinese medicine considers psoriasis to be mainly induced by Blood heat. This may manifest 
in a variety of ways: Constitutional Blood heat combined with external pathogens such as 
wind heat or wind cold; Long-term-stagnation heat induced by disturbed emotional states 
plus stagnant qi; Stagnated heat due to qi dysfunction and spleen-stomach disharmony from 
excessive intake of stimulating foods; or Exuberant Heat stirring up wind resulting from 
Heat pathogens congesting the Construction-defense (ying wei) system.  
After the disease has lasted for a long time, the Blood heat gradually lessens but the 
condition of the blood is impaired. This leads to more severe Blood-stasis and to 
wind-dryness. This condition can also be induced by Blood deficiency and the skin losing 
nutrition as can occur in some gynaecological disorders. When there is Exuberant fire toxin 
and qi and blood are both ablaze as a result of Heat toxin not being resolved, severe 
symptoms such as erythema and desquamation may occur all over the body (106).  
3.6 The TCM diagnosis of psoriasis  
3.6.1 Clinical symptoms and syndromes in TCM  
In psoriasis, the presenting symptoms are various. Yu et al 2013, analysed 369 published 
papers on case reports, and collected 598 symptoms which were classified into 226 
standardized symptoms. These were in the following four clusters: skin lesions, systemic 
symptoms (excluding tongue and blood vessels), tongue appearance and pulse manifestation. 
The highly frequent symptoms (>60%) were in the first two clusters with skin lesion forming 
the most frequent cluster (38.68%). They reported that Blood heat and Fluids insufficiency 
constituted the main pathogenic features of psoriasis (107): 
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Skin lesions: Of 35 symptoms, 5 symptoms appeared frequently (frequency ≥ 100) and 15 
symptoms appeared commonly (10 ≤ frequency < 100). The frequent symptoms included: 
erythema, scale, itch, infiltration hypertrophy and blood spots. The first two symptoms were 
the most highly frequent and appeared in over 50% of the skin lesions. Erythema included 
bright red lesions, dark red lesion, newly-appearing lesions with expansion of existing lesion 
area, light red skin, guttate lesions, refractory lesions, plaque lesions, rapidly-aggravating 
lesions, and squamiform lesions. The scales included thick scales, many scales, caduceus 
scales, tightly-adhesive scales and silvery scales. 
Systemic symptoms (excluding tongue and blood vessels): These involved 104 symptoms 
that related to the skin, consciousness, appearance, taste, sleep, temperature, pain, sweating, 
excretion, and reproduction. 8 symptoms frequently appeared (frequency ≥ 100) and 33 
appeared commonly (10 ≤ frequency < 100). The eight symptoms were dark urine, dry 
mouth, upset feeling, dry excretion, thirstiness, constipation, irritability, dry throat, and dry 
skin.   
Tongue appearance: This aspect included the tongue color, tongue shape, tongue condition, 
tongue coating (coating color and coating nature), etc. Eleven features frequently occurred 
(frequency ≥ 100): red tongue, yellow tongue fur, thin tongue fur, white tongue fur, dark 
tongue, petechial tongue, greasy tongue fur, scanty tongue fur, purple tongue, and pale 
tongue.  
Pulse manifestation: seven kinds of pulse frequently occurred (frequency ≥ 100): fine pulse, 
rapid pulse, string-like pulse, slippery pulse, sunken pulse, moderate pulse, and rough pulse 
(107). 
3.6.2 The TCM syndromes seen in psoriasis 
The TCM syndromes that manifest in psoriasis are various. There are more than 50 different 
syndromes described for psoriasis. These can be broadly divided into syndromes based on 
the characteristics of the disease and syndromes based on the method of syndrome 
differentiation used in TCM. In the former group, the syndromes can be based on 
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pathogenesis (i.e. constitution, emotions, external pathogens, dietary factors), the various 
patterns of manifestation of the disease (i.e. psoriasis vulgaris, pustular psoriasis, arthritic 
type, erythroderma pattern), the different features of the lesions (i.e. erythema, scale, pustule, 
erosion) and the stage of the disease (i.e. active, stationary and regressive). In the latter group, 
there are multiple TCM syndrome differentiation methods (108). The main TCM syndromes 
are described below. 
Li and Qu 2010 conducted a study on the distribution of TCM syndromes in 205 psoriasis 
patients. The main syndromes consisted of Blood heat, Blood heat plus blood stasis, Blood 
stasis, Blood heat plus blood dryness, and Blood stasis plus blood dryness. Blood heat plus 
blood stasis was the most frequent, and 90.2% of the sample was accounted for by this 
syndrome and two additional syndromes (Blood heat and Blood heat plus blood dryness). 
This indicated that Blood heat was the main factor in the pathogenesis of this disease. Over 
40% patients had the following six accompanying syndromes: Damp heat, Heat toxin, Cold 
and heat, Depressed liver and Yin deficiency, while there were no accompanying syndromes 
in the remaining patients. The disease can be aggravated by the accompanying syndrome at 
certain times. And Cold and heat was the most frequent among them. In the active stage, the 
main syndromes that appeared were Blood heat and Blood heat plus blood stasis, and there 
was also Blood heat plus blood dryness. In the stationary stage, there was Blood heat plus 
blood stasis, Blood heat and Blood heat plus blood dryness of which the main syndrome was 
Blood dryness (109).  
In another multi-site study with 600 psoriasis patients, Deng et al 2006 found that 78.0% 
were stable in term of their TCM syndrome while 22.0% belonged to the non-stable category. 
Blood heat, Blood dryness and Blood stasis occurred in 98.9% of the stable psoriasis patients, 
who accounted for 77.2% of the sample size. In particular, Blood heat was the most frequent 
among all syndromes, and was present in around one third of the sample. The distribution of 
syndromes was closely related to the disease stage. Blood heat primarily appeared in the 
active stage, Blood dryness mainly occurred in the regressive stage and Blood stasis often 
appeared in the stationary stage (110). 
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The main syndromes of psoriasis are Blood heat and/or Blood stasis, so the methods 
Clearing heat and draining fire, or Quickening the blood and dispelling stasis are commonly 
applied in the management of psoriasis. 
3.6.3 Contemporary TCM diagnostic criteria in psoriasis 
In psoriasis, there are numerous TCM syndromes referred to in the literature but in the 
official guidelines on the number of syndromes are considerably fewer. The diagnostic 
criteria for Bai Bi (白疕) are specified in section 3 of chapter 14 in Clinical research 
guidelines on Chinese medicinal herbs (Trials) (中药新药临床研究指导原则(试行)) (111). 
This guideline was issued by the China State Drug Administration, which provides the 
regulatory policies and scientific principles and methods that should be applied in clinical 
research. This section referred to the textbook Traditional Chinese External Medicine (中医
外科学) (edition in 1997) and National Standards of The People’s Republic of China – TCM 
Clinical Diagnosis and Treatment Terminology (中华人民共和国国家标准·中医临床诊疗
术语) (111). The following syndromes were specified in the guidelines as follows: 
1) Wind heat syndrome  
Primary Symptoms: raised lesions mainly with papules and maculopapules, lesion base is 
bright red, spotting blood after scale removal, and possible isomorphic reaction. 
Secondary Symptoms: lesions in remission or relapse stages, probably with itch at different 
severity levels, emotional upset, thirst or dry mouth, constipation, yellow urine, red tongue, 
yellow tongue fur, and rapid pulse.  
2) Blood deficiency syndrome 
Primary Symptoms: lesions mainly in patches, pale lesion base, large-sized but thin scales. 
Secondary Symptoms: long term course of disease, probably with itch, fatigue, pale tongue, 
thin white tongue fur, and fine pulse. 
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3) Blood stasis syndrome 
Primary Symptoms: thick lesions with induration, dark red lesion base, and hard to remove 
scales. 
Secondary Symptoms: long term course of the disease, persistent lesions, possible itch at 
different levels of severity, no remarkable systemic symptoms, dark or petechial tongue, and 
rough or fine-rough pulse. 
A syndrome diagnosis can be established based on at least 2 symptoms of the primary 
symptoms and 2 of the secondary symptoms (111).  
3.7 TCM management of psoriasis 
In Traditional Chinese Medicine, the management of psoriasis includes a variety of treatment 
approaches and therapies of which Chinese herbal medicine (CHM) is frequently applied. 
The internal administration of CHM is mainly used in more severe patients, with large lesion 
area, for rapidly progressing symptoms, long term disease course, or complicated cases. 
External CHM is usually applied for milder cases or uncomplicated conditions.  
Treatment based on syndrome differentiation (TSD) is frequently used in the management of 
psoriasis using internal CHM via decoction. In this approach the selection of herbal formula 
is based on the presenting syndrome and is modified according to the individual case 
according to the severity and the primary symptoms. Another approach is the use of a CHM 
preparation that is specific for the disease (PSD) which is widely applied in the internal and 
external management of psoriasis throughout the healthcare system by TCM practitioners 
and conventional clinicians including dermatologists.  
A variety of CHM preparations are employed including pills, tablets, granules, liquid 
solutions, ointments, creams, tinctures, thin gels, bath formulae, steaming formulae, etc. 
Some of these CHMs have been manufactured into Chinese patent medicines for clinical 
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application. In addition, acupuncture and the other remedies also play a role in the 
management of psoriasis.  
3.7.1 Treatment based on syndrome differentiation (TSD) and the relevant schools 
This approach can be divided into a number of contemporary schools of thought regarding 
the TCM management of psoriasis. In a review that included 123 studies of psoriasis 
treatment using the TSD approach, 116 studies based their syndrome differentiation approach 
on qi-blood and/or fluids (particularly on blood), 4 based their approach on the internal 
organs involved, and 3 took a different approach. The most highly frequent syndromes are 
listed below together with the Treatment principle, which is a statement of the objectives of 
the CHM and the names of the herbs most commonly used in the CHM formula for psoriasis 
patients who conform to each syndrome (112): 
1) Blood heat syndrome (n=100): 
Treatment principle: to clear heat and resolve toxins, cool blood and quicken blood. 
Formula ingredients: Huang qin (and/or Huang bai, Da huang, Huang lian, Shi gao, Qing 
dai), Tu fu ling (and/or Jin yin hua, Bai hua she she cao, Ban lan gen, Lian qiao, Da qing ye), 
Sheng di (and/or Chi shao, Mu dan pi, Zi cao, Xuan shen, Shui niu jiao), Dan shen (and/or Ji 
xue teng, Hong hua, E zhu, Tao ren, San leng).  
Modifications: for removing cold, add Fang feng (and/or Chan tui, Jing jie, Jiang can, Qin 
jiu, Ling yang jiao); for removing dampness, add Bai xian pi, Ku shen, Di fu zi, Yi yi ren, 
Cang zhu, and/or Fu ling (112). 
2) Blood dryness syndrome (n=84): 
Treatment principle: to nourish blood, remove cold and moisten dryness. 
Formula ingredients: Dang gui (and/or He shou wu, Bai shao, Shu di huang), Fang feng 
(and/or Chan tui, Jing jie, Jiang can, Qin jiu, Ling yang jiao), Mai dong (and/or Tian dong, 
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Huang jing, Sha shen) (112). 
3) Blood stasis syndrome (n=62): 
Treatment principle: to clear heat and resolve toxin, quicken blood and transform stasis. 
Formula ingredients: Huang qin (and/or Huang bai, Da huang, Huang lian, Shi gao, Qing 
dai), Tu fu ling (and/or Jin yin hua, Bai hua she she cao, Ban lan gen, Lian qiao, Da qing ye), 
Dan shen (and/or Ji xue teng, Hong hua, E zhu, Tao ren, San leng), Wu shao she (and/or 
Quan jie, Feng fang, Wu gong, Di long, Chuan shan jia). 
Modifications: for moving qi, add Chuan xiong (and/or Chen pi, Chai hu, Zhi ke, Ru xian, 
Mo yao) (112). 
Main Schools of thought in the TSD approach to psoriasis 
The TSD approach to the management of psoriasis has greatly developed during the last 
century and has assimilated some of the advances derived from Western Medicine. A number 
of TCM schools of thought in psoriasis have gradually built up based on the expertise of 
prestigious practitioners of TCM, such as Zhao Bin-nan, Zhu Ren-kang, Jin Qi-feng, Zhang 
Zhi-li, Gu Bo-hua, Ma Shao-yao, Qin Wan-zhang, Ouyang Heng, and Xuan Guo-wei (105, 
113-120). Amongst these experts, proponents of the Blood heat approach include Zhao 
Bin-nan, Zhu Ren-kang, Jin Qi-feng, Zhang Zhi-li and Gu Bo-hua while Ma Shao-yao and 
Xuan Guo-wei also focused on Blood stasis, Qin Wan-zhang was concerned with other 
aspects of Blood in addition to heat and stasis, and the focus of Ouyang Heng’s approach 
was on Blood heat and its relationship with the condition of the qi and body fluids (105, 
113-120).  
The main features of the approaches of these experts, their main treatment principles and 
typical treatments are outlined in Table 3.1. It should be noted that in clinical practice these 
formulas can be modified according the individual’s constitution, response and the stage of 
the disease. 
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Table 3.1 Traditional Chinese Medicine schools of thought in the syndrome differentiation of psoriasis 
Expert: 
School  
Syndrome  Treatment principles 
Primary formula,  
Ingredients 
Reference 
Zhao Bin-nan:  
Blood heat 
blood heat 
clearing heat, cooling blood, 
quickening blood 
Liang Xue Huo Xue Tang 
Sheng huai hua, Bai mao gen, Sheng di, Chi shao, Dan shen, Zi cao gen, Ji xue 
teng Shi 2009 
blood dryness 
nourishing blood, resolving 
toxin 
Yang Xue Jie Du Tang 
Dang gui, Dan shen, Tu fu ling, Feng fang, Wei ling xian 
Zhu Ren-kang:  
Blood heat 
blood heat &  
wind dryness 
clearing heat & resolving 
toxin 
Ke Yin Yi Fang 
Tu fu ling, Ren dong teng, Cao he che, Bai xian pi, Bai dou gen, Ban lan gen, 
Wei ling xian, Sheng gan cao 
Li 1985 
blood deficiency &  
wind dryness 
enriching yin, nourishing 
blood, moistening dryness 
Ke Yin Er Fang 
Sheng di, Dan shen, Yuan shen, Ma ren, Da qing ye, Bai dou gen, Bai xian pi, 
Cao he che, Lian qiao 
Jin Qi-feng:  
Blood heat 
blood heat  
cooling blood, clearing heat, 
extinguishing wind 
Kuai Lan Liang Xue Tang 
Ban lan gen, Sheng kuai hua, Zhao xiu, Bai hua she she cao, Zi cao, Sheng di, 
Chi shao, Ku shen, Bai xian pi, Tu fu ling, Quan jie, Jiang can 
Jin 1989 
dampness heat 
clearing heat, cooling blood, 
resolving toxin 
Long Zhao Xie Shi Tang 
Long dan cao, Chao shan zhi, Yan huang bai, Zhao xiu, Yin hua, Chi shao, 
Sheng yi ren, Ku shen, Bai xian pi, Di fu zi, Tu fu ling, Ze xie 
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blood dryness 
enriching yin, moistening 
dryness, clearing heat, 
removing wind, quickening 
blood, transforming stasis 
Zeng Ye Jie Du Tang 
Sheng di, Yuan shen, Mai dong, Da qing ye, Bai hua she she cao, Sheng kuai 
hua, Dang gui, Dan shen, Bai xian pi, Qi she, Ling xian 
Zhang Zhi-li:  
Blood heat 
blood heat 
clearing heat, cooling blood, 
quickening blood 
Liang Xue Huo Xue Tang (Bai Bi Yi Hao) 
Ling yang jiao feng, Sheng gan cao, Zi cao gen, Chi shao, Xuan shen, Shu jun, 
Gan sheng di, Sheng kuai hua, Da qing ye, Bai xian pi, Ci ji li, Bai mao gen 
Wang 2007 blood dryness 
nourishing blood, enriching 
yin, moistening skin 
Yang Xue Jie Du Tang (Bai Bi Er Hao) 
Tian dong, Mai dong, Dang gui, Dan shen, Xuan shen, Lu feng fang, Ji xue 
teng, Sheng di, Bai mao gen, Tu fu ling, Bai xian pi 
blood stasis 
quickening blood, dissipating 
stasis 
Huo Xue San Yu Tang (Bai Bi San Hao) 
San leng, E zhu, Tao ren, Hong hua, Dan shen, Ji xue teng, Gui jian yu, Chi 
shao, Dan pi, Sheng yi yi ren, Tu fu ling, Ban lan gen 
Gu Bo-hua: 
Blood heat 
wind cold 
effusing sweat & resolving 
flesh, harmonizing 
construction & defence 
(ying-wei),nourishing blood 
& regulating blood 
Gui Zhi Tang plus Si Wu Tang modification 
Sheng jiang, Gui zhi, Shao yao, Da zao, Gan cao, Dang gui, Shu di, Chuan 
xiong 
Gu 1977 
blood heat 
cooling blood, clearing heat, 
removing toxin 
Xi Jiao Di Huang Tang modification 
Xi jiao, Sheng di, Shao yao, Dan pi 
blood stasis 
nourishing blood, 
quickening blood 
Tao Hong Si Wu Tang modification  
Shu di, Dang gui, Bai shao, Chuan xiong, Tao ren, Hong hua, Zhen zhu mu, Mu 
li, Ci shi 
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Ma Shao-yao:  
Blood stasis & 
heat toxin 
blood heat 
cooling blood,  
clearing heat, 
resolving toxin 
NS  
Sheng di, Chi shao, Zi cao, Shui niu jiao, Da qing ye, Bai hua she she cao, Dan 
shen, Tao ren, Sheng gan cao, etc. Ma 1999 
blood stasis 
quickening blood, dissipating 
stasis, resolving toxin 
NS 
Dan shen, San leng, E zhu, Hu zhang, Hong teng, Sheng gan cao, et. 
Qin Wan-zhang: 
Regulating  
blood 
blood heat 
clearing heat, 
cooling blood 
NS 
Mu dan pi, Shan zhi, Jin yin hua, Sheng di, Da qing ye, Chi shao, Hong teng, 
Ban lan gen, etc. 
Qin 2008 
blood dryness 
nourishing yin, 
moistening dryness 
NS 
Bai shao, He shou wu, Huang jing, Ji xue teng, Sheng di, Xuan shen, Tian 
dong, Mai dong, Zhi mu, Yu zhu, Xiao hu jiao, etc. 
blood deficiency  
nourishing blood, 
moistening dryness 
NS 
Shu di huang, Huang qi, Dan shen, Zhi shou wu, Ji xue teng, Wu shao she, 
Dang gui, Zhi gan cao, etc. 
blood stasis 
quickening blood, 
dissipating stasis 
NS 
San leng, E zhu, Liu yue xue, Lang du, Dan shen, Ru xian, Mo yao, Tao ren, 
Hong hua, etc. 
blood cold 
warming blood, 
dissipating cold 
NS 
Gui zhi, Ma huang, Dang gui, Chi shao, Zhi chuan wu, Ji xue teng, Fu zi, Xi 
xin, Tong cao, Huang teng, etc. 
blood toxin 
clearing & resolving  
blood toxin 
NS 
Huang lian, Sheng shan zhi, Mu dan pi, Sheng di, Xi jiao, Ling yang jiao, 
Huang teng, Qing dai, Sheng cao, Zi cao, Zi hua di ding, Tu da huang, etc.  
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Ouyang Heng:  
Blood heat &  
qi-fluids 
detriment 
blood heat & 
yin detriment 
(vulgaris) 
clearing heat & resolving 
toxin,  
boosting qi & nourishing yin 
Zhu Huang Tang  I 
Huang lian, Zhu ye, Shi gao, Dang shen, Mai dong, Huang quan, Zhi zi, Huang 
bai, Shui niu jiao, San qi, Lou lu. 
Xiang 2008 
blood heat & 
repression 
(vulgaris) 
coursing liver & resolving 
toxin, clearing heat & 
nourishing yin 
Zhu Huang Tang  II  
Lou lu, Chai hu, Huang lian, Huang qin, Huang bai, Zhi zi, Dang shen, Mai 
dong, Sheng shi gao, Zhu ye, Sheng di huang, Dang gui, Bai shao 
toxin stasis 
(vulgaris) 
clearing heat & resolving 
toxin 
quickening blood & 
dissipating stasis 
Xian fang huo ming yin plus Lou Lu 
Jin yin hua, Lou lu, Ru xian, Mo yao, Dang gui wei, Chi shao, Tian hua fen, 
Zhe bei mu, Chuan shan jia, Zao jiao, Gan cao, Fang feng, Bai zhi, Chen pi. 
blood deficiency & 
wind dryness 
(vulgaris) 
nourishing blood & 
quickening blood, enriching 
yin & moistening dryness 
NS 
Sheng di huang, Mu dan pi, Xuan shen, Dan shen, Bai shao, Ma ren, Shan dou 
gen, Ku shen, etc. 
critical fever stage 
(pustular type) 
clearing heat & draining fire 
Liang Xue Jie Du Tang modified 
Dan gui, Sheng di huang, Niu bang zi, Hong hua, Mu tong, Chi shao, Mu dan 
pi, Lian qiao, Jie geng, Qing dai, Zi cao, Xi yang shen, Xuan shen, etc. 
paracmastic fever 
stage 
(pustular type)  
clearing & resolving 
remaining toxin, boosting qi 
& nourishing yin 
Zhu Ye Shi Gao Tang, Huang Lian Jie Du Tang plus modified Yu Nv Jian 
Zhu ye, Shi gao, Ban xia, Mai meng dong, Ren shen, Gan cao, Jing mi, Huang 
lian, Huang qin, Huang bai, Zhi zi, Shi gao, Shu di huang, Zhi mu, Niu xi. 
stable recovery stage 
(pustular type) 
enriching stomach yin 
Yi Wei Tang, Zeng Ye Tang plus Xi yang shen 
Sha shen, Mai dong, Bing tang, Xi sheng di, Yu zhu, Xuan shen, Xi yang shen. 
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Xuan Guo-wei:  
Blood heat &  
blood stasis 
blood heat clearing heat 
NS,  
Primary ingredients: Tu fu ling, Bai hua she she cao, Ban lan gen, Da qing ye, 
Di fu zi, Ban bian lian, Bai xian pi, Lu feng fang, Chuan xiong, Ze xie, Che 
qian cao, Gan cao, Shan dou gen, Sheng da huang, Sheng di huang, Mu dan pi, 
Zi cao, Chi shao, Shui niu jiao. 
Cha 2006 
blood deficiency  dispelling wind 
NS,  
Primary ingredients: Tu fu ling, Bai hua she she cao, Ban lan gen, Da qing ye, 
Di fu zi, Ban bian lian, Bai xian pi, Lu feng fang, Chuan xiong, Ze xie, Che 
qian cao, Gan cao, Dan shen, Ji xue teng, Xuan shen, Sha shen Mai dong. 
blood stasis quickening blood 
NS,  
Primary ingredients: Tu fu ling, Bai hua she she cao, Ban lan gen, Da qing ye, 
Di fu zi, Ban bian lian, Bai xian pi, Lu feng fang, Chuan xiong, Ze xie, Che 
qian cao, Gan cao, Dan shen, San leng, E zhu, Wang bu liu xing. 
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3.7.2 The approach that uses CHM preparations that are specific for the disease (PSD) 
While syndrome differentiation is commonly used to select a CHM for a particular patient, 
another common approach is the use CHM preparations that are specific for the disease 
(PSD). This approach is also typically used in Western medicine and in herbal medicine in 
other countries. When this approach is used, the CHM is not modified according to the signs 
and symptoms, rather, a standardised medicine is used. This approach is often used in the 
external management of psoriasis.  
Compared to TSD, the PSD approach is convenient to prescribe in the clinic and is widely 
applied. In addition, it is well suited to the requirements of the contemporary clinical trial 
particularly when using a RCT study design.  
There are a variety of standardised CHM treatments for the management of psoriasis. The 
following are examples of commonly used internal and external CHMs (106):  
1) Internal management:  
Ke yin pill: for Blood heat and excessive wind, 1 pill in orally, twice daily.  
Compound Qing dai capsule: for Blood heat and excessive wind, 4 capsules orally, twice 
daily. 
Leigongteng Duo Dai tablet: mainly for the arthritic type, pustular type and erythroderma 
type. Also used with caution for psoriasis vulgaris. Recommended dose: 60-80 mg daily 
divided into 2-3 oral administrations. 
Leigongteng tablet: mainly for the arthritic type, pustular type and erythroderma type. Also 
used with caution for psoriasis vulgaris. Recommended dose: 6 tablets daily divided into 2-3 
oral administrations. 
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2) External management: 
Herbal Bath: can use for all types but use with caution in acute cases. Chu tao ye and Ce bai 
ye each 250g are decocted in 5,000ml for 20 minutes. Bathe in the warm filtered decoction 
2-3 times weekly. 
Herbal ointment: for all types. Huanglian ointment, Jia Wei Huanglian ointment, or Heidou 
Liuyou ointment is externally applied on the affected surface, 2-3 times daily.  
There have been numerous clinical trials of the PSD approach for psoriasis. A number of 
these trials are included in the systematic reviews in Chapters 5 and 6. 
3.7.3 Acupuncture and the other manual therapies 
Acupuncture and other manual therapies including cupping, moxibustion, point injection and 
catgut embedding can be used singly and in combination. The focus of these treatments is 
removing wind and relieving itch. In addition, the following treatment principles can be used 
in acupuncture treatment: nourishing blood and moistening dryness, quickening blood and 
dissipating stasis, and clearing heat and cooling blood. The Selection of acupuncture points 
can be based on the syndrome differentiation (TSD) approach or upon the lesion location. 
These approaches are summarized in Table 3.2 (121).
Table 3.2 Approaches to acupoint selection for the management of psoriasis 
Prescription 
characteristic 
Syndrome/condition:  
treatment principles 
Selected acupoints 
Based on 
syndrome 
differentiation 
Wind heat & blood dryness: cooling 
heat, clearing blood & dispelling 
wind 
Feng chi (Gb-20), He gu (LI-4), Da zhui (Du-14), 
Tao dao (Du-13), Qu chi (LI-11), Xue hai 
(Sp-10), etc. 
Blood deficiency & wind dryness: 
nourishing blood, harmonizing 
blood, dispelling wind & moistening 
dryness  
Zu san li (St-36), San yin jiao (Sp-6), Xue hai 
(Sp-10), Ge shu (Bl-17), Tai xi (Kd-3), Feng chi 
(Gb-20), He gu (LI-4), etc. 
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skin-flesh stasis: quickening blood & 
dissipating stasis  
He gu (LI-4), Tai chong (Liv-3), San yin jiao 
(Sp-6), Nei guan (Pc-6), Xue hai (Sp-10), Ge shu 
(Bl-17), etc. 
Based on lesion 
location 
NS 
Governing vessel points, or Hua tuo jia ji points 
(M-BW-35) according to the relevant the 
disposable nerve segment of the skin 
 
As regards the efficacy of acupuncture treatment, it is more effective for psoriasis vulgaris 
than for the other types and acute types respond better than chronic types. In general, the 
efficacy of treatment depends upon the disease course with those in the remission stage 
responding better than those with actively progressing disease while response is least when 
the disease is in a stationary stage (121). However, a blinded RCT of 56 patients with 
long-standing plaque psoriasis reported that although PASI scores declined in both the 
active and sham acupuncture groups after 10 weeks of treatment, there was no significant 
difference between groups (122). 
In terms of its antipruritic effect, the following mechanisms of acupuncture action have been 
proposed. One possible mechanism is acupuncture can reduce or counteract nerve impulses 
to the spinal cord by its stimulation of the local area. Also, acupuncture may inhibit 
proteases and affect local bradykinin generation. Acupuncture possibly affects the spinal 
cord and the sensory area of the brain to relieve itch (121).  A review of studies on 
acupuncture for itch reported that experimental studies have shown acupuncture to reduce 
histamine-induced itch and it can also exert antipruritic effects. It appears to act via 
interference in central and peripheral itch transmission (123). In a cross-over study of 14 
participants with atopic dermatitis, the efficacy of real versus sham acupuncture was 
investigated using self-report and functional magnetic resonance imaging (MRI). The results 
showed that the real acupuncture produced significant reductions in itch and there were 
significant changes in the MRI. Particularly, acupuncture inhibited itch and itch-evoked 
activation involving the insula, putamen, and premotor and prefrontal cortical areas (124).  
However, acupuncture may not always be beneficial in psoriasis, since exogenous 
stimulation by acupuncture might also induce the skin sensory nerve endings to release 
neuropeptides, which could lead to neurogenic inflammation. In addition, considering the 
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isomorphic reaction (aka. Kobner’s phenomenon) which can occur in psoriasis, there is 
controversy regarding whether acupuncture should be used near local psoriatic lesions (125). 
Numerous experimental studies into the actions of various CHMs in psoriasis have been 
conducted in the last twenty years. These are discussed in Chapter 7. 
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Chapter 4: Methodology for systematic reviews of clinical trials 
of herbal medicine for psoriasis 
4.1 Aims 
The aim of this component of the thesis is to undertake systematic reviews of controlled 
clinical trials of herbal medicine (HM) for psoriasis. Trials could be published in English or 
Chinese or Japanese and available electronically via major databases.  
The databases selected for searching were as follows: 
 Medline via Pubmed (September 2012); 
 Cochrane Library via Wiley InterScience (September 2012);  
 Embase (September 2012); 
 China National Knowledge Infrastructure (CNKI) (中国知网) (September 2012); 
and 
 Chinese Scientific Journals Full Text Database (CQVIP) (维普网) (September 
2012). 
These were searched from their inception to September 2012 with no limits being placed on 
publication type, date, language etc. An additional identification by searching reference list 
was supplemented.  
The methodology used for the searches was based on that recommended in The Cochrane 
Handbook of Systematic Reviews (126). The results of the electronic searches were 
supplemented by examining reference lists in retrieved articles. Searches of clinical trial 
registries and hand searches of journals were not undertaken. 
4.2 Selection of search terms and search procedure 
The search terms consist of three components:  
 Clinical condition,  
 Intervention, and  
 Study style.  
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In the selection of search terms related to psoriasis, reference was made to the Cochrane 
Skin Group via http://skin.cochrane.org, and a published Cochrane review protocol on 
psoriasis (53, 127). For terms relating to study design the Cochrane library website: 
http://www.thecochranelibrary.com/view/0/index.html, and other Cochrane reviews were 
consulted (80, 128). For terms related to HM, reference was made to another Cochrane 
review protocol (53). 
The terms identified from the above procedure were supplemented by examining lists of 
MESH terms in PubMed, lists of Source and Map Terms in Embase and lists of search terms 
in other systematic reviews (36, 42).  
Separate lists of search terms were developed for PubMed, Embase and Cochrane Library. 
These had minor differences according to the characteristics of the search functions 
employed by the particular database. Search terms were further refined by undertaking trial 
searches and terms that were inclusive of others and consequently redundant were removed 
from the list. Nevertheless, since the aim of the searches was to be as comprehensive as 
possible, a broad range of terms was included. For CNKI and CQVIP the search interfaces 
are considerably different from those of the English language databases. These search 
methods are detailed below. 
Each of the sets of search terms is presented below. 
4.2.1 Embase  
The Embase search terms were divided into three main groups: 1. Clinical condition, 2. 
Intervention, and 3. Study type. These were further divided into subgroups to facilitate 
searching. The three main groups were combined with ‘AND’, and terms within a group 
were linked with the Boolean operator ‘OR’ (see Fig. 4.1).  
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Fig. 4.1:  Groups of search terms in Embase 
Finally the three main groups of search terms were linked with the operator ‘AND’ to obtain 
a result for all references which satisfied the three groups of terms. The terms used for 
Embase are listed below: 
І. Clinical condition 
a) psoriasis OR psoriasiform OR psoriatic OR psoriases OR ‘erythematosquamous skin 
disease’ OR parapsoriasis 
b) ‘palmoplantar pustulosis’ OR ‘Pustulosis Palmaris et Plamtaris’ OR ‘Acrodermatitis 
Continua’ OR ‘Impetigo Herpetiformis’ OR ‘Pustulosis Palmaris et Plantaris’ OR 
‘Palmoplantaris Pustulosis’  
c) ‘Pustulosis of Palms and Soles’  
d) ‘Pustular Psoriasis of Palms and Soles’  
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Ⅱ. Intervention 
a) ‘Medicine, Traditional’ OR ‘oriental traditional medicine’ OR ‘traditional medicine’ 
OR ‘Medicine, Chinese Traditional’ OR TCM OR T.C.M. OR ‘Medicine, Ayurvedic’ 
OR ‘Alternative Medicine’ OR ‘Complementary Medicine’ OR ‘Complementary 
Therapies’ 
b) Ethnopharmacology OR Ethnomedicine OR Ethnobotany OR ‘Medicine, Kampo’ 
OR Kanpo OR Phytotherapy OR ‘Medicine, Herbal’ OR Herbology OR  ‘Plants, 
Medicine’ OR ‘Drugs, Chinese Herbal’ OR ‘Materia Medica’ OR ‘Single 
Prescription’ OR ‘Herbal Medicine’ 
c) Acupuncture OR Meridians OR Electroacupuncture OR Moxibustion OR 
Auriculotherapy OR ‘Catgut embedding’ OR Herbs OR ‘Chinese Medicine Herb’ 
Ⅲ. Study type 
 ‘Clinical Trial’ OR ‘clinical study’ OR ‘Controlled Trial’ OR ‘Controlled study’ OR 
‘random! control! Trial’ OR ‘random! control! Study’ OR ‘Multicenter Study’ OR 
Meta-Analysis OR ‘random allocation’ OR double-blind OR single-blind OR ‘comparative 
study’ OR ‘evaluation study’ OR ‘follow-up study’ OR ‘prospective study’ OR ‘research 
design’ OR ‘control group’ OR ‘placebo control’ OR ‘dummy control’ OR blinding OR 
‘clinical research’ OR  ‘medical trial’ OR ‘in vivo study’ OR ‘case control study’ OR ‘case 
study’ OR ‘intervention study’ OR ‘longitudinal study’  
The results of the search were downloaded to a dedicated Endnote library using the ‘Export 
Citation(s)’ function in Embase and the ‘Complete Reference’ option. 
4.2.2 Medline via Pubmed 
PubMed was searched via http://www.ncbi.nlm.nih.gov/pubmed using the PubMed 
Advanced Search webpage. The three main groups of search terms are listed below: 
І. Clinical condition 
Psoriasis OR psoriases OR psoriasiform OR parapsoriasis OR Psoriasis, Arthritic OR Skin 
Diseases, Papulosquamous OR palmoplantar pustulosis OR Pustular Psoriasis of Palms and 
Soles OR Pustulosis Palmaris et Plantaris OR Pustulosis of Palms and Soles OR 
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Acrodermatitis Continua OR Impetigo Herpetiformis OR Psoriatic Erythroderma OR 
Pustulosis Palmaris et Plamtaris OR psoriatic Dermatitis OR Palmoplantaris Pustulosis OR 
Arthritis, Psoriatic OR Psoriasis Arthropathica  
Ⅱ. Intervention 
Traditional Chinese Medicine OR Chinese Traditional Medicine OR Chinese Herbal Drugs 
OR Chinese Drugs, Plant OR Medicine, Traditional OR Ethnopharmacology OR 
Ethnomedicine OR Ethnobotany OR Medicine, Kampo OR Kanpo OR TCM OR T.C.M. 
OR Medicine, Ayurvedic OR Alternative Medicine OR Complementary Medicine OR 
Phytotherapy OR Herbology OR Plants, Medicinal OR Plant Preparations OR Plant Extracts 
OR Plants, Medicine OR Materia Medica OR Single Prescription OR Acupuncture OR 
Meridians OR Electroacupuncture OR Moxibustion OR Auriculotherapy OR Catgut 
embedding OR Herbs OR Chinese Medicine Herb OR Herbal Medicine 
Ⅲ. Study type 
Clinical Trial OR clinical study OR biomedical research OR Controlled Trial OR Controlled 
study OR random* control* Trial OR random* control* study OR Multicenter Study OR 
Meta-Analysis OR random allocation OR double-blind OR single-blind OR comparative 
study OR evaluation study OR follow-up study OR prospective study OR research design 
OR control group OR blinding OR clinical research OR medical trial OR in vivo study OR 
case control study OR case study OR intervention study OR longitudinal study OR Clinical 
Trial OR Randomized Controlled Trial OR placebo OR control OR random OR ((singl*[tw] 
OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR 
(placebos[mh] OR placebo*[tw] OR random*[tw] OR control*[tw] OR prospectiv*[tw] OR 
volunteer*[tw]) 
The three main groups were combined with ‘AND’ and the results downloaded to a 
dedicated Endnote library.  
4.2.3 Cochrane Library 
The Cochrane Library was accessed at http://www.thecochranelibrary.com via Wiley 
InterScience using the ‘advanced search’ page. 
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Since the focus of the Cochrane library is clinical trials and systematic reviews of clinical 
trials the group of search term for ‘study type’ was not used for this search. The two groups 
and subgroups of terms are listed below: 
І. Clinical condition 
Psoriasis OR psoriases OR psoriasiform OR parapsoriasis OR psoriatic OR "Skin Diseases, 
Papulosquamous" OR "palmoplantar pustulosis" OR "Pustular Psoriasis of Palms and Soles" 
OR "Pustulosis Palmaris et Plamtaris" 
Ⅱ. Intervention 
a) "Chinese Medicine, Traditional" OR "Medicine, Chinese Traditional" OR "Chinese 
Traditional Medicine" OR "Traditional Chinese Medicine" OR "Medicine, Traditional" OR 
"Medicine, Oriental Traditional" OR "Medicine, Chinese Traditional" OR TCM OR T.C.M. 
OR "Medicine, Tibetan Traditional" OR "Medicine, Mongolian Traditional" OR "Medicine, 
East Asian Traditional" OR "Alternative Medicine" OR "Complementary Medicine" OR 
"Complementary Therapies" OR "Medicine, Ayurvedic" 
b) "Chinese Drugs, Plant" OR "Drugs, Chinese Herbal" OR "Chinese Herbal Drugs" OR 
Ethnopharmacology OR Ethnomedicine OR Ethnobotany OR "Medicine, Kampo" OR 
Kanpo OR Phytotherapy OR "Medicine, Herbal" OR Herbology OR "Plants, Medicinal" OR 
"Plant Preparations" OR "Plant Extracts" OR "Materia Medica" OR "Single Prescription" 
OR Herbs OR "Herbal Medicine" 
c) Acupuncture OR "Acupuncture Therapy" OR "Therapy, Acupuncture" OR "Acupuncture 
Points" OR Meridians OR Electroacupuncture OR Moxibustion OR Auriculotherapy OR 
"Acupuncture, Ear" OR "Auricular Acupuncture" OR "Catgut embedding" 
The subgroups of group 2 were combined with ‘OR’ then groups 1 and 2 were combined 
with ‘AND’. The sub-databases for ‘Clinical trials’ and ‘Cochrane Reviews’ were searched 
and the results were downloaded to a dedicated Endnote library.  
4.2.4 CNKI (中国知网) 
CNKI (中国知网) is a mainstream Chinese database. It can be accessed via its home page at 
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http://www.cnki.net by registering and logging in. It is advisable to access the New Version 
Publishing Platform (新版出版平台) for the improved interface. Furthermore, the Head 
Database of Chinese Academic Literature Net Publication (中国学术文献网络出版总库）
can be accessed, which provides the Advanced Search (高级检索) option.  
The search terms were designed in three components: Clinical condition, Intervention and 
Study type. Each component was formed of a number of core words, such as 中医药 
Zhong yi yao (Chinese medical pharmacopoeia). These terms will link to lists of additional 
relevant terms which appear in a pop-up window when you click a specific button on the 
Advanced Search webpage of CNKI (中国知网). These additional terms can then be further 
selected (See Fig. 4.2).  
 
Fig. 4.2 The selection of search terms using the CNKI Advanced Search interface 
Using this approach, most search terms were determined. For clinical condition, some search 
terms were selected from the specialized books, such as中药大辞典 Zhong Yao Da Ci Dian 
(index section) (129)and reference was made to 中医大辞典 Zhong Yi Da Ci Dian to 
identify whether they matched the description of psoriasis (130). There is a space limitation 
in the CNKI search interface so up to 14 terms can be used. Therefore the search terms for 
intervention were divided into three sub-groups: Ⅱ-a, Ⅱ-b and Ⅱ-c. The search terms are 
as follows: 
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І. Clinical condition 
银屑病 牛皮癣 白庀 白庇 庀风 庇风 干癣 白秓 顽癣 疥癣 蛇虱 松皮癣 银钱疯 
白壳疮 
Ⅱ. Intervention 
a) 中医 中医治疗 中医临床 中医辨证 中医干预 祖国医学 辨证施治 中西医 中西
医学 中西医结合 中西医治疗 中西医结合治疗 中西医结合疗法 中西医结合方法 
b) 草药 中草药 中医药 中医药学 中医中药 中药治疗 中医药治疗 中医药疗法 中
医药防治 中医药研究 中医中药治疗 中草药治疗应用 耳针 耳穴 
c) 针灸 针灸治疗 针刺治疗 针灸疗法 针灸临床 传统医学 传统医药 传统治疗 中
国传统医学 替代疗法 替代医学 替代治疗 补充和替代医学 保守治疗 
Ⅲ. Study type 
随机临床观察 随机临床试验 临床随机研究 临床随机试验 临床观察 临床研究 临床
疗效 随机试验 疗效观察  
4.2.5 CQVIP（维普网） 
CQVIP（维普网）at http:www.cqvip.com is an important retrieval platform for Chinese 
literature. It originated as The Title Database of Chinese Scientific Journals (中文科技期刊
篇名数据库), became kown as the Chinese Scientific Journal Database (中文科技期刊数据
库) and its current formal title is Chongqing Weipu Zixunwang 重庆维普资讯网. We 
usually commence to retrieve literature by clicking the Advance Search (高级检索) button 
on top right corner of the home page after registering and logging in to an account. 
The search terms were again designed in three components: Clinical condition, Intervention 
and Study type. Each component comprised a number of Key Words (关键词) and potential 
synonyms were identified as follows. Enter the key word, such as 银屑病 Ying xie bing 
(psoriasis), in the text box under the Search Term (检索词) label, then select the indistinct 
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(模糊) setting from the drop-down list, and then click on the Search Synonym (查看同义词) 
button. A new page appears with a list of synonyms which can be selected (see Fig. 4.3).  
 
Fig. 4.3: The development of CQVIP search terms using synonyms 
In this manner, most of the search terms were determined. Regarding clinical condition, 
some terms were selected from specialized books, such as 中药大辞典 Zhong Yao Da Ci 
Dian (index section) (129), and by reference to 中医大辞典 Zhong Yi Da Ci Dian (130) to 
identify whether they matched the description of psoriasis.  
Considering that quite a few potential search terms overlapped entirely with the other terms, 
a Boolean Formula was applied to identify those terms that will be discarded for further 
searching, for example, if A NOT B = 0, then A should be included in B. In the first two 
lines of the Advanced Search (高级检索) web page, set NOT (不包含) and Title/ Key Word 
(题名或关键词). In the two text boxes under Search Term (检索词), enter the narrowly 
defined term(s) and then the broader term in the box below. Then click the Search (检索) 
button (See Fig. 4.4). Note that the Boolean operators: OR, AND, NOT are correspondingly 
represented by the symbols: +, *, - in the CQVIP search fields. However, in general, the 
logical sequence in the CQVIP advanced search follows the input order rather than the 
Boolean logical priority. 
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Fig. 4.4: The refinement of CQVIP search terms using NOT 
The resultant refined search terms are as follows: 
І. Clinical condition 
银屑病+牛皮癣+松皮癣+疥癣+疥癣病+白庀+白庇+庀风+庇风+干癣+白秓+顽癣+蛇虱
+银钱疯+白壳疮+白疮 
Ⅱ. Intervention 
a) 中医+祖国医学+传统医学+传统医药+传统治疗+替代疗法+替代医学+替代治疗+补
充和替代医学+保守治疗+保守疗法+汉医+汉方医学+东医+中西医+中西药 
b) 草药+中草药+中医药+中医中药+中药治疗+调理+证侯+证治+辨证施治+辨病论治+
辨证论治+辨证用药+辨证治疗+辨症施治 
c) 针灸+针刺+体针+新针疗法+刺灸+刺络放血+刺络疗法+三棱针法+耳针+耳穴+耳压 
Ⅲ. Study type 
随机+疗效+临床观察+临床研究+临床试验+临床监测 
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4.3 Removal of duplicates 
The results of each database search were saved in separate Endnote libraries. The results of 
the three English language databases were then combined into a single library and the 
‘discard duplicates’ function was used to remove duplicate citations. The combined Endnote 
library was then scanned item by item to identify any other duplicate citations. These were 
subsequently removed to arrive at a total number of different citations identified by the three 
searches. 
A similar procedure was undertaken for the two Chinese language databases. After the 
duplicates had been removed in this Endnote library, the combined Endnote libraries for the 
English and Chinese language databases were cross referenced to identify studies that 
appeared in both. These were removed from the total search results.  
An additional process for identification was searching reference lists. This was applied to 
review articles and RCTs. When additional articles were located these were added to the 
combined Endnote library.  
4.4 Screening and categorization of citations 
A series of categorisation criteria were developed to assist in the screening of the citations. 
These are listed in the following chapter. Each of the citations in the Endnote library, which 
includes the title and in most cases the abstract, was read by the researcher (SD) and it was 
allocated a category, for example C1 ‘not related to psoriasis’ or C4. ‘in vitro study (e.g. cell 
culture)’. All citations that made reference to a clinical study in humans or a review of 
clinical studies were identified and full text articles were obtained. A second researcher 
independently scanned and checked the categories allocated in the Endnote library (BM). 
Any discrepancies were discussed and modifications made if required. A third person (TZ) 
was available to resolve any disputations. This was not required. 
Based on the full text, clinical studies were divided into sub-categories. Case-series and 
other uncontrolled studies were not considered in this review.  
For the articles reporting controlled clinical trials in humans, data on study design, treatment 
and control intervention was extracted into an Excel spread sheet to facilitate further 
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selection and evaluation of the suitability of the study for inclusion in the review. Data 
checking was carried out by BM and/or Xuedong An (another PhD candidate). 
4.5 Exclusion and inclusion criteria 
The languages of the included studies were limited to English, Chinese and Japanese. 
Studies that included a CAM treatment intervention other than herbal medicine (internal 
and/or external) were excluded. Herbal medicine was broadly defined to include 
plant-derived medicinal material excluding purified compounds. 
Studies that used a combination of HM plus ultraviolet radiation therapy in the intervention 
arm were excluded. However, studies combining HM and anti-psoriatic pharmacotherapy 
(APP) were included. APP did not include phototherapy or photochemotherapy, and can 
include but was not limited to: emollients, corticosteroids, vitamin D3 analogues, tazarotene, 
coal tar, dithranol, methotrexate (MTX), ciclosporin, retinoids, fumarates and/or biologicals 
(131). Studies that used a form of pharmacotherapy not related to anti-psoriatic 
pharmacotherapy were not included. 
Those studies that applied psychological or stress reduction techniques such as meditation, 
music therapy, hypnosis were not included. Manual therapies including acupuncture were 
excluded. Therapies based on baths and/or climate such as Dead Sea Cure were also not 
included. Vitamin and/or mineral therapies, homoeopathy, fish oils and other animal oils 
were not included but studies that employed a multi-ingredient herbal medicine that included 
a vitamin, mineral and/or animal oil in addition to the HM were not excluded. Also included 
were herb-based studies in which a vitamin, mineral and/or animal oil was added as an 
adjunctive ingredient such as an excipient or preservative.  
Studies that did not employ randomisation, or claim to have employed randomisation, in the 
allocation of participants were excluded from further evaluation. Study designs that did not 
use placebo or a standard APP therapy as a control were excluded. Also, designs that 
compared psoriasis sufferers with a normal control were excluded. 
Consequently, the included studies were randomised controlled trials, with or without 
blinding, that compared the HM therapy with a placebo, conventional pharmacotherapy or 
no treatment. The intervention could be an internal/oral or external/topical method.  
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Therefore the systematic reviews were divided into internal/oral herbal medicines and 
external/topical HMs on order to ensure valid comparisons. 
The stages in the exclusion and inclusion process were presented as a  flowcharts according 
to the PRISMA guidelines (132). 
4.6 Data extraction 
For the clinical trials not excluded under the above criteria, detailed data were extracted to 
an Excel spread sheet. These included the number, age and gender of study participants; 
duration of the study and follow-up; dosage of medications; outcome measures etc. See the 
individual characteristics of the studies details in the following chapters on the systematic 
review (Chapters 5 & 6). 
4.7 Evaluation of the Methodological Quality of the Studies 
The methodological quality of the studies was evaluated using the ‘Risk of Bias Table’ 
developed by the Cochrane Collaboration (133). Two researchers assessed Risk of Bias 
according the methods, SD, Xuedong An and BM. Any disagreements were discussed and 
resolved with recourse to a third person (Dr Yanyi Wang) if agreement could not be reached. 
4.8 Data analysis 
In cases where two or more studies employing similar designs and used the same outcome 
measures, the results were pooled and meta-analyses undertaken using RevMan 5.1. For 
continuous data Weighted Mean Difference (WMD) was used and Relative Risk (RR) was 
used for dichotomous data. A fixed effect-model or random effect-model was selected 
depending upon the level of heterogeneity (134). Heterogeneity was assessed using I2. 
Sensitivity analyses were used to explore sources of heterogeneity. When ten or more 
comparable studies were identified, publication bias was explored using a Funnel Plot.  
In order to ensure the meaningfulness of meta-analyses, studies were grouped where 
possible according to design, intervention, comparator and outcome measure. Studies of 
topically applied HMs and orally/systemically applied were considered separately.  
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When multi-ingredient herbal formulae were used, analyses were undertaken to determine 
the most frequently applied herbs. Where possible, sensitivity analyses were used to explore 
the effects of formulae that shared ingredients in common. 
The safety of the HMs was explored based on the incidence of adverse events (AEs) 
reported in the clinical studies and whether there were any serious adverse event (SAE).  
In order to determine how the herbs might function in the management of psoriasis and its 
associated symptoms, further analyses were undertaken of the main herbs used in the clinical 
trials. The methods and results for these analyses are presented in subsequent chapters. The 
method and results for the analysis of the experimental studies is presented in Chapter 7 and 
the method and results for the analysis of the therapeutic targets and biological pathways 
analysis is presented in Chapter 8. 
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Chapter 5: Results of systematic review of RCTs on internal HM 
for psoriasis 
This chapter presents the results of a systematic review of randomised controlled trials 
(RCTs) of herbal medicines (HMs) for psoriaisis. The methodology was reported in Chapter 
4. The overall search results are reported below following by the systematic review of HMs 
used internally. The results reported in this chapter have been published (135). The reviews 
of HMs used externally/topically are presented in Chapter 6. 
5.1.1 Overall results of searches of databases 
The search results for the databases are shown individually below followed by the combined 
results for all searches. These are the consolidated search results for all of the following 
systematic reviews in Chapters 5 and 6.  
The numbers are given for the initial search conducted on 2011.10.5 and the update search 
on 2012.9.12. 
5.1.1.1 PubMed  
Initial search (2011.10.5) 
Group 1 Condition = 43,671 
Group 2 Intervention = 402,781 
Group 3 Study type = 7,911,235 
Combined 1 AND 2 AND 3 = 422  
Additional citations retrieved at search update (2012.9.12) = 32 
Total = 454 
References were downloaded to a separate Endnote library. 
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5.1.1.2 Cochrane library 
Initial search (retrieved on 2011.10.5) 
Group 1 Condition = 2,898 
Group 2 Intervention = 14,021 
Combined 1 AND 2 = 40 
Additions from updated search (2012.9.12)= 0 
Total = 40 
References were downloaded to a separate Endnote library. 
5.1.1.3 Embase  
Initial search (retrieved on 2011.10.5) 
Group 1 Condition = 57,049 
Group 2 Intervention = 158,417 
Group 3 Study type = 11,568,142 
Combined 1 AND 2 AND 3 = 361 (after discarding 22 duplicated hits) 
Additions from updated search (2012.9.12) = 17 
Total = 378 
References were downloaded to a separate Endnote library. 
5.1.1.4 CQVIP (initial search on 2011.10.7, updated on 2012.9.12) 
Due to the limitations of the database, the search terms for Intervention were separated into 
three components (a, b, c) and each group was combined with the other groups of terms: 
Intervention a AND Condition AND Study type etc. Results were downloaded to an 
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Endnote library. Finally, 485 hits were located after removing 23 duplications. 40 additional 
entries were derived from the update of 2012.9.12. The total number of retrieved citations 
was 525. 
5.1.1.5 CNKI (retrieved on 2011.10.10, updated on 2012.9.12) 
Initial search (retrieved on 2011.10.5) 
a) Stage Ⅰ: 
Step 1 Condition (Ⅰ) = 20,108 
Step 2 Combined 1 AND Intervention (Ⅱ-a) = 1,464 
Step 3 Combined 2 AND Study type (Ⅲ) = 368 and downloaded to Endnote library 1 
b) Stage Ⅱ: 
Step 4 Condition (Ⅰ) = 20,108 
Step 5Combined 4 AND Intervention (Ⅱ-b) = 950 
Step 6 Combined 5 AND Study type (Ⅲ) = 249 and downloaded to Endnote library 2 
c) Stage Ⅲ: 
Step 7 Condition (Ⅰ) = 20,108 
Step 8 Combined 7 AND Intervention (Ⅱ-c) = 168 
Step 9 Combined 8 AND Study type (Ⅲ) = 50 and downloaded to Endnote library 3 
d) Stage IV: 
Step 10 Combined 3 Endnote libraries into a new Endnote library 4 = 579 (after discarding 
88 duplicated hits).  
Additions from updated search (2012.9.12) = 44 
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Total = 623 
5.1.2 Combination of database retrievals: 
a) The five databases searches were combined into a new Endnote library. After duplicate 
removal the total number of citations = 1,583 
b) Additional citations based on reference lists = 31 
c) Number of citations in combined Endnote library after filtration = 1,614 
5.1.3 Screening: 
Hit categorisation and exclusion based on condition, intervention or language 
Screening the 1,614 entries in the Endnote library resulted in the following numbers of 
entries for each of the categories (see Table 5.1). The categories defined as exclusion criteria 
are marked ‘E 1-10’ in Table 5.1. Almost 30% entries were related to disorders other than 
psoriasis or were not related to a form of CAM treatment. A small number (n=16) were not 
in English, Chinese or Japanese. 
Table 5.1 Results for categorisation criteria: 
Categorisation criterion N. Total N. % 
C1. not related to the searched disorder eg psoriasis – E1 259 x 16.05 
C2. not related to CAM (Complementary & Alternative medicine 
including Traditional Medicine)-E 2 
200 x 12.39 
C3. not in the specified languages: eg Chinese, English, Japanese, 
German- E3 
16 x 0.99 
E1-E3: Combined x 475 29.43 
C4. in-vitro study (e.g. cell culture)-E4 31 x 1.92 
C5. in-vivo study (i.e. animal study)- E4 27 x 1.67 
C6. physiological study in humans- E4 3 x 0.19 
C7. review of non-clinical studies- E4 28 x 1.74 
E4: Combined x 89 5.51 
C8. Systematic review: Other CAM-E6 5 x 0.31 
C9. General review: Other CAM- E6 19 x 1.18 
C10. Systematic review: Other Herbal Medicine (HM)- E6 1 x 0.06 
C11. General review: Other HM- E6 11 x 0.68 
C12. Systematic review: TCM- E6 22 x 1.36 
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C13. General review: TCM- E6 56 x 3.47 
C14. Discussion on TCM theory, diagnosis, differentiation etc.- E6 40 x 2.49 
E6: Combined x 154 9.54 
C15.UV: Other CAM-E9 37 x 2.29 
C15. CT: Other CAM-E9 2 x 0.12 
C15r. RCT: Other CAM- E9 22 x 1.36 
C18. CT: TCM – Acupuncture, Tui Na-E9 5 x 0.31 
C18r. RCT: TCM – Acupuncture, Tui Na-E9 27 x 1.67 
C19. CT: TCM – other-E9 4 x 0.25 
E9: Combined x 97 6.01 
C16. CT: Other HM-E10 2 x 0.12 
C17. CT: TCM – HM-E10 85 x 5.27 
E10: Combined- CTs (HM)/Non-RCTs x 87 5.39 
C16r. RCT: Other HM-RCTs 4 x 0.25 
C17r. CT: TCM – HM-RCTs 296 x 18.34 
RCTs (HM): Combined x 300 18.59 
C20. Uncontrolled study: Other CAM-E8 15 x 0.93 
C21 Uncontrolled study: Other HM-E8 2 x 0.12 
C22 Uncontrolled study: TCM – HM only-E8 297 x 18.40 
C23 Uncontrolled study: TCM – Acupuncture, Tui Na-E8 42 x 2.60 
C24 Uncontrolled study: TCM – other-E8 1 x 0.06 
E8: Combined x 357 22.12 
C25 Adverse event report, toxicology – general (inc other CAM)-E7 5 x 0.31 
C26 Adverse event report, toxicology – TCM-E7 19 x 1.18 
C27 Chemical analysis – Other HM-E7 0 x 0 
C28 Chemical analysis – TCM-E7 4 x 0.25 
E7: Combined x 28 1.74 
C29 Epidemiology, economic studies etc: WM and general-E 5 8 x 0.50 
C30 Epidemiology, economic studies etc: CAM-E5 19 x 1.18 
E5: Combined x 27 1.67 
Total: 1614 x 100 
5.1.4 Evaluation for eligibility: 
Of the 27 entries that were epidemiological and/or economic studies, most related to CAM. 
89 entries were for experimental studies and other entries rot related to clinical trials, and a 
further 28 were adverse event reports, chemical analyses or toxicological reports of 
relevance to herbal medicine. 
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The remaining 995 entries were for clinical studies or reviews of CAM therapies for 
psoriasis. These were further assessed on the basis of the full text articles. Of these entries, 
154 were reviews of at least one form of CAM. One article (136) reported results for one 
uncontrolled clinical study and two controlled clinical studies, so this study was evaluated 
further as a controlled clinical study. The references for uncontrolled clinical studies 
accounted for 357 entries leaving 484 references for controlled clinical trials of a CAM 
therapy. 
5.1.5 Evaluation of controlled clinical trials for inclusion: 
5.1.5.1 Exclusions based on the intervention (E 9) 
Of the 484 controlled clinical trials, 97 were excluded because they used a CAM therapy 
other than herbal medicine, physical therapy, or phototherapy. These included eleven studies 
employing psychological or stress reduction techniques such as meditation, music therapy, 
or hypnosis (137-147), and 32 studies that applied manual treatments such as acupuncture 
and/or reflex therapy. One study investigated seal oil for psoriatic arthritis (148) and one 
was of fish oil (149). Two studies involved the extract from sweet whey (150, 151). One 
related to climatic treatment in the Dead Sea (152). Eight studies involved physical therapy 
such as Spa baths, Laser Therapy, Ozone autohemotherapy (79, 81, 83, 84, 90, 153-155). 
Four studies used compounds purified from plants (77, 78, 82, 85). Another 37 studies used 
CAM combined with phototherapy/ photo-chemotherapy. The above 97 studies were 
excluded.  
5.1.5.2 Exclusion of the non-randomisation studies (E 10) 
Of the 387 remaining controlled studies (CTs), 87 studies did not use randomisation in the 
allocation of the subjects, or did not include a definite randomisation statement in their study 
methodology. These were not included in this systematic review on randomised trials. One 
study (156), that did report randomisation, investigated a range of skin disorders including 
psoriasis but did not report separate data for psoriasis, so it was excluded.  
5.1.5.3 Exclusions based on trial design (E 11) 
Since the aim of the reviews was to investigate the efficacy of herbal medicines for psoriasis, 
with a particular focus on the pharmaceutical actions of the HM(s), the design of the 
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included trials had to be sufficient to allow a direct comparison between the HM and a 
placebo or a pharmaceutical intervention with known effect.  
There were a variety of study designs among the 300 identified studies. In total, 96 studies 
compared different HM treatments (i.e. HM vs HM) with no comparison with a placebo, a 
no treatment group or a conventional pharmaceutical therapy or phototherapy. Ten studies 
compared HM Medicine with combination care using HM plus WM (HM vs HM + WM) 
and 18 studies used complex designs with mixed HM interventions (internal and external) 
that did not allow clear assessment of the actions of one of the intervention. In addition, 21 
studies did not involve a clear comparison in the study design, for example one group 
included a combination of a herbal medicine plus a Western medicine while the comparator 
was a different Western medicine (HM 1 + WM 1 vs WM 2). 
Psoriasis vulgaris or plaque psoriasis was not definitely diagnosed in 5 studies. 42 studies 
did not state the primary outcome measures, or provide their results. Also, 69 studies applied 
a conventional therapy other than an anti-psoriatic pharmacotherapy (APP) as the 
comparator. Therefore these 261 studies did not meet the above inclusion criteria and were 
excluded.  
5.1.6 Summary of the candidate entries for eligibility 
The included entries were further divided into two domains: 1. studies that used herbal 
medicine taken internally as the main intervention; and 2. studies that used herbal medicine 
administered externally as the main intervention. There were 11 studies in the first domain 
that are included in this chapter (results published in (135)); and 29 studies the second 
domain (2 RCTs were reported in one article), which will be separately reported in Chapter 
6 which includes three SRs (157-159).  
5.2 Systematic review 1: Herbal Medicine in the internal management of psoriasis: efficacy, 
safety and pharmacological actions of the main herbs 
5.2.1 Introduction 
For moderate to severe psoriasis, internal management is often primary clinical solution. 
Currently unwanted side effects resulting from the long-term application of internally used 
anti-psoriatic pharmacotherapies (APP) remains an issue (35). Complementary and 
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alternative medicine (CAM), including HM, is used by about 50% of psoriasis patients in 
America and Europe, often in conjunction with conventional treatments (54, 160-162). So an 
evaluation of its efficacy and safety is of relevance to physicians and patients. A number of 
reviews have examined the use of HM for psoriasis, but these did not focus upon its internal 
or oral use (35, 36, 48, 49, 157, 163-166). 
This systematic review focuses on controlled clinical trials of the efficacy and safety of oral 
herbal medicines (HM) in the management of psoriasis vulgaris. All included studies 
compared the HM with an oral placebo or conventional anti-psoriatic pharmacotherapy 
(APP) with Psoriasis Area Severity Index (PASI) as an outcome measurement. In addition, 
this review aims to identify individual herbs that show promise of efficacy and examine the 
experimental evidence for activities of relevance to psoriasis in order to identify possible 
directions for drug discovery and drug development (167).  
5.2.2 Method 
The major biomedicine databases: EMBASE, PubMed, Cochrane Library, China National 
Knowledge Infrastructure (CNKI), and Chinese Scientific Journals Full Text Database 
(CQVIP) were searched from their respective inceptions to September 2012. Three groups 
of search terms were employed: 1. Clinical condition (psoriasis etc.); 2. Intervention (herbal 
medicine etc.); and 3. Study type (controlled trial etc.). Terms were adjusted for different 
databases. Review articles were identified and their reference lists were searched (see 
Chapter 4 for details).  
The HM interventions could include the oral administration of single or multiple HMs or 
extracts thereof. HMs were classified as natural products of plant origin but multi-ingredient 
formulations could also include natural products of animal or mineral origin, vitamins, and 
excipients. Isolated bioactive compounds, homoeopathic formulations, mineral therapies, 
and specific vitamin remedies were not included. APPs could include: emollients, 
corticosteroids, vitamin D3 analogues, tazarotene, coal tar, dithranol, methotrexate (MTX), 
ciclosporin, retinoids, fumarates and/or biologicals (131). Phototherapy was not included. 
Comparisons were between HM used internally and internal placebo or internal APP. 
Topical co-interventions that were used in both arms of the study were allowed. 
Comparisons between two HMs and comparisons that combined an internal HM with an 
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APP were not included.  
Psoriasis vulgaris, presenting as plaque psoriasis, is the most common type of psoriasis. In 
order to enable valid data pooling, only studies that included participants who had been 
diagnosed with this type of psoriasis were included.   
In general, internal treatments are typically prescribed based on the amount of body surface 
area involved (168) and are mainly applied in moderate to severe conditions to control the 
disease adequately (169) while external remedies are applicable for mild psoriasis (65). 
Psoriasis Area Severity Index (PASI) can be used to assess psoriasis severity in moderate to 
severe conditions and is a well validated and sufficiently detailed measure (170). To ensure 
comparability between studies, only those that included PASI as an outcome measure were 
included. Studies that included mixed psoriasis phenotypes or did not report the type of 
psoriasis were excluded.  
Two researchers conducted searches, extracted data, and assessed Risk of Bias according the 
methods specified by the Cochrane collaboration (171). Any disagreement was resolved by 
discussion with another colleague  if agreement could not be reached (see Chapter 4 for 
details). Fig. 5.1 presents a flowchart of study selection process. 
Data were analysed in RevMan 5.1 as Relative Risk (RR) or Mean Difference (MD) with 95% 
confidence intervals (95% CI) using fixed or random-effect models depending upon 
heterogeneity (172). A 50% reduction of PASI score (PASI 50) was selected as the criterion 
for a clinically effective response in the meta-analyses (173).  
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Fig. 5.1 Flow chart of selection of randomised controlled trials (RCTs) of internal herbal 
medicine for psoriasis [adapted from Deng 2013 (135)]. 
Entries after duplicates removed 
(n = 1614)
Excluded (n = 475): 
 
E1. Not related to psoriasis, or similar disorders (259) 
E2. Not principally treated with CAM (200) 
E3. Not in Chinese, English or Japanese (16) 
 
Excluded (n = 1129): 
 
E4. Not related to clinical trials (89) 
E5. Epidemiology, economic studies etc (27) 
E6. Review of clinical studies in humans (154) 
E7. Adverse events, toxicology, chemical analysis etc (28) 
E8. Uncontrolled clinical trials (357) 
E9. Phototherapy, purified compounds, manual therapy, or 
CAM other than herbal therapy (97) 
E10. Non-randomized trials (inc. multiple conditions) (87) 
E11. Issues with study design (145) 
E12. Outcome measurement not PASI (42) 
E13. Non-APP pharmaceutical as control intervention (69) 
E14.Participants not all diagnosed as psoriasis 
vulgaris/plaque psoriasis (5) 
E15. Not internal herbal medicine (28) 
E16: Combined internal herbal medicine & APP (1) 
Full-text articles assessed for eligibility     
(n = 1139) 
Reference lists  
(n=31) 
Database retrieval  
(n=2020) 
RCTs included in qualitative synthesis     
(n = 10)
RCTs included in meta-analysis 
(n = 10)
Entries screened on basis of title & abstract 
(n = 1614) 
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5.2.3 Results 
2,020 entries were retrieved from the databases and 31 studies from reference lists. After 
removing duplicates, the remaining 1,614 entries were screened and full-texts obtained of 
1,139 articles. Ten studies met the inclusion criteria (174-183).  
9 studies were conducted in China and one was conducted in India. Eight were published in 
Chinese and the remaining two were published in English. In total, 658 patients completed 
the ten included studies (Table 5.2). The largest study was of 105 participants (174) and the 
smallest was of 50 participants (177). Study duration ranged from 4 weeks (1 study) (181) to 
6 months (1 study) (175) with the most common duration being 2 months (5 studies).  
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Table 5.2 Characteristics of the ten studies of internal herbal medicine for psoriasis [adapted from Deng 2013 (135)] 
First author, 
Publication 
year, 
Location, 
Duration, 
Follow-up 
Sample size (R/A), 
Gender (M/F), 
Age: mean ± SD (range), 
RCT design 
(T vs C) 
Diagnosis, 
Outcome measures, 
Results 
Dropouts, 
Adverse events (AEs) 
Risk of Bias 
(SG, AC, BPt, 
BPl, BOA, 
IOD, SOR) 
Fan, M. 2005; 
Shandong, 
China; 
60 days; 
0.5-1 year 
T:65/65, C:40/40; 
T:29/36, C:19/21; 
T: 30.5±9.1, (17-60) yrs, C: 32.1±10.9, 
(16-65) yrs; 
2 gps, active-control: int HM + ext WM 
vs int APP + ext WM. 
Psoriasis vulgaris; 
PASI: T≈C (t=1.25,p >0.05); 
Clearance rate: T≈C 
(χ2=0.324,p >0.05); 
Response rate: T≈C 
(χ2=0.375,p >0.05). 
 
None; 
AEs (incidence, proportion): 
T: mild diarrhoea (2, 3.1%); 
C: total (37, 92.5%) including: dry mouth (22, 55.0%), 
cheilitis (3, 7.5%), dry skin (3, 7.5%), itching (3, 
7.5%), increased serum lipids (4, 10.0%), headache (2, 
5.0%). 
T<C (χ2=84.81, p <0.01). 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Ho, S. G. Y. 
2009; 
Hong Kong, 
China; 
6 mths; 
NS 
T:21/14, C1:20/19, C2:20/17; 
T:14/7, C1:18/2, C2:18/2; 
T:48.52, (25-80) yrs, C1: 38.45, (21-68) 
yrs, 
C2:43.45, (27-61) yrs; 
3 gps, placebo & active-controls: int HM 
vs int APP vs int Plac. 
Chronic plaque psoriasis; 
PASI: T>C1 (p=0.001), C1<C2 
(p<0.01), T≈C2 (p>0.05); 
PGA: T>C1 (p=0.001), C1<C2 
(p<0.01), T≈C2 (p>0.05); 
PDI: T≈C1≈C2. 
T:7, C1:1, C2:3; 
AEs (incidence,  issues): 
T: 48%,  majority were infections & gastrointestinal 
issues, minority were developed abnormalities in liver 
function; 
C1: 65%, majority were nausea, vomiting & increased 
liver enzyme levels; 
C2: 30%, infections & increased liver enzymes. 
SG: L 
AC: U 
BPt: H 
BPl: H 
BOA: L 
IOD: H 
SOR: L 
Ma, W.L. 
2010; 
Guangdong, 
China; 
3 mths; 
NS 
T:52/52, C:51/51; 
T:28/24, C:26/25; 
T: 39.04 ±18.58, (18-72) yrs, C: 40.67 
±13. 64, (18-74) yrs; 
2 grs, active-control: int HM vs int APP. 
Psoriasis vulgaris (‘blood heat 
type’); 
Overall clinical efficacy: T≈C 
(p>0.05); 
PASI: T≈C (p>0.05). 
 
None; 
AEs (T/C): 
cheilitis (0/25), headache (0/6), tinnitus (0/2), 
gastrointestinal disorder (5/0), abnormal liver function 
(0/4), dry skin & peeling (0/34), increased serum lipid 
(0/8). 
Incidence: T<C (p<0.05). 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Pandey, S.S. 
1994; 
Varanasi, 
India; 
12 wks; 
NS 
T:34/30, C: 16/14; 
T:23/11, C:11/5; 
T:34.23 ±10.15, (18-59) yrs, C: 35.0 
±8.41, (22-54) yrs; 
2 gps, double-blind, placebo-controlled: 
int HM + ext WM vs int Plac + ext WM. 
Uncomplicated psoriasis vulgaris; 
PASI: T<C (p<0.001). 
T:4, C:2; 
AEs: No toxic effects. 
SG: U 
AC: L 
BPt: L 
BPl: L 
BOA: U 
IOD: U 
SOR: L 
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Qiu, S. 2005; 
Shanxi, 
China; 
2 mths; 
NS 
T:32/32, C:32/32, N:30/30; 
T:18/14, C:17/15,N:17/13; 
T: 30.42±8.57, (15-62) yrs, C: 
33.34±8.21, (16-65) yrs, N: 31.45±7.5, 
(20-58) yrs; 
3 gps, active-control with a normal 
reference group: int HM vs int APP vs 
non-intervention. 
Psoriasis vulgaris in stable stage; 
Response: T≈C (p>0.05); 
Clearance: T<C (p<0.05); 
Lesion area, erythema, scaling, 
itching & PASI: reduced after study 
in T & C (p<0.01); 
Haemorheology parameters: 
reduced after study in T (p<0.05). 
None; 
AEs: 
T: diarrhoea (2),  constipation & vomiting (1); 
C: liver enzymes↑ (3), BUN (blood urea nitrogen) ↑ 
(1), serum lipid ↑ (5). 
 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Wu, Y.S. 
2003; 
Shanghai, 
China; 
8 wks; 
NS 
T:30/30, C:20/20; 
T:24/6, C:15/5; 
T: 70.03±7.4 yrs, C: 67.10±4.5 yrs; 
2 gps, active-control: 
int HM vs int APP. 
Psoriasis vulgaris (‘blood heat 
type’); 
PASI: T≈C (p=0.071); 
Clinical efficacy: T≈C (p>0.05); 
Syndrome score: 
T (post-care) > T (pre-care) 
(p<0.05); 
Pulse, urine & stool, and skin colour 
score: C (post-care) > C (pre-care) 
(p<0.05);  
Tongue score: C (post-care) ≈ C 
(pre-care) (p<0.05); 
Thirstiness score: C (post-care) < C 
(pre-care) (t=-6.84). 
None; 
AEs:  
T: stomach disorder (n=2, 6.7%); 
C: obvious dry mouth, mild desquamation of lips 
(n=15, 75.0%). 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Xie, S.Q. 
2009; 
Shanghai, 
China; 
8 wks; 
NS 
T:41/41, C:30/30; 
T:21/20, C:16/14; 
T:42.5, (16-69) yrs, C:37.5, (17-66) yrs; 
2 gps, active-control: 
int HM vs int APP. 
Psoriasis vulgaris; 
Clearance: T>C (p<0.05); 
Response: T≈C (p>0.05); 
PASI: T<C (p<0.05). 
None; 
AEs: T<C (4.9% vs 80.0%, p<0.01). 
T: gastrointestinal disorder (2); 
C: dry skin & mucous (23), increased liver enzymes 
(2), increased serum lipids (2), headache, tinnitus, etc. 
(1), gastrointestinal disorder (2).  
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Zhang, F.R. 
1999; 
Shang Dong, 
China; 
4 wks; 
NS 
T:29/25, C:32/27; 
T:16/9, C:20/7; 
T:26.68±12.3, (16-45) yrs, 
C:28.62±14.23, (16-60) yrs; 
2 gps, double-blind, placebo-controlled: 
int HM + ext WM vs int Plac + ext WM. 
Psoriasis vulgaris; 
PASI: T<C (p<0.001); 
Clinical efficacy: T>C (p<0.001). 
T:4, C:5; 
AEs: mild gastrointestinal tract (T=4) including 3 mild 
abdominal pain and 1 instance of diarrhoea; prolonged 
menstruation (T=1). C. no information on AEs 
reported.  
SG: L 
AC: U 
BPt: L 
BPl: L 
BOA: U 
IOD: H 
SOR: L 
Zhang, M. 
2007; 
T:NS/34, C:NS/33; 
T:25/9, C:27/6; 
Moderate to severe plaque psoriasis; 
Reduction of PASI: T≈C (p>0.05); 
NS; 
AEs: T: mild gastrointestinal tract (5), menstrual 
SG: L 
AC: U 
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Sichuan, 
China; 
8 wks; 
NS 
T:32.4 (18-57) yrs, C:30.5 (21-52) yrs; 
2 gps, active-control: 
int HM + ext WM vs int APP + ext WM. 
PASI50/PASI70: T≈C (p>0.05); 
Change of DLQI: T≈C (p>0.05); 
DLQI  ∝ PASI: C (r = 0.784, p 
<0.01), T ( r = 0.851, p < 0.01); 
Change of DLQI ∝ Reduction of 
PASI: C (r = 0.625, p < 0.01), T (r = 
0.578, p < 0.01). 
disorder (1); 
C: dry mouth (26), dry skin/itching (17), cheilitis (12), 
palmoplantar desquamation & dry eyes (5), which 
were mild to moderate, and increased liver enzymes 
(1) & increased blood lipids (2). 
BPt: L 
BPl: L 
BOA: U 
IOD: U 
SOR: L 
Zhang, H.Y., 
2008; 
Anhui, China; 
3 mons; 
NS 
T:34/34, C:18/18, N:10/10; 
T:17/17, C:10/8, N:5/5; 
T: 35.12 ±13.63 yrs, C: 34.50±12.99 yrs, 
N:27.40±8.68 yrs; 
3 gps, activated-controlled RCT 
compared with normal population: int 
HM vs int APP vs non-intervention. 
 
Progressive psoriasis vulgaris; 
Clinical efficacy: T≈C (χ2=0.416, 
p>0.05); 
PASI: T≈C (p>0.05); 
TNF-α & IL-8: significantly 
decreased in T gp (p<0.01). 
 
No; 
AEs: NS. 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
T: treatment group, C: control group, N: normal group, R/A: registration/analysis, M/F: male/female, NS: not stated, CM: Chinese medicine, WM: Western medicine, top.: 
topical, sys.: systemic, yrs: years, wks: weeks, mins: minutes, RCT: randomised clinical trial 
 
Risk of Bias Categories 
SG: Sequence Generation, AC: Allocation Concealment, BPt: Blinding of Participants, BPl: Blinding of Personnel, BOA: Blinding of Outcome Assessment, IOD: 
Incomplete Outcome Data, SOR: Selective Outcome Reporting. 
 
Risk of Bias Judgements 
L: low risk, U: Unclear risk, H: High risk 
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Two studies compared internal HM with internal placebo and seven used a comparison with 
an internal APP (Table 5.3). Both comparisons were conducted in one study (175). Acitretin 
was the most common APP (176, 178-180, 182, 183). Other APPs included methotrexate 
(175) and vitamin A acid (174). PASI score was measured in each study. In addition to 
PASI, the outcome measures also included: clinical efficacy (174-183); Dermatology Life 
Quality Index (DLQI) (184), Physician’s Global Assessment (PGA) and Psoriasis Disability 
Index (PDI) (175), Tumour necrosis factor alpha (TNF-α) and Interleukin 8 (IL-8) (182), 
CM syndrome score (179), and symptom scores (scaling, erythema, itching and lesion area) 
and haemorheology indices (178).  
The internal HMs involved single herbs (n=2) and multiple ingredient formulae (n=8) (Table 
5.3). The internal HMs were administered as: decoctions (n=6), capsules (n=3), or granule 
(n=1). Ten different herbs or formulae were investigated: aqueous extract of neem leaves in 
capsules, Triptergium wilfordii (TW) capsules, Lanchuan Qingre (also called Longfuan) 
decoction, Wentonghuayu formula in capsules, Yinxiebing formula as decoction, Huoxue 
Sanyu Xiaoyin decoction, Qingre Jiedu decoction, Kangyin No. 1 formula as decoction, 
Haitang decoction, and Compound Zeqi granule.  
Three studies used 3 groups (175, 178, 182) and the remaining studies used 2 groups. In 
addition to the internal medicines, 3 studies used an external remedy as a co-intervention 
(174, 177, 183). In one study, internal methotrexate was combined with folic acid (175).  
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Table 5.3 Interventions used in the ten studies of internal herbal medicine for psoriasis [adapted from Deng 2013 (135)] 
Study ID Internal HM and ingredients HM vs APP/Plac (T vs C) Co-intervention (same in T&C) 
Fan 2005 Lanchuan Qingre (Long fu an) decoction 
(250 ml): Ban lan gen (Isatis tinctoria root) 
30g, Bai mao gen (Imperata cylindrica 
stem) 30g, Sheng di (Rehmannia glutinosa 
root) 30g, Zi cao (Lithospermum 
erythrorhizon root) 30g, Dan shen (Salvia 
miltiorrhiza root) 30g, Chi shao (Paeonia 
veitchii root) 10g, Chuan xiong (Ligusticum 
wallichii dried root) 10g, Tu fu ling (Smilax 
glabra root) 15g, Bai hua she she cao 
(Oldenlandia diffusa grass) 10g, Wu shao 
she (Zaocys dhumnades) 10g, Bai xian pi 
(Dictamnus dasycarpus bark) 10g, Gan cao 
(Glycyrrhiza uralensis root) 6g, etc, which 
was prepared by the authors’ hospital 
(H062003001)  
T: 250 ml daily divided into 2 
administrations; 
 
C: vitamin A acid tablet (10 mg) 
manufactured by Shandong Liangfu 
Pharmaceutical Co., Ltd (H1097005). 
20 mg daily divided into 2 
administrations. 
Skin heal Cream (Compound 
Triamcirolone acetonide Cream): 10g/tube, 
manufactured by Xinxiang Forever 
Pharmaceutical Co., Ltd. 2 X day. 
Ho 2009 
 
T:  
Wen-tong-hua-yu formula (capsule): Ma 
huang (Ephedra sinica herb) 6g, Chuan wu 
(Aconitum carmichaeli root) 10g, Baijiezi 
(Brassica alba seed) 10g, Rou gui 
(Cinnamomum cassia bark) 3g, Gan jiang 
(Zingiber officinale rhizome) 3g, Lu jiao 
shuang (Cervus nippon antler) 15g, Shu di 
(Rehmannia glutinosa root) 10g, Tu fu ling 
(Smilax glabra root) 60g, Bai xian pi 
(Dictamnus dasycarpus bark) 30g, Bai mao 
gen (Imperata cylindrica stem) 30g, Dan 
shen (Salvia miltiorrhiza root) 15g, Ji xue 
teng (Spatholobus suberectus stem) 30g, Zi 
cao (Lithospermum erythrorhizon root) 30g, 
Huai hua (Sophora japonica flower) 30g, 
Zhi gan cao (Glycyrrhiza uralensis root) 6g, 
Qing dai (Indigo naturalis) 6g. 
T: NS; 
 
C1: Methotrexate, initial doses of 2.5–
5 mg, increased to 10 mg/week if 
normality of complete blood count 1 
week later, then added with 2.5 
mg/week (≤30 mg/week) till a good 
clinical response.  
Folic acid: 5 mg daily; 
 
C2: identical placebo capsule used in 
T gp. 
None. 
Ma 2010 Yinxiebing formula: Tu bie chong T: 1 decoction daily divided into two None. 
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(Eupolyphaga sinensis), Qing dai (Indigo 
naturalis), Gan cao (Glycyrrhiza uralensis 
root) each 10g, Dan shen (Salvia 
miltiorrhiza root), Bai hua she she cao 
(Oldenlandia diffusa herb), Sheng di huang 
(Rehmannia glutinosa root) each 30g. For 
dry stool, add Sheng da huang (Rheum 
palmatum root), Tao ren (Prunus persica 
seed), Huo ma ren (Cannabis sativa seed), 
Rou cong rong (Cistanche salsa herb), etc. 
For severe itching, add Quan xie (Buthus 
martensii), Wu gong (Scoropendra 
subspinipes mutilans), Wu shao she (Zaocys 
dhumnades), Chan tui (Cyptotympana 
atrata slough), Lu feng fang (Polistes 
olivaceous nest), etc. For head, face & upper 
limbs involved, add Jing jie (Schizonepeta 
tenuifolia herb), Fang feng (Saposhnikovia 
divaricata root), Bo he (Mentha haplocalyx 
leaf), Sang zhi (Morus alba branchlet), Gui 
zhi (Cinnamomum cassia twig), Ye ju hua 
(Chrysanthemum indicum flower), Ling 
xiao hua (Campsis radicans flower), etc. 
For trunk & lower limbs involved, add Yi 
ren (Coix lacryma-jobi seed), Shan yao 
(Dioscorea opposita root), Tu fu ling 
(Smilax glabra root), Bai zhu (Atractylodes 
macrocephala rhizome), Ba qia (Smilax 
china root), Gua lou gen (Tirchosanthes 
kirilowii fruit), Chuan niu xi (Cyathula 
officinalis root), etc. For whole body 
involved, add Wei ling xian (Clematis root). 
doses (in the morning and in the 
evening); 
 
C: acitretin capsule (Fang xi) 
manufactured by Huapont Pharm Co., 
Ltd. 10 mg, 3 X day. 
Pandey 1994 Aqueous extract of neem leaves: Yin jian 
(Azadirachta indica leaf), major ingredient 
is Nimbidin. 
T: 1 capsule, 3 X day, total 90 
capsules; 
 
C: placebo- 1 capsule, 3 X day. 
Ointment (5% crude coal tar & 3% 
salicylic acid in vaseline base): in night & 
next day to expose to sun for 15 mins after 
a thorough bath. 
Qiu 2005 
 
Huoxue Sanyu Xiaoyin decoction: San leng 
(Sparganium stoloniferum root) 10g, E zhu 
(Curcuma phaeocaulis rhizome) 10g, Tao 
T: 1 decoction daily divided into two 
doses (in the morning and in the 
evening); 
None. 
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ren (Prunus persica seed) 10g, Hong hua 
(Sophora japonica flower) 10g, Ji xue teng 
(Spatholobus suberectus stem) 30g, Gui jian 
yu (Euonymus alatus herb) 30g, Bai hua she 
she cao (Oldenlandia diffusa herb) 30g, Dan 
shen (Salvia miltiorrhiza root) 30g, Chen pi 
(Citrus tangerina peel) 30g.  
 
C: acitretin tablet manufactured by 
Chongqing Huapont Pharm. Co., LTD. 
10 mg, 2 X day. 
Wu 2003 
 
Qingre Jiedu decoction: Sheng di 
(Rehmannia glutinosa root) 30g, Chi shao 
(Paeonia veitchii root) 15g, Zi cao 
(Lithospermum erythrorhizon root) 30g, 
Ban lan gen (Isatis tinctoria root) 30g, Shan 
dou gen (Sophora tonkinensis root) 9g, Bai 
mao gen (Imperata cylindrica stem) 30g, Ba 
qia (Smilax china root) 30g, Ze qi 
(Euphorbia helioscopia herb) 15g.  
T: daily, divided into 2 (in the 
morning & evening, after meal); 
 
C: acitretin (Neotigason), Roche, 
X20000166. 10 mg, 2 X day. 
None. 
Xie 2009 Kang Yin No. 1 formula: Sheng di huang 
(Rehmannia glutinosa root), Bai hua she she 
cao (Oldenlandia diffusa grass), Tu fu ling 
(Smilax glabra root) each 30g, Bai xian pi 
(Dictamnus dasycarpus bark) 20g, Dan shen 
(Salvia miltiorrhiza root), Da qing ye (Isatis 
indigotica leaf), Sheng huai hua (Sophora 
japonica flower), Ye jiao teng (Polygonum 
multiflorum dried vine) each 15g, Mu dan pi 
(Paeonia suffruticosa bark), Chi shao yao 
(Paeonia veitchii root), Zi cao 
(Lithospermum erythrorhizon root) each 
12g, Shan dou gen (Sophora tonkinensis 
root), Gan cao (Glycyrrhiza uralensis root) 
each 6g.  
T: 1 decoction daily divided into two 
administrations (after meals in the 
morning and in the evening); 
 
C: acitretin capsule manufactured by 
Huapont Pharm Co., Ltd. H20010788, 
10 mg, 2 X day. 
None 
Zhang 1999 Triptergium wilfordii (TW) capsule: 
contained 3g TW crude drug (equivalent), 
which was extracted using alcohol & ethyl 
acetate at Dermatology Institute, Chinese 
Academy of Medical Sciences, and packed 
in identical opaque capsules.   
T: 6 capsules daily; 
 
C: placebo capsule contained edible 
starch, packed in identical opaque 
capsule. 6 capsules daily. 
Urea cream. 
Zhang 2007 Haitang decoction: Kunming shan hai tang T: 20-30 ml, 3 X day; Pine Tar ointment: prepared by the 
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(Tripterygium hypoglaucum root), Lai fu zi 
(Raphanus sativus seed), Fo shou (Citrus 
medica fruit), etc.   
 
C: acitretin capsule, initial 20 mg, 
1Xday for a week, then increased to 
0.5-0.7 mg/(kg·d) (30-40 mg, 1 X day 
for 7 wks.  
authors’ hospital.  1 X day. 
Zhang 2008 Compound Zeqi granule: Ze qi (Euphorbia 
helioscopia herb), Bai hua she she cao 
(Oldenlandia diffusa herb), Da qing ye 
(Isatis indigotica leaf), Ban lan gen (Isatis 
tinctoria root), Ji xue teng (Spatholobus 
suberectus stem), etc, which were provided 
by the authors’ hospital.  
T: 1 bag (30g crude drug), 3 X day for 
3 mths; 
 
C: acitretin capsule (Fang xi) 
manufactured by Huapont Pharm Co., 
Ltd. 10 mg, 3 X day. 
None. 
T: treatment group, C: control group, HM: herbal medicine, SHM: systemic herbal medicine, SAPP: systemic anti-psoriatic pharmacotherapy, SPlac: systemic placebo 
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5.2.3.1 Description of studies 
Compound Zeqi granule 
Zhang et al (2008) compared Compound Zeqi granule with acitretin (Fangxi) in an 
active-controlled RCT with an untreated normal group as a reference (182). After 3 months, 
there were no significant differences in clinical efficacy and PASI score between the 
treatment group and the control group. Serum TNF-α and IL-8 were significantly decreased 
in both the test and control groups although the levels were still higher than in the normal 
group. The authors concluded that the formula could remarkably alleviate the symptoms of 
the disease and decreased the abnormal serum levels of TNF-α and IL-8. 
Azadirachta indica leaf (capsule) 
Pandey et al (1994) reported a double-blind, placebo-controlled RCT of an aqueous extract 
of neem (Azadirachta indica) leaves in capsules with an ointment that contained 5% crude 
coal tar and 3% salicylic acid being used in both groups (177). After 12 weeks, there was a 
significant difference in PASI between groups in favour of the HM group. No side effects or 
toxicity issues were found during the trial. The authors concluded that the addition of 
Azadirachta indica produced a faster and better response compared to the conventional coal 
tar ointment alone. 
Triptergium wilfordii capsule 
Zhang et al (1999) conducted a comparison between Tripterygium wilfordii (TW) capsule 
plus topical urea cream versus placebo plus urea cream in a randomised double blinded trial 
(181). After 4 weeks, there were significant differences in PASI score and clinical efficacy 
between groups in favour of TW. Regarding the treatment group, the authors concluded that 
TW exerted a remarkably quick efficacy in patients without any severe AEs in the 
short-term. 
Wentonghuayu formula (capsule) 
Ho et al (2009) conducted a 3-group comparison of Wentonghuayu formula in the form of a 
capsule versus a placebo capsule versus methotrexate (MTX) for 6 months (175). The first 
two groups were double blind but the APP group was single blind owing to the difference in 
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the medication appearance compared to the HM and placebo capsules. PASI, Physician’s 
Global Assessment (PGA) and Psoriasis Disability Index (PDI) were assessed on a monthly 
basis. The study confirmed the efficacy of methotrexate but found no difference between 
HM and placebo groups which were both less effective than the MTX group. 
Qingre Jiedu decoction 
Wu et al (2003) compared Qingre Jiedu decoction with acitretin (Neotigason) in elderly 
patients with ‘blood-heat’ type psoriasis vulgaris based on the principle of Chinese Medicine 
Syndrome Differentiation. They used PASI, clinical efficacy, and syndrome assessment 
(tongue, pulse, urine & stool, thirstiness level, and skin colour) as outcomes (179). After 8 
weeks, no difference was found in PASI or clinical efficacy between the two groups. In 
terms of syndrome assessment, there were significant differences between pre-care and 
post-care in the treatment group. Whereas there was no significant difference in tongue, 
urine & stool, or skin colour between pre-care and post-care in the control group. The 
thirstiness level was aggravated in the control group during the study. Therefore, the authors 
considered that the HM formula produced effects comparable to acitretin in elderly patients 
with blood-heat type psoriasis vulgaris. In particular, the improvement in thirstiness was 
remarkably superior in the treatment group. 
Lanchuan Qingre (aka Longfuan) decoction  
Fan et al (2005) compared Lanchuan Qingre decoction with vitamin A acid tablets in 
patients with psoriasis vulgaris. All participants topically applied Skinheal Cream 
(compound triamcirolone acetonide cream) (174). After 60 days, there were no significant 
differences in PASI score, clearance rate or response rate between the two groups. Erythema 
and itching responded better to the herbal formula (decoction) whereas lesion size and 
thickness trended to improve in the vitamin A acid group. The AE incidence rates were 3.1% 
(treatment group) and 92.5% (control group), which were significantly different. The former 
was mild diarrhoea (n=2), and the latter involved: dry mouth (n=22), cheilitis (n=3), dry skin 
(n=3), itching (n=3), increased serum lipids (n=4) and headache (n=2). The authors 
concluded that Lanchuan Qingre decoction was an effective formula for psoriasis with fewer 
AEs than vitamin A acid tablets. 
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Huoxue Sanyu Xiaoyin decoction 
Qiu et al (2005) assessed the efficacy of Huoxue Sanyu Xiaoyin Decoction on psoriasis 
vulgaris in a 3-group RCT controlled by acitretin, with a normal population as the reference 
for haemorheology parameters (178). After 2 months, there was no significant difference in 
response rate between groups but there was a significant difference in clearance rate (T 
46.88% vs C: 56.25%). In terms of lesion area, erythema, scaling, itching & PASI score, 
reductions were found in both groups during the study. In the treatment group, 
haemorheology parameters reduced during the treatment period in the HM but remained 
higher than in the normal group. The authors concluded that Huoxue Sanyu Xiaoyin 
decoction showed remarkable effectiveness in psoriasis and its mechanism of action 
possibly involved the promotion of microcirculation. 
Haitang decoction 
In Zhang et al (2007), the comparison was between the retinoid acitretin and the HM Hai 
Tang decoction with topical pine tar ointment being used in both groups but the authors 
placed the HM in the control group and the report focused on the result for acitretin (183). 
The scores for PASI and DLQI indicated improvements in both groups but there was no 
statistic reported for the between-group differences in the paper. The authors concluded that 
acitretin was effective in moderate to severe plaque psoriasis and was comparable to 
Haitang decoction.    
Kangyin No. 1 formula (decoction) 
Xie et al (2009) conducted a clinical comparison between Kangyin (No.1) formula decoction 
and acitretin capsules (180). After 8 weeks, significant differences were found in clearance 
rate and PASI score between the two groups, but there was no significant difference for 
response rate. The incidence of adverse effects in the treatment group was lower than in the 
control group. Therefore, the authors thought the HM was a safe and effective medication 
with an efficacy similar to that of acitretin but with fewer side effects. 
Yinxiebing formula (decoction) 
Ma et al (2010) compared Yinxiebing Formula with modifications according to symptoms 
with acitretin in patients diagnosed with ‘blood heat type’ psoriasis vulgaris according to 
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Chinese medicine principles (176). For clinical efficacy and PASI score, there were no 
significant differences between the two groups after 3-months of treatment. Meta-analysis 
was applied to the clinical efficacy scores but the PASI score data were not suitable for 
analysis. The authors concluded that Yinxiebing formula can be used as a routine treatment 
for blood-heat type psoriasis and had an efficacy comparable to that of acitretin. 
5.2.3.2 Methodological assessment 
Methodological assessment was undertaken according to the Cochrane Handbook, the 
relevant Risk of Bias evaluations (171) are summarised in Table 5.2. All studies stated 
‘randomized’ or used a similar expression. Three stated the specific method of random 
sequence generation: including ‘shuffling random cards’ (175), and ‘random number table’ 
(181, 183), which were judged as low risk on this item. As one study used sequentially 
numbered drug containers, it was judged as low risk on the method of allocation 
concealment (177). In two placebo-controlled studies, identical capsules were used to blind 
the participants, so these studies were assessed as low risk of bias on this item (177, 181). In 
a 3-group study that compared a placebo group and APP group to the HM group (175), the 
APP was presented in a different form to the placebo and HM, so the study was judged as 
high risk on blinding of participants. The remaining 7 studies were also assessed as high risk 
for this item.  
The above eight studies were also judged as high risk of bias for blinding of personnel 
whereas the remaining two were considered low risk (177, 181). One study was blinded to 
outcome assessors and assessed as low risk (175). The others did not provide any 
information on this item so they were judged as unclear risk of bias. As missing outcome 
data due to dropouts resulted in imbalance in numbers across the intervention and control 
groups, two studies were judged as high risk of bias on incomplete outcome data (175, 181). 
Another two studies were judged as unclear risk of bias for missing data since they either did 
not provide reasons for dropouts (177), or the enrolment numbers of participants were not 
stated (183). The other studies reported all patients completed the study and were judged as 
low risk. Each study reported all outcomes stated in the methods, so bias regarding selective 
reporting was judged as low. There were too few studies (less than 10) in each of the two 
groups for assessments of publication bias. 
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5.2.3.3 Meta-analysis 
Meta-analyses were conducted for PASI and clinical efficacy,in RevMan 5.1 (Table 5.4). All 
studies provided PASI data but the PASI values in one study were significantly different 
between groups at baseline and therefore not suitable for the pooling of between groups 
effects at the end of treatment, so the pre- and post- intervention scores were assessed for 
this study (176). Two studies did not provide suitable data on clinical efficacy (177, 182). 
Therefore, RevMan 5.1 was applicable to 10 studies for PASI (174-183) and 8 studies for 
clinical efficacy (174-176, 178-181, 183).  
The other outcome measures were varied and were each used in only one study so these 
were not included in the meta-analyses.  
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Table 5.4 Distribution of data available for meta-analysis in Review Manager 5.1 by outcome measure and study design 
                                                   Study design 
Outcome measures 
Int. HM  
vs 
Int. Placebo*  
Int. HM 
vs 
Int. APP* 
Clinical efficacy 
Ho 2009 
Zhang 1999 
Fan 2005 
Ho 2009 
Ma 2010 
Qiu 2005 
Wu 2003 
Xie 2009 
Zhang 2007 
Scaling score X Qiu 2005 
Erythema score X Qiu 2005 
Itching score X Qiu 2005 
Lesion area X Qiu 2005 
Haemorheology X Qiu 2005 
CM syndrome score X Wu 2003 
TNF-α X Zhang 2008 
IL-8 X Zhang 2008 
PASI Ho 2009 Fan 2005 
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Pandey 1994 
Zhang 1999 
Ho 2009 
Ma 2010# 
Qiu 2005 
Xie 2009 
Wu 2003 
Zhang 2007 
Zhang 2008 
DLQI X Zhang 2007 
PGA Ho 2009 Ho 2009 
PDI Ho 2009 Ho 2009 
*: including co-intervention used in both arms 
#: PASI baseline differences between treatment group and control group. This study was not suitable for meta-analysis - so pre- and post- intervention analyses were 
conducted. 
HM: Herbal Medicine, APP: Anti-psoriatic Pharmacotherapy, CM: Chinese Medicine, WM: Western Medicine, Int. internal treatment, Ent.: external treatment, PASI: 
Psoriasis Area Severity Index, DLQI: Dermatology Life Quality Index, PGA: Physician’s Global Assessment, PDI: Psoriasis Disability Index 
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Meta-analysis of PASI score 
For PASI score, nine studies provided data suitable for meta-analysis. These were divided 
into two groups based on study design: 1. Internal HM versus Internal Placebo, and 2. 
Internal HM versus Internal APP. These included studies with identical co-interventions 
used in both arms (Table 5.4). Since PASI baseline in the HM group was significantly 
higher than in the acitretin group at the beginning of Ma et al 2010, this study was not 
included in the pool. At end of treatment, PASI reduced in both groups and there was no 
difference between the two groups (176). 
Both the Internal HM versus Internal Placebo (175, 177, 181), and Internal HM versus 
Internal APP (174, 175, 178-180, 182, 183) groups included studies that had identical 
co-interventions used in both arms (Table 5.4).  
Group 1.  Internal HM vs Internal Placebo (3 studies, 6 groups) 
For Pandey et al 1994 and Zhang et al 1999, which both used single HMs in capsules, i.e. 
aqueous extract of neem leaves (Azadirachta indica leaf) and Tripterygium wilfordii (TW) 
respectively, the HMs were both superior to the placebo capsules, (MD -4.73; 95% CI: 
-6.49, -2.97, and MD -7.52; 95% CI: -8.45, -6.59 respectively). However, no significant 
difference was found between Wentonghuayu formula (capsule) and its placebo capsule 
(MD 2.10; 95% CI: -4.93, 9.13) in Ho et al 2009. These meta-analysis results supported 
the authors’ conclusions (Fig. 5.2).  
The pooled data found internal HM was superior to internal placebo for PASI score (MD 
-5.00; 95% CI: -8.20, -1.81) but the heterogeneity was high (85%). When Zhang et al 
(1999) was removed the heterogeneity was reduced (71%) but remained high. This, 
heterogeneity could have resulted from the following differences between the studies: 
treatment duration (1, 3, or 6 months), intervention (multi-herb formula vs single herb). 
Another reason could be the severity of the psoriasis. In Zhang et al. 1999 the mean score 
at baseline was about 10, but the mean PASI score was about 19 in Pandey 1994 and it 
was 18 to 22 in Ho et al. 2009.  
Group 2. Internal HM versus Internal APP (7 studies, 14 groups) 
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For the comparison with acitretin and various HM preparations, there were no significant 
differences in PASI score as follows: Huoxue Sanyu Xiaoyin Decoction (MD -0.05; 95% 
CI: -0.46, 0.36) (178), Qinre Jiedu decoction (MD 0.83; 95% CI: -1.35, 3.01) (179), 
Kangyin No.1 formula (MD -0.78; 95% CI: -1.64, 0.08) (180), Hai Tang decoction (MD 
-1.05; 95% CI: -2.41, 0.31) (183), and Compound Zeqi granule (MD -1.17; 95% CI: 
-3.09,  0.75)  (182). These results were consistent with the authors’ conclusions.  
The pooled data showed no difference between the HMs and acitretin (MD -0.39; 95% 
CI: -0.92 to 0.15, I2=27%) on PASI score. Lanchuan Qingre decoction appeared superior 
to vitamin A acid on PASI score (MD -0.45; 95% CI: -0.76,  -0.14) (174) whereas the 
authors reported no significant difference between the two groups. Methotrexate was 
superior to Wentonghuayu formula in Ho et al 2009 (MD 10.30; 95% CI: 3.90, 16.70). 
This result supported the authors’ conclusions.  
For the pooled data of Group 2, no significant difference between internal HM versus 
internal APP was found on PASI score (MD -0.36, 95% CI: -0.93, 0.20, I2=64%) (Fig. 
5.2). The high heterogeneity was related to Ho et al 2009. When this study was removed 
the pooled result still showed no difference but with low heterogeneity (MD -0.37, 95% 
CI:-0.68, -0.07, I2=19%). 
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Fig. 5.2 Forest plot of PASI score: Internal Herbal Medicine (HM) versus placebo or 
Anti-psoriatic Pharmacotherapy (APP) (with or without co-intervention used in both groups)
Meta-analysis of Clinical efficacy  
For clinical efficacy, the rates were generated by calculating PASI scores based on a number 
of different thresholds according to the particular study. For data pooling, to enable 
comparison between studies only cases having at least a 50% efficacy rate or a 50% 
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reduction in PASI were included (185). Results were analysed with risk ratio (RR) and a 
random-effects model was used as the calculation methods for clinical efficacy were 
different between studies. In the meta-analyses, a higher score showed greater efficacy. 
For the eight studies that provided data suitable for meta-analysis, 2 groups were identified 
as follows: 1. Internal HM versus Internal Placebo (175, 181), and 2. Internal HM versus 
Internal APP (174-176, 178-180, 183). These included studies that used identical 
co-interventions in both arms (Table 5.4).  
Group 1.  Internal HM vs Internal Placebo (2 studies, 4 groups) 
For Ho et al (175), no significant difference between Wentonghuayu formula (capsule) and 
placebo (capsule) was found on clinical efficacy (RR 0.61, 95% CI: 0.13, 2.84). However, 
the comparison between Tripterygium wilfordii (TW) capsule and placebo, with urea cream 
as co-intervention, showed a significant difference (RR 8.64, 95% CI: 2.96,25.19) in favour 
of TW (181). Both meta-analysis results were consistent with their respective authors’ 
conclusion.  
For the pooled data, no significant difference was found between HM and placebo on 
clinical efficacy (RR 2.43, 95% CI: 0.18, 32.75) but the heterogeneity was high (87%) 
(Fig.5.3). This could be due to the following differences between the studies: treatment 
duration (6 months vs 1 month) and intervention (multi-herb formulation vs single herb). 
The high heterogeneity indicated that the pooled effect was not interpretable. 
Group 2. Internal HM versus Internal APP (7 studies, 14 groups) 
No significant difference was found between acitretin and its five different HM comparators: 
Yinxiebing formula (RR 1.00; 95% CI: 0.96, 1.04) (176), Huoxue Sanyu Xiaoyin decoction 
(RR 0.86; 95% CI: 0.67, 1.09) (178), Qinre Jiedu decoction (RR 0.67; 95% CI: 0.32, 1.38) 
(179), Kangyin No.1 formula (RR 1.10; 95% CI: 0.84, 1.43) (180), and Hai Tang decoction 
(RR 1.11; 95% CI: 0.79, 1.55) (183).  
The pooled data showed no difference between the HMs and acitretin (RR 1.00; 95% CI: 
0.96, 1.04,  I2 = 0%) on clinical efficacy. For Vitamin A Acid, there was no significant 
difference in comparison with Lanchuan Qingre decoction in Fan et al 2005 (RR 0.95; 95% 
CI: 0.81, 1.11). However, for Ho et al (2009), methotrexate was superior to Wentonghuayu 
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formula (RR 0.18; 95% CI: 0.05, 0.67). These results were consistent with the authors’ 
conclusions (Fig. 5.3). 
 
Fig. 5.3 Forest plot of clinical efficacy: Internal Herbal Medicine (HM) versus placebo or 
Anti-psoriatic Pharmacotherapy (APP) (with or without co-intervention used in both groups)
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5.2.3.4 Adverse events (AEs) 
Zhang et al 2008 did not provide any information on adverse events (182), Zhang et al 
2009 only reported AEs for the treatment group (181) and Pandey et al 1994 reported 
there were ‘no toxic effects’ (177). The most frequent side effects were xerosis including 
cheilitis, dry mouth and dry skin, and gastrointestinal reactions such as vomiting and 
diarrhoea. Other AEs included elevated blood lipids, elevated liver enzymes, elevated 
blood urea nitrogen (BUN) and reduced white blood cells (WBC). 26 AE cases were 
reported among the 257 participants in the assessable treatment groups (10.12% 
incidence rate) whereas 89 AEs in 109 participants were reported in the APP control 
groups, so there was a higher incidence rate (81.65%) in the four accessible APP control 
groups. In the three placebo groups, 6 AEs were reported among the 58 participants 
(10.34% incidence rate). 
The AEs incidence was pooled for 7 studies. For internal HM versus internal placebo 
(175, 177, 181), no difference was found (RR 2.80, 95% CI: 0.73, 10.74, I2=28%) (Fig. 
5.4). For internal HM versus internal APP (174, 175, 179, 180), there was a lower AE 
incidence in the HM groups (RR 0.12, 95% CI: 0.02-0.89, I2=93%). The high 
heterogeneity was due to Ho et al. 2009. When it was removed, the heterogeneity 
reduced to zero. 
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Fig. 5.4 Forest plot of Adverse Events (AEs): Internal herbal medicine (HM) versus internal 
placebo or Anti-psoriatic Pharmacotherapy (APP) (with or without co-intervention used in 
both groups) 
The incidence of abnormal laboratory test results was zero in the HM groups with respect to: 
elevated blood lipids (vs 11.29 % for APP groups), elevated liver enzymes (vs 6.02 % for 
APP groups), elevated BUN (vs 3.13 % for APP groups), or reduced WBC (vs 0 % for APP 
groups). None of the above abnormal laboratory test results were associated with 
hospitalisation. In one study, AEs led to short-term cessation of vitamin A acid treatment but 
this was resumed after the AEs had subsided (see Fan 2005). In Zhang et al 1999, 2 dropouts 
in the HM group resulted from gastrointestinal reactions. In other cases the AEs did not lead 
to discontinuation of participation. 
5.2.3.5 Principal herbs used in the studies 
Among the examined test HMs, 39 different medicinal plants were internally applied in two 
single herb preparations and nine multiple-ingredient formulae that were administered as 
granule (n=1), capsule (n=3), or decoction (n=6). The most commonly used individual herbs 
in the internal management of psoriasis were the three herbs that were each used in 5 studies: 
Di huang (Rehmannia glutinosa Libosch, root) including Sheng di (dried root) and Shu di 
(steamed root), Dan shen (Salvia miltiorrhiza Bge., dried root) and Bai hua she she cao 
(Oldenlandia diffusa (Willd.) Roxb., herb). These were followed by two herbs that were 
used in 4 studies each: Zi cao (Lithospermum erythrorhizon Sieb.et Zucc., root) and Gan cao 
(Glycyrrhiza uralensis Fisch., dried root).  Six herbs each appeared in 3 studies: Bai mao 
gen (Imperata cylindrica (L.) P.Beauv. var. major (Nees) C.E.Hubb, stem), Ban lan gen 
(Isatis tinctoria L., root), Bai xian pi (Dictamnus dasycarpus Turcz., bark), Chi shao 
(Paeonia veitchii Lynch, root), Ji xue teng (Spatholobus suberectus Dunn., stem), and Tu fu 
ling (Smilax glabra Roxb., root). Five herbs were used twice and 23 were applied once. 
5.2.4 Discussion 
All studies were found to demonstrate at least some methodological reporting issues. Only 
three studies stated the method of sequence generation and one reported allocation 
concealment. Two were blind to participants and one also was blind to outcome assessment. 
In six studies, outcome data were provided completely. In general, the better quality trials 
appeared to be Pandey et al 1994, Zhang et al 1999 and Ho et al 2009.  
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Local xerosis (lips, mouth and skin) and gastrointestinal reactions were mostly frequently 
reported AEs in these trials of internal HM for the management of psoriasis. Regarding AE 
incidence, it was significantly lower in the internal HM groups than in the internal APP 
groups (10.12% vs 81.65%). Also the AE incidence in the HM groups was similar to the 
internal placebo groups (10.12% vs 10.34%). For the laboratory test results including: 
elevated Blood Lipids, elevated Liver Enzymes, elevated BUN, and reduced WBC, there 
were no adverse findings for the HM groups. Therefore, the internal herbal medicines for 
which safety data were reported appeared to be safe for psoriasis management at the dosages 
and in the timeframes used. However there was considerable variation in the adequacy of 
AE reporting with no reporting in Zhang HY 2008 and brief reporting in Pandey 1994. Also 
the following three HMs, Dictamnus dasycarpus, Tripterygium wilfordii and Neem 
(Azadirachta indica), have been associated with safety concerns in the literature.  
Dictamnus dasycarpus (Bai xian pi) was included in the formulations used in three studies 
(174, 180, 186). AEs involving acute hepatitis have been reported which appear to have been 
due to the oral use of this herb (187-190). In Xie et al 2009, two AEs in the acitretin group 
were reported that related to increases in liver enzymes but none were reported in the HM 
group (180). In Ho et al 2009, liver enzyme abnormalities were reported in all three groups 
including the placebo group but the exact incidence of increased enzymes in each group 
cannot be determined from the report. Some dropouts resulted from acute hepatitis but no 
information was provided on the number, group or causes of the hepatitis (186). In Fan et al 
2005, liver enzymes were not assessed but two AEs involving mild diarrhoea in the HM 
group were reported but there were no dropouts (174). Whether the addition of D. 
dasycarpus to the HM formulations in these studies had adverse effects on liver function is 
not possible to determine from the reported data. Some experimental evidence has also 
suggested that D. dasycarpus had anti-inflammatory effects (157), however we urge caution 
and careful monitoring if this plant is used in therapy or in clinical trials. 
T. wilfordii (Lei gong teng) was used in one of the included studies (181). Experimental 
studies of T. wilfordii have shown it to have immunosuppressive activity but it is considered 
a toxic plant and crude preparations of this plant have been associated with a wide range of 
AEs including renal failure, subacute hepatic necrosis and chromosomal aberrations (191, 
192). Consequently, such crude preparations are no longer used and a number of extracts 
have been developed that show reduced toxicity, including ethyl acetate and chloroform–
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methanol extracts of the herb (191). Although there were no serious AEs reported for the 
ethyl acetate extract used in the included study (181), and the results of the blood, 
neurological, liver function and kidney function tests were normal in this study, there were 
some instances of AEs typically associated with this plant and other studies have reported 
serious AEs, so the safety profile of T. wilfordii and its extracts remains a concern. 
Consequently, this plant should not be used in the clinical management of psoriasis (192).  
Various preparations of Azadirachta indica have received research attention for their 
anti-inflammatory (193), cancer-preventative (194), anti-proliferative (195-197), 
contraceptive, and anti-parasitic effects (198). However, Neem preparations have raised 
safety concerns including dermatological reactions related to Neem oil (199). Azadirachtin, 
a Neem constituent, has shown in-vitro genotoxic effects (200) but another in-vivo 
experiment found no cumulative effects on postnatal development in rats (201). Other 
studies have reported that a methanolic extract of Neem leaves may affect fertility in female 
rats (202), Neem oil adversely affected organ function in mice (203) and an ethanolic stem 
bark extract induced a similar effect in rats (204).  
In a review of Neem safety, Boeke et al 2004 demonstrated that the non-aqueous extracts 
were more toxic than the aqueous extracts but the safe dose in humans was difficult to 
quantify with the best estimate being 0.3 mg/kg bw/day (205). Pandey et al 1994 found that 
when an aqueous extract of Neem leaf was used there was no evidence of toxicity during the 
study but the dosage was not clearly specified (177). In another human study, an 
acetone-water Neem leaf extract (1.0 g/day) was found to have no toxicity in HIV/AIDS 
after 12 weeks (206). Since there is a variety of Neem preparations (including seed oils, 
stem bark, root bark, leaf & flower) in use as topical and systemic medicines and in 
pesticides and there are a variety of extraction processes used, it is hard to make an overall 
evaluation of the safety of Neem use in psoriasis, therefore caution is urged. 
In terms of the efficacy of the HMs, the meta-analyses of the outcomes for clinical efficacy 
based on PASI 50 and PASI score, found no differences between the internal HMs and 
acetritin based on five studies and there was no difference between HM and vitamin A acid 
based on one study. Therefore, the internal HMs appear to have exerted effects similar to 
those of acitretin and vitamin A acid. One study showed an internal HM to be inferior to 
MTX. 
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For the comparisons of internal HM versus internal placebo, the data showed a significant 
improvement for PASI score for Neem leaf extract and T. wilfordii extract (177, 181), and 
there was improved clinical efficacy for T. wilfordii extract.  
In contrast, the study by Ho et al 2009 found no effect for the HM on PASI or clinical 
efficacy (186). It is notable that the HM used in Ho et al 2009 was a commercial formulation 
that is not similar to the HM formulations used in the other studies and is not typically 
recommended for psoriasis (106). The method used in this study also suffered from a lack of 
blinding. The magnitude of effect in the placebo group was large with 21.4% of participants 
achieving PASI 50 and 18% achieving PASI 75 which is at the top of the range reported for 
control groups by Lamel et al 2012 and well above the average of 4.1% (207).  
As a primary endpoint, PASI is considered as a detailed and validated measure of psoriasis 
severity (170). Although PASI 75 is frequently used a major endpoint in clinical trials, PASI 
50 also provides a clinically meaningful measure of improvement in psoriasis (173). 
Therefore, the improvements in clinical efficacy based on PASI 50 or above reported in the 
trials represent potentially clinically important results that require further consideration.  
In total, nine studies reported that HM was either superior to placebo or had effects that were 
not significantly different to those of the APPs acitretin and vitamin A acid. Of these studies, 
two used single herb extracts while the remaining seven used multi-ingredient formulae. 
Amongst these formulae, the most frequently used individual HM was Bai hua she she cao 
(Oldenlandia diffusa herb) which was used in five studies. This was followed by Dan shen 
(Salvia miltiorrhiza dried root) (n=4), Sheng di (Rehmannia glutinosa dried root) (n=4), then 
Zi cao (Lithospermum erythrorhizon root) (n=3), Chi shao (Paeonia veitchii root) (n=3) and 
Gan cao (Glycyrrhiza uralensis root) (n=3). To further explore the possible effects of the 
individual HMs used in multiple studies, evidence derived from experimental studies of the 
actions of O. diffusa, R. glutinosa, and S. miltiorrhiza that are relevant to psoriasis were 
evaluated. This aspect is discussed in chapter 7.  
5.2.5 Limitations of this review 
A major limitation of this review is that the methodological issues identified in the clinical 
trials increase the risk of bias in the reported results. Lack of blinding or ineffective blinding 
of the participants and the personnel in seven of the ten trials could have influenced the 
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assessment of PASI scores and the reporting of adverse events. In terms of the magnitude of 
the effects of the interventions, assessments were only available for PASI 50 and above, not 
for PASI 75, so comparisons between HM and APP were based on which is considered the 
minimum threshold for clinical efficacy. Nevertheless, as the study by Carlin et al (2004) 
found, PASI 50 is still an important endpoint for the assessment of a clinical intervention 
(173). 
The small sample sizes and relatively short durations of the included trials also limit the 
meaningfulness of the results. Moreover, the lack of duplication of studies that use the same 
intervention limits the reliability of results.  
The statistical heterogeneity for pooled studies of HMs versus acetritin was low, but the 
variability in the test interventions, the methods used and the way outcomes were measured 
could all have affected the meta-analysis results. Nevertheless, there is similarity between a 
number of the HM interventions in terms of the main plants used. Also, there are 
experimental studies that suggest that these plants are not inactive and at least some of their 
pharmaceutical actions are of relevance to psoriasis (see chapter 7 for more detail). It is also 
possible that additive and/or synergistic effects in the multi-ingredient HMs may have 
increased efficacy beyond that expected of a single plant extract (208). 
Despite these cautions on the over-interpretation of the evidence from the clinical studies, 
the analysis of such studies can help to identify directions for further and more rigorous 
clinical and experimental research endeavours. 
5.2.6 Summary 
This systematic review and meta-analysis of ten clinical trials on herbal medicines used 
internally for psoriasis found that there were short-term responses that were greater than 
placebo in two out of three studies. When compared to APPs, responses were not inferior to 
acetritin in seven studies, similar to vitamin A acid in one study and inferior to MTX in one 
study. These responses were based on PASI 50 or greater so they appear to be clinically 
significant. 
While these potential benefits for clinical response were similar to those of the conventional 
APP interventions, the AE incidence significantly was lower in the HM groups and the HM 
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used in the trials appear to have been safe, at least in the short term. However, AE reporting 
may have been inadequate in some trials and three of the herbs have raised safety concerns. 
Also, methodological weaknesses in the trials limit the meaningfulness of the results, so 
well-designed trials are needed to further evaluate the potential benefits identified in this 
review. 
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Chapter 6: Results of systematic review of RCTs on external HM 
for psoriasis 
As stated in Chapter 5, eligibility of the studies to be included in our meta-analysis was 
established using our standard procedure. The studies included in analysis can be divided 
into 3 categories: 1. comparisons of topical treatments using a single-herb preparation with 
placebo or anti-psoriatic pharmacotherapy (APP); 2. comparison of the effect of topically 
applied herbal formula and that of placebo or APP and 3. comparisons of treatment with HM 
in combination with APP and with APP alone. Categories 1 and 2 also include studies in 
which the primary comparison is between externally administered HM and external placebo 
or APP but with an additional intervention (the same in both groups) such as another 
pharmaceutical or an internal HM treatment. The data in the following three reviews has 
been published (157-159). 
6.1 Results of systematic review 2: Single herbs for the external management of 
psoriasis: A systematic review with meta-analysis of RCTs 
6.1.1 Introduction 
At present, almost half of the people with skin disorders in North America and Europe 
receive complementary and alternative medicine (CAM) treatment. CAM that includes 
herb-based preparations is often combined with conventional pharmacotherapy (54, 
160-162). Therefore, practitioners and dermatologists should be aware of the properties of 
single herbs and their extracts commonly used in psoriasis therapy. This review analyses the 
available evidence regarding the efficacy and safety of single-herb preparations used for the 
external treatment of psoriasis. 
6.1.2 Method 
We evaluated several reviews describing the effects of externally applied HM in the 
management of psoriasis (35, 36, 48, 157, 164). To find the relevant publications, we 
searched the following databases: EMBASE, PubMed, Cochrane Library, China National 
Knowledge Infrastructure (CNKI) Database and Chinese Scientific Journals Full Text 
Database (CQVIP) (up to September 2012). Search terms comprised 3 groups: clinical 
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condition; intervention and study type, with adjustments for different databases (see Chapter 
4 for lists of terms). We also searched reference lists in review articles.  
Herb extracts were simply defined as preparations of plant origin. We excluded purified 
bioactive components, vitamins and homeopathic preparations. Languages were limited to 
English, Chinese or Japanese. In comparisons between RCTs analysed in this subsection, 
only studies on topical applications of single herbs were included. Herbal formulae and 
interventions that combined HMs with pharmaceuticals were not included. Other substances 
used in the vehicle preparation, necessary for the extraction or used as preservatives were 
allowed. The included studies compared the effect of topical treatment with a single-extract 
preparation with that of placebo vehicle base, other topical placebo, no treatment or 
conventional topical pharmacotherapy.  
Two of the researchers, SD and BHM, conducted the searches and extracted the 
characteristics of each study. The collected information included the location, duration, 
design, participants, interventions, outcome measures, dropouts, adverse events and assessed 
risk of bias (171). The third researcher, ALZ, participated in the discussions and helped to 
resolve any disagreements if agreement could not be reached. A flowchart for the process of 
study selection is presented in Fig. 6.1. Review Manager 5.1 was employed for data analysis. 
Risk ratio (RR) with a 95% confidence interval (95% CI) or mean difference (MD) was used 
with fixed- or random-effect models, depending on heterogeneity (172).   
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* 2 RCTs derived from 1 article 
Fig. 6.1 Flow chart of selection of randomised controlled trials (RCTs) on externally applied 
single-herb preparations used for treating psoriasis [adapted from Deng 2013 (159)]
Entries after duplicates removed 
(n = 1614) 
Excluded (n = 475): 
 
E1. Not related to psoriasis, or similar disorders (259) 
E2. Not principally treated with CAM (200) 
E3. Not in Chinese, English or Japanese (16) 
 
Excluded (n =1128): 
E4. Not related to clinical trials (89) 
E5. Epidemiology, economic studies etc (27) 
E6. Review of clinical studies in humans (154) 
E7. Adverse events, toxicology, chemical analysis etc 
(28) 
E8. Uncontrolled clinical trials (357) 
E9. Phototherapy, manual therapy, purified bioactive 
compounds, or CAM other than botanical therapy (97) 
E10. Non-randomized trials (inc. multiple conditions) 
(87) 
E11. Issues with study design/comparison/ methods 
(209) 
E12. Not an extract of a single plant used topically (80) 
Full-text articles assessed for eligibility    
(n = 1139) 
Reference lists  
(n=31) 
Database retrieval 
(n=2020) 
RCTs included in qualitative synthesis    
(n = 12*) 
RCTs included in meta-analysis 
(n = 6) 
Entries screened on basis of title & abstract
(n = 1614) 
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6.1.3 Results 
In total, 2,020 potential entries were obtained from the database searches and 31 studies 
were identified from reference lists. After the removal of duplicates, the remaining 1,614 
records were screened and the full text of 1,139 entries was obtained. Among these, 11 
articles satisfied the inclusion criteria, resulting in 12 RCTs (209-219).  
The 12 RCTs were from the following countries: China (3), Germany (2), USA (2), USA 
and Canada (1), Canada (1), Thailand (1), Denmark (1) and Pakistan (1). Most papers were 
written in English (11), and 1 paper was in Chinese. Half-body intra-patient bilateral 
comparisons were reported in 7 of these studies (209, 213-216, 219). The 12 RCTs had 
initially enrolled 858 patients, 790 of whom (aged 16–85 years) participated in the studies 
(Table 6.1). The greatest sample size was 184 participants (218). All the participants were 
diagnosed with mild to moderate psoriasis. In 11 studies, all criteria for inclusion and/or 
exclusion were specified. The intervention courses lasted from 4 weeks (5 studies) to 6 
months (1 study). A topical single-herb preparation and topical placebo were used in 9 RCTs, 
and topical APPs, including dithranol (209), calcipotriol plus fluticasone propionate (213) 
and triamcinolone acetonide (212), were used in 3 RCTs. Outcome measures included 
clinical efficacy (n = 8) (212-219), symptom score (n = 6) (211-215, 217), Psoriasis Area 
and Severity Index (PASI) (n = 7) (210-213, 215-217), Dermatology Life Quality Index 
(DLQI) (n = 2) (212, 213) and Quality of Life Index (QLI) (n = 1) (210). 
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Table 6.1 Characteristics of the 12 studies on topical preparations of single herbs for treating psoriasis [adapted from Deng 2013 (159)] 
First author, 
Publication 
year, 
Location, 
Duration, 
Follow-up 
Sample size (R/A), 
Gender (M/F), 
Age: Mean ± SD 
(Range); 
RCT design 
(T vs C) 
Preparation ingredients,  
Application, 
Manufacture 
Diagnosis, 
Outcome measures, 
Results 
Dropouts (reasons), 
Adverse events (AEs) 
Risk of Bias (SG, 
AC, BPt, BPl, 
BOS, IOD, SOR) 
Augustin, M. 
1999; 
Freiburg, 
Germany; 
4 weeks; 
NS 
60/49; 
NS; 
NS; 
half-body, 1 group, 
active- control. 
T: Mahonia aqulifolium ointment, 3 
X day, NS. 
C: dithranol in rising 
concentrations, 1 X day, NS. 
Psoriasis vulgaris. 
ICAM-1↓, CD 3↓, 
HLA-DR↓ (T>C); KI 
67↓, Keratin 6↓, and 
Keratin 16↓(T≈C); 
biopsy (NS) 
11 (no reasons); 
AEs: NS 
SG: U 
AC: U 
BPt: H 
BPl: U 
BOS: L 
IOD: U 
SOR: L 
Bernstein, S. 
2006; 
US & Canada; 
12 weeks; 
NS 
T:100/97, C:100/74; 
T:51/49, C:42/58; 
T:48.3±13.7, 
(18-80) yrs  
C:48.3±14.0,(18-80) 
yrs; 
2 groups, 
double-blind, 
vehicle-control. 
T: psoberine emulsion cream 
(extract of Mahonia aqulifolium 
10%), 2 X day, manufactured by 
IGI, Inc, NJ; Canadian Custom 
Packaging , Canada). 
C: vehicle cream (without active 
component), 2 X day, manufacturer 
same as for Test. 
 
Plaque  psoriasis 
(mild to moderate). 
PASI change T>C 
(T:-3.58±3.47, (-11 
to 3), C:-2.22±3.25, 
(-11.9 to 4, 
p=0.0095)  
QLI change T>C 
(T:25.5±28.76, (-41 
to 98), C:15.1±22.45, 
(-31 to 81, p=0.0186) 
 
T:3, C:26; 
AEs: 
No SAE, T: staining (1), C: rash (1) and 
burning (2) 
SG: U 
AC: U 
BPt: L 
BPl: L 
BOS: U 
IOD: L 
SOR: H 
Brown, A. C. 
2005; 
Hawaii (Oahu), 
USA; 
12 weeks; 
NS 
T:15/13, C:15/11; 
T: 5/8, C:7/4; 
(18-78)/(20-75) yrs; 
2 groups, 
double-blind, 
placebo-control. 
T: Kukui nut oil (Aleurites 
moluccana 9.10% saturated fat, 
21.20% monounsaturated fat, 69.70 
polyunsaturated fat, plus 102 
IU/100 g of vitamin E, and 2.7 
mg/100g of vitamin C) Vitamins E 
& C were added as antioxidant 
preservatives for the 
polyunsaturated fats.  
Used on target plaque/lesions: just 
enough to moisten lesions, 3 X day 
Mild stable plaque 
psoriasis. 
Photographs of target 
lesions: PASI T≈C 
(p=0.468), 
Global Severity of 
Psoriasis Scale T≈C 
(p>0.05),  
 
T:2, C:4 (reasons given); 
AEs: No 
SG: U 
AC: U 
BPt: L 
BPl: U 
BOS: L 
IOD: L 
SOR: H 
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(after showering, at noon, and 
before bed), also on remaining 
lesions. Oil left on for 8 hrs. 
C: mineral oil (NS).  
Used on target plaque/lesions: just 
enough to moisten lesions,  3 X 
day Application same as for Test. 
Choonhakarn, 
C. 
2010; 
Khon Kaen, 
Thailand; 
8 weeks; 
NS 
T:40/37, C:40/38; 
T:17/20, C:19/19; 
T:43.4 ± 11.2, (27–
65) yrs,  
C:44.2 ± 13.0, (23–
71) yrs; 
2 groups, 
double-blind, 
active-control 
T: Aloe vera cream (70% aloe 
mucilage). 2 X day, no emollient 
was used. Prepared by Faculty of 
Pharmaceutical Sciences, Khon 
Kaen University. 
C: 0.1% triamcinolone acetonide 
cream. Same application & 
manufacturer as the Test  
Plaque psoriasis (< 
10% of body 
surface). 
PASI change T>C 
(T:6.6±2.1, 
C:7.7±2.3, p=0.0237) 
DLQI change T≈C 
(T:5.8±2.0, 
C:6.1±2.1, p=0.5497) 
T:3, C:2  
lost during follow-up; 
AEs:  
No SAE, T: stinging and itching (6), C: no 
significant complaint 
SG: L 
AC: L 
BPt: L 
BPl: L 
BOS: U 
IOD: U 
SOR: L 
Gulliver, W. P., 
2005 (study 2); 
NY, US; 
6 months; 
NS 
32/30; 
NS; 
NS; 
1 group, single 
blind, active control 
T: Mahonia aqulifolium cream 
(0.1% berberine). Manufactured by 
Prime Pharmaceutical Corporation.  
C: calcipotriol cream & 
fluticasone propionate 
Mild to moderate 
bilateral psoriasis, 
half-body. Patient’s 
ratings of T: 84% as 
good to excellent; 
patient’s ratings of 
the comparison with 
C: 63% as equal to 
better than C 
2 (did not return); 
AEs: No 
SG: U 
AC: U 
BPt: L 
BPl: U 
BOS: L 
IOD: U 
SOR: U 
Gulliver, W. P., 
2005 (study 3); 
Niagara Falls, 
Ontario, 
Canada; 
4 weeks; 
NS 
33/33; 
NS; 
NS; 
2 groups, single 
blind, active control 
T: 1) Mahonia aqulifolium cream 
(0.1% berberine): manufactured by 
Prime Pharmaceutical Corporation.  
2) Calcipotriol cream plus 
tazarotene gel. 
C: vehicle cream. (NS). 
Mild to moderate 
psoriasis. 
photographs,  
physician ratings 
T>C (all participants) 
None; 
AEs: seem not to be related the treatment 
SG: U 
AC: U 
BPt: L 
BPl: U 
BOS: U 
IOD: L 
SOR: H 
Lin, Y-K., 
2007; 
Taoyuan & 
Taipei, China; 
8 weeks; 
3 months 
14/10; 
M/F:11/3; 
35.8±10.4, (21-54) 
yrs; 
half-body, 1 group, 
vehicle-control 
T: Indigo naturalis ointment (20% 
Baphicacanthus cusia powder, 80% 
vehicle ointment). Areas of target 
lesions were measured and the 
Indigo naturalis ointment was 
applied with 1g/100cm2 each time, 1 
Recalcitrant plaque 
psoriasis. Psoriasis 
severity index (PSI): 
T<C (p<0.05); 
Clearance % of target 
lesions: T>C 
4 (non compliance); 
AEs: short term itching (2) 
SG: U 
AC: U 
BPt: U 
BPl: L 
BOS: U 
IOD: L 
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 X day. Wash hands thoroughly 
between each application. Sample 
was identified and provided by the 
Chinese Medicine Pharmacy of the 
authors’ institution.  
C: vehicle ointment: (25% 
petroleum jelly, 30% yellow wax, 
and 45% olive oil). Application 
same as for Test.   
 
(p<0.05); 
Histological 
examination of skin 
biopsies, and 
Representative 
photos: T better than 
C 
SOR: H 
Lin, Y-K., 
2008; 
Taoyuan & 
Taipei, China; 
12 weeks; 
NS 
42/34; 
M/F:32/10; 
34.6±11.5  
(18-58) yrs; 
half-body,1 group, 
vehicle-control, 
observer-blind 
T: Indigo naturalis ointment (1.4% 
Strobilanthes formosanus 
containing 0.16% indirubin): Indigo 
naturalis powder and vehicle mixed 
in the ratio of 1:10. Ointment was 
prepared by a research pharmacist 
who knew the treatment assignment. 
1 fingertip unit=0.5g per100cm2 
applied to lesions on one side. Wash 
hands thoroughly between each 
application. 
C: Vehicle ointment (petroleum 
jelly: yellow wax: olive oil = 5:6:9). 
Ointment was prepared by a 
research pharmacist who knew the 
treatment assignment.  
Application same as for Test. 
Recalcitrant 
psoriasis. 
Scores (scaling, 
erythema, induration, 
and sum): T<C 
(p<0.001) 
Clearing percentage 
of target plaque: T>C 
(p<0.001); Clinical 
efficacy: T>C 
(p<0.001) 
 
8 (3 due to slow effect, 3 due to work, 2 lost to 
follow-up); 
AEs: no SAE 
T: itching (4), C: NS 
Liver & Kidney function normal 
SG: U 
AC: L 
BPt: H 
BPl: U 
BOS: L 
IOD: L 
SOR: L 
Paulsen, E., 
2005; 
Odense, 
Denmark; 
4 weeks; 
1-2 months 
41/40; 
M/F:26/14; 
44, (23-77) yrs; 
half-body, 1 group, 
double-blind, 
vehicle-control 
T: Aloe vera gel (98% Aloe vera 
leaf gel, with less than 100 p.p.m. of 
anthraquinones, and the additives 
xanthan gum, potassium sorbate, 
sodium benzoate, sodium sulphite & 
citric acid). 2 X day. Extracted from 
Mexican plantations by Aloe Vera 
Group ApS, Søborg, Denmark.  
C: vehicle gel: same ingredients as 
Test except Aloe vera replaced by 
water. 2 X day. 
 
Slight to moderate 
psoriasis vulgaris. 
PASI of target lesion: 
reduction of 
symptom scores 
(erythema, 
infiltration & 
desquamation): T<C 
(p=0.0197) 
1 dropout in week 2; 
AEs: no SAE. 
Local AEs (n=22), most were dry skin, some 
were stinging, soreness, or fissures, incl. 2 
erythema (one together with a slight tingling 
sensation) in T grp. 
C: some cases of tingling & tightness of the 
skin.  
SG: L 
AC: L 
BPt: L 
BPl: L 
BOS: U 
IOD: L 
SOR: H 
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Syed, T. A., 
1996; 
Punjab, 
Pakistan; 
4 weeks; 
8 months 
T:30/30, C:30/30; 
T:18/12, C:18/12; 
T:25.9, C:25.2; 
2 groups, 
double-blind, 
vehicle-control 
T: Aloe vera extract cream (0.5% 
Aloe vera extract by weight in a 
hydrophilic vehicle cream 
containing mineral oil and castor oil 
(B.P.)). 3 X day for 5 consecutive 
days (<=15 times/week), avoiding 
occlusion or exposure of lesions to 
sunlight. Prepared as 100g tubes by 
Department of Chemistry, 
University of the Punjab, Lahore. 
C: vehicle cream: same ingredients 
as left without Aloe vera, in 
identical 100g tubes.  Application  
& manufacturer same as for Test. 
 
Slight to moderate 
chronic plaque 
psoriasis. Cured rate: 
T>C (p<0.001); 
Clearing of plaques: 
T>C (p<0.001); 
Mean PASI: 
substantial decrease 
in T (9.7→2.2) vs C 
(8.9→8.2).  
Laboratory tests: 
complete blood cell 
count & urinalysis, 
and biopsy analysis 
No; 
AEs: no 
SG: U 
AC: U 
BPt: L 
BPl: L 
BOS: U 
IOD: L 
SOR: H 
Wang, A.M., 
1998; 
Hubei, China; 
60 days; 
NS 
T1: 40/40,  
T2: 86/86, 
T3: 38/38,  
C: 20/20; 
M/F (total): 108/76; 
Age (total): 
10-30 yrs: 80, 
30-50 yrs: 41, 
> 50 yrs: 33; 
4 groups, vehicle 
-controls 
T1: Camptotheca acuminata nut 
thin gel*: (Camptotheca acuminata 
nut extract 20g, ethanol 5g, glycerol 
5g, Sodium hydroxymethyl 
cellulose 4g, polyvinyl alcohol 
(PVA-124) 3g)  
T2: Camptotheca acuminata nut 
ointment: (Camptotheca acuminata 
nut extract 20g, petroleum jelly 72g, 
lanolin 8g). 
T3: Camptotheca acuminata nut 
tincture: (dried Camptotheca 
acuminata nut 100g, Dimethyl 
sulfoxide (DMSO) 250ml, 75% 
ethanol 750ml).  
All 2 X day (interval 12 hrs) 
(excluding broken skin and mucous 
membranes). 
C: vehicle thin gel (ethanol 5g, 
glycerol 5g, Sodium hydroxymethyl 
cellulose 4g, polyvinyl alcohol 
(PVA-124) 3g). 
2 X day (interval 12 hrs). 
Psoriasis vulgaris. 
Reduction of lesion 
area: 
T1>C (χ2 =17.96, 
p<0.01), 
T1>T2 (χ2 =4.16, 
p<0.05), 
T1>T3 (χ2 =6.25, 
p<0.05), 
T2≈T3 (χ2 =0.64, 
p>0.05) 
None; 
NS 
SG: U 
AC: U 
BPt: H 
BPl: U 
BOS: U 
IOD: L 
SOR: L 
Wiesenauer, 82/80; T: Ointment (10% Mahonia Psoriasis vulgaris . 2 dropouts; SG: U 
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M., 
1996; 
Germany; 
4 weeks 
(median); 
NS 
M/F: 43/39; 
47±14, (16-85) yrs; 
1 group, 
double-blind, 
vehicle -control, 
multi-centre 
aqulifolium bark extract) Ointment 
base (anhydrous lanolin, paraffin, 
wool wax alcohols, cetylstearyl 
alcohol and white petroleum jelly). 
Massage ointment on afflicted area 
2-3 X day and at night (wrapped in 
bandages) for 8 weeks. Prepared in 
100g/tube according to German 
Homeopathic Pharmacopoeia 
(HAB1). 
C:  Ointment base (anhydrous 
lanolin, paraffin, wool wax 
alcohols, cetylstearyl alcohol and 
white petroleum jelly). Applied 
same as for Test. 
3 point global 
symptom scale.  
Agreement of 
assessments of 
efficacy by Patient 
(T>C, p=0.008) & 
physician (T≈C, 
p=0.013) 
AEs: 
allergic reaction (1), strong itching (1), 
burning & irritation of skin (2) 
 
no serious AEs 
AC: U 
BPt: U 
BPl: U 
BOS: U 
IOD: L 
SOR: L 
T: treatment group, C: control group, R/A: registration/analysis, M/F: male/female, NS: not stated, WM: Western medicine, sys: systemic, yrs: years, wks: weeks, mins: 
minutes, RCT: randomised clinical trial, PASI: Psoriasis Area and Severity Index 
*Note that this gel preparation was mistranslated as ‘lacquer’ in the original paper. 
 
Risk of Bias Categories 
SG: sequence generation, AC: allocation concealment, BPt: blinding of participants, BPl: blinding of personnel, BOS: blinding of outcome assessment, IOD: incomplete 
outcome data, SOR: selective outcome reporting 
 
Risk of Bias Judgements 
L: low risk, U: Unclear risk, H: High risk
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Five types of single-herb preparations were tested. They were obtained from the following: 
Mahonia aquifolium (5 studies), Aloe vera (3 studies), indigo naturalis (2 studies), kukui nut 
oil (1 study) and 3 different preparations of Camptotheca acuminate nut (1 study). 
M. aquifolium (5 RCTs) 
In a double-blind half-body placebo-control RCT, Wiesenauer and Ludtke (1996) analysed 
the results of treatment with an ointment containing 10% M. aquifolium bark extract using 
the ointment base as the control. The 2 preparations were applied to symmetrically 
distributed lesions. The test ointment was more effective than the ointment base, as judged 
by intention-to-treat analysis. However, a large proportion of patients and some physicians 
stated that the treatment had been ineffective. The probability of symptom improvement as a 
result of this treatment appeared to be 3 to 4 times higher in moderately severe cases than in 
mild cases (219). 
In 1999, in another half-body RCT, Augustin et al. (209) tested the M. aquifolium ointment 
and dithranol. Their study examined the effect of these two treatments on cellular cutaneous 
immune mechanisms and hyperproliferation of keratinocytes (keratin 6, keratin 15 and 
Ki-67), adhesion molecules (ICAM-1) and other activation markers (HLA-DR). The 
researchers used a pre- and post-intervention blinded assessment of biopsy performed by 2 
independent physicians (209). Both the treatments reduced epidermal and dermal T-cell 
infiltration; however, the effect was less pronounced for the Mahonia ointment. The authors 
reported a marked regression of proliferation and adhesion markers caused by the Mahonia 
ointment and stated that both treatments were effective. However, dithranol provides better 
results than the Mahonia ointment. 
Gulliver and Donsky conducted 3 studies testing the use of M. aquifolium cream in psoriasis 
(213). The first was a safety study, and the other 2 were RCTs using different half-body 
designs. In the second study, all 32 patients applied Mahonia cream to 1 of the bilateral 
lesions and a similar cream, containing calcipotriol and fluticasone propionate, to the other 
lesion. Of the 30 patients who completed the study, 25 assessed Mahonia cream as good to 
excellent; however, 3 patients did not respond to the cream. In the third study, 33 patients 
with bilateral lesions were randomly assigned to 1 of 2 groups. In 1 group, Mahonia cream 
was used on the lesion on 1 side, while the vehicle cream was applied to the lesion on the 
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opposite side. In the second group, a cream containing calcipotriol and tazarotene gel was 
used on 1 side and the vehicle cream was on the other side. The authors reported that 
participants had been blinded. Photographs of the plaques were evaluated by physicians. In 
both the treatments, the thickness and redness of the plaques diminished over the 4-week 
therapy. The study reports that the results obtained using Mahonia cream are as good or 
better than, but not substantially superior to, the topical pharmaceuticals (213).  
In a double-blind placebo-controlled RCT, Bernstein et al. examined the efficacy of 
Psoberine®, a commercial cream containing the extract of M. aquifolium, at 6 sites in the 
USA and Canada (210). A group of 200 patients with mild to moderate plaque psoriasis (but 
no administration of anti-psoriatic medications during the previous 28 days) was enrolled in 
the study. The patients were randomly assigned to 1 of the 2 groups: 1 to use the Mahonia 
extract cream and the other to use the vehicle cream as placebo. The creams were applied to 
a selected area twice a day for 12 weeks. Only 171 patients completed the study; ‘no 
response’ was the main reason for discontinuation. Intention-to-treat analysis (worst case) of 
PASI scores revealed a statistically significant reduction in the scores. The group using 
Mahonia cream showed mean reduction of 3.39 from 6.93 at baseline. QLI scores also 
improved significantly for the patients using Mahonia cream. Therefore, the authors 
concluded that Mahonia cream was a well-tolerated and satisfactory treatment for mild to 
moderate psoriasis. 
A. vera (3 RCTs) 
In a 60-participant double-blind placebo-controlled study, Syed et al. compared a cream 
containing 0.5% A. vera extract with the vehicle cream for treating moderate chronic plaque 
psoriasis (217). After a month, there was a significant improvement in PASI scores in the A. 
vera group (baseline mean: 9.3, endpoint mean: 2.2). No medication-related adverse events 
were reported in the study, either local or systemic, and there were no cases of 
hypersensitivity or dermatitis. The authors concluded that the A. vera preparation was well 
tolerated and appeared to be remarkably effective.  
In a double-blind placebo-controlled half-body study, Paulsen et al. tested a commercial A. 
vera gel, using the vehicle gel as the control (216). Forty patients with stable symmetrical 
bilateral lesions used A. vera or placebo gel on a right- or left-side lesion. Emollients, 
petroleum jelly, salicylic acid and tar-containing shampoo were allowed for other lesions. 
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The authors found that modified PASI scores were reduced in both the groups. However, the 
effect of placebo was stronger than that of the commercial A. vera gel at the end of treatment 
(but not during the follow-up). Some skin irritation associated with dryness was reported in 
both the groups; however, there were no serious adverse events.  
In a double-blind parallel-group RCT, Choonhakarn et al. compared treatment with A. vera 
cream and 0.1% triamcinolone acetonide cream (212). The study recruited 80 patients with 
chronic plaque psoriasis. The participants were requested not to take any topical or systemic 
anti-psoriatic treatments for 4 weeks prior to the study. The treatment was administered 
twice a day for 8 weeks. Both the groups improved their PASI and DLQI, with a 
significantly greater improvement in PASI in the A. vera group. No inter-group difference 
was observed for DLQI. The authors concluded that A. vera cream was safe and its efficacy 
was at least similar to that of triamcinolone acetonide cream. 
I. naturalis (2 RCTs) 
In a 14-patient blinded placebo-controlled study, Lin et al. compared the indigo naturalis 
ointment (extract of Baphicacanthus cusia) with the vehicle ointment, applied to comparable 
bilateral lesions (215). Outcome measures included PSI, percentage clearance of target 
lesions and histological examination of skin biopsies. After 8 weeks, the clinical scores were 
reduced in the indigo group; this decline was closely correlated with the length of treatment. 
Skin biopsies revealed a marked decrease in the epidermal thickness in the indigo group in 
comparison with the vehicle ointment group. There were no adverse events; however, 
short-term itching was reported by 2 participants. 
The same research group also examined another indigo ointment, based on a Strobilanthes 
formosanus preparation, which contained 1.4% indigo and 0.16% indirubin. The study used 
the vehicle ointment as the control (214). The outcome measures included the scaling score, 
erythaema score, induration score, sum of these scores and area of target plaque based on 
photographs. The comparisons were conducted by blinded assessors. Itching was reported 
by 4 patients for 2 days after starting the indigo ointment treatment; 3 patients withdrew 
because of no response and 5 failed to complete the treatment for other reasons. 
Intention-to-treat analysis revealed significant improvements in the summation score 
weighted by the lesion area, scaling, erythaema and induration in the indigo group. The 
score improvement was positively correlated with the duration of the treatment. The placebo 
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ointment also resulted in some improvements but to a lesser degree. Blood test results in 
both indigo studies showed normal liver and kidney functions (214, 215). 
Kukui nut oil (1 RCT) 
In a 30-participant double-blind parallel-group placebo-controlled study, Brown et al. 
compared kukui nut oil (a Hawaiian traditional medicine derived from Aleurites moluccana) 
with a mineral oil in the treatment of mild, stable plaque psoriasis (211). Outcomes included 
PASI and Global Severity of Psoriasis Scale, assessed on the basis of photographic evidence. 
Both the groups showed improvement; however, no significant differences were observed 
between the groups in terms of PASI or Global Severity of Psoriasis Scale. However, a 
number of patients became unblinded (n = 13), and there were more dropouts in the placebo 
group than in the test group (11 out of 13).  
C. acuminata nut preparations (1 RCT) 
In an open-label parallel-group study, Wang et al. (1998) tested the efficacy of 3 
preparations of C. acuminata nut (thin gel, n = 40; ointment, n = 86 and tincture, n = 38) in 
comparison with that of the thin gel used as placebo (n = 20) (218). In terms of the efficacy 
rate based on reduction of the lesion area, the Camptotheca gel preparation resulted in a 
significantly greater improvement in comparison with the 2 other Camptotheca preparations 
(which did not differ) and the placebo gel. The tincture caused some skin irritation and the 
ointment stained clothes. No side effects were reported for the gel. The authors concluded 
that the thin gel was superior to the other 2 preparations.  
6.1.4 Methodological assessment 
The study quality with risk of bias is reported in Table 6.1. All the authors stated that their 
studies were ‘randomised’ or used a similar expression. The randomisation sequence 
generation method was reported in 2 of the studies; these studies were assessed as ‘low’ risk 
of bias for this item (212, 216). ‘Unclear’ risk of bias was assigned to the remaining 10 
studies. The allocation concealment method was described by 3 studies (212, 214, 216); 
these were judged as having ‘low’ risk in this category, while other studies were judged as 
having ‘unclear’ risk of bias.  
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Blinding of participants failed in 3 studies. These studies applied clearly different 
interventions for the 2 groups (209, 214, 218) and were judged as having ‘high’ risk of bias. 
Two studies did not provide details of blinding (215, 219), and their risks of bias were 
judged as ‘unclear’. The remaining 7 studies used appropriate methods of blinding and were 
judged as having ‘low’ risk on blinding of participants. In 5 of the studies, appropriate 
procedures prevented physicians or investigators from identifying the groups; therefore, they 
were judged as having ‘low’ risk of bias in the domain of personnel blinding (210, 212, 
215-217). The methods for blinding of outcome assessors were described in 4 studies (209, 
211, 213, 214); these were judged as having ‘low’ risk of bias for this item. 
Because the dropout reasons were not reported in 4 studies, they were judged as having 
‘unclear’ risk of bias for incomplete outcome reporting (209, 212, 213, 219). The 8 studies 
that reported the reasons for dropouts or stated that there were no dropouts were judged as 
having ‘low’ risk. In 5 studies, not all data for outcomes stated in the methods were reported 
in the results; these were judged as having ‘high’ risk of selective data reporting (210, 211, 
215-217). One study was judged as ‘unclear’ (213), and the remaining studies were judged 
as having ‘low’ risk of bias in this category. 
6.1.5 Meta-analysis 
After careful scrutiny of available data, we decided that 7 of the examined studies contained 
data suitable for meta-analysis (210, 212, 214, 216-219). Outcome measures included 
clinical efficacy (n = 6) (212, 214, 216-219), symptom score (n = 1) (214), PASI (n = 1) 
(212), PASI change (n = 1) (210, 212), DLQI (n = 1) (212) and DLQI change (n = 1) (212) 
(Table 6.2).  
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Table 6.2 Results of meta-analyses for clinical efficacy, PASI, DLQI and symptom score [adapted from Deng 2013 (159)] 
Outcomes,  
RCT No. (overall sample size) 
First author,  
Publication year 
meta-analysis on endpoint results 
Incidence % (n/N) or 
MD ± SD 
RD (%) 
Clinical efficacy  
Indigo vs placebo, 1 (84) Lin 2008 4.83 [2.24, 10.42] RE* T: 69.0% (29/42) 
C: 14.3% (6/42) 
54.7 
Aloe vera vs placebo, 1 (82) Paulsen 2005 0.67 [0.20, 2.19] RE T: 9.8% (4/41) 
C: 14.6% (6/41) 
-4.8 
Aloe vera vs placebo, 1 (60) Syed 1996 12.50 [3.25, 48.14] RE* T: 83.3% (25/30) 
C: 6.7% (2/30) 
76.6 
Aloe vera vs placebo (pooled), 2 (142)  2.84 [0.16, 50.12] I² =90% RE T: 40.8% (29/71) 
C: 11.3% (8/71) 
29.5 
Camptotheca tincture vs placebo†, 1 (58) Wang 1998 6.05 [1.59, 23.11] RE* T: 60.5% (23/38) 
C: 10.0% (2/20) 
50.5 
Camptotheca thin gel vs placebo, 1 (60) Wang 1998 8.75 [2.34, 32.75] RE* T: 87.5% (35/40) 
C: 10.0% (2/20) 
77.5 
Camptotheca ointment vs placebo†, 1 (106) Wang 1998 
 
6.51 [1.73, 24.47] RE* T: 65.1% (56/86) 
C: 10.0% (2/20) 
55.1 
Camptotheca vs placebo (pooled), 1 (224)  7.02 [3.26, 15.12] I² =0% RE* T: 69.5% (114/164) 
C: 10.0% (6/60) 
59.5 
Mahonia vs placebo, 1 (164) Wiesenauer 1996 1.71 [1.02, 2.85] RE* T: 35.4% (29/82) 
C: 20.7% (17/82) 
14.7 
HM vs placebo (pooled), 5 (450)  3.37 [1.36, 8.33] I² =78% RE* T: 51.9% (122/235) 
C: 15.3% (33/215) 
41.5 
Aloe vera vs pharm., 1 (80) Choonhakarn 2010  0.90 [0.67, 1.21] RE T: 65.0% (26/40) 
C: 72.5% (29/40) 
-7.5 
PASI score 
Aloe vera vs pharm.†, 1 (75) Choonhakarn 2010 -0.40 [-1.26, 0.46] FE T: before 11.6±2.9, after 
3.9±1.7 
C: before 10.9±3.1, after 
4.3±2.1 
NA 
PASI change 
Mahonia vs placebo†, 1 (200) Bernstein 2006 -3.30 [-4.48,-2.12] FE* NA  
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DLQI 
Aloe vera vs pharm.†, 1 (75) Choonhakarn 2010 0.20 [-0.30, 0.70] FE T: before 8.6±1.7, after 
2.5±1.2 
C: before 8.1±1.8, after 
2.3±1.0 
NA 
QLI change 
 
Mahonia vs placebo†, 1 (199) Bernstein 2006 27.48 [17.24,37.72] FE* NA 
 
Symptom score 
Scaling (Indigo naturalis vs placebo)†, 1 (68) Lin 2008 -2.20 [-2.93, -1.47] FE* T: before 6.8±1.31, after 
1.5±1.46 
C: before 6.7±1.31, after 
3.7±1.60 
NA 
Erythema (Indigo naturalis vs placebo)†, 1 (68) Lin 2008 -2.30 [-3.04, -1.56] FE* T: before 6.0±1.42, after 
2.6±1.60 
C: before 6.0±1.40, after 
4.9±1.50 
NA 
Induration (Indigo naturalis vs placebo)†, 1 (68) Lin 2008 -2.00 [-2.68, -1.32] FE* T: before 6.1±1.28, after 
2.2±1.49 
C: before 6.0±1.32, after 
4.2±1.37 
NA 
Summation (Indigo naturalis vs placebo)†, 1 (68) Lin 2008 -6.50 [-8.45, -4.55] FE* T: before 18.9±2.97, after 
6.3±4.28 
C: before 18.7±3.08, after 
12.8±3.92 
NA 
T: test group; C: control group; RR: risk ratio; N: total number of participants in group; n: number of participants in sub-group; I²: test of heterogeneity of meta-analysis 
of pooled data, over 50% represents substantial heterogeneity; MD: mean difference; SD standard deviation; RD: Risk difference; NA: not applicable; RE: 
random-effect model; FE: fixed-effect model 
HM: herbal medicine; Pharm.: pharmacotherapy; QLI: Quality of Life Index; PASI: Psoriasis Area and Severity Index; DLQI: Dermatology Life Quality Index 
*Significantly different; †Not included in pooling 
138 
 
Clinical efficacy 
Different studies used different systems for classifying clinical efficacy and PASI reduction. 
Therefore, our clinical efficacy assessment only included cases with an efficacy rate of 50% 
or above or PASI reduction of 50% or more (185). One study also reported the numbers of 
participants whose condition improved (219). Results were analysed using risk ratio (RR) 
and a random-effect model. In meta-analysis, a higher score indicates greater efficacy. Of 
the 6 studies suitable for meta-analysis, 5 compared a herbal extract with the vehicle as 
placebo (214, 216-219) and 1 used an active control (212).  
The Indigo naturalis ointment had superior efficacy than placebo (RR 4.83, 95% CI: 2.24–
10.42) in the study of Lin et al. (2008), similar to the findings with the M. aquifolium 
ointment (RR 1.87, 95% CI: 2.44–8.89) in the report of Wiesenauer et al. (1996). The A. 
vera preparation was significantly more effective than placebo in the study of Syed et ak, 
(1996) (RR 12.50, 95% CI: 3.25–48.14); however, there was no difference between 
experimental and control groups in the study by Paulson (2005) (RR 0.67, 95% CI: 0.20–
2.19) (Fig. 6.2).
 
Fig. 6.2 Forest plot of clinical efficacy of single herb used topically for psoriasis 
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The three different Camptotheca preparations, namely ointment (RR 6.51, 95% CI: 1.73–
24.47), tincture (RR 6.05, 95% CI: 1.59–23.11) and thin gel (RR 8.75, 95% CI: 2.34–32.75), 
showed a significantly greater effect than placebo (Fig. 6.2). The thin gel was superior to the 
ointment (RR 1.34, 95% CI: 1.11–1.63) and to the tincture (RR 1.45, 95% CI: 1.09–1.92); 
however, there was no significant difference between the ointment and tincture (RR 1.08, 95% 
CI: 0.80–1.45). This was in accordance with conclusions of the authors. 
The pooled data for this group of 5 studies showed a difference between clinical efficacy of 
the plant extracts and their vehicles (used as placebo) (RR 3.37, 95% CI: 1.36–8.33). 
However, the heterogeneity was high (78%), and sensitivity analyses could not identify an 
optimal sub-group of studies. No significant difference was observed between the efficacy of 
A. vera and triamcinolone acetonide preparations (RR 0.90, 95% CI: 0.67–1.21, p = 0.47) 
(Fig. 6. 2). 
Other outcomes 
No significant differences were observed between PASI (MD −0.40, 95% CI: −1.26, 0.46) or 
DLQI (MD 0.20, 95% CI: −0.30, 0.70) values in the experimental and control groups in the 
study of Choonhakarn et al. (2010). Lin et al. (2008) reported significant improvements in 
symptom scores for scaling, erythaema, induration and summation of symptoms (Table Ch. 
6.2). 
6.1.6 Adverse events (AEs) 
There were 11 studies that discussed AEs, and 1 study did not provide any information (209). 
Three studies reported that there were no adverse effects (211, 213, 217). One Mahonia 
study reported bilateral exacerbations, which the authors thought unlikely to be related to the 
Mahonia (213). Of the 7 remaining studies, 5 stated that there were no severe AEs (210, 212, 
214, 216, 218). In the studies that reported AEs, the most frequent were local skin irritations 
or other problems described as staining, itching, dryness and burning or tingling sensation.  
6.1.7 Summary 
In 10 studies, the single-herb preparations were shown to be effective; however, the data in 6 
of those studies (209-211, 213, 215) were not suitable for meta-analysis. Inconclusive results 
were reported for kukui nut oil treatment (211), and negative results were found in 1 study of 
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A. vera preparations (216). Meta-analyses produced conflicting results for clinical efficacy 
in 2 studies comparing the effects of A. vera and placebo (216, 217). However, the results of 
the study of Paulsen et al. (2005) may have been confounded by the concurrent use of other 
medications. A well-designed, relatively recent study by Choonhakarn et al. (2010) showed 
that treatment with A. vera cream have similar benefits to treatment with 0.1% triamcinolone 
acetonide cream (Fig. 2). The 2 RCTs of indigo naturalis (214, 215) reported the efficacy of 
this remedy in plaque psoriasis, and a more recent RCT comparing 2 indigo preparations 
reported similar results (220). A number of case reports have also reported beneficial effects 
of indigo (221, 222), and a recent uncontrolled study of 32 patients with nail psoriasis found 
a decrease in the nail PSI after 24 weeks of treatment (223). However, there has been no 
independent confirmation of these results. The efficacy of C. acuminata nut preparations 
was higher than in the placebo group; however, the study was not blind (218). All the studies 
of M. aquifolium (209, 210, 213, 219) reported positive effects and were conducted by 
different research groups. However, the reports showed inadequacies, and variation in 
outcome data precluded pooling and assessment of the bias.  
For indigo, Mahonia and Camptotheca trials, the clinical findings have been confirmed by 
experimental studies. However, further research is required to characterise the compounds 
derived from or based on these herbs. The clinical trial data, obtained from several studies, 
have provided some evidence of potential benefits of the topical use M. aquifolium, indigo 
naturalis and A. vera preparations in the management of mild to moderate plaque psoriasis. 
The preparations used did not appear to produce any serious AEs; however, the duration of 
indigo naturalis and A. vera treatments was relatively short. However, most studies were 
rather small and the methodology had some weaknesses; therefore, definitive conclusions 
cannot be made. Because the effects cannot be accurately measured, the assessment of the 
clinical relevance of these studies remains difficult. 
6.2 Results of systematic review 3: Herbal formula for the external management of 
psoriasis: A systematic review with meta-analysis of RCTs 
6.2.1 Introduction 
Traditional HM tends to combine various medicinal herb recipes or formulae, which may 
enhance the desired therapeutic effects and avoid side effects. Such preparations are often 
administered internally; however, many are used topically in the form of washes, baths, 
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sprays, tinctures, powders, ointments, creams, gels and cataplasms (224). Here we review 
clinical studies of the efficacy and safety of such multi-ingredient herbal formulae in the 
external management of psoriasis vulgaris. This study identifies some individual herbs 
showing promising efficacy. We also examine the experimental evidence of activities 
relevant to psoriasis for identifying possible new directions for drug discovery and 
development (167).  
6.2.2 Method 
We evaluated several reviews describing the role of externally applied HM in the 
management of psoriasis (35, 36, 48, 157, 164). To fund the relevant publications, we 
searched the following databases: EMBASE, PubMed, Cochrane Library, CNKI Database 
and CQVIP (up to September 2012). Search terms comprised 3 groups: clinical condition, 
intervention and study type, with adjustments for different databases (see Chapter 4 for lists 
of terms). We also searched reference lists in review articles. 
Herbal formulae were defined as preparations of multiple herbs, which mainly contain plant 
material but may also include natural products of animal or mineral origin. Dead Sea cure, 
homeopathy, ultraviolet radiation therapy, fish and animal oils and specific vitamin and/or 
mineral therapies were excluded. Only studies that investigated topical herbal formulae in 
experimental intervention were included, excluding single herbs and treatments combining 
plant preparations with topical APP. Studies employing identical systemic co-interventions 
using herbal medicines, vitamins, minerals or pharmaceuticals in both experimental and 
control groups were included.  
Two researchers (SD & BHM) conducted searches, extracted data and assessed risk of bias 
(171). Disagreements were resolved by discussions with a third researcher (ALZ) if 
agreement could not be reached. A flowchart of the study selection procedure is presented in 
Fig. 6.3 (132). Data were analysed using RevMan 5.1 with RR with 95% CI employing 
fixed- or random-effect models depending on heterogeneity (172).  
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Fig. 6.3 Flow chart of the selection procedure of randomised controlled trials (RCTs) on 
external formula for treating psoriasis [adapted from Deng 2013 (158)] 
Entries after duplicates removed 
(n = 1614)
Excluded (n = 475): 
E1. Not related to psoriasis, or similar disorders (259) 
E2. Not principally treated with CAM (200) 
E3. Not in Chinese, English or Japanese (16) 
Excluded (n =1130): 
E4. Not related to clinical trials (89) 
E5. Epidemiology, economic studies etc (27) 
E6. Review of clinical studies in humans (154) 
E7. Adverse events, toxicology, chemical analysis etc 
(28) 
E8. Uncontrolled clinical trials (357) 
E9. Phototherapy, manual therapy, or CAM other than 
herbal therapy (93) 
E10. Non-randomized trials (inc. multiple conditions) 
(87) 
E11. Issues with study design/comparison/methods 
(209) 
E12. Not external formula in predominating therapy 
(86) 
Full-text articles assessed for eligibility   
(n = 1139) 
Reference lists  
(n=31) 
Database retrieval  
(n=2020) 
RCTs included in qualitative synthesis    
(n = 9) 
RCTs included in meta-analysis 
(n = 8) 
Entries screened on basis of title & 
abstract 
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6.2.3 Results 
Database searches yielded 2,020 potentially relevant articles, and 31 studies were identified 
using reference lists. After the removal of duplicates, the remaining 1,614 records were 
screened and the full text was obtained for 1,139 articles. Nine RCTs met all the inclusion 
criteria (225-233).  
Eight of the included RCTs were conducted in China and 1 in Finland; 2 were published in 
English and 7 in Chinese. Altogether, 1,214 participants completed the 9 studies (Table Ch. 
6.3). The largest study enrolled 376 participants (225) and the smallest enrolled 42 
participants (226). The criteria for inclusion and/or exclusion were provided in 8 of the 
studies (225-228, 230, 231, 233, 234), and 7 studies stated the diagnostic criteria for 
inclusion (225, 228-233). The study duration ranged from 2 weeks (1 study) to 12 weeks (1 
study), with a median of 4 weeks (2 studies).  
Three studies compared the effect of topical HM with that of topical placebo, and 5 studies 
used topical APP as the comparator (Table 6.4). One study compared topical HM with 
topical placebo as well as with APP (228). APPs included clobestasol (225, 231), 
fluocinonide (227), calcipotriol (228), anthralin (229) and tretinoin (233). Outcome measures 
included the PASI score (n = 5) (225, 229, 231-233) and modified PASI score (n = 2) (228, 
230). Various psoriatic symptom scores were also used: 2 studies provided scores for scaling, 
pruritus/itching, erythaema and induration (226, 227), 2 studies also included a ‘lesion area’ 
score (228, 230) and 1 study measured ‘itching’ as a symptom (232). In the study by Zhou et 
al. (2009), the outcomes measured also included AEs and safety. Each study provided an 
assessment of the overall clinical efficacy on the basis of the abovementioned outcome 
measures; however, the methods of calculation were variable.  
The topical formulae used in the studies were in the form of cream/ointment (4 studies), 
spraying agent (1study), tincture (1study), bath decoction (1study) and cataplasm (1 study). 
One study did not specify the form of preparation. Nine different HM formulae were 
assessed: Liubai Baibi (cream/cataplasm), Qinbai Ruangao (conventional/fine ointment), 
oleum horwathiensis spraying agent (Psoricur®), Queyin tincture, compound E-Bei 
ointment, Herbal Bath Formula (No. 1 or No. 2), New Pulian Ointment and Xiaoxuanling 
formula.  
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Two studies used 3 experimental groups (228, 230), and the remaining 7 studies used 2 
groups. In 2 studies, oral pharmaceuticals were used in addition to the topical preparations 
(225, 231), and 3 studies applied oral herbal formulae as co-interventions (228, 230, 232). 
No co-intervention was employed in the remaining 4 studies (226, 227, 229, 233).
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Table 6.3 Characteristics of the 9 studies on external herbal formulae for psoriasis [adapted from Deng 2013 (158)] 
First author, 
Publication 
year, 
Location, 
Duration, 
Follow-up 
Sample size (R/A), 
Gender (M/F), 
Age: Mean ± SD (Range), 
RCT Design 
(T vs C) 
Diagnosis, 
Outcome measures, 
Results 
Dropouts, 
Adverse events (AEs) 
Risk of Bias 
(SG, AC, BPt, 
BPl, BOA, 
IOD, SOR) 
Gao, W.Y. 
2006; 
Qingdao, 
China; 
8 weeks; 
NS 
T:NS/192, C:NS/184; 
T:103/89, C:97/87; 
T:36.5, (18-65) yrs, C:33.5, (18-62) yrs; 
2 groups, active-control: 
ext. HM + int. pharm. vs ext. APP + int. 
pharm. 
Psoriasis vulgaris. 
Clinical efficacy based on reduction of PASI score 
T>C (χ2 =36.15, p<0.01).   
No details; 
AEs:  
No SAE,  
mild itching & burning 
(T=7, C=9)  
SG: U 
AC: U 
BPt: U 
BPl: U 
BOA: U 
IOD: U 
SOR: L 
Lassus, A., 
1991; 
Helsinki, 
Finland; 
12 weeks; 
12 weeks 
T: 25/19, C: 25/23; 
T: 9/10, C: 10/13; 
T: 43.1, (22-50) yrs,  
C: 42.5, (29-50) yrs; 
2 groups, double-blind, vehicle-control： 
ext. HM vs ext. Placebo. 
Chronic stable psoriasis. 
Changes in mean symptom severity: T>C 
Scaling (96.8% vs 75.5%), Pruritus (93.3% vs 
54.3%), Erythema (58.1% vs 49.0%), Induration 
(68.0% vs 46.5%) 
T: 6, C: 2; 
AEs: 
T: local irritation (1),  
C: NS 
SG: U 
AC: U 
BPt: L 
BPl: L 
BOA: U 
IOD: L 
SOR: L 
Lu, Y. P., 
2004; 
Shenyang, 
China; 
18 days; 
NS 
T: 31/31, C: 22/22; 
T: 16/15, C: 12/10; 
NS; 
2 groups, 
ext. HM vs ext. APP. 
Stable psoriasis vulgaris. 
Clinical efficacy based on reduction of symptom 
score: T>C (p<0.05) 
None; 
AEs: NS 
SG: U 
AC: U 
BPt: U 
BPl: U 
BOA: U 
IOD: L 
SOR: L 
Song, P., 
2007; 
Beijing, 
China; 
4 weeks; 
0.5 years 
T:60/60, C1(WM):30/29, 
C2(Placebo):30/29; 
T:39/21, 
C1(WM):19/11, 
C2(Placebo):16/14; 
T:42.4 ±12.5, C1(WM):37.0 ±10.1,  
C2(Placebo):38.8 ±10.5; 
3 groups, block-randomized, active and 
vehicle controls,  
Plaque psoriasis. 
Modified PASI scores: T<C2 (p<0.01), C1<C2 
(p<0.01), T<C1 (p<0.01); 
Clinical efficacy: T>C2 (p<0.01), C1>C2 (p<0.01), 
T≈C1 (p>0.05), 
Single symptom scores: T<C2 (p<0.01), C1<C2 
(p<0.01); 
Time to symptom improvement:  
1) itching: T<C1/C2 (p<0.01), 
T: 0, 
C1 (WM):1, 
C2 (Placebo): 1; 
AEs: 
T: slight erythema & 
irritation (2), 
C1: erythema & lesion 
enlarged (2), 
C2: none 
SG: L 
AC: U 
BPt: U 
BPl: U 
BOA: U 
IOD: U 
SOR: L 
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ext. HM + int. HM vs ext. APP + int. HM vs 
ext. placebo + int. HM. 
 
2) erythema, scaling & induration: T/C1<C2 
(p<0.01), 
3) lesion area: T≈C1≈C2 
Wang, J. X., 
2002; 
Changsha, 
China; 
8 weeks; 
1 year 
T: 112/112, C: 56/56; 
T: 64/48, C: 30/26; 
T: 28-70 yrs, C: 32-68 yrs; 
2 groups, active-control: ext. HM vs ext. 
APP. 
Psoriasis vulgaris. 
Global PASI: T<C (p<0.001), 
Clinical efficacy: T>C (χ2 =6.25, p<0.05), 
Relapse comparison: T<C (χ2 =5.50, p<0.05) 
None; 
AEs: NS 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Xu, J.,  
2009; 
Beijing, 
China; 
8 weeks; 
3 months 
T1:31/30, T2:31/30, C:31/30; 
T1:21/9, T2:22/8, C:23/7; 
T1:37.47±11.49 yrs, 
T2:39.10±11.41 yrs, 
C:38.13±12.79 yrs; 
blood-heat syndrome, 
3 groups: 
ext. HM + int. HM vs ext. HM + int. HM vs 
ext. placebo + int. HM. 
Active psoriasis. 
Clinical efficacy: T1/T2>C (p<0.05), T1≈T2 
(p>0.05); 
Reduction of modified PASI scores: T1/T2>C 
(p<0.05),  
Lesion area rating: T1≈T2≈C;  
Single symptom scores (erythema, scaling, 
infiltration & itching): all T1/T2<C (p<0.05); 
Single symptom time to improvement: all T1/T2<C 
(p<0.05) 
T1: 1,T2: 1,C: 1; 
AEs: slight erythema & 
irritation (T1=2, T2=1, 
C=1) 
SG: L 
AC: U 
BPt: L 
BPl: U 
BOA: U 
IOD: L 
SOR: L 
Yang, Y. D., 
2011; 
Qingdao, 
China; 
8 weeks; 
NS 
T: NS/96, C: NS/86; 
T: 51/45, C: 45/41; 
T: 36.5, (18-65) yrs,  
C: 33.5, (18-62) yrs; 
2 groups, active-control: 
ext. HM + int. pharm. vs ext. APP + int. 
pharm. 
Psoriasis vulgaris. 
Clinical efficacy based on reduction of PASI score 
T>C (χ2 =5.0, p<0.05) 
NS; 
AEs:  
No SAE,  
mild itching & burning 
(T=4, C=5) 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: U 
SOR: L 
Zhou, N., 
2009; 
Beijing, 
China; 
4 weeks; 
NS 
T: 54/51, C: 54/49; 
T: 23/28, C: 28/21; 
T: (39.4±15.0) yrs, C: (41.2±13.3) yrs; 
2 groups, multi-centre, placebo-controlled, 
RCT: ext. HM + int. HM vs ext. placebo + 
int. HM. 
Blood-heat syndrome Psoriasis. 
Remarkably effective rate (RER): T>C (χ2 
=13.0998, p=0.0003); 
total effective rate (TER): T>C (χ2=12.7298, 
p=0.0004); 
PASI scores: T<C (p<0.05); 
Score of erythema, infiltration & lesion area: all 
T<C (p<0.01); 
Score of scaling: T≈C (p>0.05); 
Score of itching: T<C (χ2=8.1145, p=0.0044) 
T: 3 (1 dissatisfied with 
efficacy, 2 various 
reasons), C: 5 (1 
dissatisfied with 
efficacy, 4 various 
reasons); 
AEs: none 
SG: L 
AC: U 
BPt: L 
BPl: U 
BOA: U 
IOD: L 
SOR: L 
Zhu, L., T: 41/41, C: 44/44; Psoriasis vulgaris. None; SG: U 
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2008; 
Sichuan, 
China; 
2 weeks; 
NS 
T: 24/17, C: 26/18; 
T: 39.5±11.3, (18-65) yrs,  
C: 41±10.5, (19-64) yrs; 
2 groups, placebo-control: 
ext. HM vs ext. APP. 
Clinical efficacy based on PASI: 
T≈C (χ2=2.125, p=0.05) 
AEs: 
T: slight tingling 
sensation (7),  
C: slight burning (6) 
AC: U 
BPt: U 
BPl: U 
BOA: U 
IOD: L 
SOR: L 
T: treatment group, C: control group, R/A: registration/analysis, M/F: male/female, NS: not stated, Pharm.: pharmaceutical treatment, ext.: external, int.: internal, 
yrs: years, wks: weeks, mins: minutes, RCT: randomised clinical trial 
 
Risk of Bias Categories 
SG: sequence generation, AC: allocation concealment, BPt: blinding of participants, BPl: blinding of personnel, BOA: blinding of outcome assessment, IOD: 
incomplete outcome data, SOR: selective outcome reporting 
Risk of Bias Judgements 
L: low risk, U: unclear risk, H: high risk 
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Table 6.4 Interventions used in the 9 studies on topical herbal formulae for treating psoriasis [adapted from Deng 2013 (158)] 
 
Study ID External HMs and ingredients HM vs APP/Plac (T vs C) Co-intervention (same in T&C) 
Gao 2006 Liubai Baibi cream: Bai xian pi (Dictamnus dasycarpus Turcz., bark) 30g, 
Bai zhi (Angelica dahurica (Fisch. ex Hoffm.) Benth. & Hook.f., root) 10g, 
Bai ji li (Tribulus terrestris L., fruit) 10g, Bai fan (Alunite) 10g, Bai lian 
(Ampelopsis japonica (Thunb.) Makino, root) 15g, Duan mu li (Ostrea 
rivularis Gould, shell) 30g, Zi cao (Lithospermum erythrorhizon Sieb.et 
Zucc., root) 20g, Xue jie (Daemonorops draco Bl., fruit-resin) 3g, Mu bie 
zi (Momordica cochinchinensis (Lour.) Spreng., seed) 10g, Fang feng 
(Saposhnikovia divaricata (Turcz.) Schischk., root) 10g, Hu huang lian 
(Picrorhiza scrophulariiflora Pennell, root) 10g, Da feng zi (Hydnocarpus 
anthelmintica Pier., seed) 10g, Ku shen (Sophora flavescens Ait., root) 15g, 
Ce bei ye (Biota orientalis (L.) Endl., leaf) 10g, Sheng gan cao 
(Glycyrrhiza uralensis Fisch., root) 30g. Vehicle consisted of stearic acid 
300 g, white petrolatum 250 g, glycerol 50 g, triethanolamine 200 ml (used 
in water phase) and sesame oil (used in oil phase). 
T: 2 X day (30 mins before 
sleep, and after getting up) use 
enough cream to cover the 
lesions. 
 
C: En Fu cream (clobestasol), 
2 X day. 
Folic acid (10 mg): oral, 3 X day; 
Vitamin E (0.2 g): oral, 3 X day 
Lassus 1991 
 
Oleum horwathiensis spraying agent (Psoricur®): manufactured by 
Unifarm International, Sweden. Achillea millefolium L. herb, Allium 
sativum L. bulb, Calendula officinalis L., flower, Taraxacum officinale F.H 
Wigg, root, Urtica dioica L. leaf and Veronica officinalis L. herb, in 
cosmetic soft paraffin.  
 
T: apply to affected areas with 
a mechanical spray pump 
directly from the plastic bottle 
package, 1 X day. 
 
C: vehicle oil (spraying 
agent): apply to affected areas 
with a mechanical spray pump 
directly from the plastic bottle 
package, 1 X day. 
None 
Lu 2004 
 
Queyin tincture: Bai xian pi (Dictamnus dasycarpus Turcz., bark), Ku shen 
(Sophora flavescens Ait., root) each 30g, Huang qin (Scutellaria 
baicalensis Georgi, root) 20g, Lei gong teng (Tripterygium wilfordii Hook. 
f., root), Tu da huang (Rheum palmatum L., root) 30g.  
T: HM in water with 75% 
alcohol, 1000ml, for two 
weeks, then filter and set 
aside. Lesion on the 
limbs/chest-back used as 
target area (7.5-30 cm2), 2 X 
day. 
 
C: Piyanning tincture 
(Compound Fluocinonide 
None 
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Tincture): Lesion on the 
limbs/chest-back used as 
target area (7.5-30 cm2).  
2 X day. 
Song 2007 T: Compound E-Bei ointment(CEBO): 2.5% volatile oil of E zhu 
(Curcuma phaeocaulis Valeton, rhizome), 5% aqueous extract of Wu bei zi 
(Rhus chinensis Mill., gall), prepared by the authors’ hospital.  
 
T:  2 X day, topically. 
 
C1 (WM): Daivonex ointment 
(Calcipotriol): manufactured 
by LEO Pharmaceutical Co., 
Ltd., Denmark.  
2 X day. 
 
C2 (Placebo): Vehicle of 
CEBO, prepared by the 
authors’ hospital.  
2 X day. 
Shaoxian Wan (0.9 g/pill): Chong 
lou (Paris polyphylla Smith, root), 
Bai xian pi (Dictamnus dasycarpus 
Turcz., bark), etc. in ratio of 1:1, 
total crude drug at 2.35g, and 
prepared by the authors’ hospital. 
Oral 1 pill X 2 X day. 
Wang 2002 
 
1# Herbal Bath Formula (for blood-heat syndrome): Sheng da huang 
(Rheum palmatum L., root) 100g, Huang bai (Phellodendron amurense 
Rupr., bark) 100g, Ku shen (Sophora flavescens Ait., root) 100g, Hu zhang 
(Polygonum cuspidatum Sieb. et Zucc., root) 100g, Ye ju hua 
(Chrysanthemum indicum L., flower) 60g, She chuang zi (Cnidium 
monnieri (L.) Cusson, seed) 60g, Pu gong ying (Taraxacum mongolicum 
Hand.-Mazz., herb) 60g, Bai zhi (Angelica dahurica (Fisch. ex Hoffm.) 
Benth. & Hook.f. , root) 60g, Qian li guang (Senecio scandens Buch.-Ham. 
aerial parts) 60g, Shi chang pu (Acorus tatarinowii Schott., root) 30g, Hong 
hua (Carthamus tinctorius L., flower) 30g, Bo he (Mentha haplocalyx 
Briq., leaf) 30g, Pi xiao (Mirabilite) 30g, Ku fan (Alumen) 30g.  
2# Herbal Bath Formula (for blood-deficiency syndrome): Da sheng di 
(Rehmannia glutinosa (Gaertn.) Libosch., root) 100g, Quan dang gui 
(Angelica sinensis (Oliv.) Diels, root) 100g, Ji xue teng (Spatholobus 
suberectus Dunn., stem) 100g, Ci wu jia pi (Acanthopanax senticosus 
(Rupr. et Maxim.) Harms., bark) 60g, Di gu pi (Lycium barbarum L., root) 
60g, Qi ye yi zhi hua (Paris polyphylla Smith, root) 60g, Xu chang qing 
(Cynanchum paniculatum (Bge.) Kitag., root) 60g, Ci ji li (Tribulus 
terrestris L., fruit) 60g, Hang bai ju (Chrysanthemum morifolium Ramat., 
flower) 60g, Wei ling xian (Clematis hexapetala Pall., root) 60g, Chu tao 
ye (Broussonetia papyrifera (L.) Vent., fruit) 60g, Ce bai ye (Biota 
orientalis (L.) Endl., leaf) 60g, Dan shen (Salvia miltiorrhiza Bge., root) 
T: 1#/2#: in 180-200L water 
boiled for 20 mins, then filter 
into warm liquid for bath, 20 
mins, 2 X day. 
 
C: 0.1% anthralin ointment  
2 X day (in the morning and at 
night). 
None 
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60g, Hua jiao (Zanthoxylum bungeanum Maxim., seed) 30g. 
Xu 2009 
 
T1: Conventional Qinbai Ruangao (ointment): 10% Huang qin (Scutellaria 
baicalensis Georgi, root) and 10% Huang bai (Phellodendron amurense 
Rupr., bark), prepared by the authors’ hospital.  
T2: Fine Qinbai Ruangao (ointment): same ingredients as the above (finely 
ground), prepared by the authors’ hospital and Tsinghua University.  
T1/T2: clean affected skin, 
then apply the ointment, 2 X 
day. 
 
C: white vaseline ointment: 
provided by Hebei Lanlian 
Feitian Petro Chemical Co., 
Ltd. Clean the affected skin, 
then apply the ointment, 2 X 
day. 
Liangxue Huoxue Tang (decoction): 
Huai hua (Sophora japonica L., 
flower), Zi cao gen (Lithospermum 
erythrorhizon Sieb. et Zucc., root), 
Chi shao (Paeonia veitchii Lynch, 
root), Bai mao gen (Imperata 
cylindrica Beauv.var.major (Nees) 
C.E., stem), Sheng di (Rehmannia 
glutinosa (Gaertn.) Libosch., root), 
Dan shen (Salvia miltiorrhiza Bge., 
root), Ji xue teng (Spatholobus 
suberectus Dunn., stem), etc. in 
400ml decoction, prepared by the 
authors’ hospital, oral, 2 X day. 
Yang 2011 Liubaibaibi cataplasm: Sheng gan cao (Glycyrrhiza uralensis Fisch. root), 
Bai xian pi (Dictamnus dasycarpus Turcz., bark), Bai ji li (Tribulus 
terrestris L., fruit), Bai Lian (Ampelopsis japonica (Thunb.) Makino root), 
Zi cao (Lithospermum erythrorhizon Sieb. et Zucc., root), Hu huang lian 
(Picrorhiza scrophulariiflora Pennell, root), Ku shen (Sophora flavescens 
Ait., root), Ce bai ye (Biota orientalis (L.) Endl., leaf), Bai zhi (Angelica 
dahurica (Fisch.ex Hoffm.) Benth.& Hook.f., root), Bai fan (Alunite), 
Sheng mu li (Ostrea rivularis Gould, shell), Fang feng (Saposhnikovia 
divaricata (Turcz.) Schischk., root), Da feng zi (Hydnocarpus 
anthelmintica Pier., seed), and Mu bie zi (Momordica cochinchinensis 
(Lour.) Spreng., seed).  
T: apply enough cataplasm to 
cover the lesions for 6 hours, 2 
X day (morning & evening). 
 
C: En Fu cream (clobestasol), 
2 X day. 
Folic acid (10 mg): oral, 3 X day; 
Vitamin E (0.2 g): oral, 3 X day 
Zhou 2009 New Pulian Ointment: Huang qin (Scutellaria baicalensis Georgi, root), 
Huang bai (Phellodendron amurense Rupr., bark), Qing dai (Indigo 
naturalis, namely dried powder manufactured from: Baphicacanthus cusia 
(Nees) Brem., Indigofera tinctoria L., Isatis tinctoria L., Isatis indigotica 
Fort., or Polygonum tinctorium Ait.), Zi cao (Lithospermum erythrorhizon 
Sieb. et Zucc., root), Bing pian (borneol), water phase (lauryl sulfonate), 
and oil phase (sesame oil, glycerine monostearate, tween-80, and ethyl 
hydroxy benzoate) prepared by the authors’ hospital.  
 
T: 2 X day, topically. 
 
C: placebo ointment: mainly 
contained Jian qu  
(Massa Fermentata 
Medicinalis) prepared by the 
same hospital. 2 X day. 
conventional clearing heat & 
cooling blood decoction: mainly 
consisted of Pu gong ying 
(Taraxacum mongolicum 
Hand.-Mazz., herb) 10g, Lian qiao 
(Forsythia suspensa (Thunb.) Vahl, 
fruit) 12g, Ban lan gen (Isatis 
tinctoria L., root) 30g, Da qing ye 
(Isatis indigotica Fortune, leaf) 15g, 
Bai mao gen (Imperata cylindrica 
Beauv. var. major (Nees) C.E., 
stem) 30g, Jin yin hua (Lonicera 
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japonica Thunb., flower) 15g, Xia 
ku cao (Prunella vulgaris L., herb) 
15g, Mu dan pi (Paeonia 
suffruticosa Andr., bark) 15g, Chi 
shao (Paeonia veitchii Lynch, root) 
15g, Bai shao (Paeonia lactiflora 
Pall. , root) 15g, Sheng di 
(Rehmannia glutinosa (Gaertn.) 
Libosch., root) 15g, Xuan shen 
(Scrophularia ningpoensis Hemsl., 
root) 15g. 1 X day, which was 
decocted to divide into 2 parts for 
twice (in the morning and evening) 
oral application with swallowing 
0.3g powder of Ling yang jiao 
(Saiga tatarica L., horn).  
Zhu 2008 Xiaoxuanling formula: mainly contained Wu bei zi (Rhus chinensis Mill., 
gall), Yang shu ye (Populus simonii Carr., leaf), Shou wu (Polygonum 
multiflorum Thunb., root), Zhi liu huang (sulphur), Di fu zi (Kochia 
scoparia (L.), fruit), which was prepared by the authors’ hospital.  
T: 2 X day, topically. 
 
C: tretinoin cream (0.025% 
Diwei cream- Vitamin A acid 
cream): manufactured by 
Chongqing Huapont Pharm. 
Co., Ltd., 2 X day. 
None 
T: treatment group, C: control group, HM: herbal medicine, APP: anti-psoriatic pharmacotherapy
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6.2.3.1 Description of studies 
Oleum horwathiensis formula (1 RCT) 
Lassus and Forsström have conducted a double-blind placebo-controlled study involving 50 
patients with mild to moderate psoriasis vulgaris. They revealed that a multi-herb 
proprietary medicine called Oleum horwathiensis sprayed on psoriatic lesions produced a 
marked decrease in symptom severity after 12 weeks (226). The placebo group also 
experienced some improvements; these were less pronounced than those in the treatment 
group. However, no significance tests were performed. The tolerability and cosmetic 
acceptance of Oleum horwathiensis was found to be good; this preparation was effective on 
scalp lesions. 
Herbal bath formula (1 RCT) 
Wang et al. compared the effect of No. 1 and No. 2 herbal bath formula with that of the 0.1% 
anthralin ointment (n = 56) in the treatment of psoriasis vulgaris (229). Participants in 
‘blood-heat’ syndrome and ‘blood-deficiency’ syndrome groups (n = 112 for both groups) 
were administered No. 1 formula and No. 2 formula, respectively. The outcomes were PASI 
score, clinical efficacy and relapse proportion. Data for the 2 herbal bath formulae were 
pooled. The authors reported significant differences between clinical efficacy and a relapse 
rate in the HM and anthralin groups after 8 weeks of treatment. 
Queyin formula (1 RCT) 
Lu and Miao compared the effect of a compound HM called Queyin tincture (n = 31) with 
that of a steroid agent, Piyanning tincture, (n = 22) on randomly selected target lesions (7.5–
30 cm2) (227). The overall clinical efficacy was evaluated on the basis of changes in PASI 
scores. After 18 days of treatment, there was a significant difference between the 2 groups. 
Queyin tincture was considered to have satisfactory efficacy for external use in cases of 
psoriasis. 
Liubai Baibi formula (2 RCTs) 
The study of Gao et al. evaluated the efficacy of a compound HM called Liubai Baibi, 
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administered in a cream form (n = 192), in comparison with that of clobestasol (En Fu cream) 
(n = 184). Both the groups also received oral folic acid and vitamin E (225). The overall 
clinical efficacy was assessed after 8 weeks on the basis of PASI score change. There was a 
significant difference between the 2 groups without any serious AEs (SAEs) in either group. 
Therefore, Liubai Baibi cream was considered to be safe for the treatment for psoriasis 
vulgaris. 
A comparison between the efficacy of the Liubai Baibi cataplasm (n = 96) and clobestasol 
(En Fu cream) (n = 86), with oral folic acid and vitamin E as co-interventions, was the 
subject of another RCT. The trial lasted for 8 weeks (231). The cataplasm contained similar 
ingredients to those in the cream (225, 231). A significant reduction in the PASI score was 
found for the cataplasm. No SAEs were reported in either group. Moreover, the cataplasm 
group had fewer cases of slight skin irritation than the clobestasol group. The authors 
concluded that the Liubai Baibi cataplasm was safe and effective and recommended its 
application in treating psoriasis vulgaris. 
Compound E-Bei (1 RCT) 
Song et al. compared the E-Bei ointment (n = 60) with the calcipotriol ointment (n = 30) and 
placebo, which was the vehicle for the herbal ointment (n = 30). The trial lasted for 4 weeks 
with follow-ups at 3 and 9 months (228). All the 3 groups were also given the same herbal 
pill (Shaoxian Wan). The outcome measures were modified PASI, individual symptom 
scores (erythaema, scaling, induration, itching and lesion area) and overall therapeutic 
effectiveness. In comparison with the vehicle ointment group, modified PASI and individual 
symptom scores improved in both the E-Bei ointment and calcipotriol ointment groups, but 
not in lesion area. Calcipotriol and placebo groups had 1 dropout each. There were 2 cases 
of rash and irritation in the E-Bei ointment group. Slight rash and lesion expansion were 
noted in 2 cases in the calcipotriol group; these cleared within 10 days. There were no AEs 
in the placebo group. The authors concluded that the E-Bei ointment was not inferior to the 
calcipotriol ointment. The herbal ointment reduced itching more rapidly than calcipotriol. 
Xiaoxuanling formula (1 RCT) 
An RCT by Zhu et al. compared the Xiaoxuanling topical formula (made by the hospital) 
with routine therapy of Tretinoin cream (0.025% Vitamin A acid cream) as treatment for 
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psoriasis vulgaris. The measured outcome was overall clinical efficacy based on the PASI 
score change (233). The trial lasted for 2 weeks. No differences were observed between 
overall clinical efficacies or AE incidences. The authors suggested that Xiaoxuanling was a 
good clinical option for treating psoriasis; it caused no SAEs and was cheaper than the 
conventional cream. 
Compound Qinbai formula (1 RCT) 
In a participant-blinded 8-week RCT, Xu et al. compared 2 forms of the same herbal 
ointment with a petroleum jelly. There were 3 experimental groups (n = 31 in each) (230). 
The study enrolled 93 participants, and there was 1 dropout in each group. The herbal 
ointments compared were ‘conventional’ Qinbai ointment (n = 30) and ‘fine’ Qinbai 
ointment (finely ground to improve the release of constituents) (n = 30). The placebo group 
was treated with petroleum jelly (n = 30). All the patients had been diagnosed according to 
TCM principles as belonging to the ‘blood-heat’ type. All the participants also received the 
same herbal decoction, administered orally (Liangxue Huoxue Tang). The outcome 
measures, obtained at 2, 4, 6 and 8 weeks, were modified PASI and individual symptom 
scores (erythaema, scaling, induration, itching and lesion area). After 8 weeks, all 3 groups 
demonstrated significant improvements in overall modified PASI scores and lesion area in 
comparison with baseline. For both types of ointments, the improvements were greater than 
those for the petroleum jelly alone. In comparison with the control group, the 2 herbal 
ointment groups showed improvements in the individual symptom scores for scaling, 
induration and itching but not in erythaema. However, these differences were not statistically 
significant. The authors concluded that the herbal ointments were more effective than the 
petroleum jelly and that the fine Qinbai ointment was faster-acting than the conventional 
ointment.  
New Pulian formula (1 RCT) 
A single-blind RCT was conducted by Zhou et al. to examine the efficacy of New Pulian 
Ointment in comparison with that of the placebo ointment. The trial involved 108 patients 
with psoriasis vulgaris of the ‘blood-heat’ type and lasted for 4 weeks (232). The ointment 
was a modification of Pulian Ointment, made up in a less sticky vehicle than the 
conventional type to make it more acceptable to patients. The participants also received an 
oral HM decoction for ‘clearing heat and cooling blood’ and a number of foods were 
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forbidden. Outcome measures were (a) PASI scores and skin lesion symptoms (scaling, 
erythaema, infiltration and lesion area), (b) itching score and (c) AEs and safety. After 4 
weeks, significant differences were observed between the 2 groups for all the above 
mentioned measures, except the scaling score, without any AEs. The researchers concluded 
that the new ointment was safe, improved treatment efficacy and could be regarded as 
reliably effective for the ‘blood-heat’ syndrome of psoriasis.  
6.2.3.2 Methodological assessment 
Risk of bias evaluations are listed in Table 6.3 (171). The authors of all trials either stated 
that their studies had been ‘randomised’ or used a similar expression. Three studies stated 
the method of random sequence generation: ‘sealed envelopes’ (228), ‘random number table’ 
(230) and ‘randomising digital table’ (232); therefore, they were judged as having ‘low’ risk 
of bias in this category. No study provided information on the method of allocation 
concealment; therefore, they were all judged as having ‘unclear’ risk of bias for this item. 
Three placebo-controlled studies applied identical vehicle preparations and were blinded to 
participants and were considered have ‘low’ risk of bias in this category (226, 230, 232). In 
the category of blinding of participants, 2 studies were judged as having ‘high’ risk of bias 
because different interventions were applied in different groups; therefore, unblinding 
appeared likely (229, 231). The same 2 studies were also judged as having high risk of bias 
in personnel blinding (229, 231). One study was blinded to personnel and judged as having 
‘low’ risk of bias in this category (226). All the studies were judged as having ‘unclear’ risk 
of bias in blinding of outcome assessment because none provided the relevant information. 
Gao et al. (2006) and Yang et al. (2011) did not provide the number of enrolled participants 
(225, 231). Song et al. (2007) did not provide reasons for dropouts (228). These 3 studies 
were judged to have ‘unclear’ risk of bias for incomplete outcome data. The remaining 
studies reported that all the patients completed the study; these studies were judged as 
having ‘low’ risk of bias for this category. All studies reported all outcomes; therefore, bias 
due to selective reporting was judged as low. 
6.2.3.3 Meta-analysis 
Numerical outcome data suitable for meta-analysis in RevMan 5.1 were reported by eight 
studies (Table 6.5) ; 1 study did not provide suitable data (226). Outcome measures included 
overall clinical efficacy (n = 8) (225, 227-233), symptom score on scaling, erythaema, 
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induration, itching and lesion area (n = 2) (228, 230), PASI score (n = 2) (229, 232) and 
modified PASI score (n = 2) (228, 230).
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Table 6.5 Distribution of RCTs suitable to meta-analysis with RevMan 5.1 by outcome measure and study design 
[adapted from Deng 2013 (158)] 
                         Study design
Outcome measures 
ext. HM 
vs 
ext. APP 
ext. HM + int. HM 
vs 
ext. APP + int. HM 
ext. HM + int. pharm. 
vs 
ext. APP + int. pharm. 
ext. HM + int. HM 
vs 
ext. placebo + int. HM 
Clinical efficacy 
 
Lu 2004, 
Wang 2002, 
Zhu 2008 
 
Song 2007 
Yang 2011,  
Gao 2006 
Song 2007,  
Xu 2009,  
Zhou 2009 
Scaling score X Song 2007 X 
Song 2007,  
Xu 2009 
Erythaema score X Song 2007 
X Song 2007,  
Xu 2009 
Induration score X Song 2007 X 
Song 2007,  
Xu 2009 
Itching score X Song 2007 X 
Song 2007,  
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Xu 2009 
Lesion area X Song 2007 X 
Song 2007,  
Xu 2009 
PASI Wang 2002 X X Zhou 2009 
Modified PASI X Song 2007 X 
Song 2007,  
Xu 2009 
HM: herbal medicine, APP: anti-psoriatic pharmacotherapy, Pharm.: pharmaceutical treatment, ext.: external treatment, int.: internal treatment, PASI: Psoriasis Area 
Severity Index
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Clinical efficacy  
Different studies used different systems for classifying clinical efficacy and PASI reduction. 
Therefore, our clinical efficacy assessment only included cases with an efficacy rate of 50% 
or above or PASI reduction of 50% or more (185). Results were analysed using RR and 
random-effect model. In meta-analyses, a higher score reflects greater efficacy. 
Of the 8 studies that provided data suitable for meta-analysis, 4 compared topical HM with 
placebo and all used an oral Chinese medicine in both groups (230, 232, 235). Three studies 
tested external HM versus external APP (227, 229, 233), 1 used an additional internal HM in 
both groups (228) and 2 administered internal pharmaceuticals in both groups (225, 231). 
The meta-analysis used pooled data for 4 subgroups of studies, described below. 
Group 1. External HM + internal CM vs. external placebo + internal CM (3 studies, 7 
groups) 
For the study by Song et al. (2007), the comparison between the E-Bei ointment and placebo 
failed to reach statistical significance (RR 7.38, 95% CI: 0.44–124.90). Similarly, the 
differences observed between conventional and fine Qinbai ointments and placebo in the 
study by Xu et al. (2009) were not significant: conventional Qinbai ointment (RR 1.21, 95% 
CI: 1.00–1.46); fine Qinbai ointment (RR 1.17, 95% CI: 0.95–1.43). The comparison 
between New Pulian Ointment and placebo revealed significant differences in the favour of 
HM (RR 3.68, 95% CI: 1.64–8.27) (232). For the pooled data, a significant difference was 
found in the favour of HM (RR 1.40, 95% CI: 1.01–1.94, p = 0.04); however, analysis 
revealed high heterogeneity (66%) (Fig.6.4). Sensitivity analysis showed that the high 
heterogeneity was caused by the use of PASI score as the basis of efficacy evaluation (232), 
whereas the other trial used modified PASI. Although there was a tendency to favour HMs, 
meta-analyses revealed no differences between HMs and their respective placebos in the 
studies by Song et al. (2007) and Xu et al. (2009). Our results did not support the original 
conclusions that these ointments were superior to placebo for this outcome. However, the 
results of meta-analysis were in agreement with conclusions of the study by Zhou et al. 
(2009). 
Group 2. External HM vs. external APP (3 studies, 6 groups) 
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For the studies testing HM versus APP, there was a significantly higher efficacy rate for 
Queyin tincture than for Fluocinonide tincture (RR 1.42; 95% CI: 1.01–1.99) and for No. 1 
and No. 2 Herbal Bath formulae than for the 0.1% anthralin ointment (RR 1.29; 95% CI: 
1.03–1.61). No significant difference was found between efficacies of Xiaoxuanling and 
Tretinoin cream (RR 1.07; 95% CI: 0.38–3.06). These results were consistent with the 
conclusions of the study. For the pooled data, a significant difference between external HM 
and external APP was found (RR 1.32, 95% CI: 1.10–1.58, p = 0.003) (Fig. 6. 4).  
Group 3. External HM + internal CM vs. external APP + internal CM (1 study, 2 groups) 
No significant difference between the E-Bei ointment and calcipotriol control was found in 
the study of Song et al. (228) (RR 1.69, 95% CI: 0.37–7.64) (228) (Fig. 6.4). This supported 
the authors’ conclusion that the efficacy of HM was not inferior to that of calcipotriol. 
Group 4. External HM + internal WM vs. external APP + internal WM (2 studies, 4 groups) 
The 2 Liubai Baibi preparations showed better efficacy than external clobestasol (with oral 
folic acid plus vitamin E as co-intervention). The results for Liubai Baibi cream were RR 
1.39; 95% CI: 1.24–1.55 (225) and those for cataplasm were RR 1.29; 95% CI: 1.07–1.55 
(231). The pooled data revealed a significant difference in the favour of external HM (RR 
1.36; 95% CI: 1.23–1.50, p < 0.00001) with zero heterogeneity (Fig. 6.4). This result 
supported the conclusions of the study. 
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Fig. 6.4 Forest plot of clinical efficacy: external herbal medicine (HM) versus external 
placebo/anti-psoriatic pharmacotherapy (APP) with or without co-interventions of internal 
herbal medicine (int HM) or internal Western medicine (int WM) used in both groups 
[adapted from Deng 2013 (158)] 
Symptom scores 
Symptom scores were presented as outcome measures in 3 studies (228, 230, 232). The 
studies used a internal HM in both experimental arms. However, the symptom scores given 
in Zhou et al. (2009) were difference scores and were not suitable for RevMan 5.1. analysis. 
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Scaling (2 studies, 6 groups) 
A significant difference in the efficacy of the E-Bei ointment in comparison with that of 
placebo was found in the study by Song et al. (2007) (SMD −1.20, 95% CI: −1.68 to −0.72). 
However, the differences between HM and calcipotriol in the other arm of the study failed to 
reach significance (SMD 0.17, 95% CI: −0.27 to 0.62). In the study by Xu et al. (2009), 
there were significant differences between the effects of both fine and conventional Qinbai 
ointments and placebo (each SMD −0.53, 95% CI: −1.05 to −0.02), in the favour of HMs. 
Analysis of pooled data showed significant differences between the effects of external HMs 
and external placebos (SMD −0.77, 95% CI: −1.21 to −0.32) in the treatment of scaling. 
Erythaema (2 studies, 6 groups) 
In the study of Song et al. (2007), a significant difference was observed between the effect 
of the E-Bei ointment and placebo (SMD −0.88, 95% CI: −1.34 to −0.42); however, there 
were no significant differences in comparison with calcipotriol (SMD 0.38, 95% CI: −0.07 
to 0.83). Xu et al. (2009) did not demonstrate significant differences between the fine (SMD 
−0.20, 95% CI: −0.71 to 0.31) or conventional Qinbai ointment (SMD −0.09, 95% CI: −0.60 
to 0.42) and placebo. Pooled data analysis did not reveal differences between the effects of 
external HM and external placebo (SMD −0.40, 95% CI: −0.90 to 0.10, p = 0.12) on 
erythaema. 
Induration (2 studies, 6 groups) 
The comparison of the E-Bei ointment and placebo in a study by Song et al. (228) revealed a 
significant difference between efficacies (SMD −0.99, 95% CI: −1.45 to −0.52) but no 
difference in comparison with calcipotriol (SMD 0.33, 95% CI: −0.12 to 0.77). Xu et al. 
(2009) found no differences between the fine (SMD −0.61, 95% CI: −1.13 to −0.09) or 
conventional Qinbai ointment (SMD −0.54, 95% CI: −1.06 to −0.03) and placebo. The 
pooled data showed a significant difference between the effect of external HM and external 
placebo (SMD −0.73, 95% CI: −1.02 to −0.44) in the treatment of induration. 
Itching (2 studies, 6 groups) 
Song et al. (2007) have reported a significant difference between the effect of the E-Bei 
ointment in comparison with that of placebo (SMD −0.88, 95% CI: −1.34 to −0.41) but no 
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difference in comparison with the effect of calcipotriol (SMD −0.04, 95% CI: −0.48 to 0.40). 
In the study of Xu et al. (2009), there were differences between fine (SMD −0.62, 95% CI: 
−1.14 to −0.10) and conventional Qinbai ointments (SMD −0.54, 95% CI: −1.06 to −0.03) 
and placebo. The pooled data revealed a significant difference between the effect of external 
HM and external placebo (SMD −0.69, 95% CI: −0.98 to −0.41) on itching. 
Lesion area (2 studies, 6 groups) 
No significant differences were found in comparison of the E-Bei ointment with the 
calcipotriol ointment or placebo or in the comparison between fine and conventional Qinbai 
ointments with placebo. Therefore, there was no difference between the effect of HM and 
placebo in pooled result analysis (SMD −0.11, 95% CI: −0.39 to 0.17, p = 0.45).  
PASI score and modified PASI score 
PASI is used as a standard measure of psoriatic severity in terms of erythaema, induration 
and scaling (236). Currently modified versions of PASI are also used in clinical practice and 
research. The modified PASI used by Song et al. (2007) and Xu et al. (2009) adds a score 
for itching and follows the national guideline on Chinese Herbal Medicine trials (111). 
Another 2 studies used classical PASI scores (229, 232). 
PASI score (2 studies, 4 groups) 
Zhou et al. (2009) found that New Pulian Ointment was superior to external placebo when 
used with the same oral HM as co-intervention. This was confirmed (SMD −0.41, 95% CI: 
−0.80, −0.01). Wang et al. (2002) reported that the 2 herbal bath formulae were more 
effective than the anthralin ointment, and this result was also confirmed (SMD −0.97, 95% 
CI: −1.31, −0.63). 
Modified PASI score (3 studies, 7 groups) 
Both fine (SMD: −0.79, 95% CI: −1.32 to −0.27) and conventional (SMD: −0.70, 95% CI: 
−1.22 to −0.18) forms of the Qinbai ointment resulted in significant improvements in 
comparison with placebo in the study by Xu et al. (2009). Song et al. (228) reported that in 
comparison with placebo, the E-Bei ointment showed a significant effect (SMD: −0.87, 95% 
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CI: −1.33 to −0.41). Pooled data showed a significant difference between this external HM 
and external placebo (SMD: −0.79, 95% CI: −1.08 to −0.51). 
Song et al. (2007) also compared the effect of the E-Bei ointment and calcipotriol and found 
no difference (SMD: 0.15, 95% CI: −0.29 to 0.60, p = 0.50), which suggested similar 
reductions in modified PASI scores for the 2 remedies. 
6.2.3.4 AEs  
AE information was supplied by 7 studies, and 2 studies did not provide any information 
(227, 229). Among the 7 studies, 1 reported no adverse effects (232). Of the 6 remaining 
studies, 2 stated that there were no SAEs (225, 231).  
Symptoms of local irritation were found in all the studies reporting AEs. Slight erythaema 
and irritation, slight tingling sensation and mild itching and burning were the most frequent 
events. There were 24 AE cases among the 519 participants in the assessable treatment 
groups, (4.62% incidence) and no SAEs were reported.  
6.2.3.5 Principal herbs used in the studies 
Among the examined medications, 54 different herbs were externally applied, 8 of which 
were also used in co-interventions as oral herbal decoctions (2 studies) or pills (1 study). 
Another 11 herbs were exclusively used in co-interventions. The herb most commonly used 
in the external herbal formulae was Ku shen (Sophora flavescens Ait., root) (4 studies). 
Seven herbs were used in 3 studies each: Zi cao (Lithospermum erythrorhizon Sieb.et Zucc., 
root), Bai xian pi (Dictamnus dasycarpus Turcz., bark), Bai zhi [Angelica dahurica 
(Fisch.ex Hoffm.) Benth.& Hook.f., root], Bai ji li (Tribulus terrestris L., fruit), Ce bei ye 
[Biota orientalis (L.) Endl., leaf], Huang qin (Scutellaria baicalensis Georgi, root) and 
Huang bai (Phellodendron amurense Rupr., bark). Eleven herbs were used twice and 35 
were used once. 
Two studies, Gao et al. (2006) and Yang et al. (2011), used very similar topical formulae, 
with 14 herbs in common. Both the formulae were more effective than the tested APP. 
Formulae that had several herbs in common with those used by those 2 studies were used by 
Lu & Miao (2004) and Wang et al. (2002). Ku shen was used in all 4 studies. Herbal 
preparations of Bai xian pi, Bai zhi, Bai ji li and Ce bei ye were each included in 3 of these 
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studies. Because all the 4 studies analysed comparisons with APP, the data for these studies 
were pooled. Analysis showed a greater clinical efficacy for HM groups than APP groups 
(RR 1.35, 95% CI: 1.24–1.47). The studies of Xu et al. (2009) and Zhou et al. (2009) had 2 
herbs in common: Huang qin and Huang bai. Both studies compared HM with placebo; 
therefore, the data could be pooled. However, the results were conflicting (RR 1.36, 95% CI: 
0.99–1.87) (Fig. 6.5). 
 
Fig. 6.5 Forest plot of clinical efficacy of trials using formulae with similar herbal 
ingredients: herbal medicine (HM) versus anti-psoriatic pharmacotherapy (APP) or HM 
versus placebo (with co-interventions used in both groups) [adapted from Deng 2013 (158)] 
To explore the possible effects of the individual HMs used in multiple studies, evidence 
derived from experimental studies of the effect of S. flavescens (source of Ku shen) and L. 
erythrorhizon (source of Zi cao) in the treatment of psoriasis will be further investigated in 
the next chapter.  
6.2.4 Discussion 
Methodological reporting weaknesses were found in all the examined studies. Only 3 studies 
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provided the method of sequence generation and none described allocation concealment. 
Three studies were blinded to participants, and 1 described blinded outcome assessment. 
Overall, the best quality trials were those of Lassus and Forsstrom (1991), Xu et al. (2009) 
and Zhou et al. (2009), closely followed by the study of Song et al. (2007). Unfortunately, 
the data supplied by Lassus and Forsstrom were not suitable for meta-analysis. 
Meta-analysis of pooled data showed that topical herbal formulae improved the overall 
clinical efficacy (defined as an improvement of 50% or more). This improvement was 
demonstrated in comparisons with external placebo plus oral HM co-intervention, external 
APP alone and topical APP plus pharmaceutical co-intervention.  
External HMs were more effective than placebo (plus oral CM co-intervention) in 
controlling scaling, induration and itching but not for erythaema or the lesion area. No 
difference between the efficacy of HMs and APP (with oral HM as co-intervention) was 
observed for any of these symptoms; however, these results were obtained from only 1 study. 
External HMs clearly improved the modified PASI score in comparison with placebo (with 
oral HM as co-intervention). Only single studies evaluated changes in the PASI score and 
compared the effect of HM and APP.  
External HM interventions caused few AEs (<5%). In general, these were local effects such 
as slight erythaema and irritation, slight tingling sensation, and others. Therefore, these 
herbal remedies can be safely used in the treatment of psoriasis, at least in the short-term. 
One external HM was used in 2 studies, in different forms. The results were consistent; 
however, these studies had some methodological issues (225, 231). Similar HMs were used 
in 4 studies that reported that the herbal remedies performed better than external APPs. 
Unfortunately, the quality of reporting in these studies was rather low. Trials by Xu et al.  
(2009) and Zhou et al. (2009) had 2 herbs in common, and the study quality was superior to 
that of the other studies. Zhou reported superior efficacy for HM in comparison with placebo. 
However, the severity of psoriasis was moderate at baseline (mean PASI 12.94), and the 
mean PASI in the treatment group fell to 5.71 (56% reduction over 4 weeks). Becayse there 
was no follow-up, it is unclear whether this decline could be sustained and caused by oral 
HM co-intervention. Consequently, it is difficult to know how much of the change could be 
attributed to the tested ointment. In contrast, Xu et al. (2009) showed no differences between 
experimental groups; all groups showed improvement. The main difference between 
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formulae used in the 2 studies was the addition of Zi cao (L. erythrorhizon root) by Zhou et 
al. Interestingly, L. erythrorhizon root was used as the oral HM co-intervention in the trial of 
Xu et al. (230); thus, patients in both the test and control groups were receiving this 
preparation. Therefore, L. erythrorhizon root was actually used in 4 studies in total: topically 
in studies of Gao et al. (2006), Yang et al. (2011) and Zhou et al. (2009) and orally in the 
study of Xu et al. (2009). 
Because it is difficult to enrol Chinese patients in trials using placebos, many studies 
compare the effects of additional experimental intervention with the results of already 
established treatment. In case of psoriasis, this established treatment typically takes the form 
of systemic therapy. None of the Chinese studies evaluated here included a group that 
received placebo alone. Although comparisons between treatments may be informative from 
the clinical point of view, it is difficult to arrive at firm conclusions when co-interventions 
are being used.  
The results may be affected by multiple factors. Nevertheless, a list of individual HMs with 
the best evidence of efficacy can be prepared by taking into account the combination of the 
results for clinical efficacy, quality of the studies and herbs that appeared in multiple trials. 
These HMs are Ku shen (Sophora flavescens root), followed by Zi cao (L. erythrorhizon 
root) and, with lesser support, Bai xian pi (D. dasycarpus bark), Bai zhi (A. dahurica root), 
Bai ji li (T. terrestris fruit) and Ce bei ye (B. orientalis leaf).  
The methodological issues identified in the clinical trials examined here increase the risk of 
bias in the reported results. The relatively small sample sizes in some of the studies and lack 
of independent confirmation studies using the same test and control interventions also 
represent serious limitations. All these factors affect the reliability of results. Validity of 
meta-analyses using the data pooled from different studies is limited by variability in test 
and control interventions and different methods used to measure outcomes. Nevertheless, 
there is greater similarity between the interventions assessed here than the formula names 
suggest. Moreover, relatively recent experimental evidence indicates that at least some of 
these herbs have pharmacological activity relevant to psoriasis management. Certain 
combinations of herbs tend to recur in different preparations, suggesting the possibility of 
synergistic effects (208). Importantly, the caveats on over-interpretation of the evidence 
from the clinical studies should not be ignored. However, analysis of such studies can assist 
in identifying directions for more rigorous clinical and experimental research endeavours. 
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6.2.5 Summary 
We performed a systematic review and meta-analysis of external herbal formulae for the 
treatment of psoriasis tested in 9 different clinical trials. Our results confirmed some 
potential improvements that these preparations could bring to existing psoriasis therapies. 
All the herbal interventions appeared relatively safe. Unfortunately, these clinical trials 
showed methodological weaknesses, which limit the validity of the results. However, 
experimental studies of the pharmacological activity of 2 main herbs used in the external 
herbal formulae, Ku shen (S. flavescens root) and Zi cao (L. erythrorhizon root), revealed 
that these herbs have anti-inflammatory, anti-proliferative, anti-angiogenic and tissue repair 
properties, which explain their apparent benefits in treating psoriasis.  
6.3 Results for systematic review 4: External herbal medicines combined with 
pharmacotherapy for psoriasis: A systematic review with meta-analysis of RCTs 
6.3.1 Introduction 
Considerable advances have been made in the conventional management of psoriasis in 
recent years; however, some patients do not respond well to therapy and long-term 
management remains difficult (237). In Europe, 43% of psoriasis patients use some form of 
CAM, often in combination with conventional APP (36). In some Asian countries, herbal 
medicines (HMs) are commonly used. Dermatologists may advise patients to use them 
together with APP. This strategy may enhance the therapeutic effects and/or reduce the 
dosage of APP (52). The clinical efficacy and safety of externally applied HMs used in 
combination with APP were examined in this systematic review.  
6.3.2 Method 
To find the relevant publications, we searched the following databases: EMBASE, PubMed, 
Cochrane Library, CNKI Database and CQVIP (up to September 2012), with no limits on 
THE language or year. Search terms belonged to the following groups: clinical condition 
(psoriasis and others); intervention (herbal medicine and others) and study type (controlled 
trial and others), with adjustments for different databases (see Chapter 4 for lists of terms). 
We also searched reference lists in review articles. For Cochrane Library, because the focus 
is on clinical trials and systematic reviews, only the terms for clinical condition and 
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intervention were used.  
The systematic review included RCTs using externally applied HM combined with APP 
(used internally and/or externally) in English, Chinese or Japanese. APPs could include 
emollients, corticosteroids, vitamin D3 analogues, tazarotene, coal tar, dithranol, 
methotrexate (MTX), ciclosporin, retinoids, fumarates and/or biologicals. Ultraviolet 
radiation therapy was excluded. HM was defined as any remedy consisting of natural 
products of plant, animal or mineral origin used singly or in combination, in any form, 
including oils and extracts. Vitamin and/or mineral therapies, Dead Sea cure, homeopathy, 
fish and animal oils were not included. Studies of multi-ingredient HMs, including vitamins 
and mineral and/or animal oils, were taken into account. Evaluations of psychological 
interventions, stress management techniques or manual therapies were not included.  
Two researchers, SD and BHM, conducted the searches and extracted the characteristics of 
each study. The information collected included location, duration, design, participants, 
interventions, outcome measures, dropouts, AEs and assessed risk of bias. Any 
disagreements were resolved by discussions with a third researcher ALZ if agreement could 
not be reached. A flowchart for the process of study selection is presented in Fig. 6.6. 
Review Manager 5.1 was employed for data analysis. RR with 95% CI was used with fixed- 
or random-effect models, depending on heterogeneity (172).   
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Fig. 6.6 Flow chart of the selection process of randomised controlled trials (RCTs) of 
external herbal medicines (HMs) combined with anti-psoriatic pharmacotherapy (APP) 
[adapted from Deng 2013 (157)] 
 
 
Entries after duplicates removed 
(n = 1614)
Excluded (n = 475): 
 
E1. Not related to psoriasis, or similar disorders (259) 
E2. Not principally treated with CAM (200) 
E3. Not in Chinese, English or Japanese (16) 
 
Excluded (n =1131): 
E4. Not related to clinical trials (89) 
E5. Epidemiology, economic studies etc (27) 
E6. Review of clinical studies in humans (154) 
E7. Adverse events, toxicology, chemical analysis etc 
(28) 
E8. Uncontrolled clinical trials (357) 
E9. Phototherapy, manual therapy, or CAM other than 
herbal therapy (93) 
E10. Non-randomized trials (inc. multiple conditions) 
(87) 
E11. Issues with study design/comparison/methods 
(209) 
E12. Not topical HMs plus APP (87) 
Full-text articles assessed for eligibility    
(n = 1139) 
Reference lists  
(n=31) 
Database retrieval 
(n=2020) 
RCTs included in qualitative synthesis    
(n = 8) 
RCTs included in meta-analysis 
(n = 8) 
Entries screened on basis of title & abstract
(n = 1614) 
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6.3.3 Results 
6.3.3.1 Description of studies 
In total, 2,020 potential entries were obtained from the database searches and 31 studies 
were identified from reference lists. After removal of duplicates, the remaining 1,614 
records were screened and the full text of 1,139 entries was obtained. Among these, 8 
articles satisfied the inclusion criteria (Fig. 6.6) (238-245). All the RTCs found were 
conducted in China. The studies enrolled 1,449 participants and 1,446 completed the trials 
(Table 6.6). The following HM interventions were used: baths (n=4), ointments (n=3) and 
steam (n=1). All participants used APPs. S. baicalensis root (Huang qin), S. flavescens root 
(Ku shen), Cnidium monnieri seed (She chuang zi), D. dasycarpus bark (Bai xian pi) and 
borneol (bing pian) were each used in 3 studies. S. baicalensis root, Rheum palmatum root 
(Da huang), Rehmannia glutinosa root (Di huang), Salvia miltiorrhiza root (Dan shen), 
Carthamus tinctorius flower (Hong hua) and sulphur were each used in 2 studies (Table 
Ch6.6). Somewhat surprisingly, Indigo naturalis (Qing dai), which is frequently used as an 
external HM for psoriasis, was not included in any of the 8 formulations (246).  
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   Table 6.6 Characteristics of the 8 studies included in analysis [adapted from Deng 2013 (157)] 
First author, 
Publication 
year, 
Location, 
Duration, 
Follow-up 
Sample size 
(R/A), 
Gender 
(M/F), 
Age (yrs): 
Mean ± SD 
(Range), 
RCT Design 
(T vs C) 
HM: ingredients (scientific name, 
part), dosage & administration 
APP dosage & 
administration 
Diagnosis, 
Outcome measures, 
Results 
Dropouts, 
Adverse events (AEs) 
Risk of Bias 
(SG, AC, BPt, 
BPl, BOA, 
IOD, SOR) 
Feng, Y. J., 
2007; 
Beijing, China; 
 
3 weeks; 
NS 
 
T: 32/32, C: 
33/33; 
57/8; 
38 yrs (10-60); 
HM + ext. 
APP vs 
ext.APP. 
 
Herbal bath: Fengfang (Polistes 
mandarinus nest), Xiqiancao 
(Siegesbeckia orientalis herb), 
Digupi (Lycium barbarum root), 
Shengdi (Rehmannia glutinosa 
root), Tougucao (Impatiens 
balsamina herb) each 50g, Kushen 
(Sophora flavescens root), 
Baixianpi (Dictamnus dasycarpus 
bark) each 40 g, Danshen (Salvia 
miltiorrhiza root), Shechuangzi 
(Cnidium monnieri seed) each 30 
g, Honghua (Carthamus tinctorius 
flower) 20 g. in 2000 ml water, 20 
mins, 1 X day, for 3 weeks 
Kangminzhiyang 
cream (Triamcinolone 
acetonide), 2 X day,  
Ammonium 
glycyrrhizinate IV 
solution 150mg/day 
 
Psoriasis vulgaris. 
Reduction in lesion 
area T>C (χ2 =5.54, 
p=0.019);  
Clearance time T<C 
(t=4.32, p=0.001); 
Lesion score: itching 
T<C (t=2.72, 
p=0.008), scaling 
T<C (t=2.84, 
p=0.006), erythema & 
induration (not sig) 
No dropouts; 
AEs:  
slight dizziness & 
palpitation (T:2) 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Han, C. L., 
2006; 
Dongwan, 
China; 
 
3 weeks; 
1 month 
T: 43/43, C: 
32/32; 
NS; 
NS; 
HM + ext. 
APP vs ext. 
APP 
Commercial Binghuangfule 
ointment manufactured by Tibet 
GiGi Pharmaceutical Co., Ltd.: 
Dahuang (Rheum palmatum root), 
Jianghuang (Curcuma longa root), 
Liuhuang (sulphur), Huangqin 
(Scutellaria baicalensis root), 
Gancao (Glycyrrhiza uralensis 
root), Bingpian (borneol), Bohe 
(Mentha haplocalyx leaf), etc. 1 X 
day 
Clobetasol cream, 1 X 
day 
(compounded by the 
hospital) 
Psoriasis vulgaris.  
PASI T≈C (t=0.327, 
p>0.05); 
Overall clinical 
efficacy‡ T≈C (χ2 
=0.040，p>0.05); 
Follow up relapse: T. 
5 (26.32%), C. 8 
(47.06%) 
 
No dropouts; 
AEs:  
skin pigmentation 
(C:1), 
hypopigmentation & 
skin atrophy(C:2), 
Malassezia folliculitis 
(C:3),  
skin pigmentation (T:2) 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Liu, X. J.,  T: 42/42, C: Commercial Binghuang ointment 0.5% tazarotene gel Stable psoriasis No dropouts; SG: U 
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2012; 
Huangshi, 
China; 
 
4 weeks; 
NS 
42/42; 
T: 22/20, C: 
19/23; 
T: 28.5 yrs 
(5-65), C: 29.6 
yrs (10-68); 
HM + ext. 
APP vs ext. 
APP 
manufactured by Shenyang Jinlong 
Pharmaceutical Co., Ltd. (Batch 
20090301): Dahuang (Rheum 
palmatum root), Huanglian (Coptis 
chinensis root), Liuhuang 
(sulphur), Bingpian (borneol), etc. 
1 X day (night), for 4 weeks 
manufactured by 
Chongqing Huapont 
Pharm. Co. Ltd. (Batch 
20040124). 2Xday, for 
4 weeks 
vulgaris. 
Reduction in PASI: 
T>C (p<0.05) 
AEs: 
slight itching & 
burning (T:3, C:5) 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Tang, Y. Y., 
2004; 
Hangzhou, 
China; 
 
10 times (over 
10-20 days); 
NS 
T: 36/36, C: 
36/36; 
T: 23/13, C: 
26/10; 
T: 42.33 yrs ± 
13.78, C: 
41.72 yrs ± 
13.66; 
HM + ext. 
APP vs ext. 
APP. 
Herbal bath: Shengdi (Rehmannia 
glutinosa root), Kushen (Sophora 
flavescens root), Danggui 
(Angelica sinensis root), Chishao 
(Paeonia veitchii root), Baixianpi 
(Dictamnus dasycarpus bark) and 
Pugongying (Taraxacum 
mongolicum herb), each 60g of raw 
herbs. 
In warm bath, 1:40,000, 30 mins 1 
X day or 1 X 2 days, total 10 X as 
a course 
Dexamethasone 
liniment, Salicylic acid 
ointment, & 
Triamcinolone 
acetonide acetate 
ointment, 
Slow injection of 
procaine* 4-6 mg/kg 
plus vitamin C 300mg 
in 300 ml saline once a 
day for 10-15 days as a 
course, 
Warm water bath 1 X 
day or 1 X 2days (only 
for Control group) 
Psoriasis vulgaris. 
Overall clinical 
efficacy T>C (χ2 
=5.796，p<0.05)  
No dropouts; 
AEs: NS 
SG: U 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
Wang, M., 
1990; 
China; 
 
24.7 days#; 
1 year 
T:675/675, 
C:200/200; 
T: 612/63, C: 
NS; 
T: 18-49 yrs, 
C: NS; 
HM + ext. 
APP vs ext. 
APP. 
Yin Xie Ling ointment: Huangqin 
(Scutellaria baicalensis root) 
extract 39g, Diyu (Sanguisorba 
officinalis root) extract 59g and 
Huangbai (Phellodendron 
amurense bark) extract 29g, 
0.3 mm thickness, 1 X day 
Dichlorodiethyl 
sulphide (1:10000 in 
petroleum jelly), 0.3 
mm thickness, 1 X day 
Psoriasis. 
Overall clinical 
efficacy T>C 
(90.7%>84%, 
p<0.05);  
Mean inpatient time 
to lesion clearance 
T<C (24.7<32.5 
days); 
Follow up relapse: 
T<C (13%<76%)  
No dropouts; 
AEs: allergic response 
rate T<C (1.93%<5%)  
 
 
 
SG: U 
AC: U 
BPt: U 
BPl: U 
BOA: U 
IOD: L 
SOR: L 
Wang, H. Y., 
2010; 
Changchun, 
China; 
T: 22/22, C: 
20/20; 
34/8; 
37.6 yrs ± 15.1 
Herbal bath: Kushen (Sophora 
flavescens root) 30g, Aiye 
(Artemisia argyi herb) 30g, 
Shechuangzi (Cnidium monnieri 
Salicylic acid cream 
2Xday,  
Methotrexate, oral 
5-15 mg/week 
Psoriasis vulgaris. 
Overall clinical 
efficacy‡ 
No dropouts; 
AEs:  
hair loss (T:1),  
slightly increased ALT 
SG: U 
AC: U 
BPt: H 
BPl: H 
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6 weeks; 
NS 
 
(18-58); 
HM + ext. & 
int. APP vs 
ext. & int. 
APP. 
seed) 30g, Baijiangcao (Patrinia 
villosa herb) 30g, Mudanpi 
(Paeonia suffruticosa root bark) 
20g, Baixianpi (Dictamnus 
dasycarpus bark) 30g, Danshen 
(Salvia miltiorrhiza root) 20g, 
Cebaiye (Biota orientalis leaf) 30g, 
Wubeizi (Rhus chinensis gall) 30g, 
Baibu (Stemona sessilifolia root) 
10g, etc. 
As 3000 ml bath for 20-30 mins 1 
X day for wks 1-2, then 1 X  2 
days for wks 3-4, then 2Xwk for 
wks 5-6 
T>C (χ2 =8.24，
p<0.05) 
(T: 1=50U/L, C: 
1=55U/L),  
stomach discomfort 
(T:1, C:2) 
BOA: U 
IOD: L 
SOR: L 
Yang, H. Y., 
2008a; 
Xiangfan, 
China; 
 
4 weeks; 
6 months 
T: 82/82, C: 
50/47; 
83/49; 
(15-75 yrs); 
HM + ext. 
APP vs ext. 
APP. 
Herbal bath: Huajiao 
(Zanthoxylum bungeanum seed), 
Kufan (Alumen) each 120g, 
Yejuhua (Chrysanthemum indicum 
flower) 250g, and Puxiao 
(Mirabilite) 500g, decocted in 
water adequate for a body bath. 
Frequency of use not specified. 
Halcinolone acetonid 
cream 2 X day, 
Thymosin IV solution 
40mg/day 
Psoriasis vulgaris. 
Overall clinical 
efficacy‡ 
T>C (χ2 =4.649, 
p<0.05) 
Follow up relapse: T. 
1 (3.55%), C. 2 
(18.2%) 
3 dropouts; 
AEs: no obvious issues 
SG: H 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: U 
SOR: L 
Yang, X. Q., 
2008b; 
Luzhou, 
China; 
 
4 weeks; 
NS 
 
T: 58/58, C: 
46/46; 
T: 35/23, C: 
25/21; 
35.8 yrs 
(20-68); 
 HM + ext. & 
int. APP vs 
ext. & int. 
APP. 
Herbal steam: Ezhu (Curcuma 
phaeocaulis rhizome) 50g, 
Cangzhu (Atractylodes lancea 
root), Shechuangzi (Cnidium 
monnieri seed), Sanleng 
(Sparganium stoloniferum root) 
each 30g, Bingpian (Borneol) 3g, 
Honghua (Carthamus tinctorius 
flower) 15g, Houpo (Magnolia 
officinalis bark) 20g, Dingxiang 
(Syzygium aromaticum fruit) 6g, 
etc. with additions according to 
individual syndromes. Applied 
using specific device, 20 mins/day 
for 5 days, 2 days break, for 4 wks 
as a course 
Hydrocortisone 
butyrate cream 2 X 
day, 
Urea cream 2 X day, 
Acitretin capsules, oral 
30-40 mg 1 X day 
 
Psoriasis vulgaris. 
Overall clinical 
efficacy‡ 
T>C (χ2 =9. 91, 
p<0.01) 
No dropouts 
AEs (T/C): 
dry mouth, dry lips &  
chapped lips (44/46), 
dry eyes (28/38), 
dry skin on body 
(22/34), 
epistaxis (4/6), 
body itching (13/19), 
desquamation (11/25), 
increased ALT (2/8), 
hyperlipidemia (1/1) 
SG: H 
AC: U 
BPt: H 
BPl: H 
BOA: U 
IOD: L 
SOR: L 
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T: treatment group, C: control group, R/A: registration/analysis, M/F: male/female, NS: not stated, IV: intravenous injection, ext.: external, int.: internal, yrs: years, 
wks: weeks, mins: minutes, RCT: randomised controlled trial, HM: herbal medicine, APP: anti-psoriatic pharmacotherapy, ALT: alanine aminotransferase, PASI: 
Psoriasis Area and Severity Index 
 
*Procaine plus vitamin C injection is used in China for itchy skin in diseases such as neurodermatitis (247, 248). It is thought to restore the normal metabolic function 
of skin cells and relieve erythema and itching. Using this method, corticosteroid-induced complications and side effects can be avoided (249). 
#Average inpatient period for cleared participant  
‡Clinical efficacy scores based on PASI using the following formula: (PASI pre-care − PASI post-care)/PASI pre-care × 100% 
 
Risk of Bias Categories 
SG: sequence generation, AC: allocation concealment, BPt: blinding of participants, BPl: blinding of personnel, BOA: blinding of outcome assessment, IOD: 
incomplete outcome data, SOR: selective outcome reporting 
 
Risk of Bias Judgements 
L: low risk, U: Unclear risk, H: high risk 
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Two studies reported full details of diagnosis and inclusion/exclusion criteria for subject 
selection (240, 242); 3 studies described the inclusion/exclusion criteria (238, 239, 245) and 
3 studies provided no details of these methods (241, 243, 244). Details of Chinese medicine 
diagnosis were provided by 1 study (240). Adjustments of the herbal formula or assessment 
of the clinical efficacy according to the Chinese medicine diagnosis was performed in 3 
studies (238, 241, 245). No quality-control data were supplied in any of the studies. 
Clinical efficacy was variously reported as clinical efficacy based on PASI scores, clinical 
efficacy according to a national standard for Chinese medicine (241) or a similar system 
(243) or separate scores for lesion characteristics (238).  
Herbal baths plus APP vs APP (4 studies) 
In the study by Feng et al. (238), 32 psoriasis vulgaris in-patients were treated with a herbal 
bath and APP, while 33 patients were treated with APP alone (Table 6.3). Patients soaked 
themselves in the bath for 20 min, once a day for 3 weeks. Patients in both the groups were 
administered ammonium glycyrrhizinate IV solution and triamcinolone acetonide cream 
(250). In the combined therapy group, statistically significant improvements in the extent of 
itching and scaling were found after 1 week. Compared with the control group, the overall 
clinical efficacy and time to clearance in this group improved after 3 weeks.  
In the study by Tang (241), 36 patients soaked themselves in a herbal bath for 30 min once a 
day or once every 2 days. The control group (36 patients) had a warm water bath. Both the 
groups received slow IV injections of procaine plus vitamin C; dexamethasone liniment, 
salicylic acid ointment and triamcinolone acetonide acetate ointment were also applied. The 
HM group showed a greater reduction in lesion areas after 10 treatments (over 10–20 days) 
than the control group.  
A different herbal bath formula was used by Wang et al. (242); 22 patients soaked 
themselves in the bath for 20–30 min daily for weeks 1–2, once every 2 days for weeks 3–4 
and twice a week for weeks 5–6. All 42 patients used MTX and salicylic acid cream. The 
study revealed a significant difference between overall clinical efficacies in the experimental 
and control group. The efficacy was calculated on the basis of the reduction in PASI scores. 
Yang et al. (244) examined the results of treatment with a herbal bath plus thymosin IV 
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solution and halcinolone acetonide cream involving 132 psoriasis vulgaris patients. After 4 
weeks, a difference was observed between groups, with the HM group performing better 
than the controls. During the 6-month follow-up, 3 patients who had achieved ‘clearance’ 
(95% improvement) relapsed: 1 in the test group and 2 in the control group.  
Herbal steam plus APP vs. APP (1 study) 
In the study of Yang et al. (245), 58 patients were treated with herbal steam using a 
steaming device for 20 min a day for 5 days, followed by a 2-day break, during a 4-week 
course. All patients in both the groups (104 patients) were treated with acitretin capsules, 
urea cream and hydrocortisone butyrate cream. After 4 weeks, there was a significant 
difference between overall clinical efficacies in the combined therapy group and APP group.  
Herbal ointment plus APP vs. APP (3 studies)  
An ointment containing extracts of 3 herbs plus 0.05 ml of dichlorodiethyl sulphide was 
used by 675 patients in the study of Wang et al. (243). The results were compared with those 
for 200 patients who used 0.10 ml of dichlorodiethyl sulphide ointment alone. There was a 
significant benefit in using the test ointment in terms of the overall clinical efficacy, allergic 
response rate, mean inpatient time to lesion clearance and 1-year recurrence rate. The 
authors concluded that the test ointment, which used 50% less dichlorodiethyl sulphide, 
showed a higher efficacy and caused fewer allergic side effects than the standard therapy. 
The efficacy of a commercial ointment (Binghuangfule) used with clobestasol cream was 
assessed by Han et al. (239) versus clobestasol cream alone. Patients in the HM group 
applied the herbal ointment and clobestasol cream once a day. Those in the control applied 
clobestasol cream twice a day. After 3 weeks of treatment, no significant differences were 
observed between PASI values or overall clinical efficacy levels in the 2 groups. However, 
significantly fewer side effects were observed in the combined therapy group. The authors 
concluded the combined treatment had a similar curative effect to clobestasol cream but had 
fewer side effects due to the reduced dose of clobestasol.  
A comparison study between the effects of a similar commercial ointment (Binghuang) used 
with 0.5% tazarotene gel and 0.5% tazarotene gel alone was conducted by Liu et al. (240). 
Binghuang ointment was administered once each night and tazarotene gel was applied twice 
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a day. After 4 weeks, there was a difference between clinical efficacies (based on reduction 
of PASI score) in the 2 groups. Slight itching and burning were reported in both the groups 
(T = 3, C = 5). The authors concluded that the combination treatment showed better efficacy 
than 0.5% tazarotene gel alone.  
6.3.3.2 Methodological assessment 
Risk-of-bias evaluations are summarised in Table 6.6. The authors of all studies evaluated 
here stated that the trials were ‘randomised’ or used a similar expression. However, the 
method of sequence generation was not provided in 7 of the studies and 1 used a 
pseudo-randomisation method (patient’s visiting order) (245). No study provided 
information on the method of allocation concealment or blinding. Seven studies used the 
design of HM plus APP versus APP; consequently, blinding to participants and personnel 
was not possible. In 1 study (243) all HMs were combined with the ointment used in the 
control group; blinding to participants was possible; however, it was not stated. One of the 
studies (241) used a warm water bath in the control group; this may have been intended as a 
form of participant blinding; however, this was not stated and was unlikely to have been 
effective. Three subjects dropped out in 1 study; however, no reasons were provided (244). 
Other studies reported that all patients completed the study; therefore, the risk of incomplete 
outcome data was low. All studies reported all outcomes; therefore, the risk of bias due to 
selective reporting was also low. 
6.3.3.3 Meta-analysis 
The comparisons in 6 of the studies (238-241, 243, 244) were mainly made between an 
externally applied HM combined with a external APP and the external application of APP 
alone (group 1). A topical treatment with HM plus a combination of external and internal 
APPs was compared with the combination treatment alone in 2 other studies (Group 2) (242, 
245). These 2 studies are similar in terms of the study design and the used outcome 
measures; therefore, meta-analysis of pooled data was possible. 
Results for clinical efficacy were analysed using RR and a random-effect model. Various 
group 1 studies used different systems for classifying the clinical efficacy. For example, in 
Feng et al. (238), lesion reduction of 75% and above was considered ‘remarkably effective’; 
however, in Yang et al. (244) ‘remarkably effective’ referred to a reduction of 70%–95%. 
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Consequently, when pooling data, only cases with efficacy rates of 50% or more were 
included.  
Both group 2 studies defined a PASI reduction of 60% or more as ‘remarkably effective’; 
therefore, this became the threshold chosen for data pooling (242, 245). In meta-analyses, a 
higher score indicates greater efficacy. 
Group 1. External HM + external APP vs. external APP 
For 6 studies (238-241, 243, 244), increased efficacy rates were found for topical HM plus 
APP treatments in comparison with APP therapy alone (RR 1.18; 95% CI: 1.05–1.34). This 
result was consistent with the conclusions of the original studies, except for the study by 
Han (48), where similar efficacies were reported in the test and control groups (Fig. 6.7). 
However, the heterogeneity in this study was high (I2 = 63%). 
Group 2. External HM + external & internal APP vs. external & internal APP 
For the 2 studies in this group (242, 245), the pooled data showed higher efficacy for the 
external HM plus APPs in comparison with APP treatment alone (RR 1.67; 95% CI: 1.21–
2.30). This result was consistent with the conclusions of the authors (Fig. Ch. 6.7) and the 
heterogeneity was low (I2 = 0%).  
Overall, in the 8 studies, the efficacy of combined external HM and APP treatment was 
significantly higher than that of APP alone (RR 1.23; 95% CI: 1.09–1.40) (Fig. 6.7). 
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Fig. 6.7 Forest plot of clinical efficacy: external herbal medicine (HM) plus anti-psoriatic 
pharmacotherapy (APP) versus anti-psoriatic pharmacotherapy (APP) [adapted from Deng 
2013 (157)] 
6.3.3.4 AEs  
Seven studies provided a report on AEs and 1 provided no information (241). One study 
stated that no remarkable AEs occurred in either the test or control group (244). Yang et al. 
(245) reported that AEs were significantly fewer in the combined therapy group than in the 
control group, with the exception of epistaxis and the level of serum lipids, which did not 
differ. In the study of Feng et al. (238), 2 cases of mild dizziness and palpitations were 
reported in the experimental group; however, no information was provided for the control 
group. In the 5 studies supplying complete data, the incidence of AEs was lower in the 
combination therapy groups [4.65% vs. 18.8% (239); 7.14% vs. 11.91% (240), 1.93% vs. 5% 
(243); 13.6% vs. 15.0% (242) and 75.9% vs. 100% (245)] than in control groups. Reported 
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AEs were mostly local disorders (239, 245); however, there were reports of dizziness, 
palpitations, stomach discomfort, epistaxis and hyperlipidaemia. Abnormal alanine 
aminotransferase (ALT) was reported in two studies (242, 245); however, meta-analysis 
revealed no difference in its incidence between groups (RR 0.28; 95% CI: 0.08–1.05) (Fig. 6. 
8).  
 
Fig. 6.8 Forest plot of severe adverse events (ALT↑): external herbal medicine (HM) plus 
anti-psoriatic pharmacotherapy (APP) versus anti-psoriatic pharmacotherapy (APP) 
6.3.5 Discussion 
Each of the 8 RCTs found benefits in the use of combination therapy in comparison with the 
use of APP treatment alone. However, reporting methodology was inadequate, and none of 
the studies was effectively blinded. Admittedly, blinding presents practical difficulties when 
herbal baths or decoctions are used. However, without blinding, it is not possible to draw 
clear conclusions; the observed benefit may have been due to HM or an additional 
intervention.  
Combining HM and APP can address the side effects of long-term APP use. To minimise 
side effects, the clinicians can reduce the dose of medication or replace it with another drug. 
Wang et al. (243) adopted both approaches by reducing the concentration of dichlorodiethyl 
sulphide, which can cause skin erosion, while adding 2 herbs to the test ointment. Han et al. 
(239) reduced the APP dose by using the topical HM ointment and APP cream alternately. 
In the other 6 studies, the approach was to provide additional therapy in the form of baths, 
steam or ointment. Some studies used APPs of questionable clinical efficacy (238, 241, 244), 
which added further limitations to the interpretation of results. 
Meta-analysis of clinical efficacy for group 1 revealed high heterogeneity; variation in 
outcome measures, sample sizes and control interventions were the likely cause. Group 2 
trials used PASI and employed APP interventions that better reflected the established 
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treatment methods. The results of group 2 studies are particularly relevant to contemporary 
clinical practice. In one of these studies, Yang et al. (245) showed the superiority of 
combination therapy (HM + acitretin) over the conventional APP treatment; however, the 
study of Wang et al. (242) (HM + MTX) appears to be of a better quality.  
Combination therapies of the types described in these studies are often used in China. The 
possible effects of the herbal ingredients such as S. flavescens, C. monnieri, D. dasycarpus 
and borneol are of considerable interest and will be discussed in the next chapter. 
Some orally administered herbal decoctions containing Dictamnus root have been reported 
to cause acute hepatitis (187-190). Only 2 cases of mild skin sensitisation were found (n = 
25) when using 20% l-borneol in petrolatum, and no significant skin irritation was revealed 
(251). There are no reports of toxicity associated with the topical use of Dictamnus root bark, 
Cnidium seed, Sophora root, Phellodendron bark, Scutellaria root or Coptis chinensis. 
6.3.6 Summary 
This review shows that the addition of HMs to APP treatment can result in short-term 
efficacy improvements in comparison with APP therapy alone. However, the data need to be 
interpreted with caution; the trials assessed here had some methodological weaknesses and 
there are no independent studies confirming the results. These methodological deficiencies 
should be addressed in future studies investigating the efficacy and safety of HMs as 
adjunctive therapies for psoriasis. 
6.4 Conclusions regarding the external HM RCTs for psoriasis 
Clinical studies examined here suggest that combined treatment including topical application 
of CHM may be beneficial in controlling psoriasis symptoms. Although there are 
methodological flaws in each of the included studies, recent experimental evidence indicates 
that some herbs used in these studies have anti-inflammatory, anti-pruritic and 
anti-proliferative activities. Although this experimental evidence is mostly based on 
systemic use, it supports the traditional use of these herbs in the topical management of 
psoriasis. 
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Chapter 7: Investigation of the in vitro and in vivo actions of the 
main herbs 
7.1 Introduction to Part 2 
In Part 1 of the thesis, the methodology of the systematic review was used to evaluate the 
efficacy and safety of HMs used topically (three SRs (157-159)) and systemically (one SR 
(135)) for psoriasis vulgaris. In addition to the usual approach employed in SRs of HMs, 
when multi-herb formulations were employed, the herbs that were most commonly used 
were identified. This approach allowed the identification of specific herbs for which there 
was promising clinical evidence of efficacy.  
In Part 2 of the thesis, the mechanisms of action of the most promising herbs are explored in 
order to provide directions for further drug discovery investigations and to inform the design 
of future clinical trials. Part 2 involved the following three main components: 
1. Analysis of the in vivo & in vitro studies on HMs (chapter 7), 
2. Identification of herbs that share therapeutic targets with APPs, i.e. APP-like herbs, 
and exploration of the possible pathways of action of the HMs (chapter 8),  
3. General discussion and further directions (chapter 9). 
Each of these components presents a method for adding meaning and value to the results of 
the systematic reviews undertaken in Part 1 and each component also explores and develops 
methods that could be applied to other SRs of HMs. These approaches can link the clinical 
trial evidence with in silico methods of investigation that focus on the possible mechanisms 
of action of the HM and could provide indications of futre directions in drug discovery and 
clinical studies. 
In chapters 8 and 9 the methods and procedures for each of these components are separately 
described in detail followed by the results. 
7.2 Method for in vivo & in vitro studies 
The first step in this component involved the selection of the most promising herbs. 
Promising herbs were defined as the herbs for which there was evidence of clinical efficacy 
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and safety based on the results of the SRs. Since there were many herbs employed in the 
studies that were included in the studies in each of the SRs, the most promising herbs were 
selected based on frequency of use in the RCTs, with up to four of the most frequently used 
herbs being selected from each of the four SRs. 
The second step involved database searches for experimental studies that evaluated the in 
vivo and/or in vitro effects of these herbs and/or their constituents as regards actions that are 
relevant to psoriasis. Relevance was broadly defined as having effects on inflammation, 
proliferation, angiogenesis, pruritus, wound healing and/or tissue repair.  
Studies could employ herbal extracts, fractions or purified forms of compounds known to be 
major active components of the herbs. Experimental models were not limited to psoriasis but 
studies that employed keratinocytes or were otherwise focused on skin were preferentially 
selected.  
Articles located in the initial searches that had been classified as experimental studies were 
examinined and additional searches were conducted of PubMed in July 2013 using search 
terms for the plant names, for example: oldenlandia, hedyotis, bai hua she she cao; and 
compounds, for example: ursolic acid, oleanolic acid. No restrictions were placed on year, 
article type or language. Potentially relevant articles were identified based on scanning 
abstracts and full texts were obtained. Data were extracted from relevant articles by SD and 
BHM to a spreadsheet.  
A narrative method was used for data synthesis that focused on the studies most relevant to 
herbal therapy for psoriasis. Therefore this chapter does not summarise every experimental 
study on every herb and every compound contined in the herb.  
7.3 Results for in vivo & in vitro studies of the anti-psoriatic actions of the main herbs 
Based on the results of the four SRs, 13 herbs were identified as showing promise of 
efficacy for psoriasis as well as having acceptable safety profiles. These are listed in Table 
7.1. One herb appeared in the lists of herbs in two SRs, so 12 different herbs were identified. 
The results of the in vivo and in vitro studies for these herbs are presented and discussed 
below for each SR separately. The names of proteins and drug targets are multiple and the 
same protein may receive different names and aconyms in different publications. 
185 
 
Consequently a list of the various names used in chapters 7 and 8 is included in Appendix 20. 
Table 7.1: Promising herbs for psoriasis based on the results of systematic reviews of RCTs 
Scientific name Chinese character SR, study design, admin.* 
Oldenlandia diffusa 白花蛇舌草 SR1, Herbal formula vs APP/placebo, int. 
Rehmannia glutinosa 地黄 SR1, Herbal formula vs APP/placebo, int. 
Salvia miltiorrhiza 丹参 SR1, Herbal formula vs APP/placebo, int. 
Aloe vera 芦荟 SR2, Single herb vs APP/placebo, ext. 
Indigo naturalis 青黛 SR2, Single herb vs APP/placebo, ext. 
Camptotheca acuminata 喜树 SR2, Single herb vs APP/placebo, ext. 
Mahonia aquifolium 功劳木 SR2, Single herb vs APP/placebo, ext. 
Sophora flavescens 苦参 SR3, Herbal formula vs APP/placebo, ext.  
Lithospermum erythrorhizon 紫草 SR3, Herbal formula vs APP/placebo, ext. 
Sophora flavescens  苦参 SR4, HM + APP vs APP, ext.  
Cnidium monnieri  蛇床子 SR4, HM + APP vs APP, ext.  
Dictamnus dasycarpus  白藓皮 SR4, HM + APP vs APP, ext.  
Borneol  冰片 SR4, HM + APP vs APP, ext.  
* this refers to the administration route in the included studies. In clinical practice multiple routes may be used. 
 
7.4 Anti-psoriatic actions of the main herbs identified in SR1: medicinal herbs used 
internally for psoriasis (7.4.1-7.4.3) 
In this SR, three plants were each used in 5 studies: Rehmannia glutinosa Libosch, root; 
Salvia miltiorrhiza Bge., root; and Oldenlandia diffusa (Willd.) Roxb. [aka Hedyotis diffusa], 
aerial parts. The pharmacological actions of the above identified herbs in the experimental 
studies are individually summarized in the tables 7.2-7.4. 
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7.4.1 Experimental studies of Oldenlandia diffusa (bai hua she she cao) 
Oldenlandia diffusa mainly contains anthraquinone, terpenoids, flavonoids, sterols, alkanes, 
organic acids, polysaccharides, alkaloids, diffusa prime, cardiac glycosides as well as some 
trace elements, amino acids and volatile ingredients (252).  
The anti-proliferative effect of a 70% ethanol extract of Oldenlandia diffusa was 
investigated by Gu et al 2012 in normal breast epithelial cells (MCF-10A) and in four 
human breast cancer cell lines (MCF-7, T47-D, SKBR3, & tamoxifen resistant MCF-7 TRI 
cells). The extract reduced cell viability in MCF-7 cells but not in normal MCF-10A cells. It 
also inhibited proliferation in MCF-7 and estrogen receptor (ER)-positive T47-D cells but 
not in ER-negative SKBR3 breast cancer cells. The anti-proliferative action in MCF-7 cells 
was via increasing p53 [Cellular tumour antigen] and p21WAF1/Cip1 [Cyclin-dependent kinase 
inhibitor 1] protein expression and inducing apoptosis. Following fractionation, two 
bioactive compounds were identified, oleanolic and ursolic acids, which showed similar 
effects in the above cell lines. Moreover, the combination of oleanolic acid or ursolic acid 
and tamoxifen reduced proliferation in tamoxifen resistant MCF-7 TRI cells. The extract 
also up-regulated p53 and p21WAF1/Cip1 expression of MCF-7 in an ERa/Sp1-dependent 
manner (253).  
In an in vitro study, ursolic acid isolated from Oldenlandia diffusa showed cytotoxicity 
against SK-OV-3 and A2780 ovarian cancer cells with IC50 of ca. 50 and 65µM, 
respectively. In SK-OV-3 ovarian cancer cells, ursolic acid up-graduated Sub-G1 Apoptotic 
Portion, activated Caspase-9 and Caspase-3, cleaved Poly (ADP-ribose) polymerase (PARP), 
down-regulated the expression of Survival Genes, and induced the apoptosis of SK-OV-3 
ovarian cancer cells. The regulation mechanism could relate to the activation of caspases and 
phosphorylation of glycogen synthase kinase 3β (GSK 3β) (254).  
Ursolic acid induced apoptosis in a doxorubicin-resistant human hepatoma cell line 
(R-HepG2) via disruption of mitochondrial membrane potential, activating Bak protein 
[Bcl-2-associated X protein], and release of AIF [apoptosis-inducing factor] – a signalling 
pathway irrelevant to caspase. In a 3-group in vivo study of female nude mice 
subcutaneously inoculated with R-HepG2 cells, ursolic acid significantly reduced tumour 
volume by 53.13% (50 mg/kg UA group) and 66.10% (75 mg/kg UA group) (P < 0.01) with 
no significant weight loss or toxicity (based on spleen index). Immunohistostaining attested 
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accumulation of AIF in the nucleus. Therefore, ursolic acid showed potent anti-proliferative 
activity with no obvious toxicity (255). Harmand et al 2005 investigated the effect of ursolic 
acid in M4Beu human melanoma cells and reported that found that ursolic acid induced 
apoptosis via the activation of caspase-3 (256). In a mouse skin cancer model, Kowalczyk et 
al 2009 tested a number of phytochemicals and found that ursolic acid reduced epidermal 
hyperplasia and reduced the rate of mutations in codon 61 of Ha-ras oncogene in mouse skin 
(257). Wojciak-Kosior et al 2011 compared the effects of ursolic and oleanolic acid on 
normal human skin fibroblasts and found that ursolic acid had greater free radical 
scavenging activity as well as higher cytotoxicity compared to oleanolic acid (258). 
In a lipopolysaccharide (LPS)-induced inflammation model in male C57BL/6 (6 week old) 
mice peritoneal macrophages, pre-treatment with an aqueous extract of Oldenlandia diffusa 
inhibited production of TNF-α [Tumour necrosis factor-alpha], IL-6 [interleukin 6], PGE2  
[prostaglandin E2] (significantly and dose-dependently). It also inhibited the enhanced 
expression of COX-2 [cyclooxygenase-2], NO [nitrogen oxide] (dose-dependently), iNOS 
[inducible Nitric oxide synthase], IκB-α [ikappaB kinase] (significantly) in response to the 
LPS. Hentriacontane which was derived from the Oldenlandia diffusa significantly inhibited 
expression of the inflammation mediators TNF-α, IL-6, PGE2 and COX-2 as well as 
suppressed NF-κB [nuclear factor kappa-light-chain-enhancer of activated B cells] and 
caspase-1 (259). In female mice with dextran sulfate sodium (DSS)-induced colitis, an 
aqueous extract of Oldenlandia diffusa significantly relieved the clinical signs including 
weight loss and colon shortening, and remarkably decreased Disease Activity Index (DAI). 
It also inhibited IL-6, IL-1β [interleukin 1beta] and COX-2 levels. In addition, the oral 
administration of the extract significantly inhibited the activation of NF-κB p65 
[Transcription factor p65] in colitic tissues which had been induced by DSS. Similarly, the 
compound, hentriacontane, significantly suppressed the clinical signs and inhibited IL-6 
level in vivo (260).  
Kang et al 2008 investigated the effects of ursolic acid in a zymosan-induced acute 
inflammation model in mice. They found that oral ursolic acid suppressed leucocyte 
migration and it suppressed PGE2 production dose-dependently. In a Freund’s 
adjuvant-induced arthritis model in rats, the same group reported that oral ursolic acid 
reduced paw swelling, reduced the level of plasma PGE2 and reduced hyperalgesia. They 
concluded that the effect of ursolic acid was comparable to that of ibuprofen (261).  
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Oleanolic acid acetate (OAA), which is a triterpenoid closely related to oleanolic acid that is 
derived from Vigna angularis (Willd.) Ohwi & H. Ohashi, was investigated in atopic 
dermatitis (AD) and allergic contact dermatitis (ACD) models in female mice. In the AD 
model, oral OAA dose-dependently reduced epidermal and dermal thickness in the ear, 
suppressed the infiltration of eosinophils, CD4+ T cells, mast cells and serum histamine. It 
also reduced the levels of IgE [immunoglobulin E] (total and DFE-specific) and IgG2a 
[Immunoglobulin G2a]. It also suppressed the expression of pro-inflammatory cytokines and 
chemokines (TNF-α, IFN-γ [interferon-gamma], IL-4 [interleukin 4], IL-5 [interleukin 5], 
IL-10 [interleukin 10], IL-31 [interleukin 22], IL-17 [interleukin 17], IL-22 [interleukin 22]) 
and thymic stromal lymphopoietin (TSLP). In the ACD model, OAA suppressed 
lymphocyte proliferation in auricular draining lymph nodes in a dose-dependent manner. 
Serum IgG2a level, and some pro-inflammatory cytokines (TNF-α, IFN-γ and IL-17) were 
also suppressed by OAA but it only slightly inhibited other cytokines (IL-4 and IL-10), 
which demonstrated that OAA has a higher inhibitory effect of the immune reaction for Th1 
and Th17 but not for Th2. No change in body weight was induced in either model. Finally, 
in human keratinocytes (HaCaT cells) pretreatment with OAA inhibited the effect of TNF-α/ 
IFN-γ induced gene expression of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6, 
and the chemokine TARC [Thymus and activation regulated chemokine] without reducing 
cell viability. Western blot analysis indicated that the mechanism of OAA action was via 
blocking the pathways of MAPKs (p38 [Activator of 90 kDa heat shock protein ATPase 
homolog 1], ERK [Extracellular signal-regulated kinase family] and JNK [Jun kinase]) and 
NF-κB (262). 
Lim et al 2007 investigated the effects of oleanolic acid and ursolic acid on the recovery of 
epidermal barrier in mice and found that both compounds accelerated barrier formation. In 
normal human epidermal keratinocytes (HaCaT), these two compounds induced keratinocyte 
differentiation  via actions on PPAR-α [peroxisome proliferator-activated receptor alpha] 
(263). Lee et al 2006, in a similar study, reported that found that both oleanolic and ursolic 
acids enhanced recovery of epidermal barrier function. Both compounds increased ceramide 
production but the effect of oleanolic acid on inducing keratinocyte differentiation was 
marked, whereas there was only a slight effect for ursolic acid (264).  
None of the experimental studies located in the search was specific to psoriasis but they 
investigated actions of relevance to psoriasis therapy. The studies indicate that O. diffusa 
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contains compounds that have anti-inflammatory actions and can induce tissue repair in 
normal human skin cells. They can also inhibit proliferation in abnormal cells. Of the 
compounds contained in this plant, oleanolic acid and ursolic acid have been the object of 
considerable research attention. They have been shown to have liver protective, anti-tumour, 
anti-viral, anti-inflammatory, skin protective and anti-wrinkle effects. Synthetic derivatives 
of these compounds are currently the focus of drug discovery efforts (265-267). 
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Table 7.2 Summary of experimental findings on the actions of Oldenlandia diffusa [adapted from Deng 2013 (135)] 
 
Preparation,  
Active ingredients  
Study type,  
Model examined 
Outcome / Pharmaceutical 
target 
Regulating effect Reference 
ethanol extract, NS 
in vitro: normal breast epithelial cells (MCF-10A) p53 & p21WAF1/Cip1 no effect  
Gu 2012 (253) 
in vitro: human breast cancer cells (MCF-7) p53 & p21
WAF1/Cip1, PARP (86 
kDa)§ up 
oleanolic & ursolic acids in vitro: human breast cancer cells (MCF-7) p53 & p21WAF1/Cip1 up 
ursolic acid 
in vitro: SK-OV-3 & A2780 ovarian cancer cells cytotoxicity against cancer cell 
(XTT assay) 
IC50 of ca. 50 
and 65 μM 
Song 2012 
(254) 
in vitro: SK-OV-3 ovarian cancer cells sub-G1 apoptotic Portion increased  
in vitro: SK-OV-3 ovarian cancer cells caspase-9 & -3, 
& cleaved PARP 
activated  
in vitro: SK-OV-3 ovarian cancer cells expression of survival genes down 
in vitro: SK-OV-3 ovarian cancer cells apoptosis induced 
ursolic acid in vitro: M4Beu melanoma cells 
p21 not affected  
 
 
Harmand 2005 
(256) 
p53 altered: up then down 
caspase-3 
expression: up 
then down; 
activity: up 
Bax & AIF up 
ursolic acid 
in vivo: zymosan-induced mice acute 
inflammation air pouch model leucocyte migration, PGE2 down 
 
Kang 2008 
(261) in vivo: Freund's adjuvant (CFA)-induced rat 
arthritis PGE2, FLI neurons down 
ursolic acid in vitro: Ca3/7 cell lines (squamous cell carcinoma) caspase-3 & -7 up 
 
 
Kowalczyk 
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in vivo: female SENCAR mice with skin 
carcinogenesis codon 61 of Ha-ras oncogene down 
2009 (257) 
oleanolic acid (OA) & 
ursolic acid (UA)  
in vitro: CV-1 & HaCaT cells PPAR-α 
OA: up; UA: not 
affected or 
slightly up 
 
Lee 2006 (264) 
in vitro: HaCaT cells CE formation of keratinocyte OA: up; UA: slightly up 
in vivo: hairless mice treated by absolute acetone  
skin barrier recovery 
ceramide 
filaggrin & involucrin 
enhanced 
up 
OA: up; UA: 
slightly up 
Oleanolic acid acetate 
(OAA) 
in vivo:  DFE/DNCB-induced AD model 
ear swelling thickness improved 
Choi 2013 
(268) 
body weight nod changed 
epidermal & dermal thickness, 
infiltration of eosinophils & CD4+ 
T cells, infiltration of mast cells & 
serum histamine, IgE (total & 
DFE-specific) & IgG2a, all 
cytokines, TSLP (thymic stromal 
lymphopoietin)  & chemokines, 
IFN-γ, IL-4, IL-17, IL-22   
reduced/inhibited 
in vivo: DNFB-sensitized ACD model 
ear swelling thickness improved 
body weight nod changed 
lymphocyte proliferation, IgG2a, 
TNF-α, IFN-γ, IL-17, IL-4, IL-10 reduced/inhibited 
in vivo: HaCaT cells 
TNF-α, IL-1β, IL-6, TARC reduced 
cell viability not effect 
ursolic acid (UA), oleanolic 
acid (OA) 
in vivo: adult hairless mice with skin barrier 
disruption skin barrier formation accelerated 
 
 
Lim 2007 
(263) in vitro: human kertatinocytes (HaCaT)  
PPAR-α & keratinocyte 
differentiation marker expression: 
involucrin, loricrin & filaggrin 
up 
ursolic acid 
in vitro: human hepatoma cell line (R-HepG2) R-HepG2 proliferation bak 
inhibited  
up 
 
Yang 2010 
(255) in vivo: female nude mice bearing R-HepG2 
xenograft 
tumour volume 
AIF 
reduced 
up 
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aqueous extract, NS 
in vitro: mouse peritoneal macrophages with 
lipopolysaccharide (LPS) - induced inflammatory 
response 
TNF-α, IL-6, PGE2, COX-2, NO, 
iNOS, IκB-α, NF-κB activation, 
RIP-2/caspase-1 activation 
down 
 
Kim 2011 
(259) 
extract, NS in vivo: dextran sulfate sodium (DSS)-induced colitis 
clinical signs (weight loss, colon 
shortening, diarrhea, & 
occult/gross bleeding), Disease 
Activity Index (DAI), IL-6, IL-1ß 
& COX-2, NF-κB p65 
reduced Kim 2011 
(260) 
hentriacontane in vivo: dextran sulfate sodium (DSS)-induced colitis clinical signs, IL-6 Level reduced 
ursolic acid (UA) & 
oleanolic acid (OA) in vitro: normal human skin fibroblasts (HSF) 
cytotoxicity (neutral red uptake, 
MTT test) 
UA: toxic at over 
5ìM. OA: no 
toxicity  
Wójciak-Kosio
r 2011 (258) 
α-SMA: α-smooth muscle actin; p21: Cyclin-dependent kinase inhibitor 1; p38: Activator of 90 kDa heat shock protein ATPase homolog 1; p53: Cellular tumor 
antigen; AIF: apoptosis-inducing factor; AP-1: activating protein-1; Bax protein: Bcl-2-associated X protein; Bcl-2 family proteins: B-cell lymphoma 2 family of 
apoptosis regulator proteins; CAT: catalase; CD: circular dichroism; CD4+ T cells: T-cell surface glycoprotein CD4; CE: cornified envelope; CHK: cultured 
human keratinocytes; COX-2: cyclooxygenase-2; CYP: cytochrome P450; ERK/RSK2: extracellular signal-regulated protein/ ribosomal S6 kinase 2 kinase; FLI: 
Fos-like immunoreactive neurons; GSH-Px: glutathione peroxidase; GSK 3β: glycogen synthase kinase 3 beta; HaCaT: immortalized human keratinocytes cells; 
HeLa cells: a cell from a sample taken from a woman called Henrietta Lacks and was named using the two initials of her first (He) and last (La) names; ICAM-1: 
intercellular adhesion molecule 1; IFN: interferon; IgE: immunoglobulin E; IκB: ikappaB kinase; IKK: IκBα kinase; IL: interleukin; iNOS: inducible nitric oxide 
Synthase; JNK: c-Jun N-terminal kinase; MCP-1: monocyte chemotactic protein-1; mRNA: messenger RNA; NO: nitrogen oxide; N.S.: not stated; MCP: 
monocyte chemotactic protein; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NIK: NF-αB-inducing kinase; PARP: poly (ADP-ribose) 
polymerase; PGE2: prostaglandin E2; PPAR: peroxisome proliferator-activated receptor; R-HepG2: human hepatoma cell line; RAGE: receptor for advanced 
glycation end products; ROS: reactive oxygen species; THP1 human monocytic cell line; TNF-α: tumor necrosis factor-alpha; TSLP: thymic stromal 
lymphopoietin. 
 
# human solid tumor cell lines, § proteolytic form. 
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7.4.2 Experimental studies on Rehmannia glutinosa (Di huang) 
In clinical Chinese Herbal Medicine, Rehmannia glutinosa has been divided into three forms 
according to how the root is prepared: Xian di huang (fresh root), Sheng di huang (dried root) 
and Shu di huang (steamed root). For the purpose of this discussion these are considered 
together. Common bioactive constituents purified from Rehmannia glutinosa include 
glycosides, glucide and amino acids with iridoid glycosides constituting the primary 
glycosides. Of the 32 compounds that have been isolated, the iridoid glycoside catalpol has 
the highest content (269). 
Kim et al 1998 found that an aqueous extract of Rehmannia glutinosa steamed root (RGAE), 
dose-dependently reduced mortality in rats due to a compound 48/80-induced systemic 
allergic reaction and significantly inhibited the fatal shock (53.3%). Plasma histamine 
release induced by the compound was also significantly inhibited in vivo. In rats with a 
cutaneous allergic reaction induced by anti-dinitrophenyl IgE (anti-DNP IgE), RGAE 
inhibited passive cutaneous anaphylaxis (PCA) reactions in a dose-dependent manner. In an 
in vitro study of rat peritoneal mast cells (RPMC), the extract significantly inhibited 
histamine release induced by the compounds 48/80 and anti-dinitrophenyl (DNP) IgE, and 
dose-dependently inhibited TNF-α production induced by anti-DNP IgE. The authors 
indicated that the Rehmannia glutinosa extract exerted anti-inflammatory actions in these 
models of immediate type allergic reaction (270). 
In an in vitro study by Baek et al 2012 on the anti-inflammatory effect of a water extract of 
Rehmannia glutinosa [Saeng-jihwang (SJH) in Korean, aka sheng di huang] in THP-1 cells, 
found that the extract decreased the production of intracellular reactive oxygen species (ROS) 
induced by Advanced Glycation End Products (AGEs) without change in the viability of the 
THP-1 cells. SJH dose-dependently degraded cytosolic IκB-α and reduced the nuclear 
localization of NF-κB p65. NF-κB mediates the gene expression of the pro-inflammatory 
mediators monocyte chemotactic protein-1 (MCP-1), RAGE [receptor for advanced 
glycation end products], inducible protein-10 (IP-10), iNOS, COX-2, and TNF-α. It 
suppressed the expression of TNF-α, COX-2, MCP-1 [monocyte chemotactic protein-1], 
IP-10 [Interferon gamma-induced protein 10] but had no effect on COX-1 
[cyclooxygenase-1] which is not mediated by NF-κB. Pretreatment with SJH suppressed NO 
release induced by LPS (lipopolysaccharides). In addition, SJH down-regulated the 
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expression of RAGE and the mRNA expression of RAGE. These results indicated that SJH 
exerted an anti-inflammatory effect via reduction of NF-κB activity (271).  
In an in vitro study on murine monocyte/macrophage RAW264.7 cells, a crude extract of 
Rehmannia glutinosa was assessed for anti-NO production, followed by fractionation to 
identify active components. The C3 sub-fraction suppressed NO production with about 
100-fold greater potency than the crude extract. C3 also inhibited both the gene and protein 
expression of iNOS. In the LPS-stimulated macrophages, C3 down-regulated the main 
pro-inflammatory mediators/cytokines including PGE2, IL-6 and COX-2. Furthermore, two 
compounds were purified from C3: rehmapicrogenin and cinnamic acid. The former exerted 
a significant inhibition on NO production but there was no inhibition from the latter. 
Therefore, rehmapicrogenin was partly responsible for the potent anti-inflammatory effect of 
C3. C3 appeared to act via iNOS gene and protein suppression, and blocking IL-6 and PGE2 
release. In summary, the C3 fraction showed a potent anti-inflammatory effect to which its 
derivative rehmapicrogenin partly contributed (272).  
Wei and Ru 1997 conducted study to examine the effect of low-molecular-weight 
Rehmannia glutinosa polysaccharides (LRPS) on p53 gene expression in Lewis lung cancer 
cells using 3-groups: Saline group, LRPS group and Cyclophosphamide group (positive 
control). LRPS was found to inhibit the gene expression of p53 on Lewis lung cancer (273). 
Catalpol, along with other iridoid glycosides, has been shown to inhibit DNA polymerase 
(274) and has been the basis for the development of a number of derivatives that have been 
investigated as anti-proliferative agents (275, 276). 
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Table 7.3 Summary of experimental findings on the actions of Rehmannia glutinosa [adapted from Deng 2013 (135)] 
 
Preparation,  
Active ingredients  
Study type,  
Model examined 
Outcome / Pharmaceutical 
target 
Regulating effect Reference 
aqueous extract of 
Rehmannia glutinosa 
steamed root (RGAE), NS 
in vivo: rat with compound 48/80-induced 
systemic allergic reaction plasma histamine  
down  
Kim 1998 
(270) in vivo: rat with anti-DNP IgE-induced cutaneous 
allergic reaction 
passive cutaneous anaphylaxis 
reaction inhibited 
in vitro: rat peritoneal mast cells histamine, TNF-α down 
water extract, NS in vitro: human monocytes (THP-1) 
ROS, NF-κB (IκB-α, p65), 
MCP-1, RAGE, IP-10, iNOS, 
COX-2, TNF-α, protein-10, NO, 
mRNA 
COX-1 
down 
 
 
 
no change 
Baek 2012 
(271) 
 
aqueous extract 
sub-fraction C3, containing 
rehmapicrogenin & 
cinnamic acid 
 
in vitro: lipopolysaccharide (LPS)-stimulated 
RAW264.7 murine macrophages NO, iNOS, PGE2, IL-6, COX-2 down Liu 2012 (272) 
low-molecular-weight 
Rehmannia glutinosa 
polysaccharides (LRPS) 
in vivo: Lewis lung cancer model p53 up Wei 1997 
(273) 
compound 9a-b, molecular 
simplification of catalpol 
in vitro: representative 
human solid tumor cell lines A2780 (ovarian), 
HBL-100 
(breast), HeLa (cervix), SW1573 (non-small cell 
lung), T-47D 
(breast) & WiDr (colon) 
50% growth inhibition (GI50),  active 
Carcia 2010 
(275) 
in vitro: HeLa & WiDr cells annexin V binding induce apoptosis 
compoud 9b, molecular in vitro: HBL-100, SW1573 cells cell cycle disturbances cells arrested in 
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simplification of catalpol G0/G1  
in vitro: HeLa cells 
cyclin D1 reduced 
cell cycle disturbances 
cell cycle 
arrest on G1 
catapol in vivo: Tribolium castaneum larvae DNA Polymerase activity inhibited Pungitore 2004 
(274) 
α-SMA: α-smooth muscle actin; p21: Cyclin-dependent kinase inhibitor 1; p38: Activator of 90 kDa heat shock protein ATPase homolog 1; p53: Cellular tumor antigen; 
AIF: apoptosis-inducing factor; AP-1: activating protein-1; Bax protein: Bcl-2-associated X protein; Bcl-2 family proteins: B-cell lymphoma 2 family of apoptosis 
regulator proteins; CAT: catalase; CD: circular dichroism; CD4+ T cells: T-cell surface glycoprotein CD4; CE: cornified envelope; CHK: cultured human keratinocytes; 
COX-2: cyclooxygenase-2; CYP: cytochrome P450; ERK/RSK2: extracellular signal-regulated protein/ ribosomal S6 kinase 2 kinase; FLI: Fos-like immunoreactive 
neurons; GSH-Px: glutathione peroxidase; GSK 3β: glycogen synthase kinase 3 beta; HaCaT: immortalized human keratinocytes cells; HeLa cells: a cell from a sample 
taken from a woman called Henrietta Lacks and was named using the two initials of her first (He) and last (La) names; ICAM-1: intercellular adhesion molecule 1; IFN: 
interferon; IgE: immunoglobulin E; IκB: ikappaB kinase; IKK: IκBα kinase; IL: interleukin; iNOS: inducible nitric oxide Synthase; JNK: c-Jun N-terminal kinase; 
MCP-1: monocyte chemotactic protein-1; mRNA: messenger RNA; NO: nitrogen oxide; N.S.: not stated; MCP: monocyte chemotactic protein; NF-κB: nuclear factor 
kappa-light-chain-enhancer of activated B cells; NIK: NF-αB-inducing kinase; PARP: poly (ADP-ribose) polymerase; PGE2: prostaglandin E2; PPAR: peroxisome 
proliferator-activated receptor; R-HepG2: human hepatoma cell line; RAGE: receptor for advanced glycation end products; ROS: reactive oxygen species; THP1 
human monocytic cell line; TNF-α: tumor necrosis factor-alpha; TSLP: thymic stromal lymphopoietin. 
 
# human solid tumor cell lines, § proteolytic form. 
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7.4.3 Experimental studies on Salvia miltiorrhiza (Dan shen) 
The main lipid-soluble compounds of Salvia miltiorrhiza includes tanshinone (I, IIA, IIB), 
iso-tanshinone (I, II), cryptotanshinone and dihydrotanshinone I, and the water-soluble 
compounds include salvianic acid A, salvianolic acid B and rosmarinic acid. This herb and 
its constituent tanshinones have received much research attention for their cardiovascular 
effects and have been developed into a number of commercial preparations (277-281). 
Parajuli et al 2013 evaluated the effects of a standardised fraction of S. miltiorrhiza 
(PF2401-SF) on apoptosis and proliferation using in hepatic stellate cells (HSC) and in 
carbon tetrachloride (CCl4) induced injury in rats. PF2401-SF dose-dependently reduced the 
viability of t-HSC/Cl-6 cells and dose-dependently improved the protease activity of caspase 
3, time-dependently activated apoptosis flags (i.e., procaspase 3 and PARP), and 
dose-dependently activated upstream caspase 8 and 9 and their accompanied cleavage. In 
addition, PF2401-SF time-dependently improved pro-apoptotic Bax protein 
[Bcl-2-associated X protein] and suppressed anti-apoptotic Bcl2 [B-cell lymphoma 2 family 
of apoptosis regulator proteins]. These results showed a caspase-dependent pathway for 
PF2401-SF-regulated apoptosis in t-HSC/Cl-6 cells. In the in vivo study of subacute CCl4 
induced liver injury in a rat model, the extract remarkably reduced the expression of 
α-smooth muscle actin (α-SMA) and increased the amount of TdT mediated UTP Nick-End 
Labelling (TUNEL) positive cells, which indicated that PF2401-SF inhibited HSC cells by 
up-regulating apoptosis in vivo (282).  
Li FL et al 2012 investigated the effects of tanshinone IIA (Tan IIA) isolated from Salvia 
miltiorrhiza on the inhibition of the growth of mouse keratinocytes in vitro. Tan IIA dose- 
and time-dependently inhibited the growth of keratinocytes at IC50 values: 4.33±1.35, 
1.89±0.65, and 1.14±0.87 µg/mL, when incubated for 24, 48, and 72 hours, respectively. It 
also dose-dependently inhibited colony number growth curves. Apoptotic cells treated with 
Tan IIA gradually increased in a dose dependent manner, which presented about a 25-fold 
growth at the highest concentration. Subsequently, the number of DNA strand breaks was 
remarkably higher in the Tan IIA-treated groups compared with the control group. 
Caspase-3 and PARP treated with Tan IIA were increased in a dose dependent manner 
whereas Ac-DEVD-CHO, a caspase-3 specific inhibitor, reduced the apoptosis. Thus Tan 
IIA inhibited the growth of keratinocytes via a caspase-dependent apoptotic pathway. Tan 
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IIA concentration- and time-dependently decreased mitochondrial membrane potential as 
well as increased cytochrome c content. In a time-dependent manner, Tan IIA increased S 
and G2/M phase cells whereas it decreased G1 phase cells. Specifically, it down-regulated 
cyclin A and pCDK2 [phospho-Cyclin-dependent kinase 2], which relate to the S phase of 
the cell cycle, and down-regulated expression of PCNA [Proliferating Cell Nuclear Antigen] 
which is involved in cell proliferation. Therefore, Tan IIA suppressed the keratinocytes via 
cell cycle arrest (283). 
In murine hepatoma H22 cells, Tanshinone IIA Microemulsion (Tan IIA ME) resulted in 
broken and necrotic cells at 0.5 µM and 2 µM TanIIA ME for 48 hours. In H22 
tumor-bearing mice, the tumor inhibition rate reached 34.68% (dosage: 4mg/kg) or 47.17% 
(dosage: 8mg/kg) compared with 63.06% for 5-FU (25 mg/kg). In vitro and in vivo, TanIIA 
ME down-regulated Bcl-2, and up-regulated Bax and caspase-3 to induce apoptosis of 
hepatocellular carcinoma cells (284).   
In hepatocellular carcinoma H22 cells, a polysaccharide derived from Salvia miltiorrhiza 
(SMP-W1) showed its in vitro immunoregulatory and anti-proliferative properties. SMP-W1 
dose-dependently inhibited cell viability with significant cytotoxicity to H22 cells. After 48 
hours of treatment with concentrations of 200 and 400 µg/ml, the inhibition rate on H22 
cells exceeded 43%. In the H22 bearing mice, SMP-W1 dose-dependently reduced the 
tumour weight after 10 days treatment. The highest tumour inhibitory rate of 55.1% was for 
200 mg/kg of SMP-W1 which was close to the 60.5% achieved by the 5-FU positive control. 
For body weight, spleen and thymus indexes, the 5-FU positive control was significantly 
worse than the positive control whereas the SMP-W1 groups showed improvements over the 
positive and negative controls. The SMP-W1 groups also showed improvements over the 
control groups for appetite, activity and coat lustre. This implied there were no adverse 
effects of the SMP-W1 on body weight or immune organs. SMP-W1 significantly stimulated 
the secretion of TNF-α as well as anti-oxidant enzymes (SOD [superoxide dismutase], CAT 
[catalase] and GSH-Px [glutathione peroxidase]) in a dose-dependent manner. These 
experiments demonstrated SMP-W1 exerted anti-proliferative and immuno-regulatory 
effects (285).  
S. miltiorrhiza lipid-soluble extracts (SMLE) were reported to exert anti-inflammation 
effects both in vitro and in vivo. In lipopolysaccharide (LPS)-stimulated murine macrophage 
RAW 264.7 cells, SMLE dose- and time-dependently inhibited NO production without 
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cytotoxicity with an IC50 of 2.29 mg/mL. It dose-dependently inhibited the mRNA 
[messenger RNA] and protein expression of iNOS, pro-inflammatory cytokine levels 
(TNF-α, IL-1b and IL-6), and intracellular ROS (reactive oxygen species). It also 
significantly inhibited IκB-α degradation, NF-kB translocation (p65), and CD14 [cluster of 
differentiation 14] expression. Intracellular GSH [intracellular glutathione] was prevented 
from loss by the extract but it had little impact on TLR4 [Toll-like receptor 4]. Therefore, 
SMLE suppressed inflammation through NF-κB regulation in RAW 264.7 cells. In mice 
with lethal endotoxemia induced by LPS, the survival rate was reversed from 50% for LPS 
(25 mg/kg i.p.) to 70% for SMLE (10 mg/kg i.p.) and 90% for SMLE (40 mg/kg i.p.). In a 
cecal ligation and puncture (CLP)-induced sepsis model, survival was increased from 16% 
for CLP alone to 50% with SMLE (40 mg/kg i.p.) treatment. SMLE also significantly 
suppressed the serum TNF-α production induced by LPS. In a PMA-induced ear edema 
model, SMLE significantly inhibited edema when used topically but not when used orally. 
This experiment showed that SMLE induced anti-inflammatory effects in vitro and in vivo 
and had a protective effect on endotoxemia and sepsis in vivo (286). 
Jang et al 2006 found that the addition of tanshinone IIA to murine macrophages (RAW 
264.7) treatment with lipopolysaccharide (LPS) inhibited inflammatory response via 
reducing the production of pro-inflammatory mediators. It inhibited NF-κB (p65), the 
MAPKs p38 [Activator of 90 kDa heat shock protein ATPase homolog 1], ERK1/2 and JNK, 
as well as NIK [NF-κB-inducing kinase] and IKKα/β [IκBα kinase α/β] (Table 7.4) (287). 
.
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Table 7.4 Summary of experimental findings on the actions of Salvia miltiorrhiza [adapted from Deng 2013 (135)] 
 
Preparation,  
Active ingredients  
Study type,  
Model examined 
Outcome / Pharmaceutical 
target 
Regulating effect Reference 
 
tanshinone IIA 
in vitro: lipopolysaccharide (LPS)-stimulated 
RAW264.7 murine macrophages 
NF-κB (p65), p38, ERK1/2, JNK, 
NIK & IKKα/β down 
 
Jang 2006 
(287) 
 
extract, PF2401-SF 
(Standardized Fraction of S. 
miltiorrhiza) 
in vitro: hepatic stellate (t-HSC/Cl-6) cells 
caspase 3, 8 & 9, PARP, Bax 
protein 
Bcl-2 protein 
up 
 
down 
 
Parajuli 2013 
(282) 
in vivo: male Sprague-Dawley rats with CCl4 
induced subacute liver injury 
α-SMA 
TUNEL-positive cells 
reduced 
no. increased 
 
tanshinone IIA in vitro: primary mouse keratinocytes 
growth (MTS/PMS) 
caspase-3, PARP 
cyclin A, pCDK2 
retardation 
up 
down 
 
Li FL 2012 
(288) 
tanshinone IIA (micro 
emulsion) 
in vitro: murine hepatoma H22 cells; 
 
in vivo: Balb/c mice bearing tumor H22 
Bcl-2  
Bax, caspase-3 
down 
up 
Ma 2013 (284) 
tumor weight reduced 
polysaccharide (SMP-W1) 
fraction 
in vitro: hepatocellular carcinoma H22 cells  proliferation inhibited 
 
Liu 2013 (285) 
in vivo: male Balb/c mice bearing hepatoma H22 tumor growth 
TNF-α 
reduced 
up 
S. miltiorrhiza lipid-soluble 
extract (SMLE) 
in vitro: lipopolysaccharide (LPS)-stimulated 
murine macrophage RAW 264.7 cells 
NO, iNOS, IL-1b, IL-6, p65, 
NF-kB  
IκB-α 
TNF-α 
down 
up  
down 
 
 
Li M 2012 
(286) 
in vivo: Balb/c mice with: 1. lethal endotoxemia 
& sepsis; 2. ear-edema 
1. mortality;  
2. oedema  
1. reduced,  
2. reduced 
(topical use) 
α-SMA: α-smooth muscle actin; p21: Cyclin-dependent kinase inhibitor 1; p38: Activator of 90 kDa heat shock protein ATPase homolog 1; p53: Cellular tumor 
antigen; AIF: apoptosis-inducing factor; AP-1: activating protein-1; Bax protein: Bcl-2-associated X protein; Bcl-2 family proteins: B-cell lymphoma 2 family of 
201 
 
apoptosis regulator proteins; CAT: catalase; CD: circular dichroism; CD4+ T cells: T-cell surface glycoprotein CD4; CE: cornified envelope; CHK: cultured human 
keratinocytes; COX-2: cyclooxygenase-2; CYP: cytochrome P450; ERK/RSK2: extracellular signal-regulated protein/ ribosomal S6 kinase 2 kinase; FLI: Fos-like 
immunoreactive neurons; GSH-Px: glutathione peroxidase; GSK 3β: glycogen synthase kinase 3 beta; HaCaT: immortalized human keratinocytes cells; HeLa cells: a 
cell from a sample taken from a woman called Henrietta Lacks and was named using the two initials of her first (He) and last (La) names; ICAM-1: intercellular 
adhesion molecule 1; IFN: interferon; IgE: immunoglobulin E; IκB: ikappaB kinase; IKK: IκBα kinase; IL: interleukin; iNOS: inducible nitric oxide Synthase; JNK: 
c-Jun N-terminal kinase; MCP-1: monocyte chemotactic protein-1; mRNA: messenger RNA; NO: nitrogen oxide; N.S.: not stated; MCP: monocyte chemotactic 
protein; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NIK: NF-αB-inducing kinase; PARP: poly (ADP-ribose) polymerase; PGE2: 
prostaglandin E2; PPAR: peroxisome proliferator-activated receptor; R-HepG2: human hepatoma cell line; RAGE: receptor for advanced glycation end products; 
ROS: reactive oxygen species; THP1 human monocytic cell line; TNF-α: tumor necrosis factor-alpha; TSLP: thymic stromal lymphopoietin. 
 
# human solid tumor cell lines, § proteolytic form. 
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Anti-psoriatic actions of the main herbs identified in SR2: single herbs used topically 
for psoriasis (7.4.4-7.4.7) 
Four herbs, Aloe vera, Indigo naturalis, Camptotheca acuminate and Mahonia aquifolium 
were frequently used topically as single herbs in the management of psoriasis. Each showed 
effectiveness and had satisfactory safety.   
7.4.4 Experimental studies on Aloe vera (Lu hui) 
Aloe vera has been widely used in a variety of dermatological conditions (41).  Aloe vera 
applied topically, administered intraperitoneally or in combination modulated the 
inflammatory response in a salmonella OmpR [outer-membrane proteins] mediated 
inflammation model in mice (289). A study of wound healing in rats found that the topical 
application of a gel of Aloe vera mucilage applied for 14 days to surgically induced wounds 
produced greater tensile strength compared with silver sulfadizine cream (290). In a study of 
skin lesions in military personnel exposed to mustard gas, an Aloe vera/olive oil cream 
showed similar efficacy to betamethasone cream for pruritus, scaling and dry skin and was 
superior for fissure and excoriation (291). However a review of RCTs of Aloe vera products 
for wound healing was inconclusive (292).  
In the mouse tail model of psoriasis, Dhanabal et al tested the anti-psoriatic effects of an 
ethanolic extract of Aloe vera gel and reported effects similar to those of tazarotene (0.1%) 
(293). In a Croton tiglium oil skin carcinogenesis model in mice, Saini et al found that the 
topical application of Aloe vera extract as well as oral Aloe vera, reduced the number of 
papillomas (294). In human non-melanoma cancer cells, aloe emodin induced apoptosis by 
activating caspase-8, -9 and -3 expression (295).  
7.4.5 Experimental studies on Indigo naturalis (Qing dai) 
Indigo naturalis is derived from the stems and leaves of herbs described as Da qing ye and 
Ban lan gen, which may originate from the plants Isatis tinctoria, Baphicacanthus cusia, 
Polygonum tinctorium, Strobilanthes formosanus and Indigofera tinctoria (296, 297). These 
plants contain similar compounds and Qingdai (Indigo naturalis) reportedly contains 
indigotin, indirubin, isatin, nonacosane, tryptanthrin and qingdainone (297-299).  
Indirubin extracted from Polygonum tinctorium was found to effectively control 
203 
 
2,4,6-trinitro-l-chlorobenzene (TNCB)-elicited mouse ear swelling and the indirubin 
inhibited interferon-γ in the supernatants of mouse lymphocytes induced by the model (300). 
In an in vivo study of acute inflammation (xylene-induced ear edema in mice), Indigo 
naturalis showed a potent anti-inflammatory efficacy using both external and internal 
administration. However, for sub-acute inflammation (cotton ball-induced granuloma in 
mice), it only presented a remarkable anti-inflammatory effect when used externally rather 
than internally. This study implied that the anti-inflammatory effects of Indigo naturalis 
were superior when it was applied topically (301). 
As cyclin-dependent kinases (CDKs) stimulate and regulate the cell cycle, compounds that 
can inhibit CDKs have been a focus in the control of proliferative diseases such as cancer 
and psoriasis. Suzuki et al indicated that indirubin could improve the differentiation of 
human HL-60 cells by inhibiting CDK2 and activating transcription factor PU.1 (302). 
In Moon 2006, analogs and derivatives of indirubin showed high anti-proliferative effects in 
a cyclin-dependent kinase CDK2 enzyme assay (303). In addition, Lee et al reported that a 
novel CDK inhibitor, indirubin-5-nitro-30-monoxime, had a promising inhibitory effect in 
cell cycle progression and apoptosis of human lung cancer cells A549 (304). 
7.4.6 Experimental studies on Camptotheca acuminata (Xi shu) 
Camptothecin (CPT) can be derived from Camptotheca acuminata and Nothapodytes foetida 
(305). CPT has been developed into the anti-cancer agents irinotecan and topotecan (306). 
Camptotheca extracts and camptothecin have been used as anti-psoriatic therapies in China 
for decades based on experimental and clinical studies that demonstrated the anti-psoriatic 
effects of topical preparations (307, 308).  
Lin and Huang conducted a series of experiments on the anti-proliferative effects of CPT in 
mice and human keratinocytes. In mouse vaginal epithelial cells, CPT inhibited proliferation 
at 10-7-10-9 mol/L. In mouse tail scale epidermis, CPT promoted differentiation at 10-9-10-11 
mol/L. CPT also showed proliferation-inhibiting and differentiation-improving effects in 
human keratinocytes. This was related to DNA topoisomerase, which is important in 
psoriasis with its function-inducing and differentiating effects (309, 310).  
CPT was found to inhibit the proliferation of HaCaT cells in a time and 
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concentration-dependent manner, and induce apoptosis in a concentration-dependent manner 
resulting in cell-cycle arrest in the S stage. CPT inhibited telomerase activity even at 
concentrations insufficient to induce apoptosis (311). Although much of the research into 
CPT derivatives has focused on cancer, some such as isocamptothecin show promise for 
psoraisis (312).  
7.4.7 Experimental studies on Mahonia aquifolium (Gong lao mu) 
In vitro studies of Mahonia aquifolium, including its extracts, have found anti-proliferative 
(313), anti-mutagenic (314), and anti-oxidant (315) effects; inhibition of interleukin-8 
production (316), and activity against micro-organisms (314, 317). Similarly, 
anti-inflammatory (318, 319), anti-oxidant (318-320) and anti-proliferative effects (320, 321) 
have been reported for other Mahonia species.  
Berberine, which is found in various Mahonia, Berberis and Coptis species (322-325), has 
received considerable research attention. It has demonstrated dose-dependent 
anti-inflammatory effects and improved insulin resistance in vitro (323). Some other 
compounds isolated from Mahonia, such as jatrorrhizine, magnoflorine, baluchistine, and 
aromoline, have also received the research attention (314-316).  
In a study using the human monocytic cell-line THP-1, a crude hydroalcoholic extract of 
Mahonia aquifolium stem bark showed a partially inhibitory effect on IL-8 [intereukin 8] 
production after 2-days administration. However, a polysaccharide isolated from this extract, 
greatly elevated IL-8 production after 24/48-hours. This demonstrated the complex 
biological activity of the extract. The inhibitory effects may have resulted from the alkaloids 
in the extract while the polysaccharide may have increased B-lymphocyte proliferation and 
stimulated the immune system or stimulated cytokine production (326). 
Psoriasis is thought to be an inflammatory disorder involving T-cells. Psoriatic lesions result 
from CD4+ T cells adhering to endothelial cells and subsequently moving to skin tissue. In 
endothelial cells, the combination of antilymphocyte function-associated antigen type 1 
(LFA-1) and intercellular adhesion molecule 1 (ICAM-1) most effectively inhibited 
adhesion induced by TNF-alpha or peripheral blood mononuclear cells (PBMC) from 
psoriasis patients (327). In the RCT of Mahonia by Augustin et al 1999, biopsies from 
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patients that measured ICAM-1, its keratinocyte expression was found to be significantly 
inhibited along with a mild reduction in its endothelium expression (328). 
Mahonia extracts were reported to exert antimutagenic/anticarcinogenic activity in acridine 
orange (AO)-induced chloroplast mutagenesis in Euglena gracilis. Within the 
protoberberine alkaloid fractions, berberine and jatrorrhizine showed significant 
concentration-dependent inhibition (314). 
Besides the clinical studies of Mahonia, it is notable that in SR4 the clinical study by Wang 
et al. (243) included Phellodendron amurense bark while the trial by Liu et al. (240) 
contained Coptis chinensis root, both of which contain berberine (297, 329). 
Anti-psoriatic actions of the main herbs identified in SR3: external herbal formulae for 
psoriasis (7.4.8-7.4.9) 
To further explore the possible effects of the individual HMs used in multi-ingredient topical 
formulae in multiple studies, evidence derived from experimental studies of the actions of 
Sophora flavescens and Lithospermum erythrorhizon that are relevant to psoriasis were 
reviewed. These are summarised in Tables 7.5-7.6. 
7.4.8 Experimental studies on Sophora flavescens (Ku shen) 
S. flavescens contains more than 20 alkaloids including matrine and oxymatrine, and a 
number of flavonoids (330, 331). 
In an in vivo study, Kim et al 2012 used a 1-fluoro-2, 4-dinitrofluorobenzene 
(DNFB)-induced contact dermatitis mouse model to assess the effects of an extract of S. 
flavescens root. They reported that the topical application of the S. flavescens root extract 
inhibited ear swelling induced by DNFB and reduced the following histopathological 
changes: hyperplasia, edema and spongiosis. The S. flavescens root extract suppressed 
DNFB-induced increases in the levels of IFN-γ and TNF-α. In a cell-line study using 
RBL-2H3 cells, the same group reported that the S. flavescens root extract (<100 mg/mL) 
dose-dependently inhibited migration rates of RBL-2H3 cells at concentrations of up to 100 
µg/mL. They also conducted assays of β-hexosaminidase and histamine release, which 
showed that pre-treatment with the S. flavescens root extract reduced the release of 
β-hexosaminidase and histamine (> 50 µg/mL) in a dose-dependent manner. The authors 
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argued that these anti-inflammatory actions of the S. flavescens root extract involved the Th1 
skewing reaction and inhibition of mast cell degranulation (332). 
Liu et al 2007 conducted a study of human epidermal keratinocytes (HaCaT cells) and 
dermal fibroblasts which found that matrine suppressed the up-regulation of neurokinin-1 
receptor (NK-1R) expression induced by substance P (SP). Matrine also modulated the 
production of cytokines and chemokines in both cell lines. In the presence of SP, matrine 
down-regulated the production of IL-1β, IL-8 and MCP-1, and it up-regulated IFN-γ, but 
matrine had no effect on the secretion of IL-6. These results demonstrated that matrine 
exerted anti-inflammatory actions that are relevant to psoriasis and to other disorders 
characterised by chronic inflammation of the skin (333). 
An in vivo study in mice by Liao et al found that the intramuscular administration of 
oxymatrine controlled exudative inflammation and an in vitro study found that oxymatrine 
can exert a higher stabilizing effect on the red blood cell (RBC) surface compared with 
analgin, and it inhibited the heat denaturation of protein (334). 
Zheng et al. 2005 reported that the alkaloid oxymatrine reduced inflammatory symptoms 
and histological damage in a colitis model in rats (335). Jin et al 2010 investigated an 
alkaloid-free prenylated flavonoid-enriched fraction (PFS) from S. flavescens root and 
reported that it showed anti-inflammatory activity in vitro and it reduced arthritic 
inflammation in a rat arthritis model in a dose-dependent manner. In an acetic acid-induced 
writhing model, the PFS demonstrated a potent analgesic effect (336). An in vitro study by 
Zhou et al 2009 found that the pterocarpan flavonoid, trifolirhizin, which was extracted from 
S. flavescens roots showed anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated 
mouse J774A.1 macrophages by reducing the expression of TNF-α and IL-6 and by 
inhibiting COX-2 expression. In human A2780 ovarian and H23 lung cancer cells, 
trifolirhizin showed anti-proliferative actions (234).  
Burghe et al 2011 investigated the effects of kurarinone, a flavanone isolated from S. 
flavescens, in three cancer cell-lines: estrogen-unresponsive fibroblasts, ribosomal S6 kinase 
2 kinase (RSK2) knockout cells, and estrogen receptor (ER)-deficient breast tumour cells. 
They reported that kurarinone could suppress NF-κB driven IL-6 and cyclin D1 expression 
and it inhibited tumour cell proliferation (337). Liu et al 2008 investigated a lectin derived 
from S. flavescens in human HeLa cells. They reported that it time- and dose-dependently 
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induced apoptosis in the human HeLa cells and that the mechanism involved caspases 3, 8, 9, 
and 10 and pancaspace. The lectin appeared to bind to mannose branches on the cell surface 
and this led to the caspase cascade (338). 
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Table 7.5 Summary of experimental findings on the actions of Sophora flavescens [adapted from Deng 2013 (158)] 
 
Preparation  Active ingredients Study 
category 
Outcome / Pharmaceutical target Regulating  
effect 
Reference 
compound matrine 
in vitro NK-1R, IL-1β, IL-8, TNF-α, MCP-1 down 
Liu 2007 in vitro IFN-γ up 
in vitro IL-6 none 
extract NS 
in vivo IFN-γ, TNF-α down 
Kim 2012 
in vitro β-hexosaminidase and histamine down 
compound oxymatrine in vivo TNF-α, IL-6, NF-κB, ICAM-1 down Zheng 2005 
compound PFS in vitro COX-2, iNOS, TNF-α, IL-6, PGE2, 
NO  
down Jin 2010 
compound trifolirhizin in vitro 
TNF-α, IL-6, COX-2 down 
Zhou 2009 
human A2780 ovarian cells & H23 
lung cancer cells 
reduced 
proliferation 
compound mannose-binding lectin  
in vitro HeLa cells induced 
apoptosis 
Liu 2008 in vitro caspase 3,8,9,10, pancaspace up 
in vitro mannose-containing receptor up 
compound kurarinone in vitro 
NF-κB down 
Berghe 2011 
ERK/RSK2 pathways inhibited 
AP-1: activating protein-1; Bax protein: Bcl-2-associated X protein; Bcl-2 family proteins: B-cell lymphoma 2 family of apoptosis regulator 
proteins; CD: circular dichroism; CD4+ T cells: T-cell surface glycoprotein CD4; CHK: cultured human keratinocytes; COX-2: cyclooxygenase-2; 
ERK/RSK2: extracellular signal-regulated protein/ ribosomal S6 kinase 2; HeLa cells: a cell from a sample taken from a woman called Henrietta 
209 
 
Lacks and was named using the two initials of her first (He) and last (La) names; ICAM-1: intercellular adhesion molecule 1; IFN: interferon; IgE: 
immunoglobulin E; IκB: I kappa B kinase; IL: interleukin; iNOS: inducible nitric oxide synthase; mRNA: messenger RNA; NO: nitric oxide; N.S.: 
not stated; MCP: monocyte chemotactic protein; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NK-1R: neurokinin-1 
receptor; PCNA: proliferating cell nuclear antigen; PFS: prenylated flavonoid-enriched fraction; PGE2: prostaglandin E2; SPT: serine palmitoyl 
transferase; TNF-α: tumour necrosis factor-alpha. 
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7.4.9 Experimental studies on Lithospermum erythrorhizon (Zi cao) 
The herb zi cao is mainly derived from Lithospermum species particularly L. erythrorhizon. 
It contains various chemical constituents such as shikonin derivatives, phenolic and quinonic 
compounds, alkaloids, phenolic acids, triterpenes, acidic polysaccarides, and flavonoids. The 
herb is also derived from Arnebia euchroma which contains shikonin and related compounds. 
Of the compounds contained in these species, shikonin and its derivatives have shown the 
most promising pharmaceutical actions (339).  
Studies of L. erythrorhizon root extracts and its active constituents have found 
anti-proliferative and anti-inflammatory effects in cell-lines and animal models. Rajasekar et 
al 2012 investigated the effects of a root extract that contained shikonin and its derivatives 
in B16F10 melanoma cells and reported that the extract dose-dependently inhibited cell 
growth. In addition, the extract dose-dependently increased the percentage of sub-G1 phase 
cells, which reduced anti-apoptotic Bcl-2 family proteins and improved apoptotic Bax 
protein expression. In vivo, in a C57BL/6 mouse model the extract reduced the tumour size 
(A) and weight (B), and the corresponding tumor volume (calculated as V= AB2/2) in a 
concentration dependent manner by increasing necrotic cells (340). 
In murine vascular smooth muscle cells, Zhang et al 2005 reported that shikonin did not 
demonstrate cytotoxic effect but it time- and dose-dependently inhibited proliferation by 
promoting apoptosis and blocking cell cycle progression (341). In breast tumour cells, 
shikonin inhibited the proliferation by down-regulating the expression of steroid sulfatase 
genes (342). Yoon et al 1999 investigated shikonin in the HL60 human premyelocytic 
leukemia cell line and reported that shikonin inhibited proliferation via the activation of 
caspase-3 to induce apoptosis (343). In an in vivo study, Hisa et al 1998 found that shikonin 
inhibited TNF-α and B16 melanoma-induced murine angiogenesis. In addition, shikonin 
inhibited proliferation, movement and network formation in endothelial cells on Matrigel via 
suppression of integrin α V β3 expression (344). In an acute murine ear oedema model the 
addition of topical shikonin dose-dependently reduced ear oedema by blocking the 
activation of IB-α and thereby suppressing the activation of NF-κB (345).  
In a lipopolysaccharide (LPS)-induced inflammation model in mouse macrophage cells, Han 
et al 2008 reported that L. erythrorhizon extracts dose-dependently decreased the levels of 
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IFN-γ, TNF-α, IL-6, iNOS and IL-1β mRNA and suppressed the activation of AP-1 and 
NF-B via suppression of IκBα degradation. They also reported that L. erythrorhizon 
inhibited both c-Jun N-terminal kinase (JNKs) and extracellular signal-regulated signalling 
pathways (346).  
Kim et al 2007 conducted a series of experiments on L. erythrorhizon root extract. In an in 
vivo study of passive cutaneous anaphylaxis (PCA) induced by DNP-HAS injection in rats, 
they reported that prior oral administration of L. erythrorhizon root extract significantly 
inhibited PCA reaction. In a study of murine peritoneal mast cells, the L. erythrorhizon 
dose-dependently reduced compound 48/80-induced histamine release. In human mast cells 
(HMC-1), the L. erythrorhizon extract demonstrated no cytotoxic effects and it reduced the 
production of the inflammatory cytokines IL-6, IL-8, TNF-α. In addition, the extract 
inhibited the activation of the pro-inflammatory cytokine NF-B by supressing IκB-α 
degradation (347). 
L. erythrorhizon extracts have shown efficacy in animal models of dermatological disorders. 
In an oxazolone-induced murine atopic dermatitis model, Lee et al 2009 reported that L. 
erythrorhizon extracts alleviated erythema, scaling and excoriation compared to control. 
There was reduction in serum IgE and Western blotting demonstrated inhibition of COX-2 
and iNOS, and attenuation of IkBα (348). In guinea pigs with epidermal hyperproliferation 
induced by an essential fatty acid deficient diet, Kim et al 2006 reported that oral dietary 
supplementation with L. erythrorhizon extract effectively controlled the epidermal 
hyperproliferation (349). In a murine model of atopic dermatitis, an L. erythrorhizon root 
extract was administered to NC/Nga mice. Subsequently, scratching behaviour was found to 
reduce in the experimental group. This was associated with lower serum IgE levels and an 
increase in epidermal ceramide level due to a reduction in ceramide degradation (350). 
L. erythrorhizon extracts and shikonin have been reported to have skin protective effects and 
improve tissue repair. Ishida et al 2007 reported that the addition of a L. erythrorhizon 
extract to normal human epidermal keratinocytes (NHEK) that were irradiated by UVB, 
resulted in improved cell viability, and decreased the levels of IL-1β, IL-6, IL-8, and TNF-α. 
The extract dose-dependently inhibited caspase-3 activation and reduced the up-regulation 
of P53 expression. The authors concluded that the extract, which included shikonin and 
related compounds, may provide photoprotection for the skin (351).  
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In a wound healing model in rats, Ozaki et al 1998 found that both shikonin and alkannin 
dose-dependently enhanced the proliferation of granulation tissue. This was via increase in 
the number of CD11b+ cells in granulation tissue and accelerated proliferation of fibroblasts 
and collagen (352). In a wound scratch model of cultured human keratinocytes (CHK) and 
dermal fibroblasts, Kim et al 2012 reported that an aqueous extract of L. erythrorhizon 
promoted wound-healing at low-doses by promoting the movement, but not the proliferation, 
of both cell types and by accelerating lipid synthesis (353).  
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Table 7.6 Summary of experimental findings on the actions of Lithospermum erythrorhizon [adapted from Deng 2013 (158)] 
Preparation  Chemical constituents Study type Target Regulating  
effect 
Reference 
extract  
Contained shikonin & its 
derivatives 
in vitro 
B16F10 melanoma cells 
caspase 3 
induced 
apoptosis 
up 
Rajasekar 2012 in vitro Bcl-2 family proteins down 
in vitro Bax protein up 
in vivo necrotic cells up 
compound shikonin in vitro 
MCF-7 and SK-BR-3 cells reduced 
proliferation Zhang 2009 
STS mRNA & enzyme activity down 
compound shikonin in vitro 
HL60 human leukemia cells 
caspase-3 
induced 
apoptosis  
up 
Yoon 1999 
compound shikonin 
in vitro p21wif1/cipl up 
Zhang 2005 in vitro cyclin D1, E, PCNA down 
in vitro p27kipl, p53 none 
extract N.S. in vivo ceramide up Kim 2006 
extract N.S. in vivo IgE, protein expression of SPT & 
ceramidase, mRNA expression of 
down Kim 2009 
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ceramidase 
ceramide  up 
extract N.S. 
in vitro histamine down 
Kim 2007 in vitro IL-6, IL-8, TNF-α, NF-κB down 
in vitro IκB-α up 
extract N.S. in vivo IgE, IκB-α, COX-2, iNOS, down Lee 2009 
extract N.S. in vitro IFN-γ, IFN-α, IL-6, IL-1β, iNOS, 
AP-1, NF-kB 
down Han 2008 
extract N.S. in vitro COX-1, COX-2 down Kawata 2008 
extract 
Contained shikonin, β –
Hydroxyisovalerylshikonin, 
Acetylshikonin, 
Isobutyrylshikonin, β, β –
Dimethylacrylshikonin, α 
-Methyl-n-butyrylshikonin, 
Isovalerylshikonin 
in vitro IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNF-α, caspase-3, p53 
 
down Ishida 2007 
compound shikonin in vivo IκB-α, NF-κB down Andújar 2010 
compound shikonin 
in vivo TNF-α & B16 melanoma-induced 
angiogenesis 
down 
Hisa 1998 
in vitro integrin α V β3 down 
extract N.S. in vitro lipid, CHK, dermal fibroblasts up Kim 2012 
compound shikonin & alkannin in vivo CD11b+ cells  
 
increased no. 
 
Ozaki 1998 
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fibroblasts & collagen fibre accelerated 
proliferation 
AP-1: activating protein-1; Bax protein: Bcl-2-associated X protein; Bcl-2 family proteins: B-cell lymphoma 2 family of apoptosis regulator proteins; CD: 
circular dichroism; CD4+ T cells: T-cell surface glycoprotein CD4; CHK: cultured human keratinocytes; COX-2: cyclooxygenase-2; ERK/RSK2: 
extracellular signal-regulated protein/ ribosomal S6 kinase 2; HeLa cells: a cell from a sample taken from a woman called Henrietta Lacks and was 
named using the two initials of her first (He) and last (La) names; ICAM-1: intercellular adhesion molecule 1; IFN: interferon; IgE: immunoglobulin E; 
IκB: I kappa B kinase; IL: interleukin; iNOS: inducible nitric oxide synthase; mRNA: messenger RNA; NO: nitric oxide; N.S.: not stated; MCP: 
monocyte chemotactic protein; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NK-1R: neurokinin-1 receptor; PCNA: 
proliferating cell nuclear antigen; PFS: prenylated flavonoid-enriched fraction; PGE2: prostaglandin E2; SPT: serine palmitoyl transferase; TNF-α: 
tumour necrosis factor-alpha. 
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Anti-psoriatic actions of the main herbs identified in SR4: external herbs combined 
with APP for psoriasis (7.4.10-7.4.12) 
In this SR of combination therapies, the main herbs used topically were Sophora flavescens, 
Cnidium monnieri, Dictamnus dasycarpus and borneol. The effects of S. flavescens have 
been discussed earlier (see 7.4.8).  
7.4.10 Experimental studies on Cnidium monnieri 
The main bioactive ingredients of Cnidium monnieri seeds are coumarins, with osthole (aka 
osthol) having the highest concentration (354, 355)..Liao et al. 2010 assessed the effects of 
osthole and four other coumarins isolated from Cnidium in murine macrophages. They 
reported that osthole was an antioxidant and it had the most pronounced anti-inflammatory 
effects of the five compounds investigated (355). Tse et al 2006 reported that a Cnidium 
extract had an anti-proliferative effect on cultured HaCaT human epidermal keratinocytes 
(356). In addition, osthole has demonstrated anti-proliferative effects in many cell line 
studies (357).  
An in vivo study of extracts of Sophora and Cnidium in a serotonin-induced itching model in 
mice reported that both extracts exerted potent antipruritic effects. Besides, they found that 
the effect of Sophora was superior to that of Cnidium, was dosage-dependent and it did not 
inhibit locomotor activity (358).  
7.4.11 Experimental studies on Dictamnus dasycarpus 
The root-bark of Dictamnus dasycarpus includes around 11 alkaloids, 16 triterpenoids and 
16 sesquiterpenoids (359). The limonoid triterpenoid, fraxinellone, and the sesquiterpenoid, 
dictamnoside A are constituents of the root-bark of D. dasycarpus. Each has been reported to 
demonstrate activities relevant to psoriasis therapy (359). In vitro, Xu et al 1997 reported 
that an extract showed effects against liver injury in mice (360). In RAW 264.7 cells 
stimulated by LPS, pretreatment with fraxinellone demonstrated anti-inflammatory activity 
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by inhibiting nitric oxide (NO) and prostaglandin E2 (PGE2) and it also dose-dependently 
reduced the expression of iNOS and COX-2 which was due to the inhibition of NF- κB (361). 
In a mouse hepatitis model, Sun et al 2009 reported that fraxinellone demonstrated liver 
protective effects and it reduced both serum transaminases and liver damage (235). Chang et 
al 2001 reported that of seven compounds isolated from D. dasycarpus, dictamnoside A 
showed the greatest stimulating effect on T-cell proliferation in a mouse splenocyte assay 
(362).  
In a mouse model of pruritus induced by compound 48/80, a D. dasycarpus extract inhibited 
histamine release from peritoneal mast cells and inhibited scratching behaviour induced by 
compound 48/80, histamine and serotonin in a dose-dependent fashion (363). 
Tse et al 2006 reported that a root-bark extract was ineffective against the proliferation of 
human epidermal keratinocytes in vitro (356).  
7.4.12 Experimental studies on borneol 
Borneol is a terpene that can be isolated from numerous plants, notably from  
Dryobalanops aromatica, or synthesised (364). It is frequently used in topical preparations 
as a transdermal penetration enhancer (365). A number of studies have shown that borneol 
enhanced absorption. In rats, it increased the penetration of propranolol hydrochloride (366) 
and promoted the transdermal penetration of a number of components of herbal medicines 
including curcumin (367). Borneol increased the penetration of ligustrazine in pigs (368) and 
jasminoidin in frogs (369). Borneol has also been reported to assist in wound healing (370, 
371). 
7.5 Summary 
The above herbs that were used in the RCTs have each been the subject of multiple 
experimental studies. Although there is considerably variation between these herbs in the 
number of studies and the scope of the research, all have shown effects which could be 
relevant to psoriasis therapy. These are summarised below. 
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7.5.1 Inflammation 
Anti-inflammatory activity has been reported for a number of herbs and for their constituent 
compounds. For O. diffusa anti-inflammatory effects have been found for the aqueous extract 
and for the compounds ursolic acid (UA), oleanolic acid (OA), and hentriacontane and for 
the related compound oleanolic acid acetate (OAA). An aqueous extract of Rehmannia 
glutinosa has shown actions against inflammation as have a fraction that contained 
rehmapicrogenin and cinnamic acid, a polysaccharide fraction (LRPS) and the compound 
catapol. A lipid-soluble extract of S. miltiorrhiza showed anti-inflammatory effects. 
Indirubin isolated from Indigo naturalis has shown an anti-inflammatory effect. A 
hydroalcoholic extract of Mahonia aquifolium was shown to dose-dependently inhibit 
inflammatory reactions and it main active component berberine, which is also found in other 
Mahonia species as well as in Coptis chinensis (huang lian) has received much attention as 
an anti-inflammatory compound.  
Extracts from S. flavescens root have shown biological activity against inflammation, allergy 
and arthritis. The compounds responsible for its anti-inflammatory effects include the 
alkaloids matrine and oxymatrine, the flavonoid trifolirhizin and the flavanone kurarinone. 
An extract of L. erythrorhizon and the naphthoquinone pigment shikonin have demonstrated 
anti-inflammatory actions. Osthole, an active compound in Cnidium monnieri has 
anti-inflammatory effects and fraxinellone from Dictamnus dasycarpus has shown 
anti-inflammatory and liver protective effects.  
7.5.2 Proliferation 
A number of plants have been demonstrated to reduce proliferation and/or induce the 
apoptosis of keratinocytes.  
An ethanol extract and the active ingredients (ursolic acid, oleanolic acid) of O. diffusa can 
induce apoptosis. For S. miltiorrhiza extracts, a polysaccharide (SMP-W1) fraction and the 
compound tanshinone IIA have all shown anti-proliferative effects.  
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Both an ethanolic extract of Aloe vera and the compound aloe emodin can exert 
anti-proliferative actions. Indirubin from Indigo naturalis has an anti-proliferative effect and 
Camptotheca extracts as well as the compound camptothecin (CPT) have potent biological 
actions against proliferation. Camptothecin can promote cell differentiation. Mahonia 
extracts have been reported to exert anti-mutagenic/anti-carcinogenic effects.  
Extracts from S. flavescens have been shown to induce apoptosis, the flavonoid trifolirhizin 
and the flavanone kurarinone have also demonstrated anti-proliferative effects. For L 
erythrorhizon, an extract and the compound shikonin have shown anti-proliferative actions. 
An extract of C. monnieri and the compound osthole can exert anti-proliferative actions. 
Dictamnoside A, an active constituent from D. dasycarpus, can exert anti-proliferative 
effects but a root-bark extract from the herb was reported to be ineffective.  
7.5.3 Angiogenesis 
An anti-angiogenic effect was reported for shikonin. 
7.5.4 Wound healing & tissue repair 
Aloe vera mucilage has a tissue repair effect. An aqueous extract of L. erythrorhizon 
promoted wound-healing and both shikonin and alkannin enhanced proliferation of 
granulation tissue. Both oleanolic and ursolic acids enhanced recovery of epidermal barrier 
function. Borneol can also assist in wound healing. 
7.5.5 Pruritus 
Aloe vera cream has been demonstrated to be effective for pruritus. Extracts from Cnidium 
and Sophora has shown dosage-dependent anti-pruritic effects an extract of D. dasycarpus 
has been shown to be effective against pruritus. 
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Chapter 8: Large-scale biological target and pathway analysis for 
the main herbs, compounds and APPs 
8.1 Introduction 
The SRs in chapters 5 and 6 identified a number of herbs that showed promise of efficacy in 
the clinical management of psoriasis. In chapter 7, an investigation of the experimental 
studies that have been conducted on these herbs, their extracts, fractions as well as consituent 
compounds, has shown that these herbs have biological actions of relevance to psoriasis. 
This investigation also provided indications of how these herbs might act in psoriasis therapy. 
However, the experimental data on the herbs is principally derived from models that are not 
specific to psoriasis. Also the scope of the experimental data on the herbs was confined to 
models of relevance to skin or to the processes of inflammation, proliferation, angiogenesis 
and wound healing. Consequently, this cannot provide a complete view of the possible 
actions of the herbs. Moreover, although certain pharmaceuticals (i.e. the APPs) can be used 
to treat psoriasis symptoms and there has been much progress in the understanding of 
psoriasis, the underlying causes of psoriasis and the therapeutic targets of relevance to 
psoriasis remain incompletely defined (34). Also, the APPs that show efficacy in psoriasis 
tend not to be drugs that are specific for psoriasis (35, 135). Each of these issues presents 
challenges when exploring the potential actions of herbs in psoriasis management and the 
protein upon which they may act. 
Although the optimal drug targets for psoriasis therapy remain incompletely defined, some 
of the newer anti-psoriatic drugs, such as the T-cell targeted drug alefacept and the TNF 
inhibitor etanercept have well-defined targets and much is known about the proteins involved 
in the pathological pathways upon which these drugs act (372). In contast, for drugs such as 
methotrexate while some of its targets have been identified, these relate to other diseases and 
its actions in psoriasis are not yet fully understood (373). 
Pharmacotherapy mostly exerts its effect by binding to a cavity and regulating the activity of 
its protein target(s). Exploration and investigation of therapeutic targets can facilitate 
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screening for potential new drugs and drug discovery for a specific disease. Knowledge of 
the targets of drugs that are known to be effective for a particular disease can assist in 
identifying and/or designing new drugs for that disease (374).  
In the case of herbal medicines, each contains a number of compounds and for some herbal 
medicines many compounds have been characterized. Consequently it is possible that the 
herbal medicine is acting upon more than one target. This issue is compounded when herbs 
are combined in a formula. In recent years there has been interest in developing methods for 
applying in silico methods that aim to analyse the relationships between the compounds 
contained in a herbal medicine and/or a combination of herbal medicines and protein targets 
relevant to a particular disease (375-380). 
In psoriasis therapy, APPs can target the hyperproliferation of keratinocytes via proteins such 
as peroxisome proliferation activation receptor (PPAR) and transforming growth factor-beta 
(TGFbeta). Inflammation can be targeted via inhibition of pro-inflammatory factors 
including Interferon gamma (INFgamma), Cyclooxygenase (COX), Tumour necrosis factor 
(TNF) and various interleukins (IL) including those with pro-inflammatory (IL-1, IL-6, IL-8 
& IL-12) and with anti-inflammatory (IL-4, IL-10, IL-11, IL-13) effects. Angiogenesis is 
another process that is important in plaque development with targets such as Vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) having received 
attention. Leukocyte migration is another process that has been targeted in order to reduce 
inflammation, with proteins such as Intercellular adhesion molecule-1 (ICAM-1) being 
targeted by biologic APPs such as efalizumab (381, 382). 
In order to further explore how the 12 herbs discussed in chapter 7 may act with regard to 
psoriasis, and to investigate whether the actions of these herbs can provide insight into the 
targets of psoriasis therapy, the following chapter employs databases to identify the likely 
targets of the herbs and the pathways that they may affect. 
In addition, this component of the research aimed to develop a method for in silico 
investigations that can be used to link the results of systematic reviews of clinical trials of 
222 
HMs (chapters 5-6) and the results of experimental studies (chapter 7) to the processes of 
drug discovery and to provide directions for target-directed drug discovery from HMs. The 
method employed in this chapter is still under development so the results must be considered 
to be preliminary. 
A number of databases of natural products and their constituent compounds have been 
developed (383, 384). These include databases that focus on Chinese herbs such as Chemical 
Database of Traditional Chinese Medicine (CHEM-TCM) [http://chemtcm.com/] (385), and 
Herbal Ingredients’ Targets (HIT) [http://lifecenter.sgst.cn/hit/] (386). Of these, HIT contains 
extensive data on compounds and their targets and is available for free public access. 
With the expansion of therapeutic target databases and the development of methods for 
computational prediction of biological activity, in silico tools for target-directed exploration 
have become widely available (377). These online databases can greatly assist in drug-target 
directed drug discovery and can be integrated with other approaches. 
This investigation involved the following main stages.  
1. Firstly, the known compounds contained in the plant species used for each of the 12 
MHs were identified.  
2. Then database searches were used to identify the biological targets of each of the 
herbs. Also, the targets of the pharmaceuticals used for psoriasis therapy (i.e APPS) 
were identified and these were compared with the known targets of each of the herbs 
and their constituent compounds. This allowed the identification of herbs that shared 
targets with these APPs. These herbs were defined as ‘APP-like’. 
3. Since, the known targets of APPs may not be the only targets of relevance to psoriasis 
therapy, a further investigation was conducted of the likely pathways through which 
the herbal compounds may act based on all their known protein targets. This was 
undertaken for four of the 12 herbs. 
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Research questions: 
1. Do any of the promising herbs have targets similar to those of the APPs? 
2. What are the likely therapeutic targets of the most promising herbs? 
3. Which biological pathways could these herbs act upon? 
8.2 Method 
8.2.1 General approach  
Three main databases were employed in the in silico investigation. The targets of the herbs 
and the drug (APP) targets were identified using DrugBank and HIT. Following this 
investigation, the identified targets were entered into to the predictive PANTHER database to 
undertake a large scale investigation of the biological pathways upon which the herbs are 
likely to act. Figure 8.1 shows a schema of the process (Fig. 8.1). 
 
Fig. 8.1 Diagram of components of the large-scale biological targets in silico analysis 
8.2.2 Databases and resources 
The in silico investigations in this section intended not only to investigate the likely targets 
of the 12 herbs but also aimed to develop a more broadly applicable model for future 
investigations of herbs and their therapeutic targets in other diseases. Therefore, the 
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resources selected are all available for public access and all are available in English. In the 
case of the on-line databases, they all provide free access. The main resources are as follows: 
 Encyclopaedia of traditional Chinese medicines: molecular structures, 
pharmacological activities, natural sources and applications (Encyclopaedia of TCM) 
(387); and the databases: 
 HIT (China) (386);  
 DrugBank (Canada) (388); and  
 PANTHER (USA) (389).  
The application and features of each resource is detailed below.  
8.2.2.1 Encyclopaedia of TCM 
Encyclopaedia of TCM is a six volume work that provides a comprehensive survey of 
Chinese herbs including the source species and chemical ingredients. It is extensively 
indexed can be searched in a systematic manner (387). For each of the herbs, the species that 
can be used were identified using Encyclopaedia of TCM. In order to capture the all the 
possible plants that may have been used in clinical studies, both the main species and 
secondary species were included. The chemical constituents of each species were identified 
using Encyclopaedia of TCM and the journal articles cited in chapter 7. 
8.2.2.2 Herbal Ingredients' Targets database (HIT) 
Herbal Ingredients’ Targets (HIT, http://lifecenter.sgst.cn/hit/) is a curated on-line databse 
that is available in English and Chinese. It contains herb names written in Chinese pin yin 
and Latin names, compound names and chemical structures. It is searchable online via 
standard queries and keywords as well as by chemical structure similarity search (386). The 
interface is well designed and is particularly suited to searches of targets that correspond to a 
specific herb or constituent (Fig. 8.2). The database contains 5,208 entries which include 
1,301 known protein targets which are linked to 586 herbal active constituents from more 
than 1,300 herbs. HIT is linked to other target databases including DrugBank, KEGG (Kyoto 
Encyclopedia of Genes and Genomes) and Uniprot (Protein knowledgebase).  
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The HIT database was used to identify the therapeutic targets of each of the compounds in 
each of the herbs. The searches of HIT provided lists of direct and indirect targets, which 
may or may not be relevant to psoriasis. 
 
Fig. 8.2 Interface of Herbal Ingredients' Targets Database (HIT) 
8.2.2.3 DrugBank database 
DrugBank (http://www.drugbank.ca) is a curated bioinformatics and cheminformatics 
database that combines chemical, pharmacological and pharmaceutical drug data with 
comprehensive drug target information including sequence, structure and pathway (388, 390). 
It contains about 4,900 drug entries including FDA approved and experimental drugs as well 
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as nutraceuticals. The version used in the searches, DrugBank 3.0, included 1,768 
approved-drug targets, 1,424 FDA-approved drugs as well as 68 withdrawn drugs. DrugBank 
has been widely cited (> 400 citations), is integrated into many popular databases (>20), and 
is highly used by healthcare professionals and the general public with more than 4 million 
internet-hits (388). DrugBank accepts the advanced Google-style searching and boolean 
logic (AND, OR, NOT operations) on its interface (Fig. 8.3). 
The DrugBank database was used to identify the targets of the APPs used for psoriasis, and 
drugs in development for psoriasis. This provided a list of drug targets of likely relevance to 
psoriasis. 
 
Fig. 8.3 Interface of DrugBank
 
227 
8.2.2.4 PANTHER database 
The PANTHER (Protein ANnotation THrough Evolutionary Relationship) Classification 
System (http://www.pantherdb.org/) classifies proteins and their genes for a variety of 
species based on their evolutionary relationships. It is designed to facilitate high-throughput 
analysis and can be used in genetic and drug-discovery research. It has more than 7,000 
registered users, 600-800 daily users and 14,000 monthly users with 3,600 citations. 
Registered users can store data in their account for further usage. 
Version 8.0 was used in the searches. It contains 640,000 proteins from 7,729 families among 
82 genomes with 176 expert-curated pathways. (389). Based on the protein sequence 
corresponding to a biological target, PANTHER 8.0 can predict the relevant molecular 
function(s), biological process(es), cellular component(s), protein class and biological 
pathway(s).  
PANTHER was used to predict the likely biological processes and pathways, through which 
the APP-like herbs might act based on the targets identified using HIT (Fig. 8.4).
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Fig.8.4 Interface of PANTHER (Protein ANnotation THrough Evolutionary Relationship) 
Additional resources included: ‘Protein knowledgebase’ (Uniprot) [http://www.uniprot.org], 
which provides protein names and functions; the GenomeNet Database (KEGG) 
[http://www.genome.jp] which provides pathway information; and Gene Cards 
[http://www.genecards.org/] which provides comprehensive gene-related data, including 
clinical, and functional information. Uniprot and GeneCards were mainly used for target 
information while KEGG was mainly used for pathway information. However, these 
databases have many uses and show overlap with, HIT, DrugBank and PANTHER.  
It should be noted that the nomenclature of targets (full names and acronyms) and of 
pathways can vary from database to database and from publication to publication. Also the 
names used in HIT can differ from those used in PANTHER. In the results below, full names 
are used for targets in the first instance with the acronym being used in subsequent mentions. 
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8.2.3 Procedures for in silico analysis 
The in silico investigation involved a series of stages and processes as follows: 
Target level analysis 
1. Encyclopaedia of TCM: The indices (in volume 6) were used to search the Chinese 
names for each of the 12 herbs (in Chinese characters) to identify the Latin names of 
each of the species that could be used as these herbs. The initial species list was 
filtered to remove infrequently used species since these were unlikely to correspond 
to the herbs used in the clinical trials. For each of the species, the plant code was 
recorded and the plant codes were used to search for the chemical constituents for 
each species.  
2. HIT: This database was used to identify the known therapeutic targets for each 
compound in each herb. The compounds identified from the search of Encyclopaedia 
of TCM were each entered into the compound search field in HIT and the resultant 
list of Target names, Target IDs and Target types were recorded for each herb in an 
Excel spreadsheet.  
3. DrugBank: This database was used for identifying drugs used for psoriasis and the 
targets of these drugs. To identify drugs used for psoriasis the term: psoria* was 
entered into the search field. The name of each drug identified in DrugBank was 
recorded in Excel. This provided the list of APPs.  
4. APP targets: For each APP, their targets derived from DrugBank (including enzymes, 
carriers and transporters) were listed in Excel together with information on their 
actions and which category they belonged to. For example, for the APP tazarotene 
one of its targets is retinoic acid receptor alpha and its action is as an agonist. 
Enzymes, carriers and transporters for which no action was listed were discarded 
from the list. This provided the data set for the known APP targets. Such targets 
could be expected to be druggable but they may not all be relevant to psoriasis (374).  
5. Target screening: It is likely that a number of the targets of the herbs and compounds 
identified via the HIT searches were not of relevance to psoriasis therapy. In contrast, 
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the targets identified by the searches of DrugBank are more likely to be relevant to 
psoriasis therapy, although they are not necessarily the only relevant targets. In order 
to identify which herbs are likely to have activity in psoriasis, the list of herb/herbal 
compound targets was filtered using the list of APP targets, excluding the targets for 
which the action is listed as ‘unknown’ in DrugBank. This provided a short list of 
targets and consequently a set of herbs that shared targets with the known targets of 
the APPs. These were defined as ‘APP-like herbs’. For each species the specific 
APPs with which there were shared targets were identified. It was expected that this 
data could provide insight into the therapeutic applications of the herbs and could 
provide directions for further research.  
6. Selection of the most promising APP-like herbs for further investigation: Based on 
the combined results of the HIT and DrugBank searches and subsequent filtering of 
targets, the herbs were ranked according to the number of targets they shared with the 
APPs. This enabled selection of a short-list of herbs for the pathway level analysis. 
Pathway level analysis 
1 PANTHER: This database was used to further explore the likely actions of the most 
promising APP-like herbs. For each of these herbs, each of their known protein 
targets was entered into the Keyword search. Since PANTHER contains data for 
many species, all searches were conducted using the ‘homo sapiens’ setting. For each 
target, the identified Gene ID was saved as txt in a Notepad file. One Notepad file 
was created for each species. This file contained all the Gene IDs for all the known 
therapeutic targets of all the compounds that are known to be active in the species. It 
should be noted that some compounds that have been identified as present in a 
species have no known activity and consequently no known targets.  
2 The texts from each Notepad file were sequentially uploaded into the Gene List 
Analysis field in PANTHER. These files usually contained multiple Gene IDs. The 
results for each file identified five aspects for the particular species: molecular 
function(s), biological process(es), cellular component(s), protein class and 
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pathway(s). The data for each was saved as text in Excel. The Excel files were sorted 
to identify which were the most commonly identified pathways for each species.  
3 For each of the most commonly identified pathways, all the proteins that PANTHER 
identified as a component of the pathway, excluding upstream and downstream 
proteins, were entered into Excel. Since the nomenclature used by PANTHER and by 
HIT differ, cross-referencing was undertaken regarding the short and long names 
used for the proteins in both databases (see Appendix 19).  
4 Since it was impractical to cross reference every target in every herb to every 
pathway, herbs were shortlisted for the HIT / PANTHER comparison. Also, 
comparion was undertaken for a limited number of pathways. See below for the 
shortlising processes.  
5 For each of the pathways, the proteins identified in PANTHER were cross-referenced 
to the targets identified in HIT for each of the shortlisted herbs.  
6 The proteins that were identified as targets of the compounds contained in the herbs 
were identified for each pathway. 
8.3 Results 
8.3.1 Constituents of the promising herbs 
The 4 SRs identified 12 herbs as promising for psoriasis management. The names of these 
herbs and their main source species are as follows: Bai hua she she cao (Oldenlandia diffusa), 
Di huang (Rehmannia glutinosa), Dan shen (Salvia miltiorrhiza), Lu hui (Aloe vera and Aloe 
ferox), Qing dai (Indigo naturalis from Isatis or Baphicacanthus species), Xi shu 
(Camptotheca acuminata), Gong lao mu (Mahonia aquifolium and other Mahonia species), 
Ku shen (Sophora flavescens), Zi cao (Lithospermum erythrorhizon and Arnebia species), 
She chuang zi (Cnidium monnieri), Bai xian pi (Dictamnus dasycarpus) and Bing pian 
(borneol from Dryobalanops aromatica or synthetic sources).  
The Encyclopedia of TCM identified 44 specific species, forms and/or varieties relating to 
these 12 herbs and one additional species, Tai wan ma lan (Strobilanthes formosanus), was 
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identified from a clinical trial (214). Table 8.1 lists the plant code from the Encyclopedia of 
TCM, the Chinese name and the Latin names of 45 species, forms and varieties.  
The herbs Bai hua she she cao, Di huang, Xi shu, She chuang zi, Bai xian pi and Ku shen 
were each derived from a single species although Di huang was listed under four plant codes 
due to the different forms of preparation of the same species (Rehmannia glutinosa) as 
follows: the steamed root (shu di huang), dry unprocessed form of the root (gan di huang) 
and the fresh root (sheng di). Bing pian can be a synthetic product but its main natural source 
is from Dryobalanops aromatica. For the other herbs, they can derive from multiple species 
so each of the species in clinical use in Chinese medicine was included (Table 8.1). 
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Table 8.1 List of herbs, plant codes and species from Encyclopedia of TCM 
Herb name (pin yin) Plant Code Chinese names Chinese names (pin yin) Species (Latin names) 
bai hua she she cao T4485 白花蛇舌草  bai hua she she cao Oldenlandia diffusa [Syn. Hedyotis diffusa] 
di huang T5445 干地黄  gan di huang Rehmannia glutinosa [Syn. R. glutinosa f. huechingensis] 
di huang T5446 熟地黄  shu di huang Rehmannia glutinosa [Syn. R. glutinosa f. huechingensis] 
di huang T5447 鲜地黄(生地)  xian di huang (sheng di) Rehmannia glutinosa [Syn. R. glutinosa f. huechingensis] 
di huang T5448 紫地黄  zi di huang Rehmannia glutinosa var. purpurea 
dan shen T5681 白花丹参  bai hua dan shen Salvia miltiorrhiza f. alba 
dan shen T5680 丹参 dan shen Salvia miltiorrhiza 
dan shen T5692 拟丹参  ni dan shen Salvia sinica 
dan shen T5689 紫丹参  zi dan shen Salvia przewalskii var. mandarinorum 
lu hui T0348 斑纹芦荟  ban weng lu hui Aloe vera var. chinensis 
lu hui T0346 多种芦荟提取物  duo zhong lu hui ti qu wu Aloe spp. 
lu hui T0338 好望角芦荟  hao wang jiao lu hui Aloe ferox 
lu hui T0347 芦荟(库拉索芦荟)  lu hui (ku lao suo lu hui) Aloe vera [Syn. A. barbadensis] 
qing dai T3475 板蓝根  ban lan geng Isatis indigotica 
qing dai T3476 大青叶  da qing ye Isatis indigotica 
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qing dai T3477 欧洲菘蓝  ou zhou song lan Isatis tinctoria [Syn. I. indigotica] 
qing dai T0866 马蓝根  ma lan geng Baphicacanthus cusia [Syn.Strobilanthes cusia] 
qing dai T0867 马蓝叶  ma lan ye Baphicacanthus cusia [Syn.Strobilanthes cusia] 
qing dai NA 台湾马蓝 tai wan ma lan Strobilanthes formosanus*  
xi shu T1162 喜树  xi shu Camptotheca acuminata 
gong lao mu T4072 城口十大功劳  cheng kou shi da gong lao Mahonia shenii 
gong lao mu T4076 川滇十大功劳  chuan dian shi da gong lao Mahonia veitchiorum 
gong lao mu T4066 华南功劳木  hua nan gong lao mu Mahonia japonica 
gong lao mu T4067 华南功劳叶  hua nan gong lao ye Mahonia japonica 
gong lao mu T4068 华南功劳子  hua nan gong lao zi Mahonia japonica 
gong lao mu T4056 十大功劳叶  shi da gong lao ye Mahonia bealei 
gong lao mu T4063 细叶功劳叶  xi ye gong lao ye Mahonia fortunei 
gong lao mu T4054 尖叶十大功劳 jian ye shi da gong lao Mahonia aqulifolium  
gong lao mu T4061 宽苞十大功劳  kuan bao shi da gong lao Mahonia eurybracteata 
gong lao mu T4055 十大功劳木  shi da gong lao mu Mahonia bealei 
gong lao mu T4057 十大功劳子  shi da gong lao zi Mahonia bealei 
gong lao mu T4064 细柄十大功劳  xi bing shi da gong lao Mahonia gracilipes 
gong lao mu T4062 细叶功劳木  xi ye gong lao mu Mahonia fortunei 
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gong lao mu T4063 细叶功劳叶 xi ye gong lao ye Mahonia fortunei 
gong lao mu T4058 小果十大功劳  xiao guo shi da gong lao Mahonia bodinieri 
ku shen T6031 苦参  ku shen Sophora flavescens [Syn. S. angustfolia] 
ku shen T6032 苦参实  ku shen shi Sophora flavescens [Syn. S. angustfolia] 
zi cao T4500 滇紫草  dian zi cao Onosma paniculatum 
zi cao T0649 假紫草  jia zi cao Arnebia guttata 
zi cao T4499 细花滇紫草  xi hua dian zi cao Onosma hookeri 
zi cao T0648 新藏假紫草  xin zang jia zi cao Arnebia euchroma 
zi cao T3881 紫草  zi cao Lithospermum erythrorhizon 
she chuang zi T1582 蛇床子  she chuang zi Cnidium monnieri 
bai xian pi T2167 白鲜皮  bai xian pi Dictamnus dasycarpus 
bing pian T2274 冰片  bing pian Dryobalanops aromatica 
*Retrieved from Lin et al 2008.
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8.3.2 Biological targets for the compounds in each herbs identified using HIT 
In total, 482 different constituent compounds were identified via Encyclopedia of TCM for 
the 45 species, forms and varieties. When these compounds were entered into the HIT 
database, a total of 350 biological targets were identified. The database searches identified 
numerous targets for the compounds included in each of the 12 herbs. These targets are 
presented separately for each herb in the tables in Appendix 1-12.  
The names of the proteins which form the targets can vary considerably according to the 
source and multiple acronyms are used in the literature, so a table of acronyms and the full 
target names in HIT and PANTHER is provided in Appendix 19. 
It should be noted that some of the compounds identified via Encyclopedia of TCM did not 
retrieve any information from HIT. Also, some compounds can have multiple names which 
have been noted in the results. 
8.3.2.1 Compounds and targets for Bai hua she she cao (Oldenlandia diffusa) 
Of the 14 compounds contained in Oldenlandia diffusa, three compounds returned results 
from HIT: ursolic acid, oleanolic acid and stigmasterol. Notable among the targets of these 
compounds are caspase-3 and 9, which are targets of all three compounds; apoptosis 
regulator BAX [Bax] (ursolic acid, stigmasterol), apoptosis regulator Bcl-2 (ursolic acid, 
stigmasterol), intercellular adhesion molecule 1 [ICAM1] (oleanolic acid, ursolic acid), 
transcription factor AP-1 (ursolic acid, stigmasterol), tumour necrosis factor [TNF] (ursolic 
acid), prostaglandin G/H synthase 1 & 2 [COX-1 & 2] (ursolic acid), Transcription factor 
p65 [NF kappa B] (ursolic acid), NF-kappa-B inhibitor alpha [NFKBIA] (ursolic acid), 
Nitric oxide synthase, inducible [iNOS] (ursolic acid), Cyclin-dependent kinase inhibitor 1 
[p21] (ursolic acid), Cellular tumor antigen p53 [p53] (ursolic acid) and Prostaglandin E2 
receptor EP3 subtype [PGE2-R] (ursolic acid) (see full list in Appendix 1). 
8.3.2.2 Compounds and targets for Di huang (Rehmannia glutinosa) 
In total, 94 compounds were identified for Di huang, all of which were for the primary 
species Rehmannia glutinosa. Of these, the compounds that retrieved the largest numbers of 
targets were cinnamic acid (aka rosmarinic acid, caffeic acid), aucubin, catalpol, geniposide, 
hexadecanoic acid, caprylic acid, lauric acid and stigmasterol.  
237 
The most frequently retrieved targets were: apoptosis regulator Bcl-2 (aucubin, catalpol, 
geniposide, hexadecanoic acid, stigmasterol), caspase-3 (catalpol, cinnamic acid, 
stigmasterol, succinic acid), interleukin-6 [IL-6](aucubin, hexadecanoic acid, lauric acid, 
γ-aminobutyric acid), transcription factor p65 [NF kappa B](aucubin, cinnamic acid, 
hexadecanoic acid, lauric acid), apoptosis regulator BAX (aucubin, cinnamic acid, 
stigmasterol), tumour necrosis factor [TNF] (aucubin, cinnamic acid, hexadecanoic acid), 
prostaglandin G/H synthase 2 [COX-2] (cinnamic acid, hexadecanoic acid, lauric acid), 
prostaglandin G/H synthase 1 [COX-1] (cinnamic acid), nitric oxide synthase, inducible 
[iNOS](catalpol), cytochrome P450 1A1 (cinnamic acid), aldo-keto reductase family 1 
member C1 [AKR1C1](cinnamic acid), and C-C motif chemokine 2 [MCP-1] (Appendix 2).  
8.3.2.3 Compounds and targets for Dan shen (Salvia miltiorrhiza) 
For the three closely related Dan shen species Salvia miltiorrhiza, S. sinica and S. 
przewalskii, a total of 76 compounds were identified. The main compounds included 
tanshinones I & IIa, cryptotanshinone, dihydrotanshinone I, salvianolic acids A & B, ursolic 
acid, lithospermic acid B (aka salvianolic acid B), danshensu (aka salvianic acid A), caffeic 
acid (aka rosmarinic acid, cinnamic acid), and tigogenin. 
The main targets identified from HIT included: Apoptosis regulator Bcl-2 (salvianolic acid A, 
tanshinone IIa, ursolic acid), Bcl-2-like protein 1 [BCL2L1, BCLX] (cryptotanshinone, 
dihydrotanshinone I, ursolic acid), Apoptosis regulator BAX (ursolic acid), caspase-3 
(dihydrotanshinone I, lithospermic acid B, salvianolic acids A & B, tanshinone IIa, ursolic 
acid), G1/S-specific cyclin-D1 [CCND1, BCL-1] (cryptotanshinone, dihydrotanshinone I, 
salvianolic acid A, ursolic acid), transcription factor p65 [NF kappa B] (cryptotanshinone, 
danshensu, lithospermic acid B, tanshinone IIa, ursolic acid), endothelin-1 [RT-1, EDN-1] 
(cryptotanshinone, tanshinone IIa), intercellular adhesion molecule 1 [ICAM1] (lithospermic 
acid B, salvianolic acid B, tanshinone I, ursolic acid), vascular endothelial growth factor A 
[VEGF-A] (lithospermic acid B, salvianolic acid B, tanshinone I, ursolic acid), 
Cyclin-dependent kinase inhibitor 1 [CAP20, CDKN1] (salvianolic acid A, tanshinone IIa, 
ursolic acid), probable E3 ubiquitin-protein ligase HERC5 (dihydrotanshinone I, salvianolic 
acid A, ursolic acid), vascular cell adhesion protein 1 [VCAM-1] (lithospermic acid B, 
salvianolic acid B, tanshinone I), cytochrome P450 1A1, 1A2 & 3A4 (tanshinone IIa, caffeic 
acid), prostaglandin G/H synthase 1 & 2 [COX 1&2] (caffeic acid, ursolic acid, lithospermic 
acid B, salvianolic acid B, tigogenin), tumour necrosis factor [TNF] (caffeic acid, 
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cryptotanshinone, ursolic acid), Activator of 90 kDa heat shock protein ATPase homolog 1 
[p38, AHSA1] (tanshinone IIa), Mitogen-activated protein kinase 1 [ERK2, MAPK1] 
(tanshinone IIa), Poly [ADP-ribose] polymerase 4 [PARP] (tanshinone IIa), Actin, aortic 
smooth muscle [ACTA2, α-SMA] (salvianolic acid B aka lithospermic acid B) (Appendix 3). 
8.3.2.4 Compounds and targets for Lu hui (Aloe vera) 
Searches located 49 compounds in Aloe vera and Aloe ferox. Major compounds included 
hexadecanoic acid, lauric acid, linolenic acid (aka alpha-linolenic acid), p-coumaric acid, 
rutin, sucrose, aloin and aloe emodin.  
Therapeutic targets were only identified for Aloe vera and the variety chinensis. The most 
common targets were: interleukin-6 [IL-6] (hexadecanoic acid, lauric acid, rutin), 
transcription factor p65 [NF kappa B] (hexadecanoic acid, lauric acid, linolenic acid, rutin), 
prostaglandin G/H synthase 2 [COX 2] (hexadecanoic acid, lauric acid, linolenic acid), 
tumor necrosis factor [TNF] (hexadecanoic acid, rutin), Caspase-3 (succinic acid, rutin), 
Apoptosis regulator Bcl-2 (hexadecanoic acid), and Collagen alpha-1(I) chain 
[COL1A1](hexadecanoic acid) (Appendix 4).  
8.3.2.5 Compounds and targets for Qing dai (Indigo naturalis) 
In total 43 compounds were identified for three species: Isatis indigotica (aka I. tinctoria), 
Baphicacanthus cusia, and Strobilanthes formosanus. The main compounds were: indirubin, 
lupeol, salicylic acid, sucrose, tryptanthrine, β-sitosterol, indigotin, hexadecanoic acid. 
Indirubin was found in all three species. 
The most frequently identifed targets were Caspase-3 & 9 (lupeol, tryptanthrine, β-sitosterol), 
Apoptosis regulator Bcl-2 (lupeol, β-sitosterol, hexadecanoic acid), cyclin-dependent kinase 
inhibitor 3 [CDKN3] (indirubin), cytochrome P450 1A1 & 1A2 (indirubin, sucrose), 
glycogen synthase kinase-3 beta [GSK-3 beta] (indirubin), interferon gamma [IFN gamma] 
(indirubin), multidrug resistance protein 1 [ABCB1] (tryptanthrine), serum 
paraoxonase/arylesterase 1 [PON1] (salicylic acid, β-sitosterol), tumour necrosis factor [TNF] 
(hexadecanoic acid), Transcription factor AP-1 [Ap-1] (β-sitosterol), transcription factor p65 
[NF kappa B] (Salicylic acid), Interleukin-4 [IL 4] (salicylic acid), Interleukin-10 [IL 10] 
(hexadecanoic acid), and Protein kinase C alpha type [PRKCA] (β-sitosterol) (Appendix 5).  
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8.3.2.6 Compounds and targets for Xi shu (Camptotheca acuminata) 
There were 28 compounds derived from Camptotheca acuminata that were identified from 
Encyclopedia of TCM. These compounds included quercetin, hyperin, and camptothecin.  
The main targets were: apoptosis regulator bax (hyperin, quercetin), caspase-3 (hyperin, 
quercetin), Apoptosis regulator Bcl-2 (quercetin), Transcription factor AP-1 [AP1](quercetin), 
Transcription factor p65 [NF kappa B] (quercetin), catalase [CAT] (hyperin, quercetin), 
superoxide dismutase [Cu-Zn] (hyperin, quercetin), ATP-binding cassette sub-family G 
member 2 [ABCG2] (quercetin, camptothecin), cytochrome P450 1A1, 1A2 & 3A4 
(quercetin), myeloperoxidase [MPO] (quercetin), prostaglandin G/H synthase 1 & 2 [COX 1 
& 2](quercetin), tumour necrosis factor [TNF] (quercetin), Inhibitor of nuclear factor 
kappa-B kinase subunit alpha [IKK alpha] (quercetin), Interferon gamma [IFN gamma] 
(quercetin), Interleukins 1A/B, 2, 6, 8, 10 (quercetin), C-C motif chemokine 2 [CCL2] 
(quercetin), DNA topoisomerase 1 [TOP1] (quercetin, camptothecin), DNA topoisomerase 
2-alpha [TOP2A] (quercetin), and Vascular endothelial growth factor A [VEGF-A] (quercetin) 
(Appendix 6). 
8.3.2.7 Compounds and targets for Gong lao mu (Mahonia aquifolium) 
Ten compounds were identified from the following nine species: Mahonia aqulifolium, M. 
shenii, M. veitchiorum, M. japonica, M. fortunei, M. eurybracteata, M. bealei, M. gracilipes, 
M. bodinieri. Berberine was the predominant compound which occurred in multiple species. 
The other main compounds included: jatrorrhizine, palmatine, coptisine, magnoflorine and 
isotetrandrine.  
The most common targets were: G1/S-specific cyclin-D1 [CCND1] (berberine, coptisine), 
amine oxidase [flavin-containing] A & B [MAO-A & B] (jatrorrhizine, coptisine), Apoptosis 
regulator BAX (berberine), Apoptosis regulator Bcl-2 (berberine), caspase-3, 8 & 9 
(berberine), BH3-interacting domain death agonist [BID] (berberine), Transcription factor 
AP-1 (berberine), interleukin-4, 6 & 8 (berberine), ATP-binding cassette sub-family G 
member 2 [ABCG2] (berberine), cytochrome P450 1A1 (berberine), myeloperoxidase 
[MPO](berberine), prostaglandin G/H synthase 2 [COX-2](berberine), tumour necrosis 
factor [TNF] (berberine), Vascular endothelial growth factor A [VEGF-A] (berberine), 
Transcription factor p65 [NF kappa B] (berberine), NF-kappa-B inhibitor alpha [NFKBIA] 
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(berberine), Nitric oxide synthase, inducible [iNOS] (berberine), Platelet-derived growth 
factor subunit A [PDGFA] (berberine), Mitogen-activated protein kinase 1 [MAPK1] 
(berberine), and Interferon gamma [IFN gamma] (berberine) (Appendix 7). 
8.3.2.8 Compounds and targets for Ku shen (Sophora flavescens) 
81 compounds derived from Sophora flavescens were identified including matrine, 
formononetin, cytosine, sophocarpine, sophoramine, sophoridine and kuraridin.  
The main targets indentified were as follows: interleukin-6 [IL 6] (matrine, sophocarpine, 
sophoramine, sophoridine), tumour necrosis factor [TNF] (matrine, sophocarpine, 
sophoramine, sophoridine), prostaglandin G/H synthase 2 [COX-2] (kuraridin), caspase-3 
(matrine), transcription factor p65 [NF-kappa B], Intercellular adhesion molecule 1 [ICAM 
1], Transcription factor AP-1 (formononetin), Proto-oncogene c-Fos [FOS] (cytisine) 
Peroxisome proliferator-activated receptor gamma [PPARG] (formononetin) (Appendix 8).  
8.3.2.9 Compounds and targets for Zi cao (Lithospermum erythrorhizon) 
Overall, 51 constituents were located for 5 species: Lithospermum erythrorhizon, Onosma 
paniculatum, Arnebia guttata, Onosma hookeri, and Arnebia euchroma. Shikonin was the 
major constituent and it was present in four of these species while Onosma hookeri contained 
acetylshikonin. Other important constituents included: caffeic acid, acetylalkannin, 
isobutyrylshikonin, and β, β-Dimethylacrylalkannin.  
The main targets were: Caspase-3 [CASP3] (shikonin), Apoptosis regulator Bcl-2 [BCL2] 
(shikonin), Bcl2 antagonist of cell death [BBC6] (shikonin), RAC-alpha 
serine/threonine-protein kinase [AKT1] (shikonin, isobutyrylshikonin), amine oxidase 
[flavin-containing] A & B [MAO-A] (shikonin), C-C motif chemokine 3 & 5 [CCL3&5] 
(shikonin), interleukin-1 beta [IL1B] (isobutyryl shikonin), interleukin-4, 6, 8 & 10 
[IL4,6,8,10] (shikonin), G1/S-specific cyclin-D1 [CCND1] (shikonin), G1/S-specific 
cyclin-E1 [CCNE1] (shikonin), Proliferating cell nuclear antigen [PCNA] (shikonin), 
Serine/threonine-protein kinase PAK 2 [PAK2] (shikonin), Nuclear receptor subfamily 4 
group A member 1 [NR4A1] (shikonin), prostaglandin G/H synthase 1 & 2 [COX 1 & 2] 
(caffeic acid, isobutyrylshikonin), tumour necrosis factor [TNF] (caffeic acid, 
isobutyrylshikonin), cellular tumor antigen p53 [TP53] (shikonin), vascular endothelial 
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growth factor receptor 2 [VEGFR2] (shikonin), Angiopoietin-1 receptor [TEK] (shikonin), 
transcription factor p65 [NF-kappa B] (isobutyrylshikonin), NF-kappa-B inhibitor alpha 
[NFKBIA] (isobutyrylshikonin), and cytochrome P450 1A1 [CYPIA1] (caffeic acid) 
(Appendix 9).  
8.3.2.10 Compounds and targets for She chuang zi (Cnidium monnieri) 
21 compounds were identified for Cnidium monnieri. Isopimpinellin and osthole were the 
main compounds. Cytochrome P450 1A1 & 3A4 (isopimpinellin, bergapten), Nitric oxide 
synthase, inducible (osthole), Nuclear receptor subfamily 1 group I member 2 
(isopimpinellin) were the main targets (Appendix 10).  
8.3.2.11 Compounds and targets for Bai xian pi (Dictamnus dasycarpus) 
24 compounds were identified for Dictamnus dasycarpus. The major compounds included 
the dictamnosides (A, B, G, H, I, J, L, M), obaculactone (aka limonin) and fraxinellone. The 
only target identified in HIT was cytochrome P450 3A4 (obaculactone) (Table 8.12). No 
targets were identified for fraxinellone although targets have been reported (Appendix 11). 
8.3.2.12 Compounds and targets for Bing pian (Dryobalanops aromatica) 
Synthetic borneol mainly contains d-borneol and camphor. For borneol from its natural 
source, Dryobalanops aromatica, 15 ingredients were identified. Oleanolic acid was the 
main compound for which the following targets were relevant: Caspase-3 & 9 (oleanolic acid) 
and Heme oxygenase 1 (oleanolic acid). No targets were identified in HIT for d-borneol 
(Appendix 12). 
8.3.3 Identification of APP drug targets using DrugBank 
The search of DrugBank located 20 drugs that had been FDA-approved for the management 
of psoriasis and/or psoriatic arthritis. This included two drugs that have been withdrawn 
(aminopterin, etretinate). The 20 APP drugs included tazarotene, calcipotriol, acitretin, 
golimumab, desoximetasone, clobetasol, etanercept, efalizumab, calcitriol, fluticasone 
propionate, prednisolone, methotrexate, alitretinoin, dimethyl fumarate, alefacept, 
cyclosporine, aminopterin, etretinate, salicylic acid and methoxsalen. 
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For these 20 drugs, DrugBank identified 88 targets, enzymes, carriers or transporters on 
which these drugs are known to have effects. Of these, 17 targets were listed as having 
‘unknown’ actions or their actions were ‘not stated’, so these were not included in the 
comparisons with the herbs. In two cases there were carriers/transporters whose actions were 
‘not stated’ with regard to some APPs, whereas actions were listed for other APPs. These 
were not included when the actions were ‘not stated’. The major targets of the APPs included: 
Glucocorticoid receptor (NR3C1), Prostaglandin G/H synthase 1 & 2 (COX 1 & 2), Retinoic 
acid receptor (RAR) alpha, beta & gamma-1, RXR-alpha & RXR-beta, T-cell surface antigen 
CD2 (CD2), Tumour necrosis factor (TNF) and Vitamin D3 receptor (VDR). 
69 targets, enzymes, carriers and transporters were cross referenced to the lists of targets 
identified using HIT. It should be noted that the term ‘target’ in HIT is broader in meaning 
than in DrugBank, so the comparison was not limited to the proteins listed in DrugBank as 
‘targets’ but included the enzymes, carriers and transporters as well (Appendix 13). 
8.3.3.1. Targets that the herbs shared with the APPs  
Following the comparison, 10 targets were found to be common to the APP drug target lists 
and the lists of targets for the 12 herbs. Of these 12 herbs, 11 had targets in common with at 
least one of the APPs. The excluded herb was Bing pian (borneol).  
Based on the searches of DrugBank and HIT, 12 of the 20 APPs shared at least one target 
with at least one of the compounds identified in the herbs. The shared targets are as follows: 
1) Tumour necrosis factor (TNF) is a target of the biological golimumab and etanercept 
which are inhibitors of TNF. The following compounds were also identified as having down 
regulating effects on TNF: ursolic acid, aucubin, cinnamic acid (aka caffeic acid), 
cryptotanshinone, rutin, quercetin, berberine, matrine, sophocarpine, sophoramine, 
sophoridine and isobutyrylshikonin.  
In contrast, hexadecanoic acid was identified by HIT as increasing the expression level or 
activity of TNF.  
The following 9 herbs contained compounds that were identified as down regulating TNF: 
Bai hua she she cao, Di huang, Dan shen, Lu hui, Qing dai, Xi shu, Gong lao mu, Ku shen 
and Zi cao. 
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2) Prostaglandin G/H synthase 2 (COX 2) is a target that is inhibited by the topical drug 
salicylic acid and the biological etanercept.  
The following compounds were identified by HIT as decreasing the expression level or 
activity of COX 2: ursolic acid, cinnamic acid (aka caffeic acid), hexadecanoic acid, 
lithospermic acid B (aka salvianolic acid B), linolenic acid, quercetin, berberine, kuraridin 
and isobutyrylshikonin. 
The following two compounds were identified by HIT as increasing expression level or 
activity of COX 2: lauric acid and tigogenin. 
The following 8 herbs contained compounds that were identified as down regulating COX 2: 
Bai hua she she cao, Di huang, Dan shen, Lu hui, Xi shu, Gong lao mu, Ku shen, Zi cao. 
3) Prostaglandin G/H synthase 1 (COX 1) is a target that is inhibited by the topical drug 
salicylic acid.  
The following compounds were identified by HIT as decreasing the expression level or 
activity of COX 1: ursolic acid, cinnamic acid (aka caffeic acid). 
The following 4 herbs contained compounds that were identified as down regulating COX 1: 
Bai hua she she cao, Di huang, Dan shen and Zi cao. 
4) Myeloperoxidase (MPO) is inhibited by the topical vitamin D analog calcipotriol.  
The following compounds were identified by HIT as decreasing the expression level or 
activity of MPO: quercetin and berberine.  
The following 2 herbs contained compounds that were identified as down regulating MPO: 
Xi shu and Gong lao mu. 
5) Multidrug resistance protein 1 (ABCB1) is a substrate for salicyclic acid, prednisolone, 
methotrexate, alitretinoin and cyclosporine (which is also an inhibitor or inducer). The 
compound tryptanthrine was identied as an inhibitor. ABCB1 was identified as a target of 
camptothecin but the action was not available.  
The following herb contained a compound that was identified as down regulating ABCB1: 
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Qing dai. 
6) ATP-binding cassette sub-family G member 2 (ABCG2) is a substrate for methotrexate 
and is inhibited by cyclosporine. The compound quercetin was identified as increasing the 
expression level or activity of ABCG2 whereas berberine decreases expression level or 
activity. The action of camptothecin was not available.  
The following herb contained a compound that was identified as down regulating ABC G2: 
Gong lao mu. 
7) Aldo-keto reductase family 1 member C1 (AKR1C1) is inhibited by salicyclic acid. Of 
the componds identified for the herbs in HIT, salicyclic acid was one and it was listed as 
decreasing expression level or activity. In contrast cinnamic acid was identified as increasing 
expression level or activity.  
The following herb contained a compound that was identified as down regulating AKR1C1: 
Qing dai. 
8) Cytochrome P450 1A1 (CYP1A1) is inhibited by both clobetasol and methoxsalen.  
The following compounds were listed as decreasing CYP1A1 expression level or activity: 
cinnamic acid (aka rosmarinic acid, caffeic acid), indirubin, berberine and isopimpinellin 
(aka limonin).  
Tanshinone IIa was listed as up-regulating the gene while the reports for quercetin appeared 
contradictory including both inhibition and increasing expression. 
The following 6 herbs contained compounds that were identified as down regulating 
CYP1A1: Di huang, Dan shen, Qing dai, Gong lao mu, Zi cao and She chuang zi. 
9) Cytochrome P450 1A2 (CYP1A2) is inhibited by clobetasol, alitretinoin and 
methoxsalen.  
Sucrose was identified by HIT as decreasing CYP1A2 expression level or activity and 
quercetin was identified as a direct inhibitor. Tanshinone IIa was identified as increasing 
expression level or activity. 
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The following 3 herbs contained compounds that were identified as down regulating 
CYP1A2: Qing dai, Xi shu and Lu hui. 
10) Cytochrome P450 3A4 (CYP3A4) was identified by DrugBank as an enzyme target for 
the following APPs: calcitriol (substrate, inducer), fluticasone propionate (substrate, 
inhibitor), prednisolone (substrate, inhibitor), cyclosporine (substrate, inducer) and 
methoxsalen (substrate).  
The compound obaculactone (aka limonin) was identified by HIT as directly inhibiting 
CYP3A4. Both tanshinone IIA and isopimpinellin were listed as up-regulating the gene. 
Quercetin was listed by HIT as decreasing expression level or activity as well as 
up-regulating the gene.  
The following herb contained a compound that was identified as down regulating CYP3A4: 
Bai xian pi. 
8.3.3.2 Comparison of target groupings, herbs and APPs 
The targets COX 1 and COX 2 are involved in inflammation and are of direct relevance to 
psoriasis therapy (391). The following 8 herbs were all identified as potentially having 
inhibitory actions on at least one of these targets: Bai hua she she cao, Di huang, Dan shen, 
Lu hui, Xi shu, Gong lao mu, Ku shen and Zi cao. In this sense they have actions similar to 
those of the APPs etanercept, and salicylic acid.  
TNF is a major target for psoriasis that is involved in inflammation as well as multiple 
processes including apoptosis, proliferation and immunoregulation (381, 392, 393). The 
following 9 herbs were all identified as down regulating TNF: Bai hua she she cao, Di huang, 
Dan shen, Lu hui, Qing dai, Xi shu, Gong lao mu, Ku shen and Zi cao. In this sense they are 
similar to the APPs golimumab and etanercept.  
The targets ABCB1 (Multidrug resistance protein 1) and ABCG2 (ATP-binding cassette 
sub-family G member 2) are closely related proteins that are known to be involved in the 
transport of xenobiotics, including drugs, across cell membranes (394). These targets do not 
appear to be of direct relevance to psoriasis.  
MPO (Myeloperoxidase) is an enzyme involved in phagocytosis, transcriptional 
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misregulation in cancer, atherosclerotic plaques and inflammation in cardiovascular disease 
(395-397). Its relevance to psoriasis is unclear.  
Enzymes in the CYP 450 super family are well known for their roles in drug metabolism 
(398). They are also involved in skin responses to xenobiotics as well as in the metabolism of 
endogenous substrates including vitamins A and D. Since CYPs are up-regulated in psoriasis, 
the use of CYP inhibitors has been proposed as a strategy in psoriasis drug development (399, 
400). 
8.3.3.3 Comparison of herbs, species and APPs 
For each of the herbs and their included species, a comparison was undertaken to determine 
how many of the 12 APPs shared at least one target with the 12 herbs (see Table 8.2). The 
herb Xi shu (Camptotheca acuminata) was found to share targets with all of the 12 APPs. 
Dan shen (Salvia miltiorrhiza) shared targets with 10 APPs. The herbs Qing dai (species 
Isatis indigotica) and Gong lao mu (Mahonia species) shared targets with 8 of the APPs.  
Lu hui (Aloe vera), She chuang zi (Cnidium monnieri) and Qing dai (species Baphicacanthus 
cusia) shared targets with 6 of the APPs. Zi cao (species Lithospermum erythrorhizon) and 
Di huang (Rehmannia glutinosa) shared targets with 5 of the APPs. Bai xian pi (Dictamnus 
dasycarpus) shared targets with 4 of the APPs. Ku shen (Sophora flavescens) and Bai hua 
she she cao (Oldenlandia diffusa) shared targets with 3 of the APPs. Bing pian (species 
Dryobalanops aromatica) did not share a target with any of the APPs.  
In cases where there are multiple species included under one herb there was considerable 
variation in the number of targets identified, but it is likely that this was due mainly to the 
relatively larger number of research reports that cited the main species. 
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Table 8.2 Identification of the APP-like herbs (Oldenlandia diffusa,Rehmannia glutinosa, R. glutinosa var. purpurea, Salvia miltiorrhiza, S. miltiorrhiza f. alba, S. 
sinica, S. przewalskii var. mandarinorum, Aloe vera, A. vera var. chinensis, A. spp., A. ferox, Camptotheca acuminata, Mahonia aqulifolium, M. shenii, M. veitchiorum, M. 
japonica, M. bealei, M. fortunei, M. eurybracteata, M. bealei, M. gracilipes, M. fortunei, M. bodinieri, Sophora flavescens, Onosma paniculatum, O. hookeri, Arnebia 
guttata, A. euchroma, Lithospermum erythrorhizon, Cnidium monnieri, Dictamnus dasycarpus, Dryobalanops aromatica, Isatis indigotica, I. tinctoria, Baphicacanthus 
cusiaStrobilanthes formosanus) 
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O. diffusa  白花蛇舌草       √  √   √  3 
R. glutinosa  干地黄     √  √  √   √ √ 5 
R. glutinosa  熟地黄               
R. glutinosa  鲜地黄(生地)               
R. glutinosa var. purpurea 紫地黄               
S. miltiorrhiza f. alba 白花丹参               
S. miltiorrhiza 丹参 √  √ √ √ √ √ √  √ √ √ 10 
S. sinica 拟丹参  √  √ √ √  √ √  √  √ 8 
S. przewalskii var. 
mandarinorum 
紫丹参  
√  √ √ √  √ √  √  √ 8 
A. vera var. chinensis 斑纹芦荟       √     √  2 
A. spp. 多种芦荟提取物               
A. ferox 好望角芦荟               
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A. vera  芦荟(库拉索芦荟)  √   √  √  √   √ √ 6 
C. acuminata 喜树  √ √ √ √ √ √ √ √ √ √ √ √ 12 
M. shenii 城口十大功劳   √  √ √ √  √ √  √ √ 8 
M. veitchiorum 川滇十大功劳   √  √ √ √  √ √  √ √ 8 
M. japonica 华南功劳木   √  √ √ √  √ √  √ √ 8 
M. japonica 华南功劳叶               
M. japonica 华南功劳子               
M. bealei 十大功劳叶             √ 1 
M. fortunei 细叶功劳叶      √    √    2 
M. aqulifolium  尖叶十大功劳              
M. eurybracteata 宽苞十大功劳   √  √ √ √  √ √  √ √ 8 
M. bealei 十大功劳木   √  √ √ √  √ √  √  7 
M. bealei 十大功劳叶               
M. bealei 十大功劳子               
M. gracilipes 细柄十大功劳   √  √ √ √  √ √  √ √ 8 
M. fortunei 细叶功劳木   √  √  √  √   √ √ 6 
M. fortunei 细叶功劳叶               
M. bodinieri 小果十大功劳   √  √ √ √  √ √  √ √ 8 
S. flavescens . 苦参       √  √   √  3 
S. flavescens . 苦参实               
O. paniculatum 滇紫草               
249 
A. guttata 假紫草               
O. hookeri 细花滇紫草               
A. euchroma 新藏假紫草               
L. erythrorhizon 紫草     √  √  √   √ √ 5 
C. monnieri 蛇床子    √ √ √  √   √  √ 6 
D. dasycarpus 白鲜皮    √  √  √   √   4 
D. aromatica 冰片               
I. indigotica 板蓝根  √   √ √    √ √ √  6 
I. indigotica 大青叶  √   √ √ √  √ √ √ √  8 
I. tinctoria 欧州菘蓝  √    √    √ √ √  5 
B. cusia  马蓝根  √   √ √    √ √ √  6 
B. cusia 马蓝叶               
S.formosanus  台湾马蓝    √         1 
 
 
250 
8.3.3.4 APPs that share targets with the herbs 
The number of targets that the different APPs were found to share with the 12 herbs ranged 
from 0 to 10. Fig. 8.5 indicates that the biologicals golimumab and etanercept and the topical 
salicylic acid shared targets with nine of the herbs while the herbs Camptotheca (Xi shu) and 
Salvia (Dan shen) shared targets with 12 of the APPs. 
Since the above figure included the cytochromes which are mainly associated with 
metabolism of the drugs, these targets were removed from the comparison. As a result two 
herbs, Cnidium (Shi chuang zi) and Dictamnus (Bai xian pi), were removed from the matrix 
but the list of APPs was not affected. Consequently, the following 9 herbs: Dan shen (Salvia 
miltiorrhiza etc), Lu hui (Aloe vera etc), Qing dai (Indigo naturalis), Xi shu (Camptotheca 
acuminata), Gong lao mu (Mahonia aquifolium etc), Ku shen (Sophora flavescens), and Zi 
cao (Lithospermum erythrorhizon, Arnebia spp) Dan shen (Salvia miltiorrhiza, S. sinica), Di 
huang (Rehmannia glutinosa), Bai hua she she cao (Oldenlandia diffusa), Lu hui (Aloe vera, 
A. ferox), Qing dai (Indigo naturalis), Xi shu (Camptotheca acuminata), Gong lao mu 
(Mahonia spp), Ku shen (Sophora flavescens) and Zi cao (Lithospermum erythrorhizon, 
Arnebia spp) were considered to be ‘APP-like’ (Fig. 8.6). 
The commonly used drug acitretin which appeared in many of the clinical trials in the 
systematic reviews (chapters 5-6) and was frequently combined with the HMs shared no 
targets with any of the shortlisted herbs and does not appear to be metabolized by the same 
enzymes as metabolise the compounds contained in the herbs.
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F.P.: fluticasone propionate; S.A.: salicyclic acid 
Fig. 8.5 APP drugs and the corresponding herbs with the same therapeutic targets (including CYP 450) 
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F.P.: fluticasone propionate; S.A.: salicyclic acid 
Fig. 8.6 APP drugs and the corresponding herbs with the same therapeutic targets (excluding CYP 450) 
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8.3.4 Analysis of the pathways associated with biological targets of herbs using 
PANTHER 
In total, the searches of HIT located 350 biological targets that were linked to the 12 
candidate herbs. It was impractical to search every target in every herb so the following four 
herbs were selected for analysis with PANTHER. 
Dan shen (Salvia) and Xi shu (Camptotheca) shared targets with the largest numbers of APPs 
so these appeared promising for further investigation. Moreover, Dan shen is used internally 
whereas Xi shu is used topically. Di huang (Rehmannia) was selected as it is very frequently 
used in the clinical trials in internal formulae while Qing dai (Indigo) was selected as it was 
commonly used in the clinical trials as a topical preparation. This provided a sample that 
included both topical and oral herbs.  
Although Gong lao mu (Mahonia) was also used frequently as a topical medicine in the 
clinical trials, its targets are almost all focused on the compound berberine, which has 
already received considerable research attention regarding its actions and targets (321, 322, 
324, 401). Therefore it was excluded. 
In addition, analyses were conducted in PANTHER for etanercept and salicylic acid which 
are APPs that shared targets with multiple herbs including the four used in the PANTHER 
searches. The analysis was not limited to the targets that the herbs had in common with the 
APPs since it appeared likely that these herbs may act upon additional targets. In the 
previous investigation using DrugBank, targets of likely relevance to psoriasis were 
identified but there is, as yet, no complete listing of targets of relevance to psoriasis, 
therefore it was possible that the filtering of targets based on DrugBank results could exclude 
targets of relevance to psoriasis. Consequently, filtering was not used in this investigation. 
For each herb, all targets for all species of the herbs which had been identified using HIT, 
were entered into PANTHER. The PANTHER Section II results were recorded. This section 
returned results on the following five aspects relating to the proteins: cellular component, 
protein class, molecular function, biological process, and pathway. Each of these results is 
reported below with a focus on the pathways. A few targets returned no results. The results 
for gene analysis are not reported. 
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8.3.4.1 Results of PANTHER analyses 
The full lists of PANTHER Section II results are tabulated in Appendix 14-18. The main 
results are reported below for each herb. Pathways were short-listed based on the number of 
targets per pathway in descending order of frequency. 
1) Results for Dan shen (Salvia miltiorrhiza and other S. species) 
109 targets were identified by HIT for Dan shen, of which 102 were suitable to PANTHER. 
These returned the following main results for protein class in descending frequency of hits: 
hydrolase (24), enzyme modulator (19), signaling molecule (18), protease (15), transferase 
(15), receptor (15) and kinase (13). 
The main molecular functions were: binding (51), catalytic activity (47), enzyme regulator 
activity (17), and receptor activity (16). 
The main Biological Processes involved were: cellular process (62), metabolic process (59), 
cell communication (50), immune system process (36), apoptosis (27), response to stimulus 
(26), cell cycle (25), developmental process (22), transport (14) and system process (14). 
In total 59 pathways were identified. The most frequently identified pathways, based on the 
number of targets per pathway, were as follows: 
• Apoptosis signaling pathway (22) 
• Angiogenesis (18) 
• Gonadotropin releasing hormone receptor pathway (17) 
• Inflammation mediated by chemokine and cytokine signaling pathway (15) 
• Endothelin signaling pathway (12) 
• Huntington disease (11) 
• VEGF signaling pathway (11)  
• Wnt signaling pathway (10) and 
• EGF receptor signaling pathway (10).  
Appendix 18 lists all the pathways along with the percentage of the targets included in each 
pathway, for example 21.8% of the targets of Dan shen were associated with the Apoptosis 
signaling pathway. 
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2) Results for Xi shu (Camptotheca acuminata) 
143 targets were identified by HIT for Xi shu, of which 136 were suitable for analysis in 
PANTHER. These returned the following main results for protein class, in descending 
frequency of hits: nucleic acid binding (27), transcription factor (26), signaling molecule (25), 
receptor (24), transferase (20), hydrolase (20), enzyme modulator (18), oxidoreductase (16), 
kinase (14), protease (13) and extracellular matrix protein (10).  
The main molecular functions were: binding (75), catalytic activity (61), transcription 
regulator activity (26), receptor activity (26) and enzyme regulator activity (15).  
The main Biological Processes involved were: metabolic process (87), cellular process (85), 
cell communication (68), immune system process (58), response to stimulus (48), 
developmental process (33), cell cycle (32), apoptosis (28), reproduction (17), system 
process (13), cell adhesion (11) and transport (10). 
In total 58 pathways were identified. The most frequently identified pathways, based on the 
number of targets per pathway, were as follows (see also Appendix 18):  
• Gonadotropin releasing hormone receptor pathway (22) 
• Angiogenesis (20) 
• Apoptosis signaling pathway (18) 
• Interleukin signaling pathway (18) 
• Inflammation mediated by chemokine and cytokine signaling pathway (16) 
• p53 pathway (13) 
• VEGF signaling pathway (11) 
• EGF receptor signaling pathway (10) and 
• PDGF signaling pathway (10). 
3) Results for Di huang (Rehmannia glutinosa) 
The 100 targets identified by HIT for Di huang included 95 that were suitable for PANTHER. 
The anlaysis returned the following main results for protein class in descending frequency of 
hits: signaling molecule (20), transferase (17), oxidoreductase (15), hydrolase (13) and 
receptor (12). 
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The main molecular functions were: catalytic activity (49), binding (44) and receptor activity 
(13). 
The main Biological Processes involved were: metabolic process (56), cellular process (53), 
cell communication (48), immune system process (44), response to stimulus (33), apoptosis 
(21), developmental process (16), transport (13) and cell cycle (11). 
In total 56 pathways were identified. The most frequently identified pathways, based on the 
number of targets per pathway, were as follows (see also Appendix 18): 
• Inflammation mediated by chemokine and cytokine signaling pathway (18)  
• Apoptosis signaling pathway (15) 
• Gonadotropin releasing hormone receptor pathway (15) 
• Interleukin signaling pathway (13) 
• Angiogenesis (11) 
• T cell activation (11) 
• B cell activation (9) and 
• Huntington disease (8). 
4) Results for Qing dai (Indigo naturalis) 
46 targets were identified by HIT for Qing dai, of which 43 were suitable for PANTHER 
analysis. These returned the following main results for protein class in descending frequency 
of hits: hydrolase (13), transcription factor (8), signaling molecule (6), transferase (5), 
nucleic acid binding (5) and receptor (5). 
The main molecular functions were: catalytic activity (26) and binding (18). 
The main Biological Processes involved were: metabolic process (31), cellular process (20), 
immune system process (16), cell communication (15), apoptosis (12), response to stimulus 
(11) and developmental process (10). 
In total 48 pathways were identified. The most frequently identified pathways, based on the 
number of targets per pathway, were as follows (Appendix 18): 
• Apoptosis signaling pathway (11) 
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• Angiogenesis (7) 
• Gonadotropin releasing hormone receptor pathway (7) 
• Inflammation mediated by chemokine and cytokine signaling pathway (5) 
• Huntington disease (5) 
• PDGF signaling pathway (5) 
• Interleukin signaling pathway (4) and 
• FAS signaling pathway (4). 
5) Results for salicylic acid 
The 13 targets identified by DrugBank for salicylic acid were all suitable for PANTHER. 
They returned the following results for protein class in descending frequency of hits: 
transporter (8), transfer/carrier protein (6) and oxidoreductase (3). 
The main molecular functions were: transporter activity (9) and catalytic activity (4). 
The main Biological Processes involved were: localization (10), metabolic process (9), 
cellular process (6), multicellular organismal process (5) and immune system process (2). 
In total 3 pathways were identified. These were as follows (Appendix 18): 
• Inflammation mediated by chemokine and cytokine signaling pathway (2) 
• Endothelin signaling pathway (1) and 
• Toll receptor signaling pathway (1). 
6) Results for etanercept 
The 11 targets identified by DrugBank for etanercept were suitable to PANTHER. They 
returned the following results for protein class in descending frequency of hits: 
defense/immunity protein (10), receptor (6), cell adhesion molecule (5), extracellular matrix 
protein (3), signaling molecule (2), hydrolase (1), oxidoreductase (1), calcium-binding 
protein (1) and protease (1). 
The main molecular functions were: receptor activity (8), binding (3), structural molecule 
activity (3) and catalytic activity (2). 
The main Biological Processes involved were: immune system process (13), cellular process 
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(12), response to stimulus (12), developmental process (6), cellular component organization 
or biogenesis (3), apoptotic process (3), biological adhesion (3), metabolic process (2), 
reproduction (1) and biological regulation (1). 
In total 5 pathways were identified. These were as follows (Appendix 18): 
• Apoptosis signaling pathway (3) 
• Inflammation mediated by chemokine and cytokine signaling pathway (2) 
• Wnt signaling pathway (1) 
• Endothelin signaling pathway (1) and 
• Toll receptor signaling pathway (1). 
8.3.4.2 Main pathways identified for the four herbs 
The following four pathways were the most frequently identified pathways for Dan shen and 
Qing dai and they appeared in the top ten most frequently identified pathways in each of the 
four herbs:  
• Inflammation mediated by chemokine and cytokine signaling pathway,  
• Gonadotropin releasing hormone receptor pathway, 
• Apoptosis signaling pathway, and  
• Angiogenesis. 
Interleukin signaling pathway appeared on the short list for three of the herbs (Xi shu, Qing 
dai and Di huang) and was lower on the list for Dan shen.  
One of these four pathways, Inflammation mediated by chemokine and cytokine signaling 
pathway, appeared on the short list for all the four herbs and the two APPs. Apoptosis 
signaling pathway appeared for all four herbs and for etanercept but not for salicylic acid.  
Conversely, Endothelin signaling pathway and Toll receptor signaling pathway appeared for 
both APPs. For the herbs, Endothelin signaling pathway was prominent for Dan shen. It did 
not appear on the short lists above for the other herbs but this pathway was present on the 
longer lists for Di huang, Xi shu and Qing dai. Similarly, Toll receptor signaling pathway 
appeared on the longer lists of pathways for Dan shen, Xi shu, Di huang and Qing dai. There 
was a similar result for the Wnt signaling pathway which appeared on the longer pathways 
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lists for all four herbs. 
The following results are for the four most frequently identified pathways above plus the 
Interleukin signaling pathway. For each pathway, the targets that were common to multiple 
herbs are reported. Following this, the targets known to be relevant to psoriasis and/or 
inflammation, proliferation and angiogensis are short-listed in tabular format together with 
the associated herbs and compounds. 
1) Inflammation 
The Inflammation mediated by chemokine and cytokine signaling pathway involved 58 
proteins in PANTHER with no repetitions due to the accession number issues identified 
below, rather, proteins tended to be grouped into families thereby underestimating the total 
number of proteins involved. The herb Di huang was associated with 17 targets, Xi shu with 
16, Dan shen with 14 and Qing dai was associated with 8 protein targets. The targets that 
were associated with all four herbs were AP-1 [activator protein-1] aka c-Jun, EMC 
[ExtraCellular matrix protein], p65 aka NFkappaB, and PKC family. The following targets 
were each associated with three of the herbs: AKT, CHK [Chemokine aka C-C motif 
chemokine family], COX [Cyclooxygenase], IkappaB [Inhibitor of kappa light chain gene 
enhancer in B cells], Lipoxygenase [Arachidonate 5-lipoxygenase], MAPK 
[Mitogen-activated protein kinase family], PTEN [Phosphatase and tensin homologue] and 
STAT [Signal transducer and activator of transcription family]. INFgamma [Interferon 
gamma] was a target of Qing dai and Xi shu while IL2 [Interleukin-2] was identified for Di 
huang and Xi shu, as was IKK [Inhibitor of kappa-B kinase]. 
2) Gonadotropin releasing hormone receptor 
The Gonadotropin releasing hormone receptor pathway is particularly complex and involves 
216 protein components in PANTHER. It should be noted that this number is somewhat 
inflated since it is based on PANTHER accession numbers and what is basically the same 
protein or protein family can appear under different accession numbers. This phenomenon 
also occurs in the other pathways but it is comparatively infrequent. The herb Xi shu was 
associated with 31 proteins, Dan shen with 25, Di huang with 18 and Qing dai was 
associated with 14. The following proteins were associated with all four herbs: TGFbeta 
[Transforming growth factor beta], PKCs, p65 and Junc aka c-Jun [Transcription factor 
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AP-1]. The following proteins were each associated with three of the herbs: AKT, c-fos, 
COX2, ERK1/2 [Mitogen-activated protein kinase 1/3], FOS, JNK1/2 [Mitogen-activated 
protein kinase 1/2] and PPARalpha/gamma [Peroxisome proliferator-activated receptor 
alpha/gamma]. It should be noted that while TGFbeta appeared in this pathway, it is also 
associated with proliferation and is also located in a separate TGF-beta signaling pathway in 
PANTHER. Similarly, EGF [Pro-epidermal growth factor] and EGFR [Epidermal growth 
factor receptor] are targets of Xi shu which are located in this pathway but they are also 
associated with proliferation and differentiation. None of the herbs was associated with 
GnRHR [Gonadotropin-releasing hormone receptor], FSHbeta [Follitropin subunit beta] 
LHbeta [Luteinizing hormone beta] or GR [Glucocorticoid receptor]. 
3) Apoptosis 
The Apoptosis signaling pathway involves 72 proteins (402). Dan shen was associated with a 
total of 21 targets and Xi shu was associated with 18, Di huang with 16 and Qing dai with 12. 
The protein targets that appeared repeatedly for all the four herbs were: TNF, p65 
[NFkappaB], PKCs [Protein kinase C family], ATF [Activating transcription factor], c-Jun 
[Transcription factor AP-1], Caspases 3, 8 and 9, Bax and Bcl-2. In the case of etanercept, 
TNF was the only target identified. Protein targets identified for three of the herbs were 
IkappaB, MAPK family, AKT [RAC-alpha serine/threonine-protein kinase] and Fos 
[Proto-oncogene c-Fos]. 
4) Angiogenesis 
The Angiogenesis pathway included 77 components in PANTHER. The herb Xi shu was 
associated with 16 of the protein targets in the pathway, the herb Dan shen was associated 
with 14 targets, Di huang with 10 targets and Qing dai was associated with 6 targets. The 
proteins identified for all four herbs were PKC [Protein kinase C family], c-Jun, and Caspase 
9 all of which were common to the Apoptosis signaling pathway. Proteins identified for three 
herbs included AKT, c-Fos [c-Fos Transcription Factor], eNOS, and Erk [Extracellular 
regulated kinase]. The protein VEGF was identified for Dan shen and Xi shu and its receptor 
VEGFR-2 was located for Dan shen. Other proteins that are typical of angiogenesis, such as 
Ang-1 and 2 [Angiopoietin-1, 2], PDGF [Platelet-Derived Growth Factor] and FGF 
[Fibroblast Growth Factor] returned no results. It should be noted that the Wnt signaling 
pathway in PANTHER shares many proteins with the Angiogenesis pathway including: Wnt 
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[Wingless-type MMTV integration site family member], Fzd [Frizzled], Dsh [Dishelvelled], 
Axin, APC [Adenomatous polyposis coli protein], and GSK3 [Glycogen synthase kinase 3], 
all of which are involved in signal transduction through the cell wall. Of these proteins, 
results were returned for GSK3 alone which was associated with Xi shi and Qing dai. 
5) Interleukins 
The Interleukin signaling pathway involves 36 components in PANTHER. None of these 
were known targets of the two APPs. For the herbs, Xi shu was known to target 11 
components, Dan shen targeted 8 components, Di huang targeted 7, while Qing dai targeted 
4 components. All herbs targeted at least some interleukins which were all grouped together 
in PANTHER so this tended to underestimate the number of proteins included in this 
pathway. The interleukins associated with the herbs including IL-1A, IL-1B, IL-2, IL-4, IL-6, 
IL-8, and IL-10, with IL-6 and IL-10 being the most common. The proteins associated with 
three herbs included: ERK, c-fos, PKB [Protein kinase B], eNOS, p21CIP1 
[Cyclin-dependent kinase inhibitor 1A] and STAT family. The STAT family proteins were 
targeted by Dan shen, Xi shu and Di huang. The same three herbs also targeted p21, p21CIP1, 
eNOS and PKB. Xi shu and Di huang also targeted IKK. 
6) Targets not included in the above five pathways 
Some of the frequently identified targets of the herbs did not appear in the above five 
pathways. These included CCNDI [G1/S-specific cyclin-D1] which is involved in Cell-cycle 
and appears in multiple pathways in PANTHER including Cell cycle and Wnt signaling 
pathway. CRP [C-reactive protein] which is involved in inflammatory processes and was 
associated with 12 pathways in PANTHER including the Endothelin signaling pathway but 
not with any of the five pathways discussed above.  
ICAM1 [intercellular adhesion molecule 1], which is part of the immunoglobulin 
superfamily and is involved in immune response and inflammation, appeared as a frequent 
target for Dan shen, Ku shen and Bai hua she she cao but it did not locate any pathway in 
PANTHER. In KEGG, ICAM1 is located in the NF-kappaB signaling pathway and 
associated with lymphocyte adhesion and T-cell costimulation and is also in the TNF 
signaling pathway where it is associated with cell adhesion (403, 404).  
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8.3.4.3 Main pathways identified for the two APPs 
Although etanercept and salicylic acid are not from the same class of drug, the three 
pathways identified for salicylic acid were also identified for etanercept. In the case of 
salicylic acid, the three pathways were all identified based on the involvement of its target 
COX 2, whereas another target COX 1 was only involved in the Inflammation mediated by 
chemokine and cytokine signaling pathway in PANTHER. No pathways were identified for 
any of the other targets identified in DrugBank. For etanercept, COX 2 is a target, so it 
identified the same three pathways. The main target, TNF is involved in the Apoptosis 
signaling pathway and in the Toll receptor and Wnt signaling pathways. Of the other targets 
identified by DrugBank, Lymphotoxin-alpha and Tumour necrosis factor receptor 
superfamily member 1B are both from the TNF family and are associated with the Apoptosis 
signaling pathway in PANTHER. Hence, three targets were primarily responsible for the 
PANTHER pathway results for these two APPs. 
8.4 Summary and discussion of results 
8.4.1 Targets of the herbs  
The database searches identified numerous targets for the compounds included in the 12 
herbs. In some cases, these targets had been investigated by the experiments discussed in 
Chapter 7 but in other cases the results found in this chapter were additional. The following 
targets show potential relevance to psoriasis for the main herbs. 
In the case of Bai hua she she cao (Oldenlandia diffusa), many of the targets identified via 
HIT were also identified in Chapter 7 based on the searches of experimental studies. Most 
targets were associated with ursolic acid. Targets relating to apoptosis included Bax 
protein/Bcl-2, TNF, p21, and caspases 3 and 9 (393, 405-407). Targets associated with 
inflammation included COX-2, TNF, and Interleukin 6 (381, 391, 408). Targets such as 
iNOS and NF-kappa-B are involved in multiple processes including inflammation (381, 
408). 
For Di huang (Rehmannia glutinosa), targets identified in both chapters 7 and 8 included 
those related to inflammation including IL6, COX1 & 2, TNF-alpa, NFkappa B and PGE2. 
Chapter 7 targets tended to focus on inflammation with involvement of IL6 as well as RAGE 
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(aka AGER). Chapter 8 identified multiple interleukins (IL2, 4, 5, 6, 8, 10) and also targets 
associated with apoptosis including Caspases 3, 8 & 9, TNF, Bax and Bcl-2 (393, 406-408). 
The targets identified in Chapter 7 for Dan shen (Salvia miltiorrhiza) were mostly concerned 
with apoptosis and proliferation. These included Caspases 3, 8, 9, Apoptosis regulator BAX, 
TNF, ERK2 and PARP. Inflammation related targets included IL1b, IL6, NF kappa B and 
TNF alpha. In addition, p38 is thought to be related to stress. In the broader search in 
Chapter 8, similar results were found but numerous additional targets of the compounds 
found in Dan shen were also identified. These included COX 1 & 2 for inflammation, 
VEGF-A for angiogenesis, targets related to vascular function, including endothelin-1 and 
ACTA2, and targets relating to immune function such as ICAM1 and VCAM1 (408-413). 
A number of the targets that were identified for Ku shen (Sophora flavescens) in the 
experiments in chapter 7 also appeared in the Chapter 8 searches including Caspase-3, 
Interleukin-6, TNF, COX-2, NFkappaB and ICAM1. In addition, the chapter 8 searches 
located IL 4 and other targets related to inflammation and proliferation including AP-1, FOS 
and PPARG. 
The main compound in the various species used as Zi cao (Lithospermum erythrorhizon, 
Arnebia spp) was shikonin. It was the main focus of the experimental studies in chapter 7 
and returned the majority of the targets in chapter 8. In both chapters 7 and 8, targets 
associated with its actions on apoptosis included Caspase-3, TNF and Bcl-2, while the 
additional targets BBC6, AKT1 and p53 were identified in the Chapter 8 searches. Targets 
relating to inflammation that were identified in both chapters 7 and 8 included TNF, 
NF-kappa B, P53, COX 1 & 2 as well as the interleukins 1B, 6, 8, and 10. In chapter 8, 
targets relating to angiogenesis also were identified including VEGFR2 and TEK. 
The targets identified for the compounds contained in Lu hui (Aloe spp) mainly related to 
inflammation, such as the Interleukins 1beta, 6, 8 and 10, COX 2, NF kappa B and TNF. 
Others related to apoptosis including Caspase 3, TNK and Bcl-2. In addition, COL1A1 was 
associated with collagen production and tissue repair. 
For the compounds identified from the species used in the production of Qing dai (Isatis, 
Baphicacanthus and Strobilanthes spp), targets included those associated with inflammation 
such as IL4 &10, TNF and NF kappa B as well as a number of targets associated with 
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apoptosis such as Caspases 3, 8 and 9, TNF, Bax, Bcl-2, CDKN3, and with proliferation 
including AP-1, IFN gamma and PRKCA. 
The main targets of Xi shu (Camptotheca acuminata) were mostly those related to the 
actions of quercetin and camptothecin. Apoptosis related targets included Caspases 3, 8 and 9, 
TNF, Bax, Bcl-2 and Ap1. Targets related to inflammation included the Interleukins 1A/B, 2, 
6, 8, and 10, COX 1 & 2, NF kappa B and TNF. The main target relating to angiogenesis was 
VEGF-A. In addition, there were a number of targets relating to oxidative damage including 
catalase and superoxide dismutase. Other targets included those relating to DNA, notably 
TOP1 and TOP2A. 
For Gong lao mu (Mahonia spp), despite the number of species included, the targets were 
dominated by those of berberine which occurs in all the species. Apoptosis related targets 
included BAX, Bcl2, TNF, Caspases 3, 8 & 9, BID and AP-1. Targets associated with 
proliferation included CCND1, PDGFA, IFN gamma and MAPK1 while VEGF-A is 
associated with angiogenesis and PDGFA is important in wound healing. Targets relating to 
inflammation included NF kappa B, NFKBIA, COX-2, Interleukins 4, 6 & 8 and TNF. 
Overall, targets relating to inflammation and apoptosis tended to dominate the results. To 
what extent this indicates that the herbs are focused on these processes is difficult to 
determine. It is likely that the commonly found targets reflect the focus of past researches 
into these herbs. Since much natural products research is concerned with cancers and with 
chronic inflammation, targets assocated with these types of disease are likely to have high 
frequencies in data sets. 
8.4.2 Targets of the herbs and APPS  
Twelve APPs shared targets with the herbs and 11 of the 12 herbs shared at least one target 
with the APPs. It should be noted that acetretin did not share any targets with the herbs. Of 
the ten shared targets, the following were of most relevance to psoriasis therapy: COX 1 & 2 
and TNF. The Cytochrome P 450 members 1A1, 1A2 and 3A4 appear to mainly be relevant 
to the potential for interactions between the herbs and APPs (391, 398, 399, 414, 415). 
COX 1 and/or COX 2 were inhibited by compounds contained in the following 8 herbs: Bai 
hua she she cao, Di huang, Dan shen, Lu hui, Xi shu, Gong lao mu, Ku shen and Zi cao. This 
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indicated that these herbs had potential anti-inflammatory actions via COX 1 and/or 2. TNF 
was inhibited by compounds found in Bai hua she she cao, Di huang, Dan shen, Lu hui, Qing 
dai, Xi shu, Gong lao mu, Ku shen and Zi cao. Therefore each of these may exert an effect 
on TNF that could result in inhibition of the inflammatory and/or proliferative processes in 
which TNF is involved. 
Since these herbs shared therapeutic targets with the APPs etanercept, golimumab and/or 
salicylic acid, they were considered to have APP-like actions. 
8.4.3 Main pathways and proteins 
The following four pathways were the top four pathways for Dan shen and Qing dai and they 
appeared in the top ten most frequently identified pathways in each of the four herbs: 
Apoptosis signaling pathway, Angiogenesis, Gonadotropin releasing hormone receptor 
pathway, and Inflammation mediated by chemokine and cytokine signaling pathway (Table 
8.3-8.7). 
The first of these pathways was also notable for the APP etanercept while both etanercept 
and salicylic acid had targets that were included in the Inflammation mediated by chemokine 
and cytokine signaling pathway. 
It was not practicable to discuss each of the targets identified in each of the four pathways. 
Therefore, for the purpose of discussion, the main targets were selected based on being 
identified for multiple herbs and being known to be involved in processes of direct relevence 
to psoriaisis.  
It is important to note that these targets have not necessarily been investgated in the context 
of psoriasis. They are ‘main’ in the sense of the database results and having received research 
attention. It is possible that the actual clinical effects reported for the herbs may have been 
due to effects on other less-studied targets and these may have been exerted by less-studied 
compounds and/or by compounds that do not as-yet appear in the databases.  
The main targets are tabulated below for each of the four pathways together with the 
compounds that have been reported to act upon these targets. Since the same target may 
appear in multiple pathways, these are not discussed in each instance. 
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Table 8.3 Apoptosis pathway: main targets of the four herbs 
Target Herb Compound & its regulating effect on the target 
Bax Dan shen/丹参 Ursolic acid↑ 
Qing dai/青黛 Lupeol↑, β-Sitosterol↑/↓ 
Xi shu/喜树 Hyperin↓, Quercetin↑/↓ 
Bcl-2 Dan shen/丹参 Salvianolic acid A↓, Tanshinone IIa↓ 
Qing dai/青黛 Hexadecanoic acid↓, Lupeol↓, β-Sitosterol↓ 
Xi shu/喜树 Quercetin↑/↓ 
Caspase 3 Di huang/地黄  Catalpol↓, Cinnamic acid↓, Stigmasterol↑, Succinic acid↑/↓ 
Dan shen/丹参 Dihydrotanshinone I↑, Lithospermic acid B↓, Salvianolic acid A
↑/B↓, Tanshinone IIa↓, Ursolic acid↑/↓ 
Qing dai/青黛 Lupeol↑, Tryptanthrine↑, β-Sitosterol↑ 
Xi shu/喜树 Hyperin↓, Quercetin↑/↓ 
Caspase 8 Di huang/地黄  Stigmasterol↑ 
Dan shen/丹参 Ursolic acid↑ 
Qing dai/青黛 β-Sitosterol↑ 
Xi shu/喜树 Quercetin↑ 
Caspase 9 Di huang/地黄  Stigmasterol↑ 
Dan shen/丹参 Dihydrotanshinone I↑, Ursolic acid↑ 
Qing dai/青黛 Lupeol↑, β-Sitosterol↑ 
Xi shu/喜树 Quercetin↑ 
Ikk Di huang/地黄  Cinnamic acid↓ 
Xi shu/喜树 Quercetin↓ 
NFkappaB/p65 Di huang/地黄  Aucubin↓, Cinnamic acid↓, Hexadecanoic acid↓, Lauric acid↑ 
Dan shen/丹参 Cryptotanshinone↓, Danshensu↓, Lithospermic acid B↓, 
Salvianolic acid B↓, Tanshinone IIa↓, Ursolic acid↑/↓ 
Qing dai/青黛 Salicylic acid↓ 
Xi shu/喜树 Quercetin↓ 
TNF Di huang/地黄  Aucubin↓, Cinnamic acid↓, Hexadecanoic acid↑ 
Dan shen/丹参 Caffeic acid↓, Cryptotanshinone↓, Ursolic acid↑/↓ 
Qing dai/青黛 Hexadecanoic acid↑ 
Xi shu/喜树 Quercetin↓ 
Bcl-2 family members regulate the permeability of the mitochondrial membrane and play 
key roles in cell survival and death (416). It has been reported that the pro-apoptotic protein 
Bax is underexpressed in psoriatic skin while the anti-apoptotic protein Bcl-2 is 
over-expressed (406, 417). Increased levels of Tumour protein p53 (p53) were also reported 
(417). Experimental studies on cancer cell-lines have shown that ursolic acid down-regulated 
the expression of Bcl-2 and Bcl-xL (418), increased Bax expression while decreasing Bcl-2 
expression, activated Caspase-3 (256) and also down-regulated NF-kappaB (419). Quercetin 
was reported to increase Bax expression and induce apoptosis (420, 421), and also increase 
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expression of Bax and caspase-3 (421).  
Besides these up-regulating effects on effector caspases such as Caspase 3, a number of 
compounds can have more up-stream effects on initiator caspases including Caspases 8 and 9. 
Choi et al 2000 reported that ursolic acid activated Caspase -1, -3, -8 and -9 (422) while in 
human colon cancer cells a dose dependent activation of Caspases 3, 8 and 9 was associated 
with reduced proliferation (423). Kim et al 2011 found that ursolic acid acted via both the 
mitochondrial death pathway (via Bcl-2) and the extrinsic death receptor pathway (via Fas, 
caspase 8, caspase 3 & PARP) (424). 
NFkappaB is important in cell survival and its overactivity is associated with cell 
proliferation (425). In the classical IKK/NFkappaB signalling pathway, proinflammatory 
cytokines, including TNF-alpha and IL-1 beta, activate the Ikk complex resulting in 
NFkappaB release to the nucleus and the transcription of diverse genes which can suppress 
apoptosis. Hence the inhibition of NFkappaB activation has been strategy for reducing 
tumour growth (425, 426). However, the roles of NFkappaB are complex and it can also have 
a role in cell death via other pathways that involve cross-talk wth JNK (425).  
Priyadarsini and Nagini (2012) investigated the effect of quercetin on reactive oxygen 
species (ROS) and NFkappaB in a hamster buccal pouch carcinogenesis model and reported 
that quercetin attenuated ROS generation which abrogated NFκB signalling by preventing 
phosphorylation and degradation of IκB, translocation of NFκB to the nucleus and consequent 
activation of target genes associated with proliferation and apoptosis evasion (427). 
A number of the compounds known to be contained in the herbs have shown down 
regulating effects on TNF (such as quercetin, ursolic acid, cinnamic acid), NF-κB (such as 
quercetin, ursolic acid, cinnamic acid), and IKK (such as quercetin, cinnamic acid). However, 
these results are mainly based on cancer cell-lines. In the blood of healthy volunteers, 
quercetin dose-dependently inhibited in vitro lipopolysaccharide (LPS)-induced TNF-alpha 
production but it had no anti-inflammatory effect on normal blood (428).  
In psoriasis, 10 weeks treatment with the TNF inhibitor etanercept produced a reduction in 
NF-κB, Bcl-2 and Bcl-xL expression in endothelial cells during treatment. This was 
associated with a positive clinical response in terms of PASI reduction (429). It is plausible 
that some of the above-mentioned natural compounds may be exerting pro-apoptotic actions 
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similar to those of etanercept in psoriasis. 
Table 8.4 Angiogenesis pathway: main targets of the four herbs 
Target Herb Compound & its regulated effect 
Caspase 9 Di huang/地黄  Stigmasterol↑ 
Dan shen/丹参 Dihydrotanshinone I↑, Ursolic acid↑ 
Qing dai/青黛 Lupeol↑, β-Sitosterol↑ 
Xi shu/喜树 Quercetin↑ 
VEGF Dan shen/丹参 Lithospermic acid B↓, Salvianolic acid B↑/↓, Tanshinone I↓, 
Ursolic acid↑/↓ 
Xi shu/喜树 Quercetin↑/↓ 
While VEGF is one of the primary growth factors that induces angiogenesis, the 
pro-apoptotic Caspase 9 has been shown to be an inhibitor, and increasing its expression has 
been employed as an anti-angiogeneic strategy (430). All four of the herbs contain 
compounds that have been reported to up-regulate Caspase 9. 
APPs including infliximab and methotrexate have been reported to reduce angiogenesis and 
cell infiltration in psoriaisis and Avramidis et al (2010) reported that etanercept therapy 
reduced angiogenesis in the endothelial cells of psoriasis patients and reduced expression of 
VEGF (429). A number of the compounds contained in the herbs have been reported to 
inhibit VEGF including ursolic acid, salvianolic acid B and quercetin. Cao et al 2014 
reported that in melanoma cells quercetin inhibited STAT 3 actividation which had a 
down-regulating effect on VEGF (431). Pratheeshkumar et al 2012 reported that quercetin 
inhibited microvessel sprouting, proliferation, migration, invasion and tube formation of 
endothelial cells in a rat aortic ring assay when used at non-toxic concentrations and that it 
suppressed VEGF induced phosphorylation of VEGF receptor 2 and their downstream 
protein kinases AKT and mTOR (432).  
In the case of salvianolic acid B, there are reports of VEGF inhibition in U937 histiocytic 
lymphoma cells (433) but recent studies have focused on its role in cardiovascular disease. In 
cardiac fibroblasts, Wang et al 2011 investigated the effects of salvianolic acid B on cardiac 
remodeling and reported a down-regulatory effect on VEGF via MMP-9 (434). In each of 
these cases, the down-regulatory effects reported on VEGF involved upstream mechanisms 
rather than direct inhibition. 
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Table 8.5 Inflammation mediated by chemokine and cytokine signaling pathway: main 
targets of the four herbs 
Target Herb Compound & its regulated effect 
COX 1 Di huang/地黄  Cinnamic acid↓ 
Dan shen/丹参 Cinnamic acid↓, Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
COX 2 Di huang/地黄  Cinnamic acid↓, Hexadecanoic acid↓, Lauric acid↑ 
Dan shen/丹参 Caffeic acid↓, Lithospermic acid B↓, Salvianolic acid B↓, 
Tigogenin↑, Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
Ikk Di huang/地黄  Cinnamic acid↓ 
Xi shu/喜树 Quercetin↓ 
INF gamma Qing dai/青黛 Indirubin↓ 
Xi shu/喜树 Quercetin↓ 
NFkappaB/p65 Di huang/地黄  Aucubin↓, Cinnamic acid↓, Hexadecanoic acid↓, Lauric acid↑ 
Dan shen/丹参 Cryptotanshinone↓, Danshensu↓, Lithospermic acid B↓, 
Salvianolic acid B↓, Tanshinone IIa↓, Ursolic acid↑/↓ 
Qing dai/青黛 Salicylic acid↓ 
Xi shu/喜树 Quercetin↓ 
STAT Di huang/地黄  Cinnamic acid↓ 
Dan shen/丹参 Cryptotanshinone↓, Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
The Inflammation mediated by chemokine and cytokine signaling pathway in PANTHER 
illustrates chemokine-induced adhesion and migration of leukocytes, which infiltrate to the 
tissue and the transcriptional activation which enables the recruitment of more leukocytes. 
From the therapeutic perspective, inhibition of specific chemokines and receptors within this 
pathway could prevent the excessive recruitment of leukocytes to sites of inflammation 
(402). 
The cyclooxygenases Cox 1 and Cox 2 are targets of non-steroidal anti-inflammatory drugs 
including asprin and of a variety of natural products (208, 435). Hao et al 2009 investigated 
the actions of salvianolic acid B on neck squamous cell carcinoma models and found that it 
inhibited growth of tumour xenografts and reduced COX-2 expression (436). Kowalczyk et 
al 2013 investigated the effects of ursolic acid and other compounds in a skin carcinogenesis 
model in SENCAR mice. They reported that ursolic acid inhibited epidermal hyperplasia, 
reversed COX-2 mRNA levels and decreased IL-6 expression (437). 
NFkappaB is involved in multiple signaling pathways including those associated with 
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inflammation, and the aberrant regulation of NFκB is involved in cancer development. NFκB 
is also involved in regulation of COX-2 and iNOS expression. Numerous natural products 
have been reported to inhibit NFkappaB (438). Quercetin has been reported to reduce the 
transcriptional activity of NFκB in human hepatocytes (439) and in primary human 
keratinocytes it suppressed lipopolysaccharide (LPS) induced NFkappaB activation (440). 
In an ethanol induced oxidative stress rat model, the addition of quercetin decreased plasma 
levels of the pro-inflammatory cytokines TNF-alpha and INF-gamma and reduced ALT 
levels indicating anti-inflammatory and liver protective effects (441). 
Table 8.6 Interleukin signaling pathway: main targets of the four herbs 
Target Herb Compound & its regulated effect 
Ikk Di huang/地黄  Cinnamic acid↓ 
Xi shu/喜树 Quercetin↓ 
IL-1 Dan shen/丹参 Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
IL-6 Di huang/地黄  Hexadecanoic acid↑,Aucubin↓, Lauric acid↑,γ-Aminobutyric acid↓ 
Dan shen/丹参 Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
IL-10 Di huang/地黄  Hexadecanoic acid↑  
Qing dai/青黛 Hexadecanoic acid↑ 
Xi shu/喜树 Quercetin↑/↓ 
STAT Di huang/地黄  Cinnamic acid↓ 
Dan shen/丹参 Cryptotanshinone↓, Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
Interleukins are cytokines that are secreted by some leukocytes and can act upon other 
leukocytes. The Interleukin signaling pathway in PANTHER describes how they can mediate 
different biological responses via activation of a combination of different signal transduction 
pathways, including the Jak-STAT, ERK, and PI3K-PKB pathways (402).  
The IL-1 family has proinflammatory effects while IL-10 is an anti-inflammatory cytokine 
and IL-6 can have both pro- and anti-inflammatory effects. In B16F-10 melanoma cells, 
treatment with ursolic acid was found to down regulate gene expression of TNF-alpha, 
IL-1beta and IL-6 and to promote Caspase-3 mediated apoptosis (442). In diabetes mellitus 
model, quercetin reduced IL-1 beta-induced nitrite production, iNOS protein and also 
inhibited NF-κB activation but these effects were not found for its metabolites (443).  
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IL-10 inhibits synthesis of IL-1, IL-1b, TNF-a, IL-6 and IL-8 and can suppress the 
inflammatory response. In a reperfusion injury model in rats, quercetin treatment improved 
protection and increased the levels of both TNF-alpha and IL-10 (444).  
A cell-based screen using hepatoma HepG2 cells found that quercetin can activate the 
JAK/STAT pathway (445). In a recent study of quercetin in cholangiocarcinoma (CCA) cells, 
activation of the JAK/STAT pathway by IL-6 and Interferon-gamma, was suppressed by 
pre-treatment with quercetin and the effects involved STAT1 and STAT3 (446). In 
diabetes-induced glomerular hypertrophy in mice, low dose ursolic acid markedly 
ameliorated deteriation and its actions were identified as via suppression of diabetes-induced 
activations of STAT-3, ERK1/2 and JNK pathways (447). 
Table 8.7 Gonadotropin releasing hormone receptor pathway: main targets of the four 
herbs 
Target Herb Compound & its regulated effect 
COX 2 Di huang/地黄  Cinnamic acid↓, Hexadecanoic acid↓, Lauric acid↑ 
Dan shen/丹参 Caffeic acid↓, Lithospermic acid B↓, Salvianolic acid B↓, 
Tigogenin↑, Ursolic acid↓ 
Xi shu/喜树 Quercetin↓ 
NFkappaB/p65 Di huang/地黄  Aucubin↓, Cinnamic acid↓, Hexadecanoic acid↓, Lauric acid↑ 
Dan shen/丹参 Cryptotanshinone↓, Danshensu↓, Lithospermic acid B↓, 
Salvianolic acid B↓, Tanshinone IIa↓, Ursolic acid↑/↓ 
Qing dai/青黛 Salicylic acid↓ 
Xi shu/喜树 Quercetin↓ 
PPARalpha/gamma Di huang/地黄  Caprylic acid↑ 
Xi shu/喜树 Quercetin↓ 
The above components of the Gonadotropin releasing hormone receptor pathway are all 
involved in multiple pathways. Cox 2 and NFkappaB were mentioned above.  
The peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that 
function as transcription factors and regulate the expression of genes. PPAR alpha is 
involved in skin homeostasis, the control of keratinocyte proliferation and differentiation. It 
contributes to wound healing and regulates skin inflammation. Its expression decreases in 
inflamed skin and PPAR-alpha activation has been reported to to reduce experimental skin 
inflammation. In wound healing, PPAR-alpha expression is upregulated in the keratinocytes 
at the edge of the wounded skin but then declines. Studies have suggested that PPAR-alpha 
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function may be altered in psoriasis (448). A recent micro-array analysis of psoriatic skin, 
found that PPAR-alpha was lower in lesional skin versus healthy skin (449). 
A gene reporter assay found that quercetin inhibited the activation of PPAR-alpha, -beta and 
–gamma (450). Mulberry leaf-related extracts rich in quercetin were studied in human aortic 
endothelial cells and found to reduce expression of NFkappaB and activator protein (AP)-1, 
as well as increase PPAR-alpha and -gamma DNA binding (451). 
Overall, many of studies that were included in HIT and many of the subsequent studies 
referred to above were not directly related to psoriasis and most were not focussed on the 
short-listed herbs but on specific compounds such as quercetin and ursolic acid which can 
also be contained in a variety of other plants. Therefore, the database results cannot provide 
definitive indications of how the herbs might act on the various pathways, rather, they 
provide clues as to how the compounds contained in the herbs may act singly and in 
combinations, thereby these results can assist in the planning of studies that focus more 
directly on psoriasis and its associated processes. 
8.4.4 Comparison with results of other studies of targets in psoriasis using in silico 
methods 
In order to investigate the mechanisms of psoriasis, Lu et al 2013 employed DNA 
micro-arrays and in silico methods to analyse multiple transcription factors. Skin biopsy 
samples from 21 normal healthy donors and 33 patients with plaque type psoriasis were used 
to create the micro-array. Differentially expressed genes (DEGs) were identified and those 
with significant fold changes were included in the in silico analysis. Data were obtained 
from the TRANSFAC database (www.gene-regulation.com) and the Transcriptional 
Regulatory Element Database (TRED) to determine the relationships between genes and 
transcription factors, and pathways were identified using KEGG. They located large 
numbers of KEGG pathways including Leukocyte transendothelial migration, Cell adhesion 
molecules, PPAR signaling pathway, Cell cycle, Toll-like receptor (TLR) signaling pathway 
and steroid hormone biosynthesis. Transcription factors noted as significant by the authors 
included Jun proto-oncogene (JUN, c-Jun), Signal transducer and activator of transcription 1 
(STAT1) and NF-kappaB (452).  
Since PANTHER was used in this study rather than KEGG, there is no one-to-one 
correspondence between pathways. While Cell cycle and TLR were not pathways at the top 
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of the frequency lists in this project, TLR was identified as relevant to all the 4 herbs with 
Cell cycle appearing for Di huang, Xi shu and Dan shen (see Appendix 18). Of the targets, 
NF-kappaB was a target of Di huang, Xi shu, Qing dai and Dan shen, the STATs were targets 
of Di huang, Xi shu and Dan shen with STAT1 being located for Di huang in the 
Angiogenesis pathway in PANTHER. All four of the herbs in the pathway analysis showed 
hits for c-Jun and it’s associate Transcription factor AP-1. In the PANTHER analysis, c-Jun 
was associated with the Apoptosis and Angiogenesis pathways but AP-1 was related to the 
Inflammation pathway. 
Lu et al 2014 analysed the urine of psoriaisis sufferers who were being successfully treated 
with Optimized Yinxieling formula, which comprised seven herbs, using High Performance 
Liquid Chromatography (HPLC) and Mass spectrometry and compared the results with 
those from normal subjects. They used in silico metabolomics to identify potential 
biomarkers and protein targets. Nine targets were reported: Peptidyl-prolyl cis-trans 
isomerase A (PPIA), MAP kinase p38 (MAPK12), Cytosolic phospholipase A2 (PLA2), 
Integrin alpha-L (LFA-1), Integrin beta-3 (ITGB3), E selectin, 92 kDa type IV collagenase 
(MMP-9), Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A), and 
Purine nucleoside phosphorylase (PNP) (378). Only the herb Zi cao was common to 
Optimized Yinxieling formula and to our list of 12 herbs.  
These proteins were not high frequency items in our search. We retrieved results for other 
other MAPKs but not for MAPK12. In PANTHER this protein was located in 12 pathways 
including Gonadotropin-releasing hormone receptor pathway. PLA2 is included in three of 
our frequently located pathways, Angiogenesis, Inflammation mediated by chemokine and 
cytokine signaling pathway, and Gonadotropin-releasing hormone receptor pathway but 
there were no hits for the 12 herbs. Low affinity immunoglobulin gamma Fc region receptor 
II-a (FCGR2A) is one of the targets of etanercept in DrugBank but its actions are ‘unknown’, 
no pathway was located in PANTHER and no herbs were located in HIT. Results were, 
however, returned for E-selectin which is listed in HIT as a target of ursolic acid, quercetin 
and vitamin E which are components of the short-listed herbs Bai hua she she cao, Dan shen, 
Xi shu and Lu hui. Integrin beta-3 (ITGB3) was a target of tanshinone IIa in Dan shen and is 
located in the Inflammation mediated by chemokine and cytokine signaling pathway. 92 kDa 
type IV collagenase [aka Matrix metalloproteinase-9] (MMP-9) is a target of ursolic acid, 
tanshinone IIa, quercetin, apigenin, emodin and rottlerin (in Bai hua she she cao, Dan shen, 
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Xi shu, Lu hui) and is located in the Alzheimer disease-presenilin pathway and the 
Plasminogen activating cascade in PANTHER.  
Although there was only one herb in common between the formula used by Lu et al 2014 
and our list, there were still some commonalities between the targets found in both analyses. 
Notable were targets relating to inflammation and compounds contained in the herbs Bai hua 
she she cao, Dan shen, Xi shu and Lu hui. No results were returned for Zi cao which is a 
herb commonly used in psoriaisis. Considering the considerable differences between the 
study by Lu et al and this study, similar results could hardly be expected. What this 
comparison does illustrate is the potential for target level analysis to be used to explore the 
possible effects of combinations of herbs that are used in clinical settings.  
For the herb Sheng di huang (Rehmannia glutinosa), Jiang et al 2013 undertook an in silico 
analysis of the molecular network of genes that are related to psoriasis using a number of 
sources and databases to identify the active compounds in the herb and their targets (using 
http://pubchem.ncbi.nlm.nih.gov/) as well the genes of relevance to psoriasis (using 
http://www.ncbi.nlm.nih.gov/gene). This data was analysed in IPA (Ingenuity Pathway 
Analysis). The authors reported that the following protein targets were common to both the 
herb and psoriasis: Tumor protein p53 (TP53 aka p53), NF-kappaB, TNF and Matrix 
metalloproteinase-1 & 2 (MMP1 & 2). They identified the NF-kappaB signaling pathway as 
common to psoriasis and the herb sheng di huang. Glycogen synthase kinase 3-beta (GSK3B 
aka GSK3beta) was identified as the primary target via which the herb acts upon the 
NF-kappaB signaling pathway (376). 
Di huang was one of the 4 herbs for which the pathways were investigated in the present 
study. HIT did not identify p53 as a target of Di huang although it was found for a number of 
the other herbs (including Zi cao, Xi shu, Dan shen) but NF-kappaB and TNF were 
identified as targets of Di huang as well as targets of other herbs. Neither MMP1 nor MMP1 
were identified as targets of Di huang in HIT but MMP9 was identified as a target of 
numerous herbs. GSK3 was identified as a target of Qing dai and Xi shu but not of Di huang 
and was located in the Interleukin and Gonadotropin releasing pathways in PANTHER. 
These differences in results may be due to differences in the lists of compounds identified 
for Di huang which has a complex composition as well the different databases used. These 
issues remain challenges for development of in silico methods. 
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Chapter 9: General discussion and future directions 
9.1 Summary of the project  
This project aimed to investigate the clinical effects of HMs on psoriasis vulgaris (chapters 5 
& 6) and to explore the possible actions of the herbs that showed the most promise of 
efficacy in the clinical studies (chapters 7 & 8). The following sections discuss the 
approaches used, their main findings and their limitations, as well as propose future 
directions for research and implications for practice.  
9.1.1 The approach to the analysis of clinical and experimental studies 
In order to investigate the clinical trial evidence for herbal therapies for psoriasis, a 
methodological approach was used that adopted the Cochrane collaboration methods for 
systematically reviewing the RCT literature and undertaking meta-analyses of outcome 
measures and adapted these methods to the specific features of herbal therapies that may be 
applied topically or administered orally and may be composed of a single herb or multiple 
herbs.  
This modified approach also considered which herbs appeared in multiple studies and 
undertook pooling of data on this basis where possible (see Chapters 5-6 and publications 
(135, 157-159)). This approach enabled the identification of herbs for which there was 
greater or lesser evidence of clinical efficacy. 
A safety analysis was also undertaken based on the reported adverse events. It found that 
these were mainly associated with local stimulation from the topical herbal medicine and 
tended to be tolerated (212, 214, 215, 219). When herbs showed evidence of poor safety 
profiles they were not considered as candidates for further analysis, for example Lei gong 
teng (see chapter 5).  
This approach to reviewing the clinical research literature also considered the results of 
experimental studies when framing discussions of how the HMs may act in the alleviation of 
psoriasis symptoms and signs (see chapter 7 and publications (135, 157-159)). These studies 
suggest that certain of the herbs used in the clinical trials have actions that may modify 
inflammatory processes and can affect cell proliferation. Since both of these processes are 
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involved in psoriasis, it appeared possible that a least some of the reported clinical benefits 
for the use of these HMs were due to anti-inflammatory and/or anti-proliferative effects of 
compounds contained within the plants from which the herbal medicines were made. 
By adapting the methods of the systematic review and meta-analysis of randomised 
controlled trials to the specific characteristics of herbal therapy, it was possible to arrive at 
assessments of the best available evidence for topical and oral herbal medicine use in 
psoriasis vulgaris. Moreover, by synthesising these results with those from published 
experimental studies, it was possible to identify herbs for which there was corroborating 
evidence of pharmaceutical actions that are relevant to psoriasis therapy.  
9.1.2 The selection of herbs for further analysis 
The outcomes found in the experimental studies provided indirect evidence of effects of 
relevance to psoriasis therapy (see chapter 7), but the mechanisms that underlie the 
development of psoriasis remain as-yet incompletely understood (34). In addition, most of 
the experimental studies on the HMs used in vitro and in vivo models that are not specific to 
psoriasis with many being focussed on atopic dermatitis and on cancers (see chapter 7). 
Consequently it was difficult to locate experimental evidence that was of direct relevance to 
herbal therapy for psoriasis. Nevertheless, a number of the in vivo and in vitro studies 
reported that the herbs had effects on therapeutic targets such as COX and TNF that are 
known to be relevant to conventional pharmacotherapy in psoriasis. This finding in chapter 7 
led to the exploration of other methods for further investigating the outcomes of the 
systematic reviews that focussed on therapeutic targets.  
One option was to extend the searches of the biomedical databases to focus upon specific 
therapeutic targets and specific compounds that were contained in the herbs. An alternate 
approach was to develop a method and procedures for utilizing the resources available via 
on-line databases. Considering the rising importance of on-line databases in research, the 
second option was selected (453, 454). This multi-stage in silico method is described in 
Chapter 8 along with the results of the analyses.  
This approach used clinical evidence for anti-psoriatic effects combined with acceptable 
safety and experimental evidence of at least some biological activity of relevance to 
psoriasis as the basis for selection of a short list of herbs for further work (Fig. 9.1). The 
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resultant list of 12 herbs included those that were used internally: Oldenlandia diffusa, 
Rehmannia glutinosa and Salvia miltiorrhiza; and herbs that were used topically: Aloe vera, 
Indigo naturalis, Camptotheca acuminata, Mahonia aquifolium, Sophora flavescens, 
Lithospermum erythrorhizon, Cnidium monnieri, Dictamnus dasycarpus and borneol. 
However, each of the herbs in the topical group could also be used orally in traditional 
practice so the whole group was examined together. These twelve herbs formed the 
promising candidates for further exploration of their potential ‘APP-like’ properties. 
 
Fig.9.1 Diagram of the process for selection of herbs for in silico screening based on 
analysis of clinical trials
An advantage of this approach to identifying herbs for further research is that each has 
shown an acceptable safety profile in humans combined with potential clinical efficacy. A 
limitation is the top herbs were selected principally on the basis of frequency of occurrence 
in trials, many of which used multi-herb formulae. It does not necessarily follow that the 
herb that appears more frequently in formulae for which efficacy is reported, is more 
efficacious than a herb used less frequently. The current state of the RCT data for psoriasis 
is limited so the above list of herbs cannot be considered complete as a list of herbs 
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efficacious for psoriasis or as including the most effective herbs. What the list does provide 
is the herbs for which there are multiple sources of clinical and experimental evidence. 
It should be noted that in this project frequency of occurrence was not interpreted as 
evidence of efficacy, importance or significance. Frequency was used as a broad gauge of 
confidence in the reported result since the result appears multiple times. However repetition 
of a result does not necessarily indicate the result is accurate. Frequency is also used as a 
means of limiting the search space when it is not possible to consider all the available data. 
In a more comprehensive investigation, all herbs that showed potential efficacy could be 
included. 
9.2 The in silico approach to the analyses of herbal medicines in psoriasis 
Just as the methods used for conducting systematic reviews utilise resources that are broadly 
available to researchers via online platforms, it was decided that the approach taken in this 
project to the analysis of targets should use resources that are available to a broad range of 
researchers. Moreover, the approach should be adaptable to disorders other than psoriasis. 
Hence the databases HIT, DrugBank and PANTHER were selected (386, 388-390, 402) and 
all three were used in combination (Fig.9.2).  
It needs to be noted that the method presented in this project remains under development and 
the procedures used still suffer from limitations which it is expected can be improved in 
future iterations of these methods and procedures. It should also be noted that the results for 
the pathways represent a pilot study which is based on a limited number of herbs and does 
not cover all the pathways identified. 
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Fig.9.2 Conceptual diagram of the target-directed in silico analysis
9.2.1 Identifying the targets of the herbs 
Although a number of purpose-built databases of relevance to natural products research have 
be reported in the literature (383, 455, 456), these are not all broadly available. Of the on-line 
databases examined, only HIT combined the features of herbal names, species names, 
compounds, therapeutic targets and had free access (386). Major advantages of HIT as a 
primary platform were that it is a curated database that has been updated relatively recently 
and is based on a range of resources including books and published research reports. It has 
links to other online resources including Uniprot and KEGG which can assist in identifying 
target proteins and in cross-referencing the multitudinous names and acronyms by which 
they are known. HIT also contains botanical names for plants and Chinese names in both Pin 
yin and Chinese characters which makes this database of particular relevance to Chinese 
herbal medicine research.  
As a result of conducting trial searches using HIT it became evident that the lists of 
compounds contained in particular herbs were not always complete. Consequently, when 
using a herb name as the basis for undertaking a search in HIT, certain compounds known to 
be contained in the herb were not located. For example, the herb Bai hua she she cao is 
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known to contain ursolic acid but this compound was not listed for this herb in HIT although 
the compound is listed elsewhere in HIT. To compensate for this this shortcoming, the 
recently published Encyclopaedia of TCM was used to develop more comprehensive lists of 
compounds for the herbs and these compound names were used as inputs to HIT rather than 
the herb names. While this approach resulted in a more complete identification of targets, 
this aspect of the in silico method still suffers the following limitations. A number of the 
compounds that have been identified as components in herbs are not included in HIT and 
consequently could not retrieve any targets. In addition, compounds did not necessarily 
identify all the targets that have been reported in the literature. Since this is likely to have 
been due to either the literature being excluded in the curation process or the database 
awaiting an update, there was no apparent method of remediating this shortcoming beyond 
attempting supplementary literature searches or adding other databases of herb compounds 
and targets such as CHEM-TCM [http://chemtcm.com/], and TCMGeneDIT [http:// 
http://tcm.lifescience.ntu.edu.tw/].  
Searches of HIT can return a large number of targets particularly when multiple compounds 
are entered for a single herb. Consequently, certain targets may appear repeatedly in searches 
as a result of being identified by different compounds in the same herb or by being identified 
by different species used as that herb (see Chapter 8). The 482 compounds identified 350 
biological targets. Full lists appear in Appendix 1-12. In the results for herbs in Chapter 8, 
the targets that appeared more frequently were generally considered as the main targets of 
the herb for the purposes of reporting a short list of targets but frequency of occurrence is not 
necessarily related to the therapeutic importance of the target. Therefore frequency alone was 
not the only criterion for target selection and targets of known relevance to biological 
processes of relevance to psoriasis were also retrieved. 
9.2.2 Identifying targets of relevance to psoriasis 
Since the herbs are not specific for psoriasis and are thought to have activity in multiple 
diseases, the issue of which targets are more relevant to psoriasis arose. There was also the 
issue of whether these targets were suitable for pharmacoptherapy. One option was to 
examine the literature to obtain the best evidence and expert opinion on druggable targets for 
psoriasis (34, 372, 457). This was done but in the interest of developing a more generally 
applicable method, it was decided to employ the database DrugBank to identify targets that 
were highly likely to be relevant to psoriasis (388, 390).  
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The approach taken to using DrugBank was to identify the known therapeutic targets of each 
of the APPs that had been approved for the management of psoriasis. It was reasoned that at 
least some of the targets of these drugs would be of direct relevance to psoriasis. 
Consequently, the consolidated list of targets of the APPS could be used to refine the target 
lists identified via HIT. This approach could also be used to further limit the short list of 
herbs by excluding those that shared no targets with any of the APPs.  
In general, the searches of DrugBank found relatively fewer targets of the APPs than were 
found for the herbs via HIT. A principal reason for this was most of the herbs contained 
multiple compounds whereas the APPs were single purified compounds. It is also probable 
that different criteria were used when compiling lists of targets in HIT than were used in 
DrugBank and that neither database is comprehensive. Nevertheless the following nine of the 
shortlisted herbs were found to share at least one target with an APP: Dan shen (Salvia 
miltiorrhiza, S. sinica), Di huang (Rehmannia glutinosa), Bai hua she she cao (Oldenlandia 
diffusa), Lu hui (Aloe vera, A. ferox), Qing dai (Indigo naturalis), Xi shu (Camptotheca 
acuminata), Gong lao mu (Mahonia spp), Ku shen (Sophora flavescens) and Zi cao 
(Lithospermum erythrorhizon, Arnebia spp).  
The relationship between the herbs and the APPs based on the presence or absence of targets 
in common was illustrated in Figs.8.5 and 8.6 which show that the greatest overlap between 
the herbs and APPs in terms of shared targets was for etanercept, golimumab and salicylic 
acid and this relationship held when the cytochromes were not considered. Conversely, the 
herbs Camptotheca (Xi shu) and Salvia (Dan shen) shared targets with the greatest number of 
APPs. However, having more targets in common does not equate with greater efficacy nor 
does sharing a target indicate that the herb necessarily has a similar action to the 
corresponding APP. These herbs were classified as ‘APP-like’, but this it is only from the 
viewpoint of target sharing and is not based on clinical efficacy. Also, some of the targets in 
common are of known relevance to psoriasis, others are of unclear relevance while others 
may be incidental inclusions of no relevance at all to psoriasis.  
While these results should not be over-interpreted, this approach does provide a method for 
limiting the search space when presented with numerous targets. Also, there is the possibility 
that some of the targets of the APPs shared with the HMs that are currently not considered 
relevant to psoriasis may have an as-yet unknown role. Conversely, this approach is limited 
in that it excludes all targets of the herbs that were not listed under any APP, thereby limiting 
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the possibility of identifying new targets of relevance to psoriasis. Nevertheless, this 
approach could be considered for other herbs and for other diseases since it may provide 
clues to additional targets of relevance that may have not yet received research attention for 
the particular disease. 
9.2.3 Identifying the pathways 
The pathway investigation was limited to four of the nine herbs that shared targets with the 
APPs but the searches of PANTHER were based on full lists of the HIT targets for these 
herbs without any filtering for targets in common with the APPs. Therefore, this step was not 
dependent on searches of DrugBank, it used the results from the HIT/DrugBank synthesis to 
assist in limiting the number of herbs for consideration but contained the full lists of targets 
for the included herbs.  
Since analysis of all the remaining 9 herbs was impractical, four herbs were selected 
primarily on the basis of sharing multiple targets with the APPs. As noted earlier, the 
frequency of targets should not be considered a measure of the potential importance of a herb 
and is not a primary component of this method. Since this project is essentially a pilot of the 
method, frequency was used for shortlisting items for investigation since it was impractical 
to analyse every item. On the other hand, the selection of herbs for which there were 
numerous results for targets overall, and these included targets in common with APPs, 
appeared likely to lead to meaningful results in the pathways analysis. Also, the adoption of 
frequency enabled an objective approach to generating lists of results. 
When all targets were entered into PANTHER, numerous pathways were returned with each 
of the four herbs having targets that were involved in between 48 and 59 pathways. Not all of 
the targets identified by HIT were suitable for entry into PANTHER and there was 
considerable difference in the nomenclatures used by both databases, but after these issues 
had been resolved only a few of the HIT targets proved unproductive in PANTHER. This 
indicated that this aspect of the method was practicable once the interface issues were 
addressed.  
Due to the large number of pathways identified, it was impractical to investigate all of them, 
so frequency was again adopted as an objective approach to shortlisting pathways for 
consideration. Even though the target lists had not been filtered for relevance to psoriasis, the 
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pathway results showed distinct relevance to psoriasis with the pathways that included the 
larger numbers of target proteins being those associated with apoptosis, inflammation, and 
angiogenesis. Surprisingly, the Gonadotropin-releasing hormone receptor pathway was 
frequently identified. However, this result was due to targets within this complex pathway 
also being involved in processes relevant to psoriasis including inflammation and 
proliferation rather than the herbs having effects on gonadotropin and related hormones. It is 
also likely that PANTHER pathways that contain large numbers of proteins (216 in 
Gonadotropin-releasing) tend to appear higher on the frequency lists than pathways with 
fewer items (e.g. 49 in Wnt signaling pathway) so this effect needs to be considered in future 
studies.  
It is also important to note that pathways themselves are theoretical constructs. Their scope 
and their components vary according to the data source with the PANTHER pathways 
differing from those in KEGG. Although we consulted KEGG during this project, we did not 
attempt a pathway analysis using KEGG and do not have a view on which database is the 
more useful. Future studies may consider undertaking a comparative analysis using both 
PANTHER and KEGG.  
9.3 Research questions and main results  
The principal research questions and the main results of this research project were as 
follows: 
1) What is the current state of the clinical evidence for the efficacy and safety of herbal 
medicine for psoriasis? 
Based on the results of the systematic reviews of randomised controlled trials of psoriasis 
vulgaris there is promising evidence of efficacy in terms of PASI score reduction for the use 
of HMs singly and in formulations used topically or orally and for topical HMs used in 
combination with APPs. This evidence is based on multiple RCTs and these were grouped 
according to similar designs, test intervention and controls in order to enable data pooling 
(135, 157-159).  
The strength of the clinical evidence is limited by the relatively short duration of the studies 
which typically lasted between one and three months and the lack of a follow-up in most 
studies. The use of PASI 50 and above as a criterion in the meta-analyses due to the different 
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ways in which the data were reported in different studies meant that although there was 
evidence of efficacy, this was based on a minimum threshold rather than on the higher PASI 
75 which is reported for pharmaceuticals in contemporary studies.  
Methodological inadequacies in reporting and in design, limited the quality of the evidence. 
Although all studies were designated as RCTs, in some studies there was inadequate 
description of the method of random allocation so it was unclear whether this aspect of the 
design was correctly implemented. While a number of the studies that compared single HMs 
with placebo were properly blinded, lack of blinding was an issue in many studies. It is 
difficult to design a placebo for a multi-ingredient decoction and when a HM in pill or 
capsule was compared with an APP the different appearances precluded blinding. To what 
extent this lack of blinding induced a bias in favour of the HM is difficult to ascertain but it 
remains a concern. In the case of studies that combined a HM with an APP, but only used the 
APP in the control arm, there is considerable potential for bias in favour of the combination 
therapy. Future studies using this design should always use a placebo for the HM in the 
control arm.  
An additional source of possible bias is the publication of positive studies only, either as a 
result of institutional or commercial pressure, researcher bias or the preference of journals. 
Tests of publication bias were undertaken when there were sufficient numbers of studies 
available that used the same design and outcome (i.e. 10 or more) and these did not show 
evidence of publication bias but such tests were not possible for all comparisons so the 
possibility of such a bias remains.  
In the case of the multi-herbal studies, variation in the ingredients of the herbal formula from 
study to study also limited the meaningfulness of data pooling although this issue was 
addressed where possible by grouping studies with ingredients in common. Also, within a 
study it is not always clear whether there was adequate control of the use of concomitant 
medications and whether their use was equivalent in both arms of the study. In studies that 
used treatment based on syndrome differentiation (TSD) and used modified formulae, the 
reported effects are not directly based on the primary formulation alone and this could 
introduce a source of uncontrolled variation. Another source of variation could be the quality 
of the herbal ingredients. This is less a concern in commercial products but the majority of 
the studies used locally prepared medications and most did not report data on quality control. 
This presents an issue when attempting to replicate the study. 
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In terms of safety, for the topical preparations there were reports of localised adverse events 
(AEs) but these were not serious and were reported to have been managed. In the oral HMs, 
serious AEs were not reported. However, the AE reporting was not adequate in all trials so 
the safety data remains incomplete. In the case of three of the herbs T. wilfordii, Neem and 
Dictamnus dasycarpus, serious AEs have been reported in the literature although none were 
reported in the included RCTs (135). This may have been due to the range of preparations of 
these herbs that have been used but caution is urged in the oral use of these herbs. 
2) Which herbs and/or formulas have the best evidence of efficacy in the management of 
psoriasis? 
Of the topical preparations, Mahonia (Gong lao mu), Aloe vera (Lu hui) and Indigo naturalis 
(Qing dai) have been evaluated in multiple trials and these trials included comparisons with 
placebo (159). Camptotheca acuminata (Xi shu) was compared with placebo in only one of 
the included RCTs but it has also been the subject of other clinical and experimental studies 
and has been in clinical use in China for decades. Most of these trials showed evidence of 
efficacy but data pooling was not feasible for all the studies so it is not possible to determine 
which of these herbs were more or less effective.  
In the multi-ingredient topical herbal formulae, a number of herbs were used repeatedly with 
reported efficacy including Sophora flavescens (Ku shen), Lithospermum erythrorhizon/ 
Arnebia species (Zi cao), Cnidium monnieri (She chuang zi), Dictamnus dasycarpus (Bai 
xian pi), Angelica dahurica (Bai zhi), Tribulus terrestris (Bai ji li), Biota orientalis (Ce bei 
ye) and borneol (Bing pian). Of the herbs used in topical studies, Ku shen, Zi cao, Qing dai 
and Bai xian pi were also used the oral formulae used in multiple studies. However, the most 
frequently used herbs in the oral formulations were Rehmannia glutinosa (Di huang), Salvia 
miltiorrhiza (Dan shen) and Oldenlandia diffusa (Bai hua she she cao) (158). 
Of the topical multi-ingredient HMs, only Liubai Baibi formula showed efficacy in more 
than one study (158) and each of the oral multi-ingredient HMs was only used in one RCT.  
Based on the results of the RCTs, all of the above herbs showed promise of efficacy for the 
management of psoriasis vulgaris based on multiple trials employing the same herb and 
reporting clinical efficacy but it was not possible to determine which herb was more effective 
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than another and in the case of the multi-ingredient formulae it was not possible to determine 
whether the most commonly used herbs were the main contributors to the reported efficacy.  
In terms of oral or topical use, all of the herbs used frequently in the topical preparations can 
also be used orally, so there was no clear distinction between oral and topical herbs. 
However, Mahonia, Camptotheca and Aloe were not components of the oral HMs. From the 
safety perspective, of the above herbs Camptotheca and Dictamnus appear safe when used 
topically but need to be used with caution as oral medications. 
3) Which herbs show the best evidence of anti-psoriatic activity based on the combination of 
clinical and experimental studies? 
There was considerable variation in the volume of experimental studies that have been 
published in English on the above listed herbs and their constituents. Evidence of activity of 
relevance to psoriasis was notable for the following herbs and compounds: 
Ursolic acid which is a constituent of O. diffusa (Bai hua she she cao) and other plants has 
been the subject of multiple studies that have shown activity against inflammation, induction 
of apoptosis, and enhancement of epidermal barrier recovery. Indirubin from Indigo 
naturalis (Qing dai) has shown anti-inflammatory and anti-proliferative activity in multiple 
studies. Experimental studies of shikonin from Lithospermum erythrorhizon and Arnebia 
species (Zi cao) have reported anti-inflammatory, anti-proliferative and anti-angiogenic 
effects as well as benefits in wound healing. Berberine which is found in Mahonia species 
and in other plants has anti-inflammatory effects and Mahonia extracts have been reported to 
exert anti-mutagenic and anti-carcinogenic effects. 
Sophora flavescens (Ku shen) and its constituent matrine have shown anti-inflammatory 
effects and extracts have been shown to induce apoptosis and to exert anti-pruritic effects. 
Aloe vera (Lu hui) extracts have been investigated for wound healing and anti-inflammatory 
effects, have shown anti-proliferative actions and have shown efficacy for pruritus. 
Camptotheca (Xi shu) extracts as well as the compound camptothecin have been shown to 
have anti-proliferative actions.   
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Rehmannia glutinosa (Di huang) and Salvia miltiorrhiza (Dan shen) extracts have both 
shown anti-inflammatory activity and anti-proliferative effects have also been reported for 
Dan shen and its constituent tanshinone IIA.  
Few studies were located for Dictamnus (Bai xian pi), Cnidium (She chuang zi) and borneol 
but each has been reported to have effects of relevance to psoriasis with borneol also being 
known to promote the absorption of topical preparations. 
This survey of the experimental literature was mainly based on sources listed in PubMed and 
was not comprehensive in that it did not consider every study on these herbs and their 
constituents, rather it focussed on studies of relevance to psoriasis in terms of models related 
to skin and/or actions of relevance to psoriasis. In order to undertake a comprehensive 
assessment of the experimental literature, a database would need to have been constructed. 
This was impractical so existing databases were used in the final component of this study.  
4) What are the likely mechanisms of action of the most promising herbs and/or their 
constituents? 
Based on current knowledge of psoriasis, it is evident that inflammatory and proliferative 
processes are involved, there must be a reversal of these in the recovery process, and wound 
healing processes are also involved. The experimental studies on the main herbs that were 
discussed in Chapter 7 indicated that numerous herbs could potentially reduce inflammation 
and reduce proliferation by inducing the apoptosis of keratinocytes. In addition, the 
experimental studies indicated that certain of the herbs, their extracts and/or compounds 
known to be contained in the herbs had measurable effects on proteins known to be involved 
in inflammation and/or proliferation such as COX 2, TNF, Caspase 3, Bax and others. This 
suggested possible mechanisms of action but the focus of Chapter 7 was on these processes, 
so the results were confirmatory more than exploratory. 
In Chapter 8 a more objective approach was undertaken which used databases to explore the 
protein targets of the compounds contained in the 12 herbs for which there was clinical 
evidence of potential efficacy and there was evidence of activity of relevance to psoriasis 
based on in vitro and/or in vivo experimental studies. Although the process for selection of 
this list of herbs was somewhat subjective since there was no plausible way of ranking the 
herbs according to efficacy, the subsequent in silico analyses were more objective in that 
288 
 
they were based on the frequency of citation in the databases rather than a judgement 
regarding relevance to psoriasis.  
The HIT analyses returned few targets for the herbs She chuang zi (Cnidium monnieri), Bai 
xian pi (Dictamnus dasycarpus) and Bing pian (borneol, Dryobalanops aromatica) but the 
other herbs were identified as potentially affecting many targets with Caspase-3 [CASP3], 
Apoptosis regulator Bcl-2 [BCL2], Apoptosis regulator BAX, tumour necrosis factor [TNF], 
Transcription factor p65 [NF kappa B] and prostaglandin G/H synthase 1 & 2 [COX-1 & 2] 
being frequently occurring proteins.  
When the targets of the compounds contained in the herbs were compared with the targets of 
the APPs, which was a much more constrained list compared to herb-related targets, the 
proteins TNF, COX-1 and COX-2 were the main shared targets that were down-regulated by 
compounds in the herbs. This suggested a predominance of anti-inflammatory actions and 
effects of proliferation. However, based on the target list of the herbs it was also apparent 
that proteins relating to apoptosis were very frequent in the results returned from HIT.  
To further explore the possible pathways via which the herbs may act, four herbs that had 
returned multiple results from HIT (Dan shen, Xi shu, Di huang and Qing dai), were 
analysed using PANTHER. The results indicated that each of these herbs could be affecting 
more than forty PANTHER pathways so it possible that their mechanisms of action are 
complex. Based purely on the frequency of involved proteins, the Apoptosis signaling 
pathway and the Angiogenesis pathway were notable. As expected, pathways associated with 
inflammation including the Inflammation mediated by chemokine and cytokine signaling 
pathway, Interleukin signaling pathway and sections of the Gonadotropin releasing hormone 
receptor pathway were also frequent occurrences.  
What this analysis suggested was that besides anti-inflammatory effects, certain of the 
frequently used herbs may be exerting pro-apoptotic and anti-angiogenic effects. However, 
there was variation between the herbs in the numbers of targets identified so it was not 
possible to determine which pathways were of greater or lesser importance based on the 
frequency analysis or whether differences between the results for different herbs were 
indicative of their primary actions. 
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5) What are the implications of the clinical and research evidence for the clinical 
management of psoriasis and for ongoing research? 
These aspects are discussed below. 
9.4 Innovative aspects of the project 
This novelty and innovation in this project included modifications to the systematic review 
process together with a novel approach to employing the outputs of systematic reviews of 
clinical studies as inputs to in silico analyses that are focussed on target proteins and the 
biological pathways in which they are situated. This approach has the potential to build bridges 
between the meta-analysis results derived from multiple clinical trials, the results of 
experimental studies and target-focussed drug discovery and development.  
9.4.1 The use of results of SRs to select herbs for further investigation 
The first component of this study employed conventional SR methods based on the Cochrane 
Handbook to select RCTs for inclusion, evaluate study quality and undertake meta-analyses of 
outcome measures, in particular of PASI. A point of innovation at this stage was the 
determination of which of the herbs in the multi-herbal formulae had been used repeatedly in 
different RCTs that had shown evidence of efficacy based on the meta-analysis results and also 
evidence of safety based on the results for AEs. This provided a rational approach to the 
short-listing of herbs for further consideration. 
Another innovation to the SR approach was the addition of an investigation of how the 
shortlisted herbs might act in the management of psoriasis based on searches of the 
experimental literature on the effects of the short-listed herbs, their extracts and/or constituent 
compounds. This approach provided a bridge between the clinical research which frequently 
employed multi-herb formulations and the experimental research which typically focuses on 
an extract of a single herb or on a single compound.  
Both of these additions to the general methodology used for SRs are adaptations to the needs 
of researchers and clinicians who require particular data regarding which herbs in a formula 
are of relevance to the disorder and which physiological effects these herbs could exert. This 
approach is not specific to psoriasis and could be adapted to SRs of multi-ingredient formulae 
for other disorders.  
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9.4.2 Target-directed large-scale analyses using multiple databases 
The protein targets of a compound can imply the molecular mechanisms of its therapeutic 
actions and and also indicate its possible adverse effects. Targets also have pharmacogenetic 
implications for the discovery of drugs against specific conditions. However, the amount of the 
estimated potential targets on the human genome is huge (374). This suggests that database(s) 
should be employed to undertake large-scale data analyses of protein targets in an effort to 
understand how herbs, which can contain multiple compounds, and multi-ingredient formulae 
may act upon a particular disorder. 
An innovative aspect of this project was the identification of the protein targets of each of the 
short-listed herbs using HIT based on the active compounds contained in the herbs, rather than 
the herb names themselves. This broadened the scope of the searches and ensured the inclusion 
of all potentially relevant data. This large scale approach allowed the use of frequency effects 
to identify targets for further consideration. While there are limitations to the use of frequency 
(discussed earlier and also below), this provides an objective approach to short-listing targets 
and has the potential to identify targets that may not have received attention for the specific 
disorder. 
Another novelty of the in silico approach was the ‘APP-like’ herb identification and the 
herb/APP property exploration. This involved combining the results from the HIT database 
with the targets of the APPs derived from the DrugBank database which is based on FDA data. 
The results from DrugBank were used to filter the HIT data and the herb target lists that 
contained APP drug targets were identified to provide lists of the herbs that were ‘APP-like’. 
This provided an approach to comparing herbs and pharmaceuticals that are employed for the 
same disorder in terms of their likely effects on specific proteins.  
A further innovation was the use of the PANTHER database to process all the targets derived 
for a particular herb from HIT in order to generate frequency data for the molecular functions, 
biological processes, cellular components, protein classes and pathways via which the 
compounds in the herb could be acting. This provided an objective approach to organizing the 
complex data on targets into particular biological processes and enabled predictions as to 
which signaling pathways the herbs may affect. This approach may assist in understanding 
how multiple compounds may affect a biological process and may also be able to provide clues 
as to the biological mechanisms involved in imperfectly characterised diseases such as 
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psoriasis. An earlier study attempted an analogous approach for diabetes using a quite different 
method (458).  
The use of the database cluster, HIT, DrugBank and PANTHER, can provide an objective and 
rapid approach to the identification of herb targets and the exploration of the possible 
pharmaceutical actions of multiple herbs in relation to a specific disease.  
9.5 Implications for further experimental and clinical research in psoriasis 
The results of the in silico analyses suggest that a number of the herbs can affect protein 
targets of relevance to psoriasis but these predictions require further examination via 
experimental and clinical studies.  
The studies of HMs reported in chapter 7 and the targets of the HMs located in the database 
searches included proteins whose association with psoriasis has been well-established 
including TNF, COX, IFN-gamma and others (234, 259, 332). What was missing from the 
data were studies that reported on targets that have received more research in recent years 
including IL 17, IL-23 (459-461), JAK/STAT signalling members (462, 463), VEGF-A, Tie2 
and other proteins relating to angiogenesis (409, 463) and adenosine receptor and other G 
protein related proteins (464). This illustrates how databases can become dated and require 
regular revision.  
Since much of the data on the herbs is derived from cell-line studies and in vivo studies using 
models that are not directed at psoriasis, more focussed experimental studies are required. In 
vitro studies using human psoriatic keratinocytes and fibroblasts appear to closely model the 
psoriatic phenotype (465). In animals, old models such as the mouse tail model would appear 
still relevant for the preliminary testing of topical preparations (466, 467), while models such 
as Balb/C mice (468-470) and more recently developed psoriasis xenograft mouse models 
(463, 471) more closely model the clinical manifestations of psoriasis and would appear to 
be the models of choice in future studies. Such studies could up-date the literature with 
regard to the targets mentioned above and might consider measuring some of the targets 
identified in this project. 
Clinical testing of the effects of promising herbs singly and in various combinations in 
psoriasis sufferers should be considered with the use of PASI and biomarkers as outcomes. 
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An example of this approach is a study by Song et al 2010 that employed multi-ingredient 
systemic and topical formulae in 15 participants and measured PASI as well as levels of 
psoriasis-associated antigen (Pso p27) in plaque biopsies (472). Reductions in both PASI and 
Pso p27 were reported but none of the herbs short listed in Chapter 8 were employed by 
Song et al. If such an approach were used, it is suggested that the herbal formula used should 
comprise few ingredients to as to make the results more interpretable. In addition to PASI, 
micro RNA (mRNA) biomarkers in serum could be employed as outcomes (457, 473) and 
serological measures of markers of inflammation, proliferation and other processes of 
relevance to the specific herbs could be measured to assess the effects of the herbs and shed 
light on the processes involved.  
Prior to undertaking a clinical study of psoriasis using a herb or a herbal formula it is 
suggested that an in silico analysis be undertaken. Since most contemporary studies 
undertake chromatographic analysis of the test formula prior to the study, the results of this 
analysis could form the list of compounds entered into the in silico analysis. This should 
identify the potential targets and pathways via which the herbal medicine may act and can 
provide directions for the selection of appropriate serological tests and marker proteins as 
outcome measures.  
In cases where participants are likely to be using conventional APPs in addition to the herbal 
therapy, the identification of which Cytokine p 540 is involved in the metabolism of the 
compounds contained in the herbal medicine would assist in the monitoring of the safety of 
the clinical trial and could assist in determining whether any of the AEs reported were due to 
the herbs and/or interactions with pharmaceuticals.  
The finding that certain of the herbs shared targets with certain of the APPs also opens the 
possibility of the combination of herbal and APP drugs in a rational manner. Physicians 
could consider applying specific ‘APP-like’ herbs with definite therapeutic target(s) as 
replacements to the APP or to enable reduction in APP dosage in the case of drug resistance 
or AEs due to the APP. Clinical studies of such an approach could be considered. 
9.6 Implications for herbal research and natural products drug discovery 
As clinical herbal medicine moves more towards an evidence-based approach, analyses that 
can synthesise the outcomes of clinical trials and experimental studies are needed. There is, 
293 
 
however, a major disjunction between the approach used in clinical herbal medicine and that 
used in experimental studies. In general, in vitro and in vivo studies test extracts of single 
herbs, fractions of an extract or single compounds. This approach mirrors that of 
conventional drug discovery research in which a single compound that acts upon a particular 
target is sought. Also, compared with pharmaceuticals, plants tend to contain relatively low 
concentrations of each compound. In contrast, experimental studies tend to use higher 
concentrations of these compounds. So there exist a number of disjunctions between what is 
tested in experimental studies and what is used in clinical practice.  
In contrast to experimental studies, clinical herbal medicine employs single or multiple herbs 
and consequently an array of compounds which potentially can act on multiple targets. In 
taking an evidence based approach, herbal therapy could move to the use of single herbs but 
in the case of Chinese medicine that would seem like a return to an approach that was used in 
ancient times prior to the advent of rationally constructed multi-herb formulae which has 
been the mainstay of professional practice for two millennia. 
Fundamental to the concept of formula design in Chinese medicine is the notion that 
components of the formulae target components of the disease, with some components 
focusing on symptoms while others focus on underlying mechanisms. Some formulae focus 
almost wholly upon mechanism and can be used in any disease that shares this mechanism 
while other formulae are symptom focussed and are only applicable when the symptom 
presents. In practice, the formulae that are designed for a particular patient tend to combine 
both aspects and are modified as the symptoms change.  
To date, it has been difficult to assess the effects of multi-herb formulae. The SR approach 
used in this study determined that the included multi-herb formulae produced clinical 
improvements in psoriasis that were not inferior to acetritin and these HMs appeared not to 
produce any severe adverse events. Also, it was possible to identify which individual herbs 
were likely to have contributed to this therapeutic effect but the SRs could not provide data 
on the mechanisms of action of these herbs.  
Using future iterations of the in silico approach presented in this study it may be possible to 
identify all the targets of a formulae and locate these within pathways to investigate how the 
formula might act. In addition, this approach could be used to explore the possible effects of 
modification to a formula via the addition or subtraction of herbs. It is plausible that some 
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combinations of herbs may all be targeting the same proteins thereby compensating for the 
relatively low levels of the compounds contained in the herbs or their low bioavailability. As 
seen in the results, multiple herbs can contain the same compounds and different compounds 
can have the same targets. In addition, different compounds can target different proteins 
within the same pathway, so it is plausible that when this is happening smaller amounts of 
each of the compounds are needed to achieve a change in the pathway. 
Currently, the in silico modelling of the actions of multi-herb formula is still in its infancy 
and this approach remains limited due to the paucity of data on the compounds contained in 
many of the herbs in use and their protein targets. In this study, rather than choose a single 
formula we selected herbs that have been used in multiple clinical studies singly or as 
components of formulae and have been the subject of experimental studies. As a result, the 
in silico analyses returned a considerable amount of data. This indicated that these herbs may 
have targeted multiple proteins and at least some of these proteins were included in pathways 
involved in apoptosis, inflammation and angiogenesis. However, had other less-studied herbs 
been used it is likely that few results would have been returned. So the results for a 
multi-herbal formula that contained more and less intensively studied herbs would likely be 
skewed and may over emphasise the role of the herbs for which there is more data. This 
possible effect would need to be considered when interpreting results. 
Nevertheless, this approach could be used to explore combinations of herbs to determine 
whether they share the same targets or targets within the same pathway. Currently, the in 
silico approach used in this project is very time consuming to conduct and is limited by the 
available data, but the speed limitations could be overcome by the design of new software 
and the amount of data is continually increasing. Therefore, in silico methods similar to this 
could provide a new method for rational herbal formula construction in the future. 
9.7 Future research directions 
This combination of analyses of clinical trial data followed by large scale in silico analyses 
of the relationships between multiple compounds, multiple targets and multiple pathways 
could be applied to other complex diseases such as the cancers, cardiovascular diseases and 
nervous system diseases. In these diseases, the larger volume of clinical data is likely to 
provide more focussed sets of candidate herbs. Also, the higher volume of data on the targets 
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and pathways involved in these more intensively researched diseases could result in more 
focussed results from the in silico analyses.  
Following the identification of the likely targets of the multiple compounds contained in 
candidate herbs, future studies could extend the in silico analyses to virtually model the 
ligand – pharmacophore relationships of the identified compounds and targets.  
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A-1 
Appendix 1 Biological targets list for Bai hua she she cao (Oldenlandia diffusa) 
Species Chinese Compound name Compound ID Target ID Target name 
O. diffusa ????? Ursolic acid 22270 T0026 72 kDa type IV collagenase 
O. diffusa ????? Ursolic acid 22270 T0185 Acetylcholinesterase 
O. diffusa ????? Stigmasterol 20369 T0018 Apoptosis regulator BAX 
O. diffusa ????? Ursolic acid 22270 T0018 Apoptosis regulator BAX 
O. diffusa ????? Stigmasterol 20369 T0013 Apoptosis regulator Bcl-2 
O. diffusa ????? Ursolic acid 22270 T0013 Apoptosis regulator Bcl-2 
O. diffusa ????? Ursolic acid 22270 T0202 Baculoviral IAP repeat-containing protein 5 
O. diffusa ????? Ursolic acid 22270 T0014 Bcl-2-like protein 1 
O. diffusa ????? Ursolic acid 22270 T0213 Caspase-1 
O. diffusa ????? Oleanolic acid 16050 T0045 Caspase-3 
O. diffusa ????? Stigmasterol 20369 T0045 Caspase-3 
O. diffusa ????? Ursolic acid 22270 T0045 Caspase-3 
O. diffusa ????? Stigmasterol 20369 T0060 Caspase-8 
O. diffusa ????? Ursolic acid 22270 T0060 Caspase-8 
O. diffusa ????? Oleanolic acid 16050 T0019 Caspase-9 
O. diffusa ????? Stigmasterol 20369 T0019 Caspase-9 
O. diffusa ????? Ursolic acid 22270 T0019 Caspase-9 
O. diffusa ????? Ursolic acid 22270 T0207 Cathepsin B 
O. diffusa ????? Ursolic acid 22270 T0034 Cell division protein kinase 2 
O. diffusa ????? Ursolic acid 22270 T0035 Cell division protein kinase 4 
O. diffusa ????? Ursolic acid 22270 T0041 Cell division protein kinase 6 
O. diffusa ????? Ursolic acid 22270 T0046 Cellular tumor antigen p53 
A-2 
O. diffusa ????? Ursolic acid 22270 T0200 C-Jun-amino-terminal kinase-interacting protein 1 
O. diffusa ????? Ursolic acid 22270 T0201 C-Jun-amino-terminal kinase-interacting protein 2 
O. diffusa ????? Ursolic acid 22270 T0196 Cyclic AMP-dependent transcription factor ATF-2 
O. diffusa ????? Ursolic acid 22270 T0157 Cyclic AMP-responsive element-binding protein 1 
O. diffusa ????? Ursolic acid 22270 T0016 Cyclin-dependent kinase inhibitor 1 
O. diffusa ????? Ursolic acid 22270 T0205 Dual oxidase 2 
O. diffusa ????? Ursolic acid 22270 T0310 Ectonucleotide pyrophosphatase/phosphodiesterase 
family member 7 
O. diffusa ????? Ursolic acid 22270 T0174 E-selectin 
O. diffusa ????? Ursolic acid 22270 T0061 Fatty acid synthase 
O. diffusa ????? Ursolic acid 22270 T0012 G1/S-specific cyclin-D1 
O. diffusa ????? Ursolic acid 22270 T0211 G1/S-specific cyclin-D2 
O. diffusa ????? Ursolic acid 22270 T0197 Granulocyte-macrophage colony-stimulating factor 
O. diffusa ????? Oleanolic acid 16050 T0135 Heme oxygenase 1 
O. diffusa ????? Ursolic acid 22270 T0116 Heparin-binding growth factor 2 
O. diffusa ????? Ursolic acid 22270 T0182 Induced myeloid leukemia cell differentiation protein 
Mcl-1 
O. diffusa ????? Oleanolic acid 16050 T0152 Intercellular adhesion molecule 1 
O. diffusa ????? Ursolic acid 22270 T0152 Intercellular adhesion molecule 1 
O. diffusa ????? Ursolic acid 22270 T0156 Interleukin-1 beta 
O. diffusa ????? Ursolic acid 22270 T0039 Interleukin-6 
O. diffusa ????? Ursolic acid 22270 T0086 Interstitial collagenase 
O. diffusa ????? Ursolic acid 22270 T0210 Lipopolysaccharide-induced tumor necrosis factor-alpha 
factor 
O. diffusa ????? Ursolic acid 22270 T0027 Matrix metalloproteinase-9 
O. diffusa ????? Stigmasterol 20369 T0826 Microtubule-associated protein 2 
O. diffusa ????? Ursolic acid 22270 T0052 Mitogen-activated protein kinase 8 
A-3 
O. diffusa ????? Oleanolic acid 16050 T0323 NAD(P)H dehydrogenase [quinone] 1 
O. diffusa ????? Ursolic acid 22270 T0204 Neuromodulin 
O. diffusa ????? Ursolic acid 22270 T0055 NF-kappa-B inhibitor alpha 
O. diffusa ????? Ursolic acid 22270 T0206 Nitric oxide synthase, endothelial 
O. diffusa ????? Ursolic acid 22270 T0040 Nitric oxide synthase, inducible 
O. diffusa ????? Oleanolic acid 16050 T1106 Pancreatic alpha-amylase 
O. diffusa ????? Ursolic acid 22270 T0209 Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2 
O. diffusa ????? Ursolic acid 22270 T0198 Platelet endothelial cell adhesion molecule 
O. diffusa ????? Ursolic acid 22270 T0099 Probable E3 ubiquitin-protein ligase HERC5 
O. diffusa ????? Ursolic acid 22270 T0178 Prostaglandin E2 receptor EP3 subtype 
O. diffusa ????? Ursolic acid 22270 T0179 Prostaglandin G/H synthase 1 
O. diffusa ????? Ursolic acid 22270 T0054 Prostaglandin G/H synthase 2 
O. diffusa ????? Stigmasterol 20369 T0077 Protein kinase C alpha type 
O. diffusa ????? Ursolic acid 22270 T0195 Protein kinase C gamma type 
O. diffusa ????? Ursolic acid 22270 T0015 Proto-oncogene c-Fos 
O. diffusa ????? Ursolic acid 22270 T0199 Proto-oncogene tyrosine-protein kinase Src 
O. diffusa ????? Stigmasterol 20369 T0379 Serum paraoxonase/arylesterase 1 
O. diffusa ????? Ursolic acid 22270 T0008 Signal transducer and activator of transcription 3 
O. diffusa ????? Ursolic acid 22270 T0087 Stromelysin-1 
O. diffusa ????? Ursolic acid 22270 T0146 Stromelysin-2 
O. diffusa ????? Stigmasterol 20369 T0038 Transcription factor AP-1 
O. diffusa ????? Ursolic acid 22270 T0038 Transcription factor AP-1 
O. diffusa ????? Ursolic acid 22270 T0002 Transcription factor p65 
O. diffusa ????? Stigmasterol 20369 T0226 Transforming growth factor beta-1 
O. diffusa ????? Ursolic acid 22270 T0037 Tumor necrosis factor 
A-4 
O. diffusa ????? Ursolic acid 22270 T0212 Tumor necrosis factor ligand superfamily member 6 
O. diffusa ????? Ursolic acid 22270 T0208 Tyrosine-protein phosphatase non-receptor type 1 
O. diffusa ????? Ursolic acid 22270 T0203 Tyrosine-protein phosphatase non-receptor type 6 
O. diffusa ????? Ursolic acid 22270 T0025 Urokinase-type plasminogen activator 
O. diffusa ????? Ursolic acid 22270 T0010 Vascular endothelial growth factor A 
O. diffusa ????? 5-O-p-Methoxy cinnamoyl scandoside methyl 
ester 
13895 NA ?  
O. diffusa ????? 6-O-E-p-Coumaroyl scandoside methyl ester 4185 NA ?  
O. diffusa ????? 6-O-Z-p-Coumaroyl scandoside methyl ester 4186 NA ?  
O. diffusa ????? 6-O-Z-p-Methoxycinnamoyl scandoside methyl 
ester 
13894 NA ?  
O. diffusa ????? Asperulosidic acid 1894 NA ?  
O. diffusa ????? Kaempferol 
3-O-[(6-O-feruloyl)-β-D-glucopyranosyl-(1→2)
-β-Dgalactopyranoside] 
12046 NA ?  
O. diffusa ????? Panasenoside 16587 NA ?  
O. diffusa ????? Quercetin-3-O-[(6-O-feruloyl)-β-D-glucopyrano
syl-(1→2)-β-Dgalactopyranoside] 
18354 NA ?  
O. diffusa ????? Quercetin-3-O-[2-O-(6-O-E-feruloyl)-β-D-gluc
opyranosyl]-β-D -glucopyranoside 
18355 NA ?  
O. diffusa ????? Quercetin-3-O-[2-O-(6-O-E-sinapoyl)-β-D-gluc
opyranosyl]-β-Dglucopyranoside 
18396 NA ?  
O. diffusa ????? Quercetin-3-O-[β-D-glucopyranosyl-(1→2)-β-D
-galactopyrano- side] 
18362 NA ?  
A-5 
Appendix 2 Biological target list for Di huang (Rehmannia glutinosa, R. glutinosa var. purpurea) 
Species Chinesee Compound name Compound ID Target ID Target name 
R. glutinosa  ???  Cinnamic acid 3695 T0185 Acetylcholinesterase 
R. glutinosa  ???  Cinnamic acid 3695 T0881 Aldo-keto reductase family 1 member C1 
R. glutinosa  ???  Cinnamic acid 3695 T0324 Alpha-1A adrenergic receptor 
R. glutinosa  ???  Raffinose 18526 T1296 Alpha-galactosidase A 
R. glutinosa  ???  Cinnamic acid 3695 T0440 Alpha-synuclein 
R. glutinosa  ???  Cinnamic acid 3695 T0959 Antizyme inhibitor 1 
R. glutinosa  ???  Aucubin 2004 T0018 Apoptosis regulator BAX 
R. glutinosa  ???  Cinnamic acid 3695 T0018 Apoptosis regulator BAX 
R. glutinosa  ???  Stigmasterol 20369 T0018 Apoptosis regulator BAX 
R. glutinosa  ???  Aucubin 2004 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???  Catalpol 3306 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???  Catalpol 3306 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???(??)  Catalpol 3306 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???  Geniposide 8276 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???  Hexadecanoic acid 9486 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???  Stigmasterol 20369 T0013 Apoptosis regulator Bcl-2 
R. glutinosa  ???  Cinnamic acid 3695 T0279 Arachidonate 5-lipoxygenase 
R. glutinosa  ???  Catalpol 3306 T0045 Caspase-3 
R. glutinosa  ???  Catalpol 3306 T0045 Caspase-3 
R. glutinosa  ???(??)  Catalpol 3306 T0045 Caspase-3 
R. glutinosa  ???  Cinnamic acid 3695 T0045 Caspase-3 
A-6 
R. glutinosa  ???  Cinnamic acid 3695 T0045 Caspase-3 
R. glutinosa  ???  Stigmasterol 20369 T0045 Caspase-3 
R. glutinosa  ???  Succinic acid 20444 T0045 Caspase-3 
R. glutinosa  ???  Stigmasterol 20369 T0060 Caspase-8 
R. glutinosa  ???  Stigmasterol 20369 T0019 Caspase-9 
R. glutinosa  ???  Cinnamic acid 3695 T0438 C-C chemokine receptor type 3 
R. glutinosa  ???  Cinnamic acid 3695 T0546 C-C motif chemokine 16 
R. glutinosa  ???  Cinnamic acid 3695 T0167 C-C motif chemokine 2 
R. glutinosa  ???  Cinnamic acid 3695 T0434 C-C motif chemokine 3 
R. glutinosa  ???  Cinnamic acid 3695 T0308 Choline O-acetyltransferase 
R. glutinosa  ???  Hexadecanoic acid 9486 T1102 Choline-phosphate cytidylyltransferase A 
R. glutinosa  ???  Hexadecanoic acid 9486 T0267 Collagen alpha-1(I) chain 
R. glutinosa  ???  Cinnamic acid 3695 T0580 Complement C3 
R. glutinosa  ???  Cinnamic acid 3695 T1243 Complement C5 
R. glutinosa  ???  Cinnamic acid 3695 T0016 Cyclin-dependent kinase inhibitor 1 
R. glutinosa  ???  Cinnamic acid 3695 T0150 Cytochrome P450 1A1 
R. glutinosa  ???  Aucubin 2004 T1266 DNA-directed RNA polymerase II subunit RPB1 
R. glutinosa  ???  Lauric acid 12569 T0205 Dual oxidase 2 
R. glutinosa  ???  Stearic acid 20280 T0310 Ectonucleotide pyrophosphatase/ phosphodiesterase family 
member 7 
R. glutinosa  ???  Cinnamic acid 3695 T0437 Eotaxin 
R. glutinosa  ???  Cinnamic acid 3695 T0017 Eukaryotic translation initiation factor 6 
R. glutinosa  ???  Caprylic acid 3140 T0633 Fatty acid-binding protein, liver 
R. glutinosa  ???  Cinnamic acid 3695 T0246 G1/S-specific cyclin-D3 
R. glutinosa  ???  Cinnamic acid 3695 T0215 Gamma-glutamyltransferase 5 
R. glutinosa  ???  Cinnamic acid 3695 T0346 Glial fibrillary acidic protein 
A-7 
R. glutinosa  ???  Geniposide 8276 T0644 Glucagon 
R. glutinosa  ???  Cinnamic acid 3695 T0311 Glutamate--cysteine ligase catalytic subunit 
R. glutinosa  ???  Cinnamic acid 3695 T0660 Glutathione S-transferase A2 
R. glutinosa  ???  Geniposide 8276 T0645 Glutathione S-transferase Mu 1 
R. glutinosa  ???  Geniposide 8276 T0646 Glutathione S-transferase Mu 2 
R. glutinosa  ???  Cinnamic acid 3695 T0321 Glutathione S-transferase P 
R. glutinosa  ???  Geniposide 8276 T0135 Heme oxygenase 1 
R. glutinosa  ???  Caprylic acid 3140 T0632 Histone acetyltransferase p300 
R. glutinosa  ???  Cinnamic acid 3695 T0441 Ig gamma-1 chain C region 
R. glutinosa  ???  Cinnamic acid 3695 T0439 Indoleamine 2,3-dioxygenase 1 
R. glutinosa  ???  Cinnamic acid 3695 T0003 Inhibitor of nuclear factor kappa-B kinase subunit beta 
R. glutinosa  ???  Caprylic acid 3140 T0296 Inositol-3-phosphate synthase 1 
R. glutinosa  ???  Nonanoic acid 15684 T0296 Inositol-3-phosphate synthase 1 
R. glutinosa  ???  Cinnamic acid 3695 T0374 Insulin-like growth factor II 
R. glutinosa  ???  Raffinose 18526 T0152 Intercellular adhesion molecule 1 
R. glutinosa  ???  Uridine 22252 T1130 Interferon alpha/beta receptor 2 
R. glutinosa  ???  Hexadecanoic acid 9486 T0030 Interleukin-10 
R. glutinosa  ???  Hexadecanoic acid 9486 T0030 Interleukin-10 
R. glutinosa  ???  Cinnamic acid 3695 T0231 Interleukin-2 
R. glutinosa  ???  Cinnamic acid 3695 T0276 Interleukin-4 
R. glutinosa  ???  Cinnamic acid 3695 T0414 Interleukin-5 
R. glutinosa  ???  Aucubin 2004 T0039 Interleukin-6 
R. glutinosa  ???  Hexadecanoic acid 9486 T0039 Interleukin-6 
R. glutinosa  ???  Lauric acid 12569 T0039 Interleukin-6 
R. glutinosa  ???  γ-Aminobutyric acid 1048 T0039 Interleukin-6 
A-8 
R. glutinosa  ???  Caprylic acid 3140 T0181 Interleukin-8 
R. glutinosa  ???  Lauric acid 12569 T0181 Interleukin-8 
R. glutinosa  ???  Cinnamic acid 3695 T0229 Maltase-glucoamylase, intestinal 
R. glutinosa  ???  Cinnamic acid 3695 T0229 Maltase-glucoamylase, intestinal 
R. glutinosa  ???  Stigmasterol 20369 T0826 Microtubule-associated protein 2 
R. glutinosa  ???  Cinnamic acid 3695 T0029 Mitogen-activated protein kinase 1 
R. glutinosa  ???  Raffinose 18526 T0052 Mitogen-activated protein kinase 8 
R. glutinosa  ???  Geniposide 8276 T0204 Neuromodulin 
R. glutinosa  ???  Aucubin 2004 T0055 NF-kappa-B inhibitor alpha 
R. glutinosa  ???  Cinnamic acid 3695 T0206 Nitric oxide synthase, endothelial 
R. glutinosa  ???  Catalpol 3306 T0040 Nitric oxide synthase, inducible 
R. glutinosa  ???  Catalpol 3306 T0040 Nitric oxide synthase, inducible 
R. glutinosa  ???(??) Catalpol 3306 T0040 Nitric oxide synthase, inducible 
R. glutinosa  ???  Cinnamic acid 3695 T0241 Nuclear factor of activated T-cells, cytoplasmic 3 
R. glutinosa  ???  Caprylic acid 3140 T0360 Peroxisome proliferator-activated receptor alpha 
R. glutinosa  ???  Myristic acid 15203 T0597 Phosphatidylcholine-sterol acyltransferase 
R. glutinosa  ???  Hexadecanoic acid 9486 T0286 Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and 
dual-specificity protein phosphatase PTEN 
R. glutinosa  ???  Uridine 22252 T1131 Phospholipase A2, membrane associated 
R. glutinosa  ???  Geniposide 8276 T0274 Phospholipase B1, membrane-associated 
R. glutinosa  ???  Cinnamic acid 3695 T0545 Polyphenol oxidase I, chloroplastic 
R. glutinosa  ???  Hexadecanoic acid 9486 T0178 Prostaglandin E2 receptor EP3 subtype 
R. glutinosa  ???  Cinnamic acid 3695 T0179 Prostaglandin G/H synthase 1 
R. glutinosa  ???  Cinnamic acid 3695 T0054 Prostaglandin G/H synthase 2 
R. glutinosa  ???  Hexadecanoic acid 9486 T0054 Prostaglandin G/H synthase 2 
R. glutinosa  ???  Lauric acid 12569 T0054 Prostaglandin G/H synthase 2 
A-9 
R. glutinosa  ???  Stigmasterol 20369 T0077 Protein kinase C alpha type 
R. glutinosa  ???  Cinnamic acid 3695 T0194 Protein kinase C beta type 
R. glutinosa  ???  Cinnamic acid 3695 T1064 Prothrombin 
R. glutinosa  ???  Cinnamic acid 3695 T0388 P-selectin 
R. glutinosa  ???  Hexadecanoic acid 9486 T0814 Putative beta-glucuronidase-like protein SMA3 
R. glutinosa  ???  Lauric acid 12569 T0009 RAC-alpha serine/threonine-protein kinase 
R. glutinosa  ???  Cinnamic acid 3695 T0752 Ras-related C3 botulinum toxin substrate 1 
R. glutinosa  ???  Caprylic acid 3140 T0634 Retinol-binding protein 2 
R. glutinosa  ???  Stigmasterol 20369 T0379 Serum paraoxonase/arylesterase 1 
R. glutinosa  ???  Cinnamic acid 3695 T0092 Signal transducer and activator of transcription 1-alpha/beta 
R. glutinosa  ???  γ-Aminobutyric acid 1048 T1228 Sodium- and chloride-dependent GABA transporter 1 
R. glutinosa  ???  Raffinose 18526 T0862 Solute carrier family 12 member 2 
R. glutinosa  ???  Hexadecanoic acid 9486 T1101 Solute carrier family 22 member 5 
R. glutinosa  ???  Catalpol 3306 T0074 Superoxide dismutase [Cu-Zn] 
R. glutinosa  ???  Catalpol 3306 T0074 Superoxide dismutase [Cu-Zn] 
R. glutinosa  ???(??)  Catalpol 3306 T0074 Superoxide dismutase [Cu-Zn] 
R. glutinosa  ???  Cinnamic acid 3695 T0442 T-cell surface glycoprotein CD3 zeta chain 
R. glutinosa  ???  Cinnamic acid 3695 T0144 Tissue factor 
R. glutinosa  ???  Cinnamic acid 3695 T0435 T-lymphocyte activation antigen CD80 
R. glutinosa  ???  Lauric acid 12569 T0435 T-lymphocyte activation antigen CD80 
R. glutinosa  ???  Cinnamic acid 3695 T0436 T-lymphocyte activation antigen CD86 
R. glutinosa  ???  Lauric acid 12569 T0436 T-lymphocyte activation antigen CD86 
R. glutinosa  ???  Cinnamic acid 3695 T0230 Trans-cinnamate 4-monooxygenase 
R. glutinosa  ???  Stigmasterol 20369 T0038 Transcription factor AP-1 
R. glutinosa  ???  Aucubin 2004 T0002 Transcription factor p65 
A-10 
R. glutinosa  ???  Cinnamic acid 3695 T0002 Transcription factor p65 
R. glutinosa  ???  Hexadecanoic acid 9486 T0002 Transcription factor p65 
R. glutinosa  ???  Lauric acid 12569 T0002 Transcription factor p65 
R. glutinosa  ???  Stearic acid 20280 T0129 Transcription factor Sp1 
R. glutinosa  ???  Stigmasterol 20369 T0226 Transforming growth factor beta-1 
R. glutinosa  ???  γ-Aminobutyric acid 1048 T0773 Transitional endoplasmic reticulum ATPase 
R. glutinosa  ???  Aucubin 2004 T0037 Tumor necrosis factor 
R. glutinosa  ???  Cinnamic acid 3695 T0037 Tumor necrosis factor 
R. glutinosa  ???  Hexadecanoic acid 9486 T0037 Tumor necrosis factor 
R. glutinosa  ???  Hexadecanoic acid 9486 T0037 Tumor necrosis factor 
R. glutinosa  ???  Lauric acid 12569 T0578 Tumor necrosis factor receptor superfamily member 5 
R. glutinosa  ???  Cinnamic acid 3695 T0256 Tyrosinase 
R. glutinosa  ???  Cinnamic acid 3695 T0326 Tyrosine-protein kinase BTK 
R. glutinosa  ???  Cinnamic acid 3695 T0059 Xanthine dehydrogenase/oxidase 
R. glutinosa  ???  1-Ethyl-β-D-galactoside 7440 NA  
R. glutinosa  ???  2'-Acetylacteoside 305 NA  
R. glutinosa  ???  5-Hydroxymethyl furaldehyde 10493 NA  
R. glutinosa  ???  6-O-(4-Hydroxybenzoyl)-ajugol 9819 NA  
R. glutinosa  ???  6-O-(4''-O-α-L-Rhamnopyranosyl) 
vanilloylajugol 
18735 NA  
R. glutinosa  ???  6-O-E-Feruloylajugol 7769 NA  
R. glutinosa  ???  6-O-p-Coumaroylajugol 4144 NA  
R. glutinosa  ???  6-O-Vanilloylajugol 22339 NA  
R. glutinosa  ???  6-O-Z-Feruloylajugol 7770 NA  
R. glutinosa  ???  8-Epiloganic acid 6952 NA  
R. glutinosa  ???  Acetylcatalpol 347 NA  
A-11 
R. glutinosa  ???  Acteroside 580 NA  
R. glutinosa  ???  Adenine nucleoside 618 NA  
R. glutinosa  ???(??)  Adenine nucleoside 618 NA  
R. glutinosa  ???  Ajugol 815 NA  
R. glutinosa  ???  Ajugoside 816 NA  
R. glutinosa  ???(??)  Ajugoside 816 NA  
R. glutinosa  ???  Arachidic acid 1598 NA  
R. glutinosa  ???  Campesterol 3040 NA  
R. glutinosa  ???  Capric acid 3138 NA  
R. glutinosa  ???  Celebroside 3371 NA  
R. glutinosa  ???  cis-9,cis-12-Linoleic acid 12891 NA  
R. glutinosa  ???  Cistanoside A 3751 NA  
R. glutinosa  ???  Cistanoside F 3756 NA  
R. glutinosa  ???  Danmelittoside 4626 NA  
R. glutinosa  ???  Daturic acid 4672 NA  
R. glutinosa  ???  Daucosterol 4680 NA  
R. glutinosa  ???  Dihydrocarveol 5555 NA  
R. glutinosa  ???  Dihydrocatalpol 5557 NA  
R. glutinosa  ???  D-Mannitol 13504 NA  
R. glutinosa  ???  Docosanoic acid 6537 NA  
R. glutinosa  ???  Forsythoside A 7924 NA  
R. glutinosa  ???  Glucosamine 8753 NA  
R. glutinosa  ???  Glutinoside 8790 NA  
R. glutinosa  ???  Heneicosanoic acid 9360 NA  
R. glutinosa  ???  Isoacteoside 11195 NA  
A-12 
R. glutinosa  ???  Jiofuran 11872 NA  
R. glutinosa  ???  Jioglutin A 11873 NA  
R. glutinosa  ???  Jioglutin B 11874 NA  
R. glutinosa  ???  Jioglutin C 11875 NA  
R. glutinosa  ???  Jioglutin D 11876 NA  
R. glutinosa  ???  Jioglutin E 11877 NA  
R. glutinosa  ???  Jioglutolide 11878 NA  
R. glutinosa  ???  Jioglutoside A 11879 NA  
R. glutinosa  ???  Jioglutoside B 11880 NA  
R. glutinosa  ???  Jionoside A2 11881 NA  
R. glutinosa  ???  Jionoside B1 11882 NA  
R. glutinosa  ???  Jionoside B2 11883 NA  
R. glutinosa  ???  Jionoside C 11884 NA  
R. glutinosa  ???  Jionoside D 11885 NA  
R. glutinosa  ???  Jionoside E 11886 NA  
R. glutinosa  ???(??)  Manninotriose 13503 NA  
R. glutinosa  ???  Martynoside 13580 NA  
R. glutinosa  ???  Melittoside 13710 NA  
R. glutinosa  ???  Mioporosidegenin 14878 NA  
R. glutinosa  ???  Nonadecanoic acid 15672 NA  
R. glutinosa  ???  Palmitoleic acid 16561 NA  
R. glutinosa  ???  Pentadecanoic acid 16831 NA  
R. glutinosa  ???  Phenylacetic acid 17091 NA  
R. glutinosa  ???  Purpureaside A 18219 NA  
R. glutinosa  ???  Purpureaside B 18220 NA  
A-13 
R. glutinosa  ???  Purpureaside C 18221 NA  
R. glutinosa  ???(??)  Purpureaside C 18221 NA  
R. glutinosa var. 
purpurea 
???  Purpureaside C 18221 NA  
R. glutinosa ???  Pyroglutamic acid 18266 NA  
R. glutinosa  ???  Rehmaglutin A 18589 NA  
R. glutinosa  ???  Rehmaglutin A 18589 NA  
R. glutinosa  ???  Rehmaglutin B 18590 NA  
R. glutinosa  ???  Rehmaglutin C 18591 NA  
R. glutinosa  ???  Rehmaglutin D 18592 NA  
R. glutinosa  ???  Rehmaglutin D 18592 NA  
R. glutinosa  ???  Rehmaionoside A 18593 NA  
R. glutinosa  ???  Rehmaionoside B 18594 NA  
R. glutinosa  ???  Rehmaionoside C 18595 NA  
R. glutinosa  ???  Rehmannioside A 18596 NA  
R. glutinosa  ???  Rehmannioside A 18596 NA  
R. glutinosa  ???(??)  Rehmannioside A 18596 NA  
R. glutinosa  ???  Rehmannioside B 18597 NA  
R. glutinosa  ???  Rehmannioside B 18597 NA  
R. glutinosa  ???(??)  Rehmannioside B 18597 NA  
R. glutinosa  ???  Rehmannioside C 18598 NA  
R. glutinosa  ???  Rehmannioside C 18598 NA  
R. glutinosa  ???(??)  Rehmannioside C 18598 NA  
R. glutinosa  ???  Rehmannioside D 18599 NA  
R. glutinosa  ???  Rehmannioside D 18599 NA  
R. glutinosa  ???(??)  Rehmannioside D 18599 NA  
A-14 
R. glutinosa  ???  Rehmapicrogenin 18600 NA  
R. glutinosa  ???  Rehmapicroside 18601 NA  
R. glutinosa  ???  sec-Hydroxyaeginetic acid 9767 NA  
R. glutinosa  ???  Stachyose 20255 NA  
R. glutinosa  ???  Verbascose 22396 NA  
R. glutinosa  ???  Wiedemannioside C 22664 NA  
R. glutinosa  ???  β-Sitosterol 19983 NA  
A-15 
Appendix 3 Biological target list for Dan shen (Salvia miltiorrhiza, S. przewalskii var. mandarinorum, S. sinica, S. miltiorrhiza f. alba) 
Species Chinese  Compound name Compound 
ID 
Target 
ID 
Target name 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0026 72 kDa type IV collagenase 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0026 72 kDa type IV collagenase 
S. miltiorrhiza ?? Ursolic acid 22270 T0026 72 kDa type IV collagenase 
S. miltiorrhiza ?? Caffeic acid 2287 T0185 Acetylcholinesterase 
S. miltiorrhiza ?? Ursolic acid 22270 T0185 Acetylcholinesterase 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0263 Actin, aortic smooth muscle 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0263 Actin, aortic smooth muscle 
S. miltiorrhiza ?? Danshensu 4630 T1114 Actin, cytoplasmic 1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0044 Activator of 90 kDa heat shock protein ATPase 
homolog 1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0044 Activator of 90 kDa heat shock protein ATPase 
homolog 1 
S. sinica ??? Tanshinone IIa 20686 T0044 Activator of 90 kDa heat shock protein ATPase 
homolog 1 
S. miltiorrhiza ?? Tigogenin 21383 T0044 Activator of 90 kDa heat shock protein ATPase 
homolog 1 
S. miltiorrhiza ?? Hesperetic acid 9455 T0324 Alpha-1A adrenergic receptor 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0079 Amyloid beta A4 protein 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0079 Amyloid beta A4 protein 
S. sinica ??? Cryptotanshinone 4292 T0079 Amyloid beta A4 protein 
S. miltiorrhiza ?? Ursolic acid 22270 T0018 Apoptosis regulator BAX 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0013 Apoptosis regulator Bcl-2 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0013 Apoptosis regulator Bcl-2 
A-16 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0013 Apoptosis regulator Bcl-2 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0013 Apoptosis regulator Bcl-2 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0013 Apoptosis regulator Bcl-2 
S. sinica ??? Tanshinone IIa 20686 T0013 Apoptosis regulator Bcl-2 
S. sinica ??? Tanshinone IIa 20686 T0013 Apoptosis regulator Bcl-2 
S. miltiorrhiza ?? Ursolic acid 22270 T0013 Apoptosis regulator Bcl-2 
S. miltiorrhiza ?? Danshensu 4630 T1256 Atrial natriuretic factor 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0202 Baculoviral IAP repeat-containing protein 5 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0202 Baculoviral IAP repeat-containing protein 5 
S. sinica ??? Cryptotanshinone 4292 T0202 Baculoviral IAP repeat-containing protein 5 
S. miltiorrhiza ?? Ursolic acid 22270 T0202 Baculoviral IAP repeat-containing protein 5 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0014 Bcl-2-like protein 1 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0014 Bcl-2-like protein 1 
S. sinica ??? Cryptotanshinone 4292 T0014 Bcl-2-like protein 1 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0014 Bcl-2-like protein 1 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0014 Bcl-2-like protein 1 
S. sinica ??? Dihydrotanshinone I 5722 T0014 Bcl-2-like protein 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0014 Bcl-2-like protein 1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0238 Calcitonin receptor 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0238 Calcitonin receptor 
S. sinica ??? Tanshinone IIa 20686 T0238 Calcitonin receptor 
S. miltiorrhiza ?? Ursolic acid 22270 T0213 Caspase-1 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0045 Caspase-3 
A-17 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0045 Caspase-3 
S. sinica ??? Dihydrotanshinone I 5722 T0045 Caspase-3 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0045 Caspase-3 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0045 Caspase-3 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0045 Caspase-3 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0045 Caspase-3 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0045 Caspase-3 
S. sinica ??? Tanshinone IIa 20686 T0045 Caspase-3 
S. miltiorrhiza ?? Ursolic acid 22270 T0045 Caspase-3 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0143 Caspase-7 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0143 Caspase-7 
S. sinica ??? Dihydrotanshinone I 5722 T0143 Caspase-7 
S. miltiorrhiza ?? Ursolic acid 22270 T0060 Caspase-8 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0019 Caspase-9 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0019 Caspase-9 
S. sinica ??? Dihydrotanshinone I 5722 T0019 Caspase-9 
S. miltiorrhiza ?? Ursolic acid 22270 T0019 Caspase-9 
S. miltiorrhiza ?? Ursolic acid 22270 T0207 Cathepsin B 
S. miltiorrhiza ?? Ferruginol 7764 T1248 CD83 antigen 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0034 Cell division protein kinase 2 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0034 Cell division protein kinase 2 
S. sinica ??? Dihydrotanshinone I 5722 T0034 Cell division protein kinase 2 
S. miltiorrhiza ?? Ursolic acid 22270 T0034 Cell division protein kinase 2 
A-18 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0035 Cell division protein kinase 4 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0035 Cell division protein kinase 4 
S. sinica ??? Dihydrotanshinone I 5722 T0035 Cell division protein kinase 4 
S. miltiorrhiza ?? Ursolic acid 22270 T0035 Cell division protein kinase 4 
S. miltiorrhiza ?? Ursolic acid 22270 T0041 Cell division protein kinase 6 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0046 Cellular tumor antigen p53 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0046 Cellular tumor antigen p53 
S. sinica ??? Tanshinone IIa 20686 T0046 Cellular tumor antigen p53 
S. miltiorrhiza ?? Ursolic acid 22270 T0046 Cellular tumor antigen p53 
S. miltiorrhiza ?? Ursolic acid 22270 T0200 C-Jun-amino-terminal kinase-interacting 
protein 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0201 C-Jun-amino-terminal kinase-interacting 
protein 2 
S. miltiorrhiza ?? Danshensu 4630 T0267 Collagen alpha-1(I) chain 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0267 Collagen alpha-1(I) chain 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0267 Collagen alpha-1(I) chain 
S. miltiorrhiza ?? Danshensu 4630 T0344 Collagen alpha-1(III) chain 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0225 Collagen alpha-1(VII) chain 
S. miltiorrhiza ?? Ursolic acid 22270 T0196 Cyclic AMP-dependent transcription factor 
ATF-2 
S. miltiorrhiza ?? Ursolic acid 22270 T0157 Cyclic AMP-responsive element-binding 
protein 1 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0016 Cyclin-dependent kinase inhibitor 1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0016 Cyclin-dependent kinase inhibitor 1 
A-19 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0016 Cyclin-dependent kinase inhibitor 1 
S. sinica ??? Tanshinone IIa 20686 T0016 Cyclin-dependent kinase inhibitor 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0016 Cyclin-dependent kinase inhibitor 1 
S. miltiorrhiza ?? Caffeic acid 2287 T0150 Cytochrome P450 1A1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0150 Cytochrome P450 1A1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0150 Cytochrome P450 1A1 
S. sinica ??? Tanshinone IIa 20686 T0150 Cytochrome P450 1A1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0138 Cytochrome P450 1A2 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0138 Cytochrome P450 1A2 
S. sinica ??? Tanshinone IIa 20686 T0138 Cytochrome P450 1A2 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0136 Cytochrome P450 3A4 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0136 Cytochrome P450 3A4 
S. sinica ??? Tanshinone IIa 20686 T0136 Cytochrome P450 3A4 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0205 Dual oxidase 2 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0205 Dual oxidase 2 
S. miltiorrhiza ?? Ursolic acid 22270 T0205 Dual oxidase 2 
S. miltiorrhiza ?? Ursolic acid 22270 T0310 Ectonucleotide 
pyrophosphatase/phosphodiesterase family 
member 7 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0106 Endothelin-1 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0106 Endothelin-1 
S. sinica ??? Cryptotanshinone 4292 T0106 Endothelin-1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0106 Endothelin-1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0106 Endothelin-1 
A-20 
S. sinica ??? Tanshinone IIa 20686 T0106 Endothelin-1 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0105 Endothelin-1 receptor 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0105 Endothelin-1 receptor 
S. sinica ??? Tanshinone IIa 20686 T0105 Endothelin-1 receptor 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0236 Endothelin-converting enzyme 1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0236 Endothelin-converting enzyme 1 
S. sinica ??? Tanshinone IIa 20686 T0236 Endothelin-converting enzyme 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0174 E-selectin 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0017 Eukaryotic translation initiation factor 6 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0017 Eukaryotic translation initiation factor 6 
S. sinica ??? Dihydrotanshinone I 5722 T0017 Eukaryotic translation initiation factor 6 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0017 Eukaryotic translation initiation factor 6 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0061 Fatty acid synthase 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0061 Fatty acid synthase 
S. sinica ??? Tanshinone IIa 20686 T0061 Fatty acid synthase 
S. miltiorrhiza ?? Ursolic acid 22270 T0061 Fatty acid synthase 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0012 G1/S-specific cyclin-D1 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0012 G1/S-specific cyclin-D1 
S. sinica ??? Cryptotanshinone 4292 T0012 G1/S-specific cyclin-D1 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0012 G1/S-specific cyclin-D1 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0012 G1/S-specific cyclin-D1 
S. sinica ??? Dihydrotanshinone I 5722 T0012 G1/S-specific cyclin-D1 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0012 G1/S-specific cyclin-D1 
A-21 
S. miltiorrhiza ?? Ursolic acid 22270 T0012 G1/S-specific cyclin-D1 
S. miltiorrhiza ?? Ursolic acid 22270 T0211 G1/S-specific cyclin-D2 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0246 G1/S-specific cyclin-D3 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0246 G1/S-specific cyclin-D3 
S. sinica ??? Dihydrotanshinone I 5722 T0246 G1/S-specific cyclin-D3 
S. miltiorrhiza ?? Caffeic acid 2287 T0346 Glial fibrillary acidic protein 
S. miltiorrhiza ?? Ursolic acid 22270 T0197 Granulocyte-macrophage colony-stimulating 
factor 
S. miltiorrhiza ?? Ursolic acid 22270 T0116 Heparin-binding growth factor 2 
S. miltiorrhiza ?? Ursolic acid 22270 T0182 Induced myeloid leukemia cell differentiation 
protein Mcl-1 
S. miltiorrhiza ?? Caffeic acid 2287 T0374 Insulin-like growth factor II 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0239 Integrin beta-3 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0239 Integrin beta-3 
S. sinica ??? Tanshinone IIa 20686 T0239 Integrin beta-3 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0152 Intercellular adhesion molecule 1 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0152 Intercellular adhesion molecule 1 
S. miltiorrhiza ?? Tanshinone I 20685 T0152 Intercellular adhesion molecule 1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone I 20685 T0152 Intercellular adhesion molecule 1 
S. sinica ??? Tanshinone I 20685 T0152 Intercellular adhesion molecule 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0152 Intercellular adhesion molecule 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0156 Interleukin-1 beta 
S. miltiorrhiza ?? Ursolic acid 22270 T0039 Interleukin-6 
S. miltiorrhiza ?? Ursolic acid 22270 T0086 Interstitial collagenase 
S. miltiorrhiza ?? Ursolic acid 22270 T0210 Lipopolysaccharide-induced tumor necrosis 
factor-alpha factor 
A-22 
S. sinica ??? 3,4-Dihydroxybenzoic acid 5763 T0229 Maltase-glucoamylase, intestinal 
S. miltiorrhiza ?? 3,8-Dihydroxybenzoic acid 5763 T0229 Maltase-glucoamylase, intestinal 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0027 Matrix metalloproteinase-9 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0027 Matrix metalloproteinase-9 
S. sinica ??? Tanshinone IIa 20686 T0027 Matrix metalloproteinase-9 
S. miltiorrhiza ?? Ursolic acid 22270 T0027 Matrix metalloproteinase-9 
S. miltiorrhiza ?? Danshensu 4630 T0082 Metalloproteinase inhibitor 1 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0029 Mitogen-activated protein kinase 1 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0029 Mitogen-activated protein kinase 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0052 Mitogen-activated protein kinase 8 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0142 Myc proto-oncogene protein 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0142 Myc proto-oncogene protein 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0142 Myc proto-oncogene protein 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0142 Myc proto-oncogene protein 
S. miltiorrhiza ??? Tanshinone IIa 20686 T0142 Myc proto-oncogene protein 
S. miltiorrhiza ??? Tanshinone IIa 20686 T0142 Myc proto-oncogene protein 
S. miltiorrhiza ?? Danshensu 4630 T1257 Neurofibromin 
S. miltiorrhiza ?? Ursolic acid 22270 T0204 Neuromodulin 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0055 NF-kappa-B inhibitor alpha 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0055 NF-kappa-B inhibitor alpha 
S. sinica ??? Tanshinone IIa 20686 T0055 NF-kappa-B inhibitor alpha 
S. miltiorrhiza ?? Ursolic acid 22270 T0055 NF-kappa-B inhibitor alpha 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0206 Nitric oxide synthase, endothelial 
S. przewalskii var. ??? Tanshinone IIa 20686 T0206 Nitric oxide synthase, endothelial 
A-23 
mandarinorum 
S. sinica ??? Tanshinone IIa 20686 T0206 Nitric oxide synthase, endothelial 
S. miltiorrhiza ?? Ursolic acid 22270 T0206 Nitric oxide synthase, endothelial 
S. miltiorrhiza ?? Ursolic acid 22270 T0040 Nitric oxide synthase, inducible 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0234 Nuclear receptor subfamily 1 group I member 
2 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0234 Nuclear receptor subfamily 1 group I member 
2 
S. sinica ??? Tanshinone IIa 20686 T0234 Nuclear receptor subfamily 1 group I member 
2 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0235 Nucleophosmin 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0235 Nucleophosmin 
S. sinica ??? Tanshinone IIa 20686 T0235 Nucleophosmin 
S. miltiorrhiza ?? Protocatechuic aldehyde 17968 T0058 Ornithine decarboxylase 
S. przewalskii var. 
mandarinorum 
??? Protocatechuic aldehyde 17968 T0058 Ornithine decarboxylase 
S. sinica ??? Protocatechuic aldehyde 17968 T0058 Ornithine decarboxylase 
S. miltiorrhiza ?? Ursolic acid 22270 T0209 Phosphatidylinositol-3,4,5-trisphosphate 
5-phosphatase 2 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0265 Plasminogen activator inhibitor 1 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0265 Plasminogen activator inhibitor 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0198 Platelet endothelial cell adhesion molecule 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0237 Poly [ADP-ribose] polymerase 4 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0237 Poly [ADP-ribose] polymerase 4 
S. sinica ??? Tanshinone IIa 20686 T0237 Poly [ADP-ribose] polymerase 4 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0266 PRKC apoptosis WT1 regulator protein 
A-24 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0266 PRKC apoptosis WT1 regulator protein 
S. miltiorrhiza ?? Dihydrotanshinone I 5722 T0099 Probable E3 ubiquitin-protein ligase HERC5 
S. przewalskii var. 
mandarinorum 
??? Dihydrotanshinone I 5722 T0099 Probable E3 ubiquitin-protein ligase HERC5 
S. sinica ??? Dihydrotanshinone I 5722 T0099 Probable E3 ubiquitin-protein ligase HERC5 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0099 Probable E3 ubiquitin-protein ligase HERC5 
S. miltiorrhiza ?? Ursolic acid 22270 T0099 Probable E3 ubiquitin-protein ligase HERC5 
S. miltiorrhiza ?? Ursolic acid 22270 T0178 Prostaglandin E2 receptor EP3 subtype 
S. miltiorrhiza ?? Caffeic acid 2287 T0179 Prostaglandin G/H synthase 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0179 Prostaglandin G/H synthase 1 
S. miltiorrhiza ?? Caffeic acid 2287 T0054 Prostaglandin G/H synthase 2 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0054 Prostaglandin G/H synthase 2 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0054 Prostaglandin G/H synthase 2 
S. miltiorrhiza ?? Tigogenin 21383 T0054 Prostaglandin G/H synthase 2 
S. miltiorrhiza ?? Tigogenin 21383 T0054 Prostaglandin G/H synthase 2 
S. miltiorrhiza ?? Ursolic acid 22270 T0054 Prostaglandin G/H synthase 2 
S. miltiorrhiza ?? 3,4-Dihydroxybenzoic acid 5763 T0077 Protein kinase C alpha type 
S. sinica ??? 3,4-Dihydroxybenzoic acid 5763 T0077 Protein kinase C alpha type 
S. sinica ??? 3,4-Dihydroxybenzoic acid 5763 T0194 Protein kinase C beta type 
S. miltiorrhiza ?? 3,5-Dihydroxybenzoic acid 5763 T0194 Protein kinase C beta type 
S. miltiorrhiza ?? Caffeic acid 2287 T0194 Protein kinase C beta type 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0194 Protein kinase C beta type 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0194 Protein kinase C beta type 
S. sinica ??? 3,4-Dihydroxybenzoic acid 5763 T0195 Protein kinase C gamma type 
S. miltiorrhiza ?? 3,6-Dihydroxybenzoic acid 5763 T0195 Protein kinase C gamma type 
S. miltiorrhiza ?? Ursolic acid 22270 T0195 Protein kinase C gamma type 
A-25 
S. sinica ??? 3,4-Dihydroxybenzoic acid 5763 T1277 Protein kinase C zeta type 
S. miltiorrhiza ?? 3,7-Dihydroxybenzoic acid 5763 T1277 Protein kinase C zeta type 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0015 Proto-oncogene c-Fos 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0015 Proto-oncogene c-Fos 
S. sinica ??? Tanshinone IIa 20686 T0015 Proto-oncogene c-Fos 
S. miltiorrhiza ?? Ursolic acid 22270 T0015 Proto-oncogene c-Fos 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0199 Proto-oncogene tyrosine-protein kinase Src 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0199 Proto-oncogene tyrosine-protein kinase Src 
S. sinica ??? Tanshinone IIa 20686 T0199 Proto-oncogene tyrosine-protein kinase Src 
S. miltiorrhiza ?? Ursolic acid 22270 T0199 Proto-oncogene tyrosine-protein kinase Src 
S. miltiorrhiza ?? Caffeic acid 2287 T0388 P-selectin 
S. miltiorrhiza ?? Salvianolic acid A 19201 T0009 RAC-alpha serine/threonine-protein kinase 
S. miltiorrhiza ?? Caffeic acid 2287 T0752 Ras-related C3 botulinum toxin substrate 1 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0260 Ryanodine receptor 2 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0260 Ryanodine receptor 2 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0008 Signal transducer and activator of transcription 
3 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0008 Signal transducer and activator of transcription 
3 
S. sinica ??? Cryptotanshinone 4292 T0008 Signal transducer and activator of transcription 
3 
S. miltiorrhiza ?? Ursolic acid 22270 T0008 Signal transducer and activator of transcription 
3 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0264 Spermatogenic leucine zipper protein 1 
A-26 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0264 Spermatogenic leucine zipper protein 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0087 Stromelysin-1 
S. miltiorrhiza ?? Ursolic acid 22270 T0146 Stromelysin-2 
S. miltiorrhiza ?? Danshensu 4630 T0074 Superoxide dismutase [Cu-Zn] 
S. miltiorrhiza ?? Ferruginol 7764 T0577 T-cell surface glycoprotein CD1a 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0262 Thrombomodulin 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0262 Thrombomodulin 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0261 Tissue-type plasminogen activator 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0261 Tissue-type plasminogen activator 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0038 Transcription factor AP-1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0038 Transcription factor AP-1 
S. sinica ??? Tanshinone IIa 20686 T0038 Transcription factor AP-1 
S. miltiorrhiza ?? Ursolic acid 22270 T0038 Transcription factor AP-1 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0002 Transcription factor p65 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0002 Transcription factor p65 
S. sinica ??? Cryptotanshinone 4292 T0002 Transcription factor p65 
S. miltiorrhiza ?? Danshensu 4630 T0002 Transcription factor p65 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0002 Transcription factor p65 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0002 Transcription factor p65 
S. miltiorrhiza ?? Tanshinone IIa 20686 T0002 Transcription factor p65 
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIa 20686 T0002 Transcription factor p65 
S. sinica ??? Tanshinone IIa 20686 T0002 Transcription factor p65 
S. miltiorrhiza ?? Ursolic acid 22270 T0002 Transcription factor p65 
S. miltiorrhiza ?? Danshensu 4630 T0226 Transforming growth factor beta-1 
A-27 
S. miltiorrhiza ?? Caffeic acid 2287 T0037 Tumor necrosis factor 
S. miltiorrhiza ?? Cryptotanshinone 4292 T0037 Tumor necrosis factor 
S. przewalskii var. 
mandarinorum 
??? Cryptotanshinone 4292 T0037 Tumor necrosis factor 
S. sinica ??? Cryptotanshinone 4292 T0037 Tumor necrosis factor 
S. miltiorrhiza ?? Ursolic acid 22270 T0037 Tumor necrosis factor 
S. miltiorrhiza ?? Ursolic acid 22270 T0212 Tumor necrosis factor ligand superfamily 
member 6 
S. miltiorrhiza ?? Caffeic acid 2287 T0326 Tyrosine-protein kinase BTK 
S. miltiorrhiza ?? Ursolic acid 22270 T0208 Tyrosine-protein phosphatase non-receptor 
type 1 
S. miltiorrhiza ?? Ursolic acid 22270 T0203 Tyrosine-protein phosphatase non-receptor 
type 6 
S. miltiorrhiza ?? Ursolic acid 22270 T0025 Urokinase-type plasminogen activator 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0175 Vascular cell adhesion protein 1 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0175 Vascular cell adhesion protein 1 
S. miltiorrhiza ?? Tanshinone I 20685 T0175 Vascular cell adhesion protein 1 
S. przewalskii var. 
mandarinorum 
??? Tanshinone I 20685 T0175 Vascular cell adhesion protein 1 
S. sinica ??? Tanshinone I 20685 T0175 Vascular cell adhesion protein 1 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0010 Vascular endothelial growth factor A 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0010 Vascular endothelial growth factor A 
S. miltiorrhiza ?? Tanshinone I 20685 T0010 Vascular endothelial growth factor A 
S. przewalskii var. 
mandarinorum 
??? Tanshinone I 20685 T0010 Vascular endothelial growth factor A 
S. sinica ??? Tanshinone I 20685 T0010 Vascular endothelial growth factor A 
S. miltiorrhiza ?? Ursolic acid 22270 T0010 Vascular endothelial growth factor A 
S. miltiorrhiza ?? Lithospermic acid B 12926 T0021 Vascular endothelial growth factor receptor 2 
A-28 
S. miltiorrhiza ?? Salvianolic Acid B 19202 T0021 Vascular endothelial growth factor receptor 2 
S. miltiorrhiza f. alba ????   1,2,15,16-Tetrahydrotanshinone I 21080 NA  
S. miltiorrhiza ?? 1,2-Dihydrotanshiquinone 5723 NA  
S. miltiorrhiza ?? 1-Keto-isocryptotanshinone 12204 NA  
S. miltiorrhiza ?? 2-Isopropyl-8-methylphenanthrene-3,4-dione(R0-090680) 11629 NA  
S. miltiorrhiza ?? 3α-Hydroxytanshinone IIA 10736 NA  
S. miltiorrhiza ?? 3-β-Hydroxymethylenetanshiquinone 10492 NA  
S. miltiorrhiza ?? 3β-Hydroxytanshinone IIA 10737 NA  
S. miltiorrhiza ?? Baicalin 2106 NA  
S. miltiorrhiza ?? Danshenol A 4627 NA  
S. miltiorrhiza ?? Danshenol B 4628 NA  
S. miltiorrhiza ?? Danshenspiroketallactone 4629 NA  
S. miltiorrhiza ?? Danshensuan B 4631 NA  
S. miltiorrhiza ?? Danshenxinkun A 4632 NA  
S. miltiorrhiza ?? Danshenxinkun B 4633 NA  
S. miltiorrhiza ?? Danshenxinkun C 4634 NA  
S. miltiorrhiza ?? Danshenxinkun D 4635 NA  
S. miltiorrhiza ?? Daucosterol 4680 NA  
S. miltiorrhiza ?? Dehydromiltirone 4950 NA  
S. miltiorrhiza ?? Dihydroisotanshinone I 5653 NA  
S. miltiorrhiza ?? Epidanshenspiroketallactone 6877 NA  
S. miltiorrhiza ?? Isocryptotanshinone 11354 NA  
S. miltiorrhiza ?? Isotanshinone I 11729 NA  
S. miltiorrhiza ?? Isotanshinone IIA 11731 NA  
S. miltiorrhiza ?? Labiatenic acid 12420 NA  
A-29 
S. miltiorrhiza ?? Lithospermate B 12924 NA  
S. miltiorrhiza ?? Magnesium lithospermate B 13370 NA  
S. miltiorrhiza ?? Methyl tanshinonate 14736 NA  
S. przewalskii var. 
mandarinorum 
??? Methyl tanshinonate 14736 NA  
S. sinica ??? Methyl tanshinonate 14736 NA  
S. miltiorrhiza ?? Methylene tanshinquinone 14391 NA  
S. przewalskii var. 
mandarinorum 
??? Methylene tanshinquinone 14391 NA  
S. sinica ??? Methylene tanshinquinone 14391 NA  
S. miltiorrhiza ?? Miltionone I 14862 NA  
S. miltiorrhiza ?? Miltionone II 14863 NA  
S. miltiorrhiza ?? Miltipolone 14864 NA  
S. miltiorrhiza ?? Miltirone 14865 NA  
S. miltiorrhiza ?? Monomethyl lithospermate 14927 NA  
S. miltiorrhiza ?? Neocryptotanshinone 15374 NA  
S. miltiorrhiza ?? Neocryptotanshinone II 15375 NA  
S. miltiorrhiza ?? Nortanshinone 15801 NA  
S. miltiorrhiza ?? Oleoyl danshenxinkun A 16072 NA  
S. miltiorrhiza ?? Oleoyl neocryptotanshinone 16073 NA  
S. przewalskii var. 
mandarinorum 
??? Przewaquinone A 18011 NA  
S. miltiorrhiza ?? Przewaquinone B 18012 NA  
S. przewalskii var. 
mandarinorum 
??? Przewaquinone B 18012 NA  
S. sinica ??? Przewaquinone B 18012 NA  
S. przewalskii var. 
mandarinorum 
??? Przewaquinone F 18013 NA  
A-30 
S. miltiorrhiza ?? Rosmarinic acid methyl ester 18925 NA  
S. miltiorrhiza ?? Salvianolic acid C 19203 NA  
S. miltiorrhiza ?? Salvianolic acid D 19204 NA  
S. miltiorrhiza ?? Salvianolic acid E 19205 NA  
S. miltiorrhiza ?? Salvianolic acid G 19207 NA  
S. miltiorrhiza ?? Salvilenone 19217 NA  
S. miltiorrhiza ?? Salvinone 19218 NA  
S. miltiorrhiza ?? Salviol 19219 NA  
S. miltiorrhiza f. alba ???? Tanshinaldehyde 20678 NA  
S. miltiorrhiza ?? Tanshindiol A 20679 NA  
S. miltiorrhiza ?? Tanshindiol B 20680 NA  
S. miltiorrhiza ?? Tanshindiol C 20681 NA  
S. miltiorrhiza ?? Tanshinlactone 20682 NA  
S. miltiorrhiza ?? Tanshinol A 20683 NA  
S. miltiorrhiza ?? Tanshinol B 20684 NA  
S. miltiorrhiza ?? Tanshinone IIb 20687 NA  
S. przewalskii var. 
mandarinorum 
??? Tanshinone IIb 20687 NA  
S. sinica ??? Tanshinone IIb 20687 NA  
S. miltiorrhiza ?? Tanshinone VI 20688 NA  
S. miltiorrhiza ?? β-Sitosterol 19983 NA  
S. miltiorrhiza ?? Δ1-Dehydrotanshinone 4974 NA  
A-31 
Appendix 4 Biological target list for Lu hui (Aloe vera, A. vera var. chinensis, A. ferox, A. spp.) 
Species Chinese Compound name Compound ID Target ID Target name 
A. vera  ??(?????)  Rutin 19087 T0291 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T1114 Actin, cytoplasmic 1 
A. vera  ??(?????)  Sucrose 20446 T0510 Aldose reductase 
A. vera  ??(?????)  Sucrose 20446 T1162 Alpha-amylase 1 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0013 Apoptosis regulator Bcl-2 
A. vera  ??(?????)  Rutin 19087 T0279 Arachidonate 5-lipoxygenase 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T1116 BMP-binding endothelial regulator protein 
A. vera  ??(?????)  Rutin 19087 T0476 C5a anaphylatoxin chemotactic receptor 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0318 Calmodulin 
A. vera  ??(?????)  Rutin 19087 T0045 Caspase-3 
A. vera  ??(?????)  Succinic acid 20444 T0045 Caspase-3 
A. vera  ??(?????)  Rutin 19087 T0075 Catalase 
A. vera  ??(?????)  p-Coumaric acid 4135 T0546 C-C motif chemokine 16 
A. vera  ??(?????)  Sucrose 20446 T1163 Chitinase-3-like protein 1 
A. vera  ??(?????)  Hexadecanoic acid 9486 T1102 Choline-phosphate cytidylyltransferase A 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0267 Collagen alpha-1(I) chain 
A. vera  ??(?????)  Sucrose 20446 T0267 Collagen alpha-1(I) chain 
A. vera  ??(?????)  Sucrose 20446 T0225 Collagen alpha-1(VII) chain 
A. vera  ??(?????)  Sucrose 20446 T0138 Cytochrome P450 1A2 
A. vera  ??(?????)  Sucrose 20446 T0554 Delta-aminolevulinic acid dehydratase 
A. vera var. ????  Lauric acid 12569 T0205 Dual oxidase 2 
A-32 
chinensis 
A. vera var. 
chinensis 
????  Stearic acid 20280 T0310 Ectonucleotide pyrophosphatase/phosphodiesterase 
family member 7 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0061 Fatty acid synthase 
A. vera  ??(?????)  Sucrose 20446 T0094 Fos-related antigen 2 
A. vera  ??(?????)  Sucrose 20446 T0675 Glucose-6-phosphatase 
A. vera  ??(?????)  Sucrose 20446 T0485 Glutamine synthetase 
A. vera  ??(?????)  Rutin 19087 T0321 Glutathione S-transferase P 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T1002 Hepatocyte nuclear factor 1-alpha 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0775 Hepatocyte nuclear factor 4-alpha 
A. vera  ??(?????)  Sucrose 20446 T1164 Hexokinase-1 
A. vera  ??(?????)  Rutin 19087 T0316 Hyaluronan synthase 2 
A. vera  ??(?????)  Rutin 19087 T0506 Insulin 
A. vera  ??(?????)  Rutin 19087 T1153 Integrin beta-2 
A. vera  ??(?????)  Rutin 19087 T0156 Interleukin-1 beta 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0030 Interleukin-10 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0030 Interleukin-10 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0039 Interleukin-6 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0039 Interleukin-6 
A. vera  ??(?????)  Rutin 19087 T0039 Interleukin-6 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0181 Interleukin-8 
A. vera  ??(?????)  Rutin 19087 T0181 Interleukin-8 
A. vera  ??(?????)  Sucrose 20446 T0594 Lactase-phlorizin hydrolase 
A-33 
A. vera  ??(?????)  Sucrose 20446 T1165 Long-chain-fatty-acid--CoA ligase 1 
A. vera  ??(?????)  Sucrose 20446 T1166 Long-chain-fatty-acid--CoA ligase 4 
A. vera  ??(?????)  Rutin 19087 T0617 Low affinity immunoglobulin epsilon Fc receptor 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0846 Mitochondrial uncoupling protein 2 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0142 Myc proto-oncogene protein 
A. vera  ??(?????)  Rutin 19087 T0057 NADPH--cytochrome P450 reductase 
A. vera  ??(?????)  p-Coumaric acid 4135 T0206 Nitric oxide synthase, endothelial 
A. vera  ??(?????)  Rutin 19087 T0040 Nitric oxide synthase, inducible 
A. vera  ??(?????)  Sucrose 20446 T0356 Nuclear receptor subfamily 1 group I member 3 
A. vera  ??(?????)  Sucrose 20446 T1106 Pancreatic alpha-amylase 
A. vera  ??(?????)  Sucrose 20446 T0125 Peroxisome proliferator-activated receptor gamma 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0286 Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
and dual-specificity protein phosphatase PTEN 
A. vera  ??(?????)  p-Coumaric acid 4135 T0545 Polyphenol oxidase I, chloroplastic 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0101 Proliferating cell nuclear antigen 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0178 Prostaglandin E2 receptor EP3 subtype 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0054 Prostaglandin G/H synthase 2 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0054 Prostaglandin G/H synthase 2 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0054 Prostaglandin G/H synthase 2 
A. vera  ??(?????)  Rutin 19087 T0194 Protein kinase C beta type 
A. vera  ??(?????)  Sucrose 20446 T0015 Proto-oncogene c-Fos 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0814 Putative beta-glucuronidase-like protein SMA3 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0009 RAC-alpha serine/threonine-protein kinase 
A. vera var. ????  Linolenic acid 12893 T0139 Serum albumin 
A-34 
chinensis 
A. vera  ??(?????)  Hexadecanoic acid 9486 T1101 Solute carrier family 22 member 5 
A. vera  ??(?????)  Sucrose 20446 T0465 Sterol regulatory element-binding protein 1 
A. vera  ??(?????)  Sucrose 20446 T0132 Sterol regulatory element-binding protein 2 
A. vera  ??(?????)  Sucrose 20446 T0593 Sucrase-isomaltase, intestinal 
A. vera  ??(?????)  Glucuronic acid 8761 T0074 Superoxide dismutase [Cu-Zn] 
A. vera  ??(?????)  Rutin 19087 T0074 Superoxide dismutase [Cu-Zn] 
A. vera  ??(?????)  Rutin 19087 T1246 Thromboxane A2 receptor 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0435 T-lymphocyte activation antigen CD80 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0436 T-lymphocyte activation antigen CD86 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0002 Transcription factor p65 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0002 Transcription factor p65 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T0002 Transcription factor p65 
A. vera  ??(?????)  Rutin 19087 T0002 Transcription factor p65 
A. vera var. 
chinensis 
????  Stearic acid 20280 T0129 Transcription factor Sp1 
A. vera var. 
chinensis 
????  Linolenic acid 12893 T1115 Tripartite motif-containing protein 26 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0037 Tumor necrosis factor 
A. vera  ??(?????)  Hexadecanoic acid 9486 T0037 Tumor necrosis factor 
A. vera  ??(?????)  Rutin 19087 T0037 Tumor necrosis factor 
A. vera var. 
chinensis 
????  Lauric acid 12569 T0578 Tumor necrosis factor receptor superfamily member 5 
A. vera  ??(?????)  Rutin 19087 T0380 Type I iodothyronine deiodinase 
A. vera  ??(?????)  p-Coumaric acid 4135 T0256 Tyrosinase 
A. vera  ??(?????)  2''-O-Feruloylaloesin 7772 NA  
A-35 
A. vera  ??(?????)  6'-O-p-Coumaroylaloesin 4146 NA  
A. vera  ??(?????)  7-Hydroxyaloin A 9773 NA  
A. ferox ?????  Aloeemodin 967 NA  
A. vera  ??(?????)  Aloeemodin 967 NA  
A. vera var. 
chinensis 
????  Aloeemodin 967 NA  
A. vera  ??(?????)  Aloenin 972 NA  
A. spp. ???????  Aloeresin A 973 NA  
A. vera  ??(?????)  Aloeresin A 973 NA  
A. ferox ?????  Aloeresin C 974 NA  
A. ferox ?????  Aloeresin D 975 NA  
A. vera  ??(?????)  Aloeresin G 976 NA  
A. ferox ?????  Aloeresin H 977 NA  
A. ferox ?????  Aloeresin I 978 NA  
A. vera var. 
chinensis 
????  Aloesin 979 NA  
A. ferox ?????  Aloesone 980 NA  
A. ferox ?????  Aloin 981 NA  
A. vera  ??(?????)  Aloin 981 NA  
A. vera var. 
chinensis 
????  Aloin 981 NA  
A. vera  ??(?????)  Anthranol 1365 NA  
A. vera  ??(?????)  Campesterol 3040 NA  
A. vera  ??(?????)  Campherenol 3046 NA  
A. vera  ??(?????)  Capric acid 3138 NA  
A. vera  ??(?????)  Cholesterol 3585 NA  
A. vera  ??(?????)  Chrysophanol 3615 NA  
A-36 
A. vera var. 
chinensis 
????  cis-9,cis-12-Linoleic acid 12891 NA  
A. vera  ??(?????)  Daturic acid 4672 NA  
A. ferox ?????  Feralolide 7755 NA  
A. ferox ?????  Feroxidin 7761 NA  
A. ferox ?????  Feroxin A 7762 NA  
A. ferox ?????  Feroxin B 7763 NA  
A. vera  ??(?????)  Helminthosporin 9333 NA  
A. vera  ??(?????)  Homonataloin 9615 NA  
A. ferox ?????  Isoaloeresin A 11204 NA  
A. vera  ??(?????)  Isoaloesin 11205 NA  
A. vera  ??(?????)  Isoeleutherol glucoside 11409 NA  
A. vera  ??(?????)  Lactic acid 12436 NA  
A. vera  ??(?????)  Magnesium lactate 13368 NA  
A. vera  ??(?????)  Mannose 13507 NA  
A. vera  ??(?????)  Mannose-b 13508 NA  
A. vera var. 
chinensis 
????  Palmitoleic acid 16561 NA  
A. vera  ??(?????)  Pentadecanoic acid 16381 NA  
A. vera  ??(?????)  Rhamnose 18739 NA  
A. vera  ??(?????)  Xylose 20843 NA  
A. vera var. 
chinensis 
????  β-Carotene 3209 NA  
A-37 
Appendix 5 Biological target list for Qing dai (Indigo naturalis sourced from Isatis indigotica, I. tinctoria, B. cusia, S. formosanus) 
Species Chines
e  
Compound Compound 
ID 
Target 
ID 
Target name 
B. cusia  ??? Lupeol 13098 T0628 14-3-3 protein sigma 
I. indigotica ???  Salicylic acid 19187 T0831 6-phosphofructokinase, muscle type 
I. indigotica ???  Salicylic acid 19187 T0881 Aldo-keto reductase family 1 member 
C1 
I. indigotica ???  Sucrose 20446 T0510 Aldose reductase 
I. indigotica ???  Sucrose 20446 T1162 Alpha-amylase 1 
I. indigotica ???  Salicylic acid 19187 T0517 Apolipoprotein A-I 
B. cusia ??? Lupeol 13098 T0018 Apoptosis regulator BAX 
I. indigotica ???  β-Sitosterol 19983 T0018 Apoptosis regulator BAX 
I. indigotica ???  β-Sitosterol 19983 T0018 Apoptosis regulator BAX 
I. indigotica ???  Hexadecanoic acid 9486 T0013 Apoptosis regulator Bcl-2 
B. cusia  ??? Lupeol 13098 T0013 Apoptosis regulator Bcl-2 
I. indigotica ???  β-Sitosterol 19983 T0013 Apoptosis regulator Bcl-2 
I. indigotica ???  β-Sitosterol 19983 T0013 Apoptosis regulator Bcl-2 
B. cusia  ??? Lupeol 13098 T0463 Apoptotic protease-activating factor 1 
I. indigotica ???  Salicylic acid 19187 T0279 Arachidonate 5-lipoxygenase 
B. cusia  ??? Indirubin 11024 T0332 Aryl hydrocarbon receptor 
I. indigotica ???  Indirubin 11024 T0332 Aryl hydrocarbon receptor 
I. indigotica ???  Indirubin 11024 T0332 Aryl hydrocarbon receptor 
S. formosanus* ???
?* 
Indirubin 11024 T0332 Aryl hydrocarbon receptor 
I. indigotica ???  Salicylic acid 19187 T1062 Beta-glucuronidase 
A-38 
B. cusia  ??? Lupeol 13098 T0629 Carnitine O-acetyltransferase 
B. cusia  ??? Lupeol 13098 T0045 Caspase-3 
B. cusia  ??? Tryptanthrine 22059 T0045 Caspase-3 
I. indigotica ???  Tryptanthrine 22059 T0045 Caspase-3 
I. indigotica ???  Tryptanthrine 22059 T0045 Caspase-3 
I. tinctoria ???
? 
Tryptanthrine 22059 T0045 Caspase-3 
I. indigotica ???  β-Sitosterol 19983 T0045 Caspase-3 
I. indigotica ???  β-Sitosterol 19983 T0045 Caspase-3 
I. indigotica ???  β-Sitosterol 19983 T0060 Caspase-8 
I. indigotica ???  β-Sitosterol 19983 T0060 Caspase-8 
B. cusia  ??? Lupeol 13098 T0019 Caspase-9 
I. indigotica ???  β-Sitosterol 19983 T0019 Caspase-9 
I. indigotica ???  β-Sitosterol 19983 T0019 Caspase-9 
I. indigotica ???  Salicylic acid 19187 T0075 Catalase 
B. cusia  ??? Indirubin 11024 T0447 C-C motif chemokine 5 
I. indigotica ???  Indirubin 11024 T0447 C-C motif chemokine 5 
I. indigotica ???  Indirubin 11024 T0447 C-C motif chemokine 5 
S. formosanus ???
? 
Indirubin 11024 T0447 C-C motif chemokine 5 
B. cusia  ??? Lupeol 13098 T0100 Cell division control protein 2 homolog 
I. indigotica ???  Sucrose 20446 T1163 Chitinase-3-like protein 1 
I. indigotica ???  Hexadecanoic acid 9486 T1102 Choline-phosphate cytidylyltransferase 
A 
I. indigotica ???  Hexadecanoic acid 9486 T0267 Collagen alpha-1(I) chain 
I. indigotica ???  Sucrose 20446 T0267 Collagen alpha-1(I) chain 
A-39 
I. indigotica ???  Sucrose 20446 T0225 Collagen alpha-1(VII) chain 
B. cusia  ??? Indirubin 11024 T0583 Cyclin-dependent kinase inhibitor 3 
I. indigotica ???  Indirubin 11024 T0583 Cyclin-dependent kinase inhibitor 3 
I. indigotica ???  Indirubin 11024 T0583 Cyclin-dependent kinase inhibitor 3 
S. formosanus ???
? 
Indirubin 11024 T0583 Cyclin-dependent kinase inhibitor 3 
B. cusia  ??? Indirubin 11024 T0150 Cytochrome P450 1A1 
I. indigotica ???  Indirubin 11024 T0150 Cytochrome P450 1A1 
I. indigotica ???  Indirubin 11024 T0150 Cytochrome P450 1A1 
S. formosanus ???
? 
Indirubin 11024 T0150 Cytochrome P450 1A1 
I. indigotica ???  Sucrose 20446 T0138 Cytochrome P450 1A2 
I. indigotica ???  Sucrose 20446 T0554 Delta-aminolevulinic acid dehydratase 
I. indigotica ???  Salicylic acid 19187 T0106 Endothelin-1 
B. cusia  ??? Lupeol 13098 T0122 Estrogen receptor 
I. indigotica ???  Salicylic acid 19187 T0061 Fatty acid synthase 
I. indigotica ???  Salicylic acid 19187 T0821 Ferritin, mitochondrial 
I. indigotica ???  Sucrose 20446 T0094 Fos-related antigen 2 
B. cusia  ??? Lupeol 13098 T0247 G2/mitotic-specific cyclin-B1 
I. indigotica ???  Sucrose 20446 T0675 Glucose-6-phosphatase 
I. indigotica ???  Sucrose 20446 T0485 Glutamine synthetase 
I. indigotica ???  Salicylic acid 19187 T0321 Glutathione S-transferase P 
B. cusia  ??? Indirubin 11024 T0177 Glycogen synthase kinase-3 beta 
I. indigotica ???  Indirubin 11024 T0177 Glycogen synthase kinase-3 beta 
I. indigotica ???  Indirubin 11024 T0177 Glycogen synthase kinase-3 beta 
S. formosanus ??? Indirubin 11024 T0177 Glycogen synthase kinase-3 beta 
A-40 
? 
I. indigotica ???  Salicylic acid 19187 T1126 Golgi-associated plant 
pathogenesis-related protein 1 
I. indigotica ???  Salicylic acid 19187 T1122 Hairy/enhancer-of-split related with 
YRPW motif protein 1 
B. cusia  ??? Tryptanthrine 22059 T0224 Hepatocyte growth factor 
I. indigotica ???  Tryptanthrine 22059 T0224 Hepatocyte growth factor 
I. indigotica ???  Tryptanthrine 22059 T0224 Hepatocyte growth factor 
I. tinctoria ???
? 
Tryptanthrine 22059 T0224 Hepatocyte growth factor 
I. indigotica ???  Sucrose 20446 T1164 Hexokinase-1 
B. cusia  ??? Acteroside 580 T0152 Intercellular adhesion molecule 1 
I. indigotica ???  Salicylic acid 19187 T0665 Interferon beta 
B. cusia  ??? Indirubin 11024 T0275 Interferon gamma 
I. indigotica ???  Indirubin 11024 T0275 Interferon gamma 
I. indigotica ???  Indirubin 11024 T0275 Interferon gamma 
S. formosanus ???
? 
Indirubin 11024 T0275 Interferon gamma 
I. indigotica ???  Hexadecanoic acid 9486 T0030 Interleukin-10 
I. indigotica ???  Salicylic acid 19187 T0276 Interleukin-4 
I. indigotica ???  Kinetin 12227 T0051 Involucrin 
I. indigotica ???  Kinetin 12227 T0590 Keratin, type I cytoskeletal 10 
I. indigotica ???  Sucrose 20446 T0594 Lactase-phlorizin hydrolase 
I. indigotica ???  Sucrose 20446 T1165 Long-chain-fatty-acid--CoA ligase 1 
I. indigotica ???  Sucrose 20446 T1166 Long-chain-fatty-acid--CoA ligase 4 
I. indigotica ???  Salicylic acid 19187 T1127 Membrane primary amine oxidase 
I. indigotica ???  β-Sitosterol 19983 T0826 Microtubule-associated protein 2 
A-41 
I. indigotica ???  β-Sitosterol 19983 T0826 Microtubule-associated protein 2 
B. cusia  ??? Lupeol 13098 T0251 M-phase inducer phosphatase 3 
B. cusia  ??? Tryptanthrine 22059 T0223 Multidrug resistance protein 1 
I. indigotica ???  Tryptanthrine 22059 T0223 Multidrug resistance protein 1 
I. indigotica ???  Tryptanthrine 22059 T0223 Multidrug resistance protein 1 
I. tinctoria ???
? 
Tryptanthrine 22059 T0223 Multidrug resistance protein 1 
I. indigotica ???  Salicylic acid 19187 T0309 Neutrophil cytosol factor 1 
I. indigotica ???  Salicylic acid 19187 T0614 Nuclear factor NF-kappa-B p105 
subunit 
I. indigotica ???  Sucrose 20446 T0356 Nuclear receptor subfamily 1 group I 
member 3 
I. indigotica ???  Sucrose 20446 T1106 Pancreatic alpha-amylase 
I. indigotica ???  Sucrose 20446 T0125 Peroxisome proliferator-activated 
receptor gamma 
I. indigotica ???  Hexadecanoic acid 9486 T0286 Phosphatidylinositol-3,4,5-trisphosphat
e 3-phosphatase and dual-specificity 
protein phosphatase PTEN 
I. indigotica ???  Salicylic acid 19187 T0555 Plasminogen 
I. indigotica ???  Salicylic acid 19187 T1123 Prolow-density lipoprotein 
receptor-related protein 1 
I. indigotica ???  Salicylic acid 19187 T1124 Prostacyclin synthase 
I. indigotica ???  β-Sitosterol 19983 T0077 Protein kinase C alpha type 
I. indigotica ???  β-Sitosterol 19983 T0077 Protein kinase C alpha type 
I. indigotica ???  Sucrose 20446 T0015 Proto-oncogene c-Fos 
I. indigotica ???  Hexadecanoic acid 9486 T0814 Putative beta-glucuronidase-like 
protein SMA3 
I. indigotica ???  Salicylic acid 19187 T0408 Pyruvate kinase isozymes R/L 
B. cusia  ??? Indirubin 11024 T0582 Ribosyldihydronicotinamide 
dehydrogenase [quinone] 
I. indigotica ???  Indirubin 11024 T0582 Ribosyldihydronicotinamide 
A-42 
dehydrogenase [quinone] 
I. indigotica ???  Indirubin 11024 T0582 Ribosyldihydronicotinamide 
dehydrogenase [quinone] 
S. formosanus ???
? 
Indirubin 11024 T0582 Ribosyldihydronicotinamide 
dehydrogenase [quinone] 
B. cusia  ??? Lupeol 13098 T0518 Serine/threonine-protein kinase PLK1 
I. indigotica ???  Salicylic acid 19187 T0379 Serum paraoxonase/arylesterase 1 
I. indigotica ???  β-Sitosterol 19983 T0379 Serum paraoxonase/arylesterase 1 
I. indigotica ???  β-Sitosterol 19983 T0379 Serum paraoxonase/arylesterase 1 
I. indigotica ???  Hexadecanoic acid 9486 T1101 Solute carrier family 22 member 5 
I. indigotica ???  Sucrose 20446 T0465 Sterol regulatory element-binding 
protein 1 
I. indigotica ???  Sucrose 20446 T0132 Sterol regulatory element-binding 
protein 2 
I. indigotica ???  Sucrose 20446 T0593 Sucrase-isomaltase, intestinal 
B. cusia  ??? Lupeol 13098 T0074 Superoxide dismutase [Cu-Zn] 
I. indigotica ???  Salicylic acid 19187 T0074 Superoxide dismutase [Cu-Zn] 
I. indigotica ???  Salicylic acid 19187 T1128 Telomeric repeat-binding factor 1 
I. indigotica ???  Salicylic acid 19187 T1008 Thyroid peroxidase 
I. indigotica ???  β-Sitosterol 19983 T0038 Transcription factor AP-1 
I. indigotica ???  β-Sitosterol 19983 T0038 Transcription factor AP-1 
I. indigotica ???  Salicylic acid 19187 T0002 Transcription factor p65 
I. indigotica ???  β-Sitosterol 19983 T0226 Transforming growth factor beta-1 
I. indigotica ???  β-Sitosterol 19983 T0226 Transforming growth factor beta-1 
I. indigotica ???  Hexadecanoic acid 9486 T0037 Tumor necrosis factor 
I. indigotica ???  Salicylic acid 19187 T1125 Tyrosine aminotransferase 
B. cusia cusia] ??? (+)-5,5'-Dimethoxy-9-O-β-D-glucopyranosyl lariciresinol 6230 NA  
B. cusia cusia] ??? (+)-5,5'-Dimethoxy-9-O-β-D-glucopyranosyl secoisolariciresinol 6231 NA  
A-43 
B. cusia cusia] ??? (+)-Lyoniresinol-2α-O-β-D-glucopyranoside (D4) 13250 NA  
B. cusia cusia] ??? (+)-Lyoniresinol-3α-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside 13251 NA  
I. indigotica ???  (E)-2-[(3'-Indole)cyanomethylene]-3-indolinone 11030 NA  
I. indigotica ???  (E)-3-(3',5'-Dimethoxy-4'-hydroxybenzylidene)-2-indolinone 6235 NA  
I. indigotica ???  1-Thiocyanato-2-hydroxy-3-butene 21334 NA  
I. indigotica ???  2,3-Dihydro-4-hydroxy-2-indole-3-acetonitrile 5637 NA  
I. indigotica ???  3-(2'-Hydroxyphenyl)-4-(3H)-quinazolinone 10643 NA  
I. indigotica ???  4-(1,2,3-Trihydroxypropyl)-2,6-dimethoxyphenyl-1-O-β-D-glucopyranosi
de 
21840 NA  
I. indigotica ???  Adenine nucleoside 618 NA  
I. indigotica ???  Adenine nucleoside 618 NA  
I. indigotica ???  Benzoic acid 2224 NA  
B. cusia  ??? Cusianoside A 4419 NA  
B. cusia  ??? Cusianoside B 4420 NA  
I. indigotica ???  Glucobrassicin 8589 NA  
I. indigotica ???  Glucobrassicin-1-Sulfonate 8590 NA  
I. indigotica ???  Indican glucoside 11014 NA  
I. indigotica ???  Indican glucoside 11014 NA  
I. indigotica ???  Indigotiisocoumarin A 11022 NA  
I. indigotica ???  Indigotin 11023 NA  
I. indigotica ???  Indigotin 11023 NA  
S. formosanus ???
? 
Indigotin 11023 NA  
I. indigotica ???  Indole-3-acetonitrile-6-O-β-D-glucopyranoside 11028 NA  
I. indigotica ???  Isaindigodione 11186 NA  
I. indigotica ???  Isaindigotidione 11187 NA  
A-44 
I. indigotica ???  Isatan B 11188 NA  
I. indigotica ???  Isatin 11190 NA  
B. cusia  ??? Isoindigo 11463 NA  
I. indigotica ???  Neoglucobrassicin 15400 NA  
B. cusia  ??? Qingdainone 18287 NA  
I. indigotica ???  Qingdainone 18287 NA  
I. tinctoria ???
? 
Qingdainone 18287 NA  
I. indigotica ???  Sinalbine 19909 NA  
I. indigotica ???  Sinigrin 19935 NA  
I. indigotica ???  Syringic acid 20566 NA  
I. indigotica ???  Tryptophan 22060 NA  
I. indigotica ???  β-n-Butyl-D-tagatopyranoside 2806 NA  
I. indigotica ???  γ-Aminobutyric acid 1048 NA  
I. indigotica ???  γ-Sitosterol 19984 NA  
I. indigotica ???  γ-Sitosterol 19984 NA  
A-45 
Appendix 6 Biological target list for Xi shu (Camptotheca acuminata) 
Species Chinese  Compounds Compound 
ID 
Target 
ID 
Target name 
C. acuminata ??  Quercetin 18317 T0333 26S proteasome non-ATPase regulatory subunit 3 
C. acuminata ??  Quercetin 18317 T0026 72 kDa type IV collagenase 
C. acuminata ??  Quercetin 18317 T0108 78 kDa glucose-regulated protein 
C. acuminata ??  Quercetin 18317 T0128 Acetyl-CoA carboxylase 1 
C. acuminata ??  Quercetin 18317 T0044 Activator of 90 kDa heat shock protein ATPase homolog 
1 
C. acuminata ??  Quercetin 18317 T0114 Androgen receptor 
C. acuminata ??  Hyperin 10887 T0018 Apoptosis regulator BAX 
C. acuminata ??  Quercetin 18317 T0018 Apoptosis regulator BAX 
C. acuminata ??  Quercetin 18317 T0013 Apoptosis regulator Bcl-2 
C. acuminata ??  Quercetin 18317 T0279 Arachidonate 5-lipoxygenase 
C. acuminata ??  Quercetin 18317 T0332 Aryl hydrocarbon receptor 
C. acuminata ??  Quercetin 18317 T0314 ATP-binding cassette sub-family G member 2 
C. acuminata ??  Quercetin 18317 T0202 Baculoviral IAP repeat-containing protein 5 
C. acuminata ??  Quercetin 18317 T0014 Bcl-2-like protein 1 
C. acuminata ??  Quercetin 18317 T0289 Bone morphogenetic protein 2 
C. acuminata ??  Hyperin 10887 T0045 Caspase-3 
C. acuminata ??  Quercetin 18317 T0045 Caspase-3 
C. acuminata ??  Quercetin 18317 T0060 Caspase-8 
C. acuminata ??  Quercetin 18317 T0019 Caspase-9 
C. acuminata ??  Hyperin 10887 T0075 Catalase 
A-46 
C. acuminata ??  Quercetin 18317 T0075 Catalase 
C. acuminata ??  Quercetin 18317 T0372 Cathepsin D 
C. acuminata ??  Quercetin 18317 T0140 Caveolin-1 
C. acuminata ??  Quercetin 18317 T0167 C-C motif chemokine 2 
C. acuminata ??  Quercetin 18317 T0376 CD40 ligand 
C. acuminata ??  Quercetin 18317 T0100 Cell division control protein 2 homolog 
C. acuminata ??  Quercetin 18317 T0046 Cellular tumor antigen p53 
C. acuminata ??  Quercetin 18317 T0359 Claudin-4 
C. acuminata ??  Quercetin 18317 T0267 Collagen alpha-1(I) chain 
C. acuminata ??  Quercetin 18317 T0344 Collagen alpha-1(III) chain 
C. acuminata ??  Quercetin 18317 T0363 C-reactive protein 
C. acuminata ??  Quercetin 18317 T0364 C-X-C motif chemokine 10 
C. acuminata ??  Quercetin 18317 T0353 C-X-C motif chemokine 11 
C. acuminata ??  Quercetin 18317 T0354 C-X-C motif chemokine 2 
C. acuminata ??  Quercetin 18317 T0016 Cyclin-dependent kinase inhibitor 1 
C. acuminata ??  Quercetin 18317 T0042 Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3 
C. acuminata ??  Quercetin 18317 T0150 Cytochrome P450 1A1 
C. acuminata ??  Quercetin 18317 T0138 Cytochrome P450 1A2 
C. acuminata ??  Quercetin 18317 T0240 Cytochrome P450 1B1 
C. acuminata ??  Quercetin 18317 T0136 Cytochrome P450 3A4 
C. acuminata ??  Quercetin 18317 T0355 DDB1- and CUL4-associated factor 5 
C. acuminata ??  Quercetin 18317 T0352 DNA gyrase subunit B 
C. acuminata ??  Quercetin 18317 T0062 DNA topoisomerase 1 
C. acuminata ??  Quercetin 18317 T0307 DNA topoisomerase 2-alpha 
C. acuminata ??  Quercetin 18317 T0205 Dual oxidase 2 
A-47 
C. acuminata ??  Quercetin 18317 T0007 Epidermal growth factor receptor 
C. acuminata ??  Quercetin 18317 T0174 E-selectin 
C. acuminata ??  Quercetin 18317 T0122 Estrogen receptor 
C. acuminata ??  Quercetin 18317 T0123 Estrogen receptor beta 
C. acuminata ??  Quercetin 18317 T0228 Estrogen sulfotransferase 
C. acuminata ??  Quercetin 18317 T0049 ETS domain-containing protein Elk-1 
C. acuminata ??  Quercetin 18317 T0017 Eukaryotic translation initiation factor 6 
C. acuminata ??  Quercetin 18317 T0375 Extracellular superoxide dismutase [Cu-Zn] 
C. acuminata ??  Quercetin 18317 T0012 G1/S-specific cyclin-D1 
C. acuminata ??  Quercetin 18317 T0247 G2/mitotic-specific cyclin-B1 
C. acuminata ??  Quercetin 18317 T0145 Gap junction alpha-1 protein 
C. acuminata ??  Quercetin 18317 T0645 Glutathione S-transferase Mu 1 
C. acuminata ??  Quercetin 18317 T0646 Glutathione S-transferase Mu 2 
C. acuminata ??  Quercetin 18317 T0321 Glutathione S-transferase P 
C. acuminata ??  Quercetin 18317 T0177 Glycogen synthase kinase-3 beta 
C. acuminata ??  Quercetin 18317 T0362 Heat shock factor protein 1 
C. acuminata ??  Quercetin 18317 T0216 Heat shock protein beta-1 
C. acuminata ??  Quercetin 18317 T0135 Heme oxygenase 1 
C. acuminata ??  Quercetin 18317 T0383 Hexokinase-2 
C. acuminata ??  Quercetin 18317 T0384 Homeobox protein Nkx-3.1 
C. acuminata ??  Quercetin 18317 T0316 Hyaluronan synthase 2 
C. acuminata ??  Quercetin 18317 T0090 Hypoxia-inducible factor 1-alpha 
C. acuminata ??  Quercetin 18317 T0365 Inhibitor of nuclear factor kappa-B kinase subunit alpha 
C. acuminata ??  Quercetin 18317 T0358 Insulin receptor 
C. acuminata ??  Quercetin 18317 T0374 Insulin-like growth factor II 
A-48 
C. acuminata ??  Quercetin 18317 T0373 Insulin-like growth factor-binding protein 3 
C. acuminata ??  Quercetin 18317 T0152 Intercellular adhesion molecule 1 
C. acuminata ??  Quercetin 18317 T0275 Interferon gamma 
C. acuminata ??  Quercetin 18317 T0377 Interferon regulatory factor 1 
C. acuminata ??  Quercetin 18317 T0297 Interleukin-1 alpha 
C. acuminata ??  Quercetin 18317 T0156 Interleukin-1 beta 
C. acuminata ??  Quercetin 18317 T0030 Interleukin-10 
C. acuminata ??  Quercetin 18317 T0231 Interleukin-2 
C. acuminata ??  Quercetin 18317 T0039 Interleukin-6 
C. acuminata ??  Quercetin 18317 T0181 Interleukin-8 
C. acuminata ??  Quercetin 18317 T0086 Interstitial collagenase 
C. acuminata ??  Quercetin 18317 T0229 Maltase-glucoamylase, intestinal 
C. acuminata ??  Quercetin 18317 T0027 Matrix metalloproteinase-9 
C. acuminata ??  Quercetin 18317 T0029 Mitogen-activated protein kinase 1 
C. acuminata ??  Quercetin 18317 T0142 Myc proto-oncogene protein 
C. acuminata ??  Quercetin 18317 T0302 Myeloperoxidase 
C. acuminata ??  Quercetin 18317 T0323 NAD(P)H dehydrogenase [quinone] 1 
C. acuminata ??  Hyperin 10887 T0459 NAD-dependent deacetylase sirtuin-1 
C. acuminata ??  Quercetin 18317 T0057 NADPH--cytochrome P450 reductase 
C. acuminata ??  Quercetin 18317 T0309 Neutrophil cytosol factor 1 
C. acuminata ??  Quercetin 18317 T0055 NF-kappa-B inhibitor alpha 
C. acuminata ??  Quercetin 18317 T0206 Nitric oxide synthase, endothelial 
C. acuminata ??  Quercetin 18317 T0040 Nitric oxide synthase, inducible 
C. acuminata ??  Quercetin 18317 T0322 Nuclear factor erythroid 2-related factor 2 
C. acuminata ??  Quercetin 18317 T0234 Nuclear receptor subfamily 1 group I member 2 
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C. acuminata ??  Quercetin 18317 T0356 Nuclear receptor subfamily 1 group I member 3 
C. acuminata ??  Quercetin 18317 T0058 Ornithine decarboxylase 
C. acuminata ??  Quercetin 18317 T0366 Osteopontin 
C. acuminata ??  Quercetin 18317 T0598 Peroxidase C1A 
C. acuminata ??  Quercetin 18317 T0360 Peroxisome proliferator-activated receptor alpha 
C. acuminata ??  Quercetin 18317 T0361 Peroxisome proliferator-activated receptor delta 
C. acuminata ??  Quercetin 18317 T0125 Peroxisome proliferator-activated receptor gamma 
C. acuminata ??  Quercetin 18317 T0286 Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
and dual-specificity protein phosphatase PTEN 
C. acuminata ??  Quercetin 18317 T0265 Plasminogen activator inhibitor 1 
C. acuminata ??  Quercetin 18317 T0330 Poly [ADP-ribose] polymerase 1 
C. acuminata ??  Quercetin 18317 T0099 Probable E3 ubiquitin-protein ligase HERC5 
C. acuminata ??  Quercetin 18317 T0381 Procollagen C-endopeptidase enhancer 1 
C. acuminata ??  Quercetin 18317 T0031 Pro-epidermal growth factor 
C. acuminata ??  Quercetin 18317 T0178 Prostaglandin E2 receptor EP3 subtype 
C. acuminata ??  Quercetin 18317 T0179 Prostaglandin G/H synthase 1 
C. acuminata ??  Quercetin 18317 T0054 Prostaglandin G/H synthase 2 
C. acuminata ??  Quercetin 18317 T0371 Prostatic acid phosphatase 
C. acuminata ??  Quercetin 18317 T0098 Protein CBFA2T1 
C. acuminata ??  Quercetin 18317 T0077 Protein kinase C alpha type 
C. acuminata ??  Quercetin 18317 T0194 Protein kinase C beta type 
C. acuminata ??  Quercetin 18317 T0015 Proto-oncogene c-Fos 
C. acuminata ??  Quercetin 18317 T0382 Puromycin-sensitive aminopeptidase 
C. acuminata ??  Quercetin 18317 T0009 RAC-alpha serine/threonine-protein kinase 
C. acuminata ??  Quercetin 18317 T0066 RAF proto-oncogene serine/threonine-protein kinase 
C. acuminata ??  Quercetin 18317 T0368 Ras association domain-containing protein 1 
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C. acuminata ??  Quercetin 18317 T0385 Ras GTPase-activating protein 1 
C. acuminata ??  Quercetin 18317 T0109 Receptor tyrosine-protein kinase erbB-2 
C. acuminata ??  Quercetin 18317 T0378 Receptor tyrosine-protein kinase erbB-3 
C. acuminata ??  Quercetin 18317 T0033 Retinoblastoma-associated protein 
C. acuminata ??  Quercetin 18317 T0367 Runt-related transcription factor 2 
C. acuminata ??  Quercetin 18317 T0357 Serine/threonine-protein kinase Chk2 
C. acuminata ??  Quercetin 18317 T0379 Serum paraoxonase/arylesterase 1 
C. acuminata ??  Quercetin 18317 T0092 Signal transducer and activator of transcription 
1-alpha/beta 
C. acuminata ??  Quercetin 18317 T0343 Solute carrier family 2, facilitated glucose transporter 
member 4 
C. acuminata ??  Hyperin 10887 T0074 Superoxide dismutase [Cu-Zn] 
C. acuminata ??  Quercetin 18317 T0074 Superoxide dismutase [Cu-Zn] 
C. acuminata ??  Quercetin 18317 T0262 Thrombomodulin 
C. acuminata ??  Quercetin 18317 T0144 Tissue factor 
C. acuminata ??  Quercetin 18317 T0261 Tissue-type plasminogen activator 
C. acuminata ??  Quercetin 18317 T0038 Transcription factor AP-1 
C. acuminata ??  Quercetin 18317 T0369 Transcription factor E2F1 
C. acuminata ??  Quercetin 18317 T0370 Transcription factor E2F2 
C. acuminata ??  Quercetin 18317 T0002 Transcription factor p65 
C. acuminata ??  Quercetin 18317 T0226 Transforming growth factor beta-1 
C. acuminata ??  Quercetin 18317 T0037 Tumor necrosis factor 
C. acuminata ??  Quercetin 18317 T0380 Type I iodothyronine deiodinase 
C. acuminata ??  Quercetin 18317 T0025 Urokinase-type plasminogen activator 
C. acuminata ??  Quercetin 18317 T0175 Vascular cell adhesion protein 1 
C. acuminata ??  Quercetin 18317 T0010 Vascular endothelial growth factor A 
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C. acuminata ??  Quercetin 18317 T0059 Xanthine dehydrogenase/oxidase 
C. acuminata ??  10-Hydroxycamptothecin 9882 NA  
C. acuminata ??  10-Methoxy-20-O-acetylcamptothecin 13831 NA  
C. acuminata ??  10-Methoxycamptothecin 13863 NA  
C. acuminata ??  18-Hydroxycamptothecin 9883 NA  
C. acuminata ??  19-O-Methylangustoline 14139 NA  
C. acuminata ??  20-Formylbenzo[6,7]indolizino[1,2-b]quinolin-11 
(13H)-one 
7896 NA  
C. acuminata ??  20-O-Acetylcamptothecin 341 NA  
C. acuminata ??  20-O-β-Glucopyranosyl 18-hydroxycamptothecin 8667 NA  
C. acuminata ??  3,3',4-O-Trimethyl-4'-O-β-D-glucopyranosylellagic acid 21961 NA  
C. acuminata ??  3,3',4-Tri-O-methyl ellagic acid 21955 NA  
C. acuminata ??  3,4-Methylenedioxy-3',4'-O-dimethyl-5,5'-dimethoxyellagic 
acid 
14365 NA  
C. acuminata ??  3,4-Methylenedioxy-3',4'-O-dimethyl-5'-methoxyellagic 
acid 
14366 NA  
C. acuminata ??  3,4-Methylenedioxy-3'-O-methyl-5'-hydroxyellagic acid 14377 NA  
C. acuminata ??  9-Methoxycamptothecin 13864 NA  
C. acuminata ??  Astragalin 1935 NA  
C. acuminata ??  Betulinic acid 2334 NA  
C. acuminata ??  Camptothecin 3053 T0062* DNA topoisomerase 1 
T0223* Multidrug resistance protein 1 
T0314* ATP-binding cassette sub-family G member 2 
C. acuminata ??  Deoxycamptothecin 5157 NA  
C. acuminata ??  Fructose 7971 NA  
C. acuminata ??  Gentialutine 8291 NA  
C. acuminata ??  Isoquercitrin 11642 NA  
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C. acuminata ??  Nyssoside 15880 NA  
C. acuminata ??  Pumiloside 18199 NA  
C. acuminata ??  Strictosidinic acid 20391 NA  
C. acuminata ??  Trifolin 21634 NA  
C. acuminata ??  Vincosamide 22496 NA  
* DrugBank showed camptothecin affected these 3 targets.
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Appendix 7 Biological target list for Gong lao mu (Mahonia aqulifolium, M. shenii, M. veitchiorum, M. japonica, M. bealei, M. fortunei, M. 
eurybracteata, M. gracilipes, M. bodinieri) 
Species Chinese Compound Compound 
ID 
Target ID Target name 
M. japonica ?????  Coptisine 4032 T0287 Amine oxidase [flavin-containing] A 
M. japonica ????? Coptisine 4032 T0287 Amine oxidase [flavin-containing] A 
M. bealei ????? Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. bodinieri ?????? Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. eurybracteata ?????? Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. fortunei ????? Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. gracilipes ??????  Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. japonica ?????  Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. shenii ?????? Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M. veitchiorum ?????? Jatrorrhizine 11851 T0287 Amine oxidase [flavin-containing] A 
M.a bealei ????? Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M. bodinieri ?????? Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M. eurybracteata ?????? Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M.a fortunei ????? Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M. gracilipes ??????  Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M.. japonica ?????  Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M. shenii ?????? Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M. veitchiorum ?????? Jatrorrhizine 11851 T0288 Amine oxidase [flavin-containing] B 
M. bealei ????? Berberine 2303 T0079 Amyloid beta A4 protein 
M. bodinieri ?????? Berberine 2303 T0079 Amyloid beta A4 protein 
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M. eurybracteata ?????? Berberine 2303 T0079 Amyloid beta A4 protein 
M. fortunei ????? Berberine 2303 T0079 Amyloid beta A4 protein 
M. gracilipes ??????  Berberine 2303 T0079 Amyloid beta A4 protein 
M. japonica ?????  Berberine 2303 T0079 Amyloid beta A4 protein 
M. shenii ?????? Berberine 2303 T0079 Amyloid beta A4 protein 
M. veitchiorum ?????? Berberine 2303 T0079 Amyloid beta A4 protein 
M. bealei ????? Berberine 2303 T0006 Angiotensinogen 
M. bodinieri ?????? Berberine 2303 T0006 Angiotensinogen 
M. eurybracteata ?????? Berberine 2303 T0006 Angiotensinogen 
M. fortunei ????? Berberine 2303 T0006 Angiotensinogen 
M.a gracilipes ??????  Berberine 2303 T0006 Angiotensinogen 
M. japonica ?????  Berberine 2303 T0006 Angiotensinogen 
M. shenii ?????? Berberine 2303 T0006 Angiotensinogen 
M. veitchiorum ?????? Berberine 2303 T0006 Angiotensinogen 
M. bealei ????? Berberine 2303 T0018 Apoptosis regulator BAX 
M. bodinieri ?????? Berberine 2303 T0018 Apoptosis regulator BAX 
M. eurybracteata ?????? Berberine 2303 T0018 Apoptosis regulator BAX 
M. fortunei ????? Berberine 2303 T0018 Apoptosis regulator BAX 
M. gracilipes ??????  Berberine 2303 T0018 Apoptosis regulator BAX 
M. japonica ?????  Berberine 2303 T0018 Apoptosis regulator BAX 
M. shenii ?????? Berberine 2303 T0018 Apoptosis regulator BAX 
M. veitchiorum ?????? Berberine 2303 T0018 Apoptosis regulator BAX 
M. bealei ????? Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. bodinieri ?????? Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. eurybracteata ?????? Berberine 2303 T0013 Apoptosis regulator Bcl-2 
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M. fortunei ????? Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. gracilipes ??????  Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. japonica ?????  Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. shenii ?????? Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. veitchiorum ?????? Berberine 2303 T0013 Apoptosis regulator Bcl-2 
M. bealei ????? Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. bodinieri ?????? Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. eurybracteata ?????? Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. fortunei ????? Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. gracilipes ??????  Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. japonica ?????  Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. shenii ?????? Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. veitchiorum ?????? Berberine 2303 T0332 Aryl hydrocarbon receptor 
M. bealei ????? Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M.bodinieri ?????? Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. eurybracteata ?????? Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. fortunei ????? Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. gracilipes ??????  Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. japonica ?????  Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. shenii ?????? Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. veitchiorum ?????? Berberine 2303 T0314 ATP-binding cassette sub-family G member 2 
M. bealei ????? Berberine 2303 T0014 Bcl-2-like protein 1 
M. bodinieri ?????? Berberine 2303 T0014 Bcl-2-like protein 1 
M. eurybracteata ?????? Berberine 2303 T0014 Bcl-2-like protein 1 
M. fortunei ????? Berberine 2303 T0014 Bcl-2-like protein 1 
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M. gracilipes ??????  Berberine 2303 T0014 Bcl-2-like protein 1 
M. japonica ?????  Berberine 2303 T0014 Bcl-2-like protein 1 
M. shenii ?????? Berberine 2303 T0014 Bcl-2-like protein 1 
M. veitchiorum ?????? Berberine 2303 T0014 Bcl-2-like protein 1 
M. bealei ????? Berberine 2303 T0183 BH3-interacting domain death agonist 
M. bodinieri ?????? Berberine 2303 T0183 BH3-interacting domain death agonist 
M. eurybracteata ?????? Berberine 2303 T0183 BH3-interacting domain death agonist 
M. fortunei ????? Berberine 2303 T0183 BH3-interacting domain death agonist 
M. gracilipes ??????  Berberine 2303 T0183 BH3-interacting domain death agonist 
M. japonica ?????  Berberine 2303 T0183 BH3-interacting domain death agonist 
M. shenii ?????? Berberine 2303 T0183 BH3-interacting domain death agonist 
M. veitchiorum ?????? Berberine 2303 T0183 BH3-interacting domain death agonist 
M. bealei ????? Berberine 2303 T0045 Caspase-3 
M. bodinieri ?????? Berberine 2303 T0045 Caspase-3 
M. eurybracteata ?????? Berberine 2303 T0045 Caspase-3 
M. fortunei ????? Berberine 2303 T0045 Caspase-3 
M. gracilipes ??????  Berberine 2303 T0045 Caspase-3 
M. japonica ?????  Berberine 2303 T0045 Caspase-3 
M. shenii ?????? Berberine 2303 T0045 Caspase-3 
M. veitchiorum ?????? Berberine 2303 T0045 Caspase-3 
M. bealei ????? Berberine 2303 T0060 Caspase-8 
M. bodinieri ?????? Berberine 2303 T0060 Caspase-8 
M. eurybracteata ?????? Berberine 2303 T0060 Caspase-8 
M. fortunei ????? Berberine 2303 T0060 Caspase-8 
M. gracilipes ??????  Berberine 2303 T0060 Caspase-8 
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M. japonica ?????  Berberine 2303 T0060 Caspase-8 
M. shenii ?????? Berberine 2303 T0060 Caspase-8 
M. veitchiorum ?????? Berberine 2303 T0060 Caspase-8 
M. bealei ????? Berberine 2303 T0019 Caspase-9 
M.a bodinieri ?????? Berberine 2303 T0019 Caspase-9 
M. eurybracteata ?????? Berberine 2303 T0019 Caspase-9 
M. fortunei ????? Berberine 2303 T0019 Caspase-9 
M. gracilipes ??????  Berberine 2303 T0019 Caspase-9 
M. japonica ?????  Berberine 2303 T0019 Caspase-9 
M. shenii ?????? Berberine 2303 T0019 Caspase-9 
M. veitchiorum ?????? Berberine 2303 T0019 Caspase-9 
M. bealei ????? Berberine 2303 T0167 C-C motif chemokine 2 
M. bodinieri ?????? Berberine 2303 T0167 C-C motif chemokine 2 
M. eurybracteata ?????? Berberine 2303 T0167 C-C motif chemokine 2 
M. fortunei ????? Berberine 2303 T0167 C-C motif chemokine 2 
M. gracilipes ??????  Berberine 2303 T0167 C-C motif chemokine 2 
M. japonica ?????  Berberine 2303 T0167 C-C motif chemokine 2 
M. shenii ?????? Berberine 2303 T0167 C-C motif chemokine 2 
M. veitchiorum ?????? Berberine 2303 T0167 C-C motif chemokine 2 
M. bealei ????? Berberine 2303 T0100 Cell division control protein 2 homolog 
M. bodinieri ?????? Berberine 2303 T0100 Cell division control protein 2 homolog 
M. eurybracteata ?????? Berberine 2303 T0100 Cell division control protein 2 homolog 
M. fortunei ????? Berberine 2303 T0100 Cell division control protein 2 homolog 
M. gracilipes ??????  Berberine 2303 T0100 Cell division control protein 2 homolog 
M. japonica ?????  Berberine 2303 T0100 Cell division control protein 2 homolog 
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M. shenii ?????? Berberine 2303 T0100 Cell division control protein 2 homolog 
M. veitchiorum ?????? Berberine 2303 T0100 Cell division control protein 2 homolog 
M. bealei ????? Berberine 2303 T0490 Cell division control protein 42 homolog 
M. bodinieri ?????? Berberine 2303 T0490 Cell division control protein 42 homolog 
M. eurybracteata ?????? Berberine 2303 T0490 Cell division control protein 42 homolog 
M. fortunei ????? Berberine 2303 T0490 Cell division control protein 42 homolog 
M. gracilipes ??????  Berberine 2303 T0490 Cell division control protein 42 homolog 
M. japonica ?????  Berberine 2303 T0490 Cell division control protein 42 homolog 
M. shenii ?????? Berberine 2303 T0490 Cell division control protein 42 homolog 
M. veitchiorum ?????? Berberine 2303 T0490 Cell division control protein 42 homolog 
M. bealei ????? Berberine 2303 T0034 Cell division protein kinase 2 
M. bodinieri ?????? Berberine 2303 T0034 Cell division protein kinase 2 
M. eurybracteata ?????? Berberine 2303 T0034 Cell division protein kinase 2 
M. fortunei ????? Berberine 2303 T0034 Cell division protein kinase 2 
M.gracilipes ??????  Berberine 2303 T0034 Cell division protein kinase 2 
M. japonica ?????  Berberine 2303 T0034 Cell division protein kinase 2 
M. shenii ?????? Berberine 2303 T0034 Cell division protein kinase 2 
M. veitchiorum ?????? Berberine 2303 T0034 Cell division protein kinase 2 
M. bealei ????? Berberine 2303 T0035 Cell division protein kinase 4 
M. bodinieri ?????? Berberine 2303 T0035 Cell division protein kinase 4 
M. eurybracteata ?????? Berberine 2303 T0035 Cell division protein kinase 4 
M. fortunei ????? Berberine 2303 T0035 Cell division protein kinase 4 
M. gracilipes ??????  Berberine 2303 T0035 Cell division protein kinase 4 
M. japonica ?????  Berberine 2303 T0035 Cell division protein kinase 4 
M. shenii ?????? Berberine 2303 T0035 Cell division protein kinase 4 
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M.veitchiorum ?????? Berberine 2303 T0035 Cell division protein kinase 4 
M. bealei ????? Berberine 2303 T0046 Cellular tumor antigen p53 
M. bodinieri ?????? Berberine 2303 T0046 Cellular tumor antigen p53 
M. eurybracteata ?????? Berberine 2303 T0046 Cellular tumor antigen p53 
M. fortunei ????? Berberine 2303 T0046 Cellular tumor antigen p53 
M. gracilipes ??????  Berberine 2303 T0046 Cellular tumor antigen p53 
M. japonica ?????  Berberine 2303 T0046 Cellular tumor antigen p53 
M. shenii ?????? Berberine 2303 T0046 Cellular tumor antigen p53 
M. veitchiorum ?????? Berberine 2303 T0046 Cellular tumor antigen p53 
M. bealei ????? Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. bodinieri ?????? Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. eurybracteata ?????? Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. fortunei ????? Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. gracilipes ??????  Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. japonica ?????  Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. shenii ?????? Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. veitchiorum ?????? Berberine 2303 T0016 Cyclin-dependent kinase inhibitor 1 
M. bealei ????? Berberine 2303 T0455 Cytochrome c 
M. bodinieri ?????? Berberine 2303 T0455 Cytochrome c 
M. eurybracteata ?????? Berberine 2303 T0455 Cytochrome c 
M. fortunei ????? Berberine 2303 T0455 Cytochrome c 
M. gracilipes ??????  Berberine 2303 T0455 Cytochrome c 
M. japonica ?????  Berberine 2303 T0455 Cytochrome c 
M. shenii ?????? Berberine 2303 T0455 Cytochrome c 
M. veitchiorum ?????? Berberine 2303 T0455 Cytochrome c 
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M. bealei ????? Berberine 2303 T0150 Cytochrome P450 1A1 
M. bodinieri ?????? Berberine 2303 T0150 Cytochrome P450 1A1 
M. eurybracteata ?????? Berberine 2303 T0150 Cytochrome P450 1A1 
M. fortunei ????? Berberine 2303 T0150 Cytochrome P450 1A1 
M. gracilipes ??????  Berberine 2303 T0150 Cytochrome P450 1A1 
M. japonica ?????  Berberine 2303 T0150 Cytochrome P450 1A1 
M. shenii ?????? Berberine 2303 T0150 Cytochrome P450 1A1 
M. veitchiorum ?????? Berberine 2303 T0150 Cytochrome P450 1A1 
M. bealei ????? Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. bodinieri ?????? Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. eurybracteata ?????? Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. fortunei ????? Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. gracilipes ??????  Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. japonica ?????  Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. shenii ?????? Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. veitchiorum ?????? Berberine 2303 T0777 Delta-1-pyrroline-5-carboxylate synthase 
M. bealei ????? Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. bodinieri ?????? Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. eurybracteata ?????? Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. fortunei ????? Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. gracilipes ??????  Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. japonica ?????  Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. shenii ?????? Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. veitchiorum ?????? Berberine 2303 T0253 DNA damage-inducible transcript 3 protein 
M. bealei ????? Berberine 2303 T0780 Early activation antigen CD69 
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M. bodinieri ?????? Berberine 2303 T0780 Early activation antigen CD69 
M. eurybracteata ?????? Berberine 2303 T0780 Early activation antigen CD69 
M. fortunei ????? Berberine 2303 T0780 Early activation antigen CD69 
M. gracilipes ??????  Berberine 2303 T0780 Early activation antigen CD69 
M. japonica ?????  Berberine 2303 T0780 Early activation antigen CD69 
M. shenii ?????? Berberine 2303 T0780 Early activation antigen CD69 
M. veitchiorum ?????? Berberine 2303 T0780 Early activation antigen CD69 
M..bealei ????? Berberine 2303 T0022 Early growth response protein 1 
M. bodinieri ?????? Berberine 2303 T0022 Early growth response protein 1 
M. eurybracteata ?????? Berberine 2303 T0022 Early growth response protein 1 
M. fortunei ????? Berberine 2303 T0022 Early growth response protein 1 
M. gracilipes ??????  Berberine 2303 T0022 Early growth response protein 1 
M. japonica ?????  Berberine 2303 T0022 Early growth response protein 1 
M. shenii ?????? Berberine 2303 T0022 Early growth response protein 1 
M. veitchiorum ?????? Berberine 2303 T0022 Early growth response protein 1 
M. bealei ????? Berberine 2303 T0007 Epidermal growth factor receptor 
M. bodinieri ?????? Berberine 2303 T0007 Epidermal growth factor receptor 
M. eurybracteata ?????? Berberine 2303 T0007 Epidermal growth factor receptor 
M. fortunei ????? Berberine 2303 T0007 Epidermal growth factor receptor 
M. gracilipes ??????  Berberine 2303 T0007 Epidermal growth factor receptor 
M. japonica ?????  Berberine 2303 T0007 Epidermal growth factor receptor 
M. shenii ?????? Berberine 2303 T0007 Epidermal growth factor receptor 
M. veitchiorum ?????? Berberine 2303 T0007 Epidermal growth factor receptor 
M. bealei ????? Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M. bodinieri ?????? Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
A-62 
M. eurybracteata ?????? Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M.fortunei ????? Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M. gracilipes ??????  Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M. japonica ?????  Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M. shenii ?????? Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M. veitchiorum ?????? Berberine 2303 T0017 Eukaryotic translation initiation factor 6 
M. bealei ????? Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. bodinieri ?????? Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. eurybracteata ?????? Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. fortunei ????? Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. gracilipes ??????  Berberine 2303 T0012 G1/S-specific cyclin-D1 
M.japonica ?????  Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. shenii ?????? Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. veitchiorum ?????? Berberine 2303 T0012 G1/S-specific cyclin-D1 
M. japonica ?????  Coptisine 4032 T0012 G1/S-specific cyclin-D1 
M. japonica ????? Coptisine 4032 T0012 G1/S-specific cyclin-D1 
M. bealei ????? Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M. bodinieri ?????? Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M. eurybracteata ?????? Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M. fortunei ????? Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M.gracilipes ??????  Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M.japonica ?????  Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M.shenii ?????? Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M.veitchiorum ?????? Berberine 2303 T0247 G2/mitotic-specific cyclin-B1 
M.bealei ????? Berberine 2303 T0774 Galanin 
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M.bodinieri ?????? Berberine 2303 T0774 Galanin 
M.eurybracteata ?????? Berberine 2303 T0774 Galanin 
M.fortunei ????? Berberine 2303 T0774 Galanin 
M.gracilipes ??????  Berberine 2303 T0774 Galanin 
M.japonica ?????  Berberine 2303 T0774 Galanin 
M.shenii ?????? Berberine 2303 T0774 Galanin 
M.veitchiorum ?????? Berberine 2303 T0774 Galanin 
M.bealei ????? Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.bodinieri ?????? Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.eurybracteata ?????? Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.fortunei ????? Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.gracilipes ??????  Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.japonica ?????  Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.shenii ?????? Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.veitchiorum ?????? Berberine 2303 T0775 Hepatocyte nuclear factor 4-alpha 
M.bealei ????? Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.bodinieri ?????? Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.eurybracteata ?????? Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.fortunei ????? Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.gracilipes ??????  Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.japonica ?????  Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.shenii ?????? Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.veitchiorum ?????? Berberine 2303 T0090 Hypoxia-inducible factor 1-alpha 
M.bealei ????? Berberine 2303 T0506 Insulin 
M.bodinieri ?????? Berberine 2303 T0506 Insulin 
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M.eurybracteata ?????? Berberine 2303 T0506 Insulin 
M.fortunei ????? Berberine 2303 T0506 Insulin 
M.gracilipes ??????  Berberine 2303 T0506 Insulin 
M.japonica ?????  Berberine 2303 T0506 Insulin 
M.shenii ?????? Berberine 2303 T0506 Insulin 
M.veitchiorum ?????? Berberine 2303 T0506 Insulin 
M.bealei ????? Berberine 2303 T0275 Interferon gamma 
M.bodinieri ?????? Berberine 2303 T0275 Interferon gamma 
M.eurybracteata ?????? Berberine 2303 T0275 Interferon gamma 
M.fortunei ????? Berberine 2303 T0275 Interferon gamma 
M.gracilipes ??????  Berberine 2303 T0275 Interferon gamma 
M.japonica ?????  Berberine 2303 T0275 Interferon gamma 
M.shenii ?????? Berberine 2303 T0275 Interferon gamma 
M.veitchiorum ?????? Berberine 2303 T0275 Interferon gamma 
M.bealei ????? Berberine 2303 T0156 Interleukin-1 beta 
M.bodinieri ?????? Berberine 2303 T0156 Interleukin-1 beta 
M.eurybracteata ?????? Berberine 2303 T0156 Interleukin-1 beta 
M.fortunei ????? Berberine 2303 T0156 Interleukin-1 beta 
M.gracilipes ??????  Berberine 2303 T0156 Interleukin-1 beta 
M.japonica ?????  Berberine 2303 T0156 Interleukin-1 beta 
M.shenii ?????? Berberine 2303 T0156 Interleukin-1 beta 
M.veitchiorum ?????? Berberine 2303 T0156 Interleukin-1 beta 
M.bealei ????? Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.bodinieri ?????? Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.eurybracteata ?????? Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
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M.fortunei ????? Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.gracilipes ??????  Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.japonica ?????  Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.shenii ?????? Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.veitchiorum ?????? Berberine 2303 T0429 Interleukin-2 receptor subunit alpha 
M.bealei ????? Berberine 2303 T0276 Interleukin-4 
M.bodinieri ?????? Berberine 2303 T0276 Interleukin-4 
M.eurybracteata ?????? Berberine 2303 T0276 Interleukin-4 
M.fortunei ????? Berberine 2303 T0276 Interleukin-4 
M.gracilipes ??????  Berberine 2303 T0276 Interleukin-4 
M.japonica ?????  Berberine 2303 T0276 Interleukin-4 
M.shenii ?????? Berberine 2303 T0276 Interleukin-4 
M.veitchiorum ?????? Berberine 2303 T0276 Interleukin-4 
M.bealei ????? Berberine 2303 T0039 Interleukin-6 
M.bodinieri ?????? Berberine 2303 T0039 Interleukin-6 
M.eurybracteata ?????? Berberine 2303 T0039 Interleukin-6 
M.fortunei ????? Berberine 2303 T0039 Interleukin-6 
M.gracilipes ??????  Berberine 2303 T0039 Interleukin-6 
M.japonica ?????  Berberine 2303 T0039 Interleukin-6 
M.shenii ?????? Berberine 2303 T0039 Interleukin-6 
M.veitchiorum ?????? Berberine 2303 T0039 Interleukin-6 
M.bealei ????? Berberine 2303 T0181 Interleukin-8 
M.bodinieri ?????? Berberine 2303 T0181 Interleukin-8 
M.eurybracteata ?????? Berberine 2303 T0181 Interleukin-8 
M.fortunei ????? Berberine 2303 T0181 Interleukin-8 
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M.gracilipes ??????  Berberine 2303 T0181 Interleukin-8 
M.japonica ?????  Berberine 2303 T0181 Interleukin-8 
M.shenii ?????? Berberine 2303 T0181 Interleukin-8 
M.veitchiorum ?????? Berberine 2303 T0181 Interleukin-8 
M.bealei ????? Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.bodinieri ?????? Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.eurybracteata ?????? Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.fortunei ????? Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.gracilipes ??????  Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.japonica ?????  Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.shenii ?????? Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.veitchiorum ?????? Berberine 2303 T0229 Maltase-glucoamylase, intestinal 
M.bealei ????? Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.bodinieri ?????? Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.eurybracteata ?????? Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.fortunei ????? Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.gracilipes ??????  Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.japonica ?????  Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.shenii ?????? Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.veitchiorum ?????? Berberine 2303 T0029 Mitogen-activated protein kinase 1 
M.bealei ????? Berberine 2303 T0302 Myeloperoxidase 
M.bodinieri ?????? Berberine 2303 T0302 Myeloperoxidase 
M.eurybracteata ?????? Berberine 2303 T0302 Myeloperoxidase 
M.fortunei ????? Berberine 2303 T0302 Myeloperoxidase 
M.gracilipes ??????  Berberine 2303 T0302 Myeloperoxidase 
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M.japonica ?????  Berberine 2303 T0302 Myeloperoxidase 
M.shenii ?????? Berberine 2303 T0302 Myeloperoxidase 
M.veitchiorum ?????? Berberine 2303 T0302 Myeloperoxidase 
M.bealei ????? Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.bodinieri ?????? Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.eurybracteata ?????? Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.fortunei ????? Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.gracilipes ??????  Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.japonica ?????  Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.shenii ?????? Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.veitchiorum ?????? Berberine 2303 T0055 NF-kappa-B inhibitor alpha 
M.bealei ????? Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.bodinieri ?????? Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.eurybracteata ?????? Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.fortunei ????? Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.gracilipes ??????  Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.japonica ?????  Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.shenii ?????? Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.veitchiorum ?????? Berberine 2303 T0040 Nitric oxide synthase, inducible 
M.bealei ????? Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.bodinieri ?????? Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.eurybracteata ?????? Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.fortunei ????? Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.gracilipes ??????  Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.japonica ?????  Berberine 2303 T0778 Platelet-derived growth factor subunit A 
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M.shenii ?????? Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.veitchiorum ?????? Berberine 2303 T0778 Platelet-derived growth factor subunit A 
M.bealei ????? Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.bodinieri ?????? Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.eurybracteata ?????? Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.fortunei ????? Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.gracilipes ??????  Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.japonica ?????  Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.shenii ?????? Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.veitchiorum ?????? Berberine 2303 T0099 Probable E3 ubiquitin-protein ligase HERC5 
M.bealei ????? Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.bodinieri ?????? Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.eurybracteata ?????? Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.fortunei ????? Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.gracilipes ??????  Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.japonica ?????  Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.shenii ?????? Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.veitchiorum ?????? Berberine 2303 T0776 Proprotein convertase subtilisin/kexin type 9 
M.bealei ????? Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.bodinieri ?????? Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.eurybracteata ?????? Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.fortunei ????? Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.gracilipes ??????  Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.japonica ?????  Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.shenii ?????? Berberine 2303 T0054 Prostaglandin G/H synthase 2 
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M.veitchiorum ?????? Berberine 2303 T0054 Prostaglandin G/H synthase 2 
M.bealei ????? Berberine 2303 T0098 Protein CBFA2T1 
M.bodinieri ?????? Berberine 2303 T0098 Protein CBFA2T1 
M.eurybracteata ?????? Berberine 2303 T0098 Protein CBFA2T1 
M.fortunei ????? Berberine 2303 T0098 Protein CBFA2T1 
M.gracilipes ??????  Berberine 2303 T0098 Protein CBFA2T1 
M.japonica ?????  Berberine 2303 T0098 Protein CBFA2T1 
M.shenii ?????? Berberine 2303 T0098 Protein CBFA2T1 
M.veitchiorum ?????? Berberine 2303 T0098 Protein CBFA2T1 
M.bealei ????? Berberine 2303 T0015 Proto-oncogene c-Fos 
M.bodinieri ?????? Berberine 2303 T0015 Proto-oncogene c-Fos 
M.eurybracteata ?????? Berberine 2303 T0015 Proto-oncogene c-Fos 
M.fortunei ????? Berberine 2303 T0015 Proto-oncogene c-Fos 
M.gracilipes ??????  Berberine 2303 T0015 Proto-oncogene c-Fos 
M.japonica ?????  Berberine 2303 T0015 Proto-oncogene c-Fos 
M.shenii ?????? Berberine 2303 T0015 Proto-oncogene c-Fos 
M.veitchiorum ?????? Berberine 2303 T0015 Proto-oncogene c-Fos 
M.bealei ????? Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.bodinieri ?????? Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.eurybracteata ?????? Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.fortunei ????? Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.gracilipes ??????  Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.japonica ?????  Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.shenii ?????? Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
M.veitchiorum ?????? Berberine 2303 T0752 Ras-related C3 botulinum toxin substrate 1 
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M.bealei ????? Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.bodinieri ?????? Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.eurybracteata ?????? Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.fortunei ????? Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.gracilipes ??????  Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.japonica ?????  Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.shenii ?????? Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.veitchiorum ?????? Berberine 2303 T0065 Ras-specific guanine nucleotide-releasing factor 2 
M.bealei ????? Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.bodinieri ?????? Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.eurybracteata ?????? Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.fortunei ????? Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.gracilipes ??????  Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.japonica ?????  Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.shenii ?????? Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.veitchiorum ?????? Berberine 2303 T0587 Solute carrier family 2, facilitated glucose transporter member 1 
M.bealei ????? Berberine 2303 T0448 Stromal cell-derived factor 1 
M.bodinieri ?????? Berberine 2303 T0448 Stromal cell-derived factor 1 
M.eurybracteata ?????? Berberine 2303 T0448 Stromal cell-derived factor 1 
M.fortunei ????? Berberine 2303 T0448 Stromal cell-derived factor 1 
M.gracilipes ??????  Berberine 2303 T0448 Stromal cell-derived factor 1 
M.japonica ?????  Berberine 2303 T0448 Stromal cell-derived factor 1 
M.shenii ?????? Berberine 2303 T0448 Stromal cell-derived factor 1 
M.veitchiorum ?????? Berberine 2303 T0448 Stromal cell-derived factor 1 
M.bealei ????? Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
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M.bodinieri ?????? Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.eurybracteata ?????? Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.fortunei ????? Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.gracilipes ??????  Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.japonica ?????  Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.shenii ?????? Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.veitchiorum ?????? Jatrorrhizine 11851 T0319 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
M.bealei ????? Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.bodinieri ?????? Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.eurybracteata ?????? Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.fortunei ????? Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.gracilipes ??????  Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.japonica ?????  Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.shenii ?????? Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.veitchiorum ?????? Berberine 2303 T0593 Sucrase-isomaltase, intestinal 
M.bealei ????? Berberine 2303 T0080 Telomerase protein component 1 
M.bodinieri ?????? Berberine 2303 T0080 Telomerase protein component 1 
M.eurybracteata ?????? Berberine 2303 T0080 Telomerase protein component 1 
M.fortunei ????? Berberine 2303 T0080 Telomerase protein component 1 
M.gracilipes ??????  Berberine 2303 T0080 Telomerase protein component 1 
M.japonica ?????  Berberine 2303 T0080 Telomerase protein component 1 
M.shenii ?????? Berberine 2303 T0080 Telomerase protein component 1 
M.veitchiorum ?????? Berberine 2303 T0080 Telomerase protein component 1 
M.bealei ????? Berberine 2303 T0038 Transcription factor AP-1 
M.bodinieri ?????? Berberine 2303 T0038 Transcription factor AP-1 
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M.eurybracteata ?????? Berberine 2303 T0038 Transcription factor AP-1 
M.fortunei ????? Berberine 2303 T0038 Transcription factor AP-1 
M.gracilipes ??????  Berberine 2303 T0038 Transcription factor AP-1 
M.japonica ?????  Berberine 2303 T0038 Transcription factor AP-1 
M.shenii ?????? Berberine 2303 T0038 Transcription factor AP-1 
M.veitchiorum ?????? Berberine 2303 T0038 Transcription factor AP-1 
M.bealei ????? Berberine 2303 T0002 Transcription factor p65 
M.bodinieri ?????? Berberine 2303 T0002 Transcription factor p65 
M.eurybracteata ?????? Berberine 2303 T0002 Transcription factor p65 
M.fortunei ????? Berberine 2303 T0002 Transcription factor p65 
M.gracilipes ??????  Berberine 2303 T0002 Transcription factor p65 
M.japonica ?????  Berberine 2303 T0002 Transcription factor p65 
M.shenii ?????? Berberine 2303 T0002 Transcription factor p65 
M.veitchiorum ?????? Berberine 2303 T0002 Transcription factor p65 
M.bealei ????? Berberine 2303 T0037 Tumor necrosis factor 
M.bodinieri ?????? Berberine 2303 T0037 Tumor necrosis factor 
M.eurybracteata ?????? Berberine 2303 T0037 Tumor necrosis factor 
M.fortunei ????? Berberine 2303 T0037 Tumor necrosis factor 
M.gracilipes ??????  Berberine 2303 T0037 Tumor necrosis factor 
M.japonica ?????  Berberine 2303 T0037 Tumor necrosis factor 
M.shenii ?????? Berberine 2303 T0037 Tumor necrosis factor 
M.veitchiorum ?????? Berberine 2303 T0037 Tumor necrosis factor 
M.bealei ????? Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.bodinieri ?????? Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.eurybracteata ?????? Berberine 2303 T0285 Tyrosine 3-monooxygenase 
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M.fortunei ????? Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.gracilipes ??????  Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.japonica ?????  Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.shenii ?????? Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.veitchiorum ?????? Berberine 2303 T0285 Tyrosine 3-monooxygenase 
M.bealei ????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.bodinieri ?????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.eurybracteata ?????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.fortunei ????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.fortunei ????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.fortunei ????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.gracilipes ??????  Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.japonica ?????  Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.japonica ????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.shenii ?????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.veitchiorum ?????? Palmatine 16555 T0285 Tyrosine 3-monooxygenase 
M.bealei ????? Berberine 2303 T0010 Vascular endothelial growth factor A 
M.bodinieri ?????? Berberine 2303 T0010 Vascular endothelial growth factor A 
M.eurybracteata ?????? Berberine 2303 T0010 Vascular endothelial growth factor A 
M.fortunei ????? Berberine 2303 T0010 Vascular endothelial growth factor A 
M.gracilipes ??????  Berberine 2303 T0010 Vascular endothelial growth factor A 
M.japonica ?????  Berberine 2303 T0010 Vascular endothelial growth factor A 
M.shenii ?????? Berberine 2303 T0010 Vascular endothelial growth factor A 
M.veitchiorum ?????? Berberine 2303 T0010 Vascular endothelial growth factor A 
M.bealei ????? Berberine 2303 T0779 Wee1-like protein kinase 
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M.bodinieri ?????? Berberine 2303 T0779 Wee1-like protein kinase 
M.eurybracteata ?????? Berberine 2303 T0779 Wee1-like protein kinase 
M.fortunei ????? Berberine 2303 T0779 Wee1-like protein kinase 
M.gracilipes ??????  Berberine 2303 T0779 Wee1-like protein kinase 
M.japonica ?????  Berberine 2303 T0779 Wee1-like protein kinase 
M.shenii ?????? Berberine 2303 T0779 Wee1-like protein kinase 
M.veitchiorum ?????? Berberine 2303 T0779 Wee1-like protein kinase 
M.fortunei ????? Berbamine 2300 NA  
M.japonica ?????  Berbamine 2300 NA  
M.japonica ?????  Columbamine 3934 NA  
M.japonica ????? Columbamine 3934 NA  
M.aqulifolium  ?????? Isocorydine 11344 NA  
M.japonica ?????  Isotetrandrine 11736 NA  
M.japonica ????? Isotetrandrine 11736 NA  
M.japonica ????? Isotetrandrine 11736 NA  
M.fortunei ????? Magnoflorine 13374 NA  
M.fortunei ????? Magnoflorine 13374 NA  
M.fortunei ????? Magnoflorine 13374 NA  
M.japonica ?????  Magnoflorine 13374 NA  
M.japonica ????? Magnoflorine 13374 NA  
M.bealei ?????  NA    
M.bealei ????? NA    
M.bealei ????? NA    
M.aqulifolium  ?????? Oxyacanthine 16439 NA  
M.fortunei ????? Oxyacanthine 16439 NA  
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Appendix 8 Biological target list for Ku shen (Sophora flavescens) 
Species Chinese Compound Compound ID Target ID Target name 
S. flavescens  ?? Formononetin 7883 T0638 3 beta-hydroxysteroid dehydrogenase/Delta 
5-->4-isomerase type 1 
S. flavescens  ?? Formononetin 7883 T0637 3 beta-hydroxysteroid dehydrogenase/Delta 
5-->4-isomerase type 2 
S. flavescens  ?? Matrine 13606 T0026 72 kDa type IV collagenase 
S. flavescens  ?? Kuraridin 12341 T0317 Acyl-CoA wax alcohol acyltransferase 1 
S. flavescens  ?? Cytisine 4594 T0647 Alpha-conotoxin BuIA 
S. flavescens  ??? Cytisine 4594 T0647 Alpha-conotoxin BuIA 
S. flavescens  ?? Matrine 13606 T0114 Androgen receptor 
S. flavescens  ?? Formononetin 7883 T0635 ATP synthase subunit beta, mitochondrial 
S. flavescens  ?? Matrine 13606 T0045 Caspase-3 
S. flavescens  ?? Matrine 13606 T0627 CD44 antigen 
S. flavescens  ?? Formononetin 7883 T0122 Estrogen receptor 
S. flavescens  ?? Formononetin 7883 T0123 Estrogen receptor beta 
S. flavescens  ?? Matrine 13606 T0396 Heparanase 
S. flavescens  ?? Matrine 13606 T0626 Immediate early response 3-interacting protein 1 
S. flavescens  ?? Matrine 13606 T0152 Intercellular adhesion molecule 1 
S. flavescens  ?? Formononetin 7883 T0276 Interleukin-4 
S. flavescens  ?? Matrine 13606 T0039 Interleukin-6 
S. flavescens  ?? Sophocarpine 20077 T0039 Interleukin-6 
S. flavescens  ?? Sophoramine 20094 T0039 Interleukin-6 
S. flavescens  ?? Sophoridine 20100 T0039 Interleukin-6 
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S. flavescens  ?? Matrine 13606 T0142 Myc proto-oncogene protein 
S. flavescens  ?? Formononetin 7883 T0459 NAD-dependent deacetylase sirtuin-1 
S. flavescens  ?? Formononetin 7883 T0636 NADH-ubiquinone oxidoreductase chain 6 
S. flavescens  ?? Cytisine 4594 T0568 Neuronal acetylcholine receptor subunit alpha-7 
S. flavescens  ??? Cytisine 4594 T0568 Neuronal acetylcholine receptor subunit alpha-7 
S. flavescens  ?? Formononetin 7883 T0125 Peroxisome proliferator-activated receptor gamma 
S. flavescens  ?? Kuraridin 12341 T0054 Prostaglandin G/H synthase 2 
S. flavescens  ?? Cytisine 4594 T0015 Proto-oncogene c-Fos 
S. flavescens  ??? Cytisine 4594 T0015 Proto-oncogene c-Fos 
S. flavescens  ?? Formononetin 7883 T0038 Transcription factor AP-1 
S. flavescens  ?? Matrine 13606 T0002 Transcription factor p65 
S. flavescens  ?? Matrine 13606 T0037 Tumor necrosis factor 
S. flavescens  ?? Sophocarpine 20077 T0037 Tumor necrosis factor 
S. flavescens  ?? Sophoramine 20094 T0037 Tumor necrosis factor 
S. flavescens  ?? Sophoridine 20100 T0037 Tumor necrosis factor 
S. flavescens  ?? Kuraridin 12341 T0256 Tyrosinase 
S. flavescens  ?? (+)-Allomatrine 938 NA  
S. flavescens  ?? 2'-Methoxykurarinone 13985 NA  
S. flavescens  ?? 2-n-Heneicosyl-5,7-dihydroxy-6,8-dimethyl 
chromone 
9361 NA  
S. flavescens  ?? 2-n-Heptadecy-5,7-dihydroxy-6,8-dimethyl 
chromone 
9391 NA  
S. flavescens  ?? 2-n-Nonadecyl-5,7-dihydroxy-6,8-dimethyl 
chromone 
15674 NA  
S. flavescens  ?? 2-n-Pentacosyl-5,7-dihydroxy-6,8-dimethyl 
chromone 
16826 NA  
S. flavescens  ?? 2-n-Pentadecyl-5,7-dihydroxy-6,8-dimethyl 
chromone 
16834 NA  
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S. flavescens  ?? 2-n-Tridecyl-5,7-dihydroxy-6,8-dimethyl 
chromone 
21623 NA  
S. flavescens  ?? 5-O-Methyl kushenol C 14545 NA  
S. flavescens  ?? 7,11-Dehydromatrine 4948 NA  
S. flavescens  ?? 8-Isopentenyl-kaempferol 11588 NA  
S. flavescens  ?? 9α-Hydroxysophoramine 10714 NA  
S. flavescens  ?? Anagyrine 1134 NA  
S. flavescens  ?? Baptifoline 2145 NA  
S. flavescens  ?? Isoanhydroicaritin 11222 NA  
S. flavescens  ?? Isokuraramine 11473 NA  
S. flavescens  ?? Isokurarinone 11474 NA  
S. flavescens  ?? Isomatrine 11531 NA  
S. flavescens  ?? Isoxanthohumol 11783 NA  
S. flavescens  ?? Kosamol A 12280 NA  
S. flavescens  ?? Kosamol Q 12281 NA  
S. flavescens  ?? Kosamol R 12282 NA  
S. flavescens  ?? Kosamol S 12283 NA  
S. flavescens  ?? Kosamol T 12284 NA  
S. flavescens  ?? Kosamol U 12285 NA  
S. flavescens  ?? Kosamol V 12286 NA  
S. flavescens  ?? Kosamol W 12287 NA  
S. flavescens  ?? Kuraramine 12340 NA  
S. flavescens  ?? Kuraridinol 12342 NA  
S. flavescens  ?? Kurarinol 12343 NA  
S. flavescens  ?? Kurarinone 12344 NA  
S. flavescens  ?? Kushenin 12353 NA  
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S. flavescens  ?? Kushenol A 12354 NA  
S. flavescens  ?? Kushenol B 12355 NA  
S. flavescens  ?? Kushenol C 12356 NA  
S. flavescens  ?? Kushenol D 12357 NA  
S. flavescens  ?? Kushenol E 12358 NA  
S. flavescens  ?? Kushenol F 12359 NA  
S. flavescens  ?? Kushenol G 12360 NA  
S. flavescens  ?? Kushenol H 12361 NA  
S. flavescens  ?? Kushenol I 12362 NA  
S. flavescens  ?? Kushenol J 12363 NA  
S. flavescens  ?? Kushenol K 12364 NA  
S. flavescens  ?? Kushenol L 12365 NA  
S. flavescens  ?? Kushenol M 12366 NA  
S. flavescens  ?? Kushenol N 12367 NA  
S. flavescens  ?? Kushenol O 12368 NA  
S. flavescens  ?? Kushenol P 12369 NA  
S. flavescens  ?? Kushenol X 12370 NA  
S. flavescens  ?? Kushenquinone A 12371 NA  
S. flavescens  ?? Leachianone A 12595 NA  
S. flavescens  ?? Leachianone G 12597 NA  
S. flavescens  ?? Lehmannine 12605 NA  
S. flavescens  ?? Lupanine 13089 NA  
S. flavescens  ?? Maackiain 13281 NA  
S. flavescens  ?? Mamanine 13462 NA  
S. flavescens  ?? Neokurarinol 15425 NA  
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S. flavescens  ?? N-Methylcytisine 14279 NA  
S. flavescens  ?? Norkurarinol 15769 NA  
S. flavescens  ?? Norkurarinone 15770 NA  
S. flavescens  ?? N-Oxysophocarpine 16474 NA  
S. flavescens  ??? N-Oxysophocarpine 16474 NA  
S. flavescens  ?? Oxymatrine 16451 NA  
S. flavescens  ?? Sophoflavescenol 20078 NA  
S. flavescens  ?? Sophoraflavanone G 20086 NA  
S. flavescens  ?? Sophoraflavoside II 20090 NA  
S. flavescens  ?? Sophoraflavoside III 20091 NA  
S. flavescens  ?? Sophoraflavoside IV 20092 NA  
S. flavescens  ?? SophoraflavosideI 20089 NA  
S. flavescens  ?? Sophoranol 20096 NA  
S. flavescens  ?? Sophoranol N-oxide 20097 NA  
S. flavescens  ?? Soyasaponin I 20127 NA  
S. flavescens  ?? Trifolirhizin-6''-O-malonate 21638 NA  
S. flavescens  ?? Xanthohumol 22761 NA  
S. flavescens  ?? α-Maackiain-β-D-glucoside 13282 NA  
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Appendix 9 Biological target list for Zi cao (Lithospermum erythrorhizon, Arnebia guttata, A. euchroma, Onosma hookeri, O. paniculatum) 
Species Chinese Compound Compound 
ID 
target ID target name 
L. erythrorhizon ?? Caffeic acid 2887 T0185 Acetylcholinesterase 
A. euchroma ????? Shikonin 19819 T0287 Amine oxidase [flavin-containing] A 
A. guttata ??? Shikonin 19819 T0287 Amine oxidase [flavin-containing] A 
L. erythrorhizon ?? Shikonin 19819 T0287 Amine oxidase [flavin-containing] A 
O. paniculatum ??? Shikonin 19819 T0287 Amine oxidase [flavin-containing] A 
A. euchroma ????? Shikonin 19819 T0288 Amine oxidase [flavin-containing] B 
A. guttata ??? Shikonin 19819 T0288 Amine oxidase [flavin-containing] B 
L. erythrorhizon ?? Shikonin 19819 T0288 Amine oxidase [flavin-containing] B 
O. paniculatum ??? Shikonin 19819 T0288 Amine oxidase [flavin-containing] B 
A. euchroma ????? Shikonin 19819 T1298 Angiopoietin-1 receptor 
A. guttata ??? Shikonin 19819 T1298 Angiopoietin-1 receptor 
L. erythrorhizon ?? Shikonin 19819 T1298 Angiopoietin-1 receptor 
O. paniculatum ??? Shikonin 19819 T1298 Angiopoietin-1 receptor 
A. euchroma ????? Shikonin 19819 T0013 Apoptosis regulator Bcl-2 
A. guttata ??? Shikonin 19819 T0013 Apoptosis regulator Bcl-2 
L. erythrorhizon ?? Shikonin 19819 T0013 Apoptosis regulator Bcl-2 
O. paniculatum ??? Shikonin 19819 T0013 Apoptosis regulator Bcl-2 
A. euchroma ????? Shikonin 19819 T0970 Arylamine N-acetyltransferase 1 
A. guttata ??? Shikonin 19819 T0970 Arylamine N-acetyltransferase 1 
L. erythrorhizon ?? Shikonin 19819 T0970 Arylamine N-acetyltransferase 1 
O.paniculatum ??? Shikonin 19819 T0970 Arylamine N-acetyltransferase 1 
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A. euchroma ????? Shikonin 19819 T0072 Bcl2 antagonist of cell death 
A. guttata ??? Shikonin 19819 T0072 Bcl2 antagonist of cell death 
L. erythrorhizon ?? Shikonin 19819 T0072 Bcl2 antagonist of cell death 
O. paniculatum ??? Shikonin 19819 T0072 Bcl2 antagonist of cell death 
A. euchroma ????? Shikonin 19819 T0045 Caspase-3 
A. guttata ??? Shikonin 19819 T0045 Caspase-3 
L. erythrorhizon ?? Shikonin 19819 T0045 Caspase-3 
O. paniculatum ??? Shikonin 19819 T0045 Caspase-3 
A. euchroma ????? Shikonin 19819 T0434 C-C motif chemokine 3 
A. guttata ??? Shikonin 19819 T0434 C-C motif chemokine 3 
L. erythrorhizon ?? Shikonin 19819 T0434 C-C motif chemokine 3 
O. paniculatum ??? Shikonin 19819 T0434 C-C motif chemokine 3 
A. euchroma ????? Shikonin 19819 T0447 C-C motif chemokine 5 
A. guttata ??? Shikonin 19819 T0447 C-C motif chemokine 5 
L. erythrorhizon ?? Shikonin 19819 T0447 C-C motif chemokine 5 
O. paniculatum ??? Shikonin 19819 T0447 C-C motif chemokine 5 
A. euchroma ????? Shikonin 19819 T0046 Cellular tumor antigen p53 
A. guttata ??? Shikonin 19819 T0046 Cellular tumor antigen p53 
L. erythrorhizon ?? Shikonin 19819 T0046 Cellular tumor antigen p53 
O. paniculatum ??? Shikonin 19819 T0046 Cellular tumor antigen p53 
L. erythrorhizon ?? Caffeic acid 2887 T0150 Cytochrome P450 1A1 
A. euchroma ????? Shikonin 19819 T1300 Ephrin type-B receptor 2 
A. guttata ??? Shikonin 19819 T1300 Ephrin type-B receptor 2 
L. erythrorhizon ?? Shikonin 19819 T1300 Ephrin type-B receptor 2 
O. paniculatum ??? Shikonin 19819 T1300 Ephrin type-B receptor 2 
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A. euchroma ????? Shikonin 19819 T1286 Fatty acid-binding protein, adipocyte 
A. guttata ??? Shikonin 19819 T1286 Fatty acid-binding protein, adipocyte 
L. erythrorhizon ?? Shikonin 19819 T1286 Fatty acid-binding protein, adipocyte 
O. paniculatum ??? Shikonin 19819 T1286 Fatty acid-binding protein, adipocyte 
A. euchroma ????? Shikonin 19819 T0012 G1/S-specific cyclin-D1 
A. guttata ??? Shikonin 19819 T0012 G1/S-specific cyclin-D1 
L. erythrorhizon ?? Shikonin 19819 T0012 G1/S-specific cyclin-D1 
O. paniculatum ??? Shikonin 19819 T0012 G1/S-specific cyclin-D1 
L. erythrorhizon ?? Caffeic acid 2887 T0346 Glial fibrillary acidic protein 
L. erythrorhizon ?? Caffeic acid 2887 T0374 Insulin-like growth factor II 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0156 Interleukin-1 beta 
A. euchroma ????? Shikonin 19819 T0030 Interleukin-10 
A. guttata ??? Shikonin 19819 T0030 Interleukin-10 
L. erythrorhizon ?? Shikonin 19819 T0030 Interleukin-10 
O. paniculatum ??? Shikonin 19819 T0030 Interleukin-10 
A. euchroma ????? Shikonin 19819 T0276 Interleukin-4 
A. guttata ??? Shikonin 19819 T0276 Interleukin-4 
L. erythrorhizon ?? Shikonin 19819 T0276 Interleukin-4 
O. paniculatum ??? Shikonin 19819 T0276 Interleukin-4 
A. euchroma ????? Shikonin 19819 T0039 Interleukin-6 
A. guttata ??? Shikonin 19819 T0039 Interleukin-6 
L. erythrorhizon ?? Shikonin 19819 T0039 Interleukin-6 
O. paniculatum ??? Shikonin 19819 T0039 Interleukin-6 
A. euchroma ????? Shikonin 19819 T0181 Interleukin-8 
A. guttata ??? Shikonin 19819 T0181 Interleukin-8 
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L. erythrorhizon ?? Shikonin 19819 T0181 Interleukin-8 
O. paniculatum ??? Shikonin 19819 T0181 Interleukin-8 
A. euchroma ????? Shikonin 19819 T0173 Lipoprotein lipase 
A. guttata ??? Shikonin 19819 T0173 Lipoprotein lipase 
L. erythrorhizon ?? Shikonin 19819 T0173 Lipoprotein lipase 
O. paniculatum ??? Shikonin 19819 T0173 Lipoprotein lipase 
A. euchroma ????? Shikonin 19819 T1299 Lysyl-tRNA synthetase 
A. guttata ??? Shikonin 19819 T1299 Lysyl-tRNA synthetase 
L. erythrorhizon ?? Shikonin 19819 T1299 Lysyl-tRNA synthetase 
O. paniculatum ??? Shikonin 19819 T1299 Lysyl-tRNA synthetase 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0055 NF-kappa-B inhibitor alpha 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0040 Nitric oxide synthase, inducible 
A. euchroma ????? Shikonin 19819 T0742 Nuclear receptor subfamily 4 group A member 1 
A. guttata ??? Shikonin 19819 T0742 Nuclear receptor subfamily 4 group A member 1 
L. erythrorhizon ?? Shikonin 19819 T0742 Nuclear receptor subfamily 4 group A member 1 
O. paniculatum ??? Shikonin 19819 T0742 Nuclear receptor subfamily 4 group A member 1 
A. euchroma ????? Shikonin 19819 T0125 Peroxisome proliferator-activated receptor gamma 
A. guttata ??? Shikonin 19819 T0125 Peroxisome proliferator-activated receptor gamma 
L. erythrorhizon ?? Shikonin 19819 T0125 Peroxisome proliferator-activated receptor gamma 
O. paniculatum ??? Shikonin 19819 T0125 Peroxisome proliferator-activated receptor gamma 
A. euchroma ????? Shikonin 19819 T0101 Proliferating cell nuclear antigen 
A. guttata ??? Shikonin 19819 T0101 Proliferating cell nuclear antigen 
L. erythrorhizon ?? Shikonin 19819 T0101 Proliferating cell nuclear antigen 
O. paniculatum ??? Shikonin 19819 T0101 Proliferating cell nuclear antigen 
L. erythrorhizon ?? Caffeic acid 2887 T0179 Prostaglandin G/H synthase 1 
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L. erythrorhizon ?? Caffeic acid 2887 T0054 Prostaglandin G/H synthase 2 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0054 Prostaglandin G/H synthase 2 
A. euchroma ????? Shikonin 19819 T1297 Proteasome subunit beta type-4 
A. guttata ??? Shikonin 19819 T1297 Proteasome subunit beta type-4 
L. erythrorhizon ?? Shikonin 19819 T1297 Proteasome subunit beta type-4 
O. paniculatum ??? Shikonin 19819 T1297 Proteasome subunit beta type-4 
L. erythrorhizon ?? Caffeic acid 2887 T0194 Protein kinase C beta type 
L. erythrorhizon ?? Caffeic acid 2887 T0388 P-selectin 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0009 RAC-alpha serine/threonine-protein kinase 
A. euchroma ????? Shikonin 19819 T0009 RAC-alpha serine/threonine-protein kinase 
A. guttata ??? Shikonin 19819 T0009 RAC-alpha serine/threonine-protein kinase 
L. erythrorhizon ?? Shikonin 19819 T0009 RAC-alpha serine/threonine-protein kinase 
O. paniculatum ??? Shikonin 19819 T0009 RAC-alpha serine/threonine-protein kinase 
L. erythrorhizon ?? Caffeic acid 2887 T0752 Ras-related C3 botulinum toxin substrate 1 
A. euchroma ????? Shikonin 19819 T1183 Ribonuclease P protein subunit p21 
A. guttata ??? Shikonin 19819 T1183 Ribonuclease P protein subunit p21 
L. erythrorhizon ?? Shikonin 19819 T1183 Ribonuclease P protein subunit p21 
O. paniculatum ??? Shikonin 19819 T1183 Ribonuclease P protein subunit p21 
A. euchroma ????? Shikonin 19819 T1301 Serine/threonine-protein kinase PAK 2 
A. guttata ??? Shikonin 19819 T1301 Serine/threonine-protein kinase PAK 2 
L. erythrorhizon ?? Shikonin 19819 T1301 Serine/threonine-protein kinase PAK 2 
O. paniculatum ??? Shikonin 19819 T1301 Serine/threonine-protein kinase PAK 2 
A. euchroma ????? Shikonin 19819 T0465 Sterol regulatory element-binding protein 1 
A. guttata ??? Shikonin 19819 T0465 Sterol regulatory element-binding protein 1 
L. erythrorhizon ?? Shikonin 19819 T0465 Sterol regulatory element-binding protein 1 
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O. paniculatum ??? Shikonin 19819 T0465 Sterol regulatory element-binding protein 1 
A. euchroma ????? Shikonin 19819 T0277 Trans-acting T-cell-specific transcription factor GATA-3 
A. guttata ??? Shikonin 19819 T0277 Trans-acting T-cell-specific transcription factor GATA-3 
L. erythrorhizon ?? Shikonin 19819 T0277 Trans-acting T-cell-specific transcription factor GATA-3 
O. paniculatum ??? Shikonin 19819 T0277 Trans-acting T-cell-specific transcription factor GATA-3 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0002 Transcription factor p65 
L. erythrorhizon ?? Caffeic acid 2887 T0037 Tumor necrosis factor 
L. erythrorhizon ?? Isobutyryl shikonin 11300 T0037 Tumor necrosis factor 
L. erythrorhizon ?? Caffeic acid 2887 T0326 Tyrosine-protein kinase BTK 
A. euchroma ????? Shikonin 19819 T0021 Vascular endothelial growth factor receptor 2 
A. guttata ??? Shikonin 19819 T0021 Vascular endothelial growth factor receptor 2 
L. erythrorhizon ?? Shikonin 19819 T0021 Vascular endothelial growth factor receptor 2 
O.paniculatum ??? Shikonin 19819 T0021 Vascular endothelial growth factor receptor 2 
A. euchroma ????? (−)-Alkannin 909 NA  
A. euchroma ????? 1-Methyl-acetylshikonin 14120 NA  
L. erythrorhizon ?? 1-Methyl-acetylshikonin 14120 NA  
A. euchroma ????? 2α,19α-Dihydroxyursolic acid 6178 NA  
A. euchroma ????? 3,4-Teracrylshikonin 20968 NA  
A. guttata ??? 3,4-Teracrylshikonin 20968 NA  
L. erythrorhizon ?? 3,4-Teracrylshikonin 20968 NA  
A. euchroma ????? Acetylalkannin 309 NA  
A. guttata ??? Acetylalkannin 309 NA  
L. erythrorhizon ?? Acetylalkannin 309 NA  
O. paniculatum ??? Acetylalkannin 309 NA  
A. euchroma ????? Acetylshikonin 514 NA  
A. guttata ??? Acetylshikonin 514 NA  
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L. erythrorhizon ?? Acetylshikonin 514 NA  
O. hookeri ????? Acetylshikonin 514 NA  
O. paniculatum ??? Acetylshikonin 514 NA  
L. erythrorhizon ?? Alkannan 908 NA  
L. erythrorhizon ?? Alkannin angelate 910 NA  
A. euchroma ????? Anhydroalkannin 1259 NA  
L. erythrorhizon ?? Anhydroalkannin 1259 NA  
A. euchroma ????? Arnebifuranone 1744 NA  
L. erythrorhizon ?? Arnebifuranone 1744 NA  
A. euchroma ????? Arnebinol 1746 NA  
A. euchroma ????? Arnebinone 1747 NA  
A. euchroma ????? Deoxyshikonin 5214 NA  
A. guttata ??? Deoxyshikonin 5214 NA  
A. euchroma ?? Deoxyshikonin 5214 NA  
A. euchroma ????? Des-O-methyllasiodiplodin 5258 NA  
L. erythrorhizon ?? Des-O-methyllasiodiplodin 5258 NA  
A. euchroma ????? Dipotassium rabdosiin 6495 NA  
L. erythrorhizon ?? Docosyl caffeate 6539 NA  
L. erythrorhizon ?? Eicosanol 6722 NA  
L. erythrorhizon ?? Eicosyl caffeate 6726 NA  
L. erythrorhizon ?? Hydroxymyoscorpine 10535 NA  
L. erythrorhizon ?? Intermedine 11107 NA  
A. euchroma ????? Isobutyryl shikonin 11300 NA  
L. erythrorhizon ?? Isovalerylshikonin 11765 NA  
L. erythrorhizon ?? Lithospermidin A 12927 NA  
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L. erythrorhizon ?? Lithospermidin B 12928 NA  
L. erythrorhizon ?? Myoscorpine 15145 NA  
A. euchroma ????? NP02140176-38-K 15850 NA  
L. erythrorhizon ?? NP02140176-38-K 15850 NA  
A. euchroma ????? NP02140176-39-Na 15851 NA  
L. erythrorhizon ?? NP02140176-39-Na 15851 NA  
A. euchroma ????? NP02140176-40 15852 NA  
L. erythrorhizon ?? NP02140176-40 15852 NA  
A. euchroma ????? NP02140176-41-KNa 15853 NA  
L. erythrorhizon ?? NP02140176-41-KNa 15853 NA  
A. euchroma ????? NP02140176-42-K 15854 NA  
L. erythrorhizon ?? NP02140176-42-K 15854 NA  
A. euchroma ????? O7-Angeloylretronecine 1233 NA  
L. erythrorhizon ?? O7-Angeloylretronecine 1233 NA  
A. euchroma ????? O9-Angeloylretronecine 1234 NA  
L. erythrorhizon ?? O9-Angeloylretronecine 1234 NA  
L. erythrorhizon ?? Octadecanyl caffeate 15953 NA  
A. euchroma ????? Potassium rosmarinate 17747 NA  
L. erythrorhizon ?? Propionylshikonin 17933 NA  
L. erythrorhizon ?? Rhizonone 18780 NA  
L. erythrorhizon ?? Shikonine 19820 NA  
L. erythrorhizon ?? Shikonofuran A 19821 NA  
A. euchroma ????? Shikonofuran B 19822 NA  
L. erythrorhizon ?? Shikonofuran B 19822 NA  
A. euchroma ????? Shikonofuran C 19823 NA  
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L. erythrorhizon ?? Shikonofuran C 19823 NA  
L. erythrorhizon ?? Shikonofuran D 19824 NA  
L. erythrorhizon ?? Shikonofuran E 19825 NA  
A. euchroma ????? Sodium ferulate 20032 NA  
A. euchroma ????? Sodium rosmarinate 20036 NA  
L. erythrorhizon ?? Tetracosyl caffeate 21039 NA  
A. euchroma ????? α-Acetoxyisovalerylalkannin 244 NA  
L. erythrorhizon ?? α-Acetoxyisovalerylalkannin 244 NA  
L. erythrorhizon ?? α-Methyl-n-butyrylshikonin 14202 NA  
A. euchroma ????? β,β-Dimethylacrylalkannin 6302 NA  
L. erythrorhizon ?? β,β-Dimethylacrylalkannin 6302 NA  
O. paniculatum ??? β,β-Dimethylacrylalkannin 6302 NA  
A. euchroma ????? β,β-Dimethylacrylshikonin 6303 NA  
A. guttata ??? β,β-Dimethylacrylshikonin 6303 NA  
L. erythrorhizon ?? β,β-Dimethylacrylshikonin 6303 NA  
O. paniculatum ??? β,β-Dimethylacrylshikonin 6303 NA  
A. euchroma ????? β-Hydroxyisovalerylshikonin 10266 NA  
A. guttata ??? β-Hydroxyisovalerylshikonin 10266 NA  
L. erythrorhizon ?? β-Hydroxyisovalerylshikonin 10266 NA  
O. paniculatum ??? β-Hydroxyisovalerylshikonin 10266 NA  
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Appendix 10 Biological target list for She chuang zi (Cnidium monnieri) 
Species Chinese Compound Compound ID target ID target name 
C. monnieri ???  Osthole 16261 T0291 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
C. monnieri ???  Osthole 16261 T0044 Activator of 90 kDa heat shock protein ATPase homolog 1 
C. monnieri ???  Osthole 16261 T0289 Bone morphogenetic protein 2 
C. monnieri ???  Osthole 16261 T0293 Carnitine O-palmitoyltransferase 1, liver isoform 
C. monnieri ???  Isopimpinellin 11601 T0150 Cytochrome P450 1A1 
C. monnieri ???  Isopimpinellin 11601 T0320 Cytochrome P450 2B10 
C. monnieri ???  Bergapten 2309 T0136 Cytochrome P450 3A4 
C. monnieri ???  Isopimpinellin 11601 T0136 Cytochrome P450 3A4 
C. monnieri ???  Isopimpinellin 11601 T0321 Glutathione S-transferase P 
C. monnieri ???  Osthole 16261 T0292 Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
C. monnieri ???  Osthole 16261 T0290 Mothers against decapentaplegic homolog 1 
C. monnieri ???  Osthole 16261 T0040 Nitric oxide synthase, inducible 
C. monnieri ???  Isopimpinellin 11601 T0234 Nuclear receptor subfamily 1 group I member 2 
C. monnieri ???  1(7),8(10)-p-Menthadien-9-ol 13725 NA  
C. monnieri ???  2'-Acetylangelicin 316 NA  
C. monnieri ???  3'-Isobutyryloxy-O-acetyl-2',3'-dihydro-oroselol 11297 NA  
C. monnieri ???  Alloimperatorin 933 NA  
C. monnieri ???  Archangelicin 1619 NA  
C. monnieri ???  Cnidiadin 3854 NA  
C. monnieri ???  Cnidioside A 3857 NA  
C. monnieri ???  Columbianadin 3935 NA  
C. monnieri ???  Columbianetin 3936 NA  
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C. monnieri ???  Columbianetin acetate 3937 NA  
C. monnieri ???  D-Quinovitol 18443 NA  
C. monnieri ???  Edultin 6709 NA  
C. monnieri ???  Imperatorin 11001 NA  
C. monnieri ???  Isovaleroxy-hydroxy dihydrovaltrate 11755 NA  
C. monnieri ???  O-Isovalerylcolum bianetin 11761 NA  
C. monnieri ???  Umtatin 22203 NA  
C. monnieri ???  Xanthotoxin 22774 NA  
C. monnieri ???  Xanthotoxol 22775 NA  
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Appendix 11 Biological target list for Bai xian pi (Dictamnus dasycarpus) 
Species Chinese Compound Compound ID target ID target name 
D. dasycarpus ??? Obaculactone 15882 T0136 Cytochrome P450 3A4 
D. dasycarpus ??? Campesterol 3040 NA  
D. dasycarpus ??? Dasycarpamine 4663 NA  
D. dasycarpus ??? Dictamnine 5445 NA  
D. dasycarpus ??? Dictamnoside A 5446 NA  
D. dasycarpus ??? Dictamnoside B 5447 NA  
D. dasycarpus ??? Dictamnoside G 5448 NA  
D. dasycarpus ??? Dictamnoside H 5449 NA  
D. dasycarpus ??? Dictamnoside I 5450 NA  
D. dasycarpus ??? Dictamnoside J 5451 NA  
D. dasycarpus ??? Dictamnoside K 5452 NA  
D. dasycarpus ??? Dictamnoside L 5453 NA  
D. dasycarpus ??? Dictamnoside M 5454 NA  
D. dasycarpus ??? Dictamnoside N 5455 NA  
D. dasycarpus ??? Evodol 7669 NA  
D. dasycarpus ??? Fraxinellone 7945 NA  
D. dasycarpus ??? Isomaculosidine 11518 NA  
D. dasycarpus ??? Kihadanin B 12226 NA  
D. dasycarpus ??? Obacunoic acid 15883 NA  
D. dasycarpus ??? Pregnenolone 17805 NA  
D. dasycarpus ??? Preskimmianine 17849 NA  
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D. dasycarpus ??? Skimmianine 20002 NA  
D. dasycarpus ??? Trigonelline 21662 NA  
D. dasycarpus ??? γ-Fagarine 7703 NA  
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Appendix 12 Biological target list for Bing pian (Dryobalanops aromatic, synthetic borneol) 
Species Chinese Compound Compound ID Target ID Target name 
D. aromatica ?? Oleanolic acid 16050 T0045 Caspase-3 
D. aromatica ?? Oleanolic acid 16050 T0019 Caspase-9 
D. aromatica ?? Oleanolic acid 16050 T0135 Heme oxygenase 1 
D. aromatica ?? Oleanolic acid 16050 T0152 Intercellular adhesion molecule 1 
D. aromatica ?? Oleanolic acid 16050 T0323 NAD(P)H dehydrogenase [quinone] 1 
D. aromatica ?? Camphor 3048 T0672 Neuronal acetylcholine receptor subunit alpha-4 
D. aromatica ?? Oleanolic acid 16050 T1106 Pancreatic alpha-amylase 
D. aromatica ?? Alphitolic acid 984 NA  
D. aromatica ?? Asiatic acid 1853 NA  
D. aromatica ?? Benzyl acetone 2274 NA  
D. aromatica ?? D-Borneol 2553 NA  
D. aromatica ?? Dipterocarpol 6502 NA  
D. aromatica ?? D-Isoborneol 11259 NA  
D. aromatica ?? Dryobalanone 6610 NA  
D. aromatica ?? Erythrodiol 7338 NA  
D. aromatica ?? L-Isoborneol 11260 NA  
D. aromatica ?? α-Humulene 9669 NA  
D. aromatica ?? β-Caryophyllene 3242 NA  
D. aromatica ?? β-Elemene 6741 NA  
D. aromatica ?? γ-Caryophyllene 3241 NA  
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Appendix 13 The list of APP drug targets (from DrugBank) 
App target name Category Action APP drug associated herb 
6-phosphogluconate dehydrogenase, decarboxylating Enzymes inhibitor Methotrexate No 
Aldehyde oxidase Enzymes substrate Methotrexate No 
Aldo-keto reductase family 1 member C1 Targets inhibitor Salicyclic acid Yes 
ATP-binding cassette sub-family G member 2 Transporters substrate Methotrexate Yes 
Transporters inhibitor Cyclosporine 
ATP-binding cassette transporter sub-family C member 11 Transporters substrate Methotrexate No 
Bifunctional purine biosynthesis protein PURH [Includes: 
Phosphoribosylaminoimidazolecarboxamide formyltransferase] 
Enzymes inhibitor Methotrexate No 
Bile salt export pump Transporters inhibitor Cyclosporine No 
Calcineurin subunit B isoform 2 Targets inhibitor Cyclosporine No 
Calcium signal-modulating cyclophilin ligand Targets binder Cyclosporine No 
Canalicular multispecific organic anion transporter 1 Transporters substrate, inhibitor Methotrexate No 
Transporters inhibitor Cyclosporine No 
Canalicular multispecific organic anion transporter 2 Transporters substrate, inhibitor Methotrexate No 
Transporters inhibitor Cyclosporine 
Cellular retinoic acid-binding protein 1 Carriers NS Alitretinoin NA 
Carriers NS Etretinate (w) NA 
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Cellular retinoic acid-binding protein 2 Carriers NS Alitretinoin NA 
Complement C1q subcomponent subunit A Targets NS Etanercept NA 
 
Targets NS Efalizumab 
Targets NS Alefacept 
Complement C1q subcomponent subunit B Targets NS Etanercept NA 
 
Targets NS Efalizumab 
Targets NS Alefacept 
Complement C1q subcomponent subunit C Targets NS Etanercept NA 
 
Targets NS Efalizumab 
Targets NS Alefacept 
Complement C1r subcomponent Targets NS Etanercept NA 
Targets NS Efalizumab 
Targets NS Alefacept 
Targets NS Etanercept 
Corticosteroid-binding globulin Carriers NS Fluticasone Propionate NA 
Corticosteroid-binding globulin Carriers binder Prednisolone No 
Cytochrome P450 19A1 Enzymes inhibitor Etretinate (w) No 
Cytochrome P450 1A1 Enzymes inhibitor Clobetasol Yes 
Enzymes inhibitor Methoxsalen 
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Cytochrome P450 1A2 Enzymes inhibitor Clobetasol Yes 
Enzymes inhibitor Alitretinoin 
Enzymes inhibitor Methoxsalen 
Cytochrome P450 24A1, mitochondrial Enzymes substrate Calcipotriol No 
Enzymes substrate, inducer Calcitriol 
Cytochrome P450 26A1 Enzymes substrate Acitretin No 
Enzymes substrate Etretinate (w) 
Cytochrome P450 2A6 Enzymes inhibitor Prednisolone No 
Enzymes inhibitor Methoxsalen 
Cytochrome P450 2A13  Enzymes inhibitor Methoxsalen No 
Cytochrome P450 2C19 Enzymes inhibitor Cyclosporine No 
Cytochrome P450 2C8 Enzymes substrate Tazarotene No 
Enzymes inhibitor Cyclosporine 
Cytochrome P450 2C9 Enzymes substrate Salicyclic acid No 
Enzymes inhibitor Cyclosporine 
Cytochrome P450 2D6 Enzymes inhibitor Cyclosporine No 
Cytochrome P450 3A4 Enzymes substrate, inducer Calcitriol Yes 
Enzymes substrate, inhibitor Fluticasone Propionate 
Enzymes substrate, inhibitor Prednisolone 
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Enzymes substrate, inducer Cyclosporine 
Enzymes substrate Methoxsalen 
Cytochrome P450 3A5 Enzymes substrate, inhibitor Fluticasone Propionate No 
Enzymes substrate, inducer Cyclosporine 
Cytochrome P450 3A7 Enzymes substrate Fluticasone Propionate No 
Enzymes substrate, inducer Cyclosporine 
Cytosolic phospholipase A2 Targets inhibitor Fluticasone Propionate No 
Dihydrofolate reductase Targets inhibitor Methotrexate No 
Dihydrofolate reductase Enzymes substrate Methotrexate No 
Enzymes inhibitor Aminopterin (w) 
DNA  Targets intercalation Methoxsalen No 
Folylpolyglutamate synthase, mitochondrial Enzymes substrate Methotrexate No 
Gamma-glutamyl hydrolase Enzymes substrate Methotrexate No 
Glucocorticoid receptor Targets agonist Desoximetasone No 
Targets agonist Clobetasol 
Targets agonist Fluticasone Propionate 
Targets agonist Prednisolone 
Heme carrier protein 1 Transporters substrate, inhibitor Methotrexate No 
Heme carrier protein 1 Transporters NS Aminopterin (w) NA 
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High affinity immunoglobulin gamma Fc receptor I Targets NS Etanercept NA 
Targets NS Efalizumab 
Targets NS Alefacept 
Ileal sodium/bile acid cotransporter Transporters inhibitor Cyclosporine No 
Integrin alpha-L Targets antibody Efalizumab No 
Kelch-like ECH-associated protein 1 (KEAP1_HUMAN) Targets binder Dimethyl fumarate No 
Low affinity immunoglobulin gamma Fc region receptor II-a Targets NS Etanercept NA 
  
Targets NS Efalizumab 
Targets NS Alefacept 
Low affinity immunoglobulin gamma Fc region receptor II-b Targets NS Etanercept NA 
  
Targets NS Efalizumab 
Targets NS Alefacept 
Low affinity immunoglobulin gamma Fc region receptor II-c Targets NS Etanercept NA 
   
Targets NS Efalizumab 
Targets NS Alefacept 
Low affinity immunoglobulin gamma Fc region receptor III-A Targets NS Etanercept NA  
  
Targets NS Efalizumab 
Targets NS Alefacept 
Low affinity immunoglobulin gamma Fc region receptor III-B Targets NS Etanercept NA  
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Targets NS Efalizumab   
Targets NS Alefacept 
Lymphotoxin-alpha Targets NS Etanercept NA 
Methylenetetrahydrofolate reductase Enzymes substrate Methotrexate No 
Mineralocorticoid receptor Targets antagonist Fluticasone Propionate No 
Monocarboxylate transporter 1 Transporters substrate Salicyclic acid No 
Transporters substrate Methotrexate 
Multidrug resistance protein 1 Transporters substrate Salicyclic acid Yes 
Transporters substrate Prednisolone 
Transporters substrate Methotrexate 
Transporters substrate Alitretinoin 
Transporters substrate, inhibitor, inducer Cyclosporine 
Multidrug resistance-associated protein 1 Transporters substrate, inhibitor Methotrexate No 
Transporters inhibitor Cyclosporine 
Multidrug resistance-associated protein 4 Transporters substrate, inhibitor Methotrexate No 
Multidrug resistance-associated protein 7 Transporters inhibitor Methotrexate No 
Transporters inhibitor Cyclosporine 
Myeloperoxidase Enzymes inhibitor Calcipotriol Yes 
Peptidyl-prolyl cis-trans isomerase A Targets NS Cyclosporine NA 
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Progesterone receptor Targets agonist Fluticasone Propionate No 
Prostaglandin G/H synthase 1 Targets inhibitor Salicyclic acid Yes 
Prostaglandin G/H synthase 2 Targets inhibitor Salicyclic acid Yes 
Prostaglandin G/H synthase 2 Enzymes inhibitor Etanercept 
Retinoic acid receptor alpha Targets agonist Tazarotene No 
Targets agonist Acitretin 
Targets agonist Alitretinoin 
Targets agonist Etretinate (w) 
Retinoic acid receptor beta Targets agonist Tazarotene No 
Targets agonist Acitretin 
Targets agonist Alitretinoin 
Targets agonist Etretinate (w) 
Retinoic acid receptor gamma-1 Targets agonist Tazarotene No 
Targets agonist Acitretin 
Targets agonist Alitretinoin 
Targets agonist Etretinate (w) 
Retinoic acid receptor RXR-alpha Targets agonist Acitretin No 
Targets agonist Alitretinoin 
Targets agonist Etretinate (w) 
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Retinoic acid receptor RXR-beta Targets agonist Tazarotene No 
Targets agonist Acitretin 
Targets agonist Alitretinoin 
Targets agonist Etretinate (w) 
Retinoic acid receptor RXR-gamma Targets agonist Acitretin No 
Targets agonist Alitretinoin 
Targets agonist Etretinate (w) 
Retinol-binding protein I, cellular Targets agonist Acitretin No 
Serum albumin Carriers other/unknown Salicyclic acid No  
Carriers NS Acitretin NA 
Carriers NS Methotrexate 
Sodium/bile acid cotransporter Transporters inhibitor Cyclosporine No 
Solute carrier family 22 member  Transporters substrate Salicyclic acid No 
Solute carrier family 22 member 10 Transporters inhibitor Salicyclic acid No 
Solute carrier family 22 member 11 Transporters inhibitor Salicyclic acid No 
Transporters substrate Methotrexate 
Solute carrier family 22 member 6 Transporters inhibitor Salicyclic acid No 
Transporters substrate, inhibitor Methotrexate 
Transporters inhibitor Cyclosporine 
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Solute carrier family 22 member 7 Transporters substrate Methotrexate No 
Solute carrier family 22 member 8 Transporters inhibitor Salicyclic acid No 
Transporters substrate, inhibitor Methotrexate 
Solute carrier organic anion transporter family member 1A2 Transporters inhibitor Prednisolone No 
Transporters substrate Methotrexate 
Transporters inhibitor Cyclosporine 
Solute carrier organic anion transporter family member 1B1 Transporters substrate Methotrexate No 
Transporters inhibitor Cyclosporine 
Solute carrier organic anion transporter family member 1B3 Transporters substrate Methotrexate No 
Solute carrier organic anion transporter family member 1C1 Transporters substrate Methotrexate No 
Solute carrier organic anion transporter family member 2B1 Transporters substrate Salicyclic acid No 
Solute carrier organic anion transporter family member 3A1 Transporters substrate Methotrexate No 
Solute carrier organic anion transporter family member 4C1 Transporters NS Methotrexate NA 
T-cell surface antigen CD2 Targets inhibitor Alefacept No 
Thymidylate synthase Enzymes substrate Methotrexate No 
Tumor necrosis factor Targets antibody golimumab Yes 
Targets antibody Etanercept 
Tumor necrosis factor receptor superfamily member 1B Targets NS Etanercept NA 
Vitamin D3 receptor Targets antagonist Calcipotriol No 
A-103 
Vitamin D3 receptor Targets antagonist Calcitriol No 
(w): withdrawn by FDA; NA: not available; NS: not stated.
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Appendix 14 List of Molecular Functions identified in PANTHER 
Dan shen: 
Molecular function Accession target hits 
binding  (GO:0005488) 51 
catalytic activity  (GO:0003824) 47 
enzyme regulator activity  (GO:0030234) 17 
receptor activity  (GO:0004872) 16 
transcription regulator activity  (GO:0030528) 9 
structural molecule activity  (GO:0005198) 6 
transporter activity  (GO:0005215) 4 
ion channel activity  (GO:0005216) 1 
translation regulator activity  (GO:0045182) 1 
antioxidant activity  (GO:0016209) 1 
Xi shu: 
Molecular function Accession target hits 
binding  (GO:0005488) 75 
catalytic activity  (GO:0003824) 61 
transcription regulator activity  (GO:0030528) 26 
receptor activity  (GO:0004872) 26 
enzyme regulator activity  (GO:0030234) 15 
transporter activity  (GO:0005215) 7 
structural molecule activity  (GO:0005198) 6 
antioxidant activity  (GO:0016209) 5 
ion channel activity  (GO:0005216) 2 
translation regulator activity  (GO:0045182) 1 
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Di huang: 
Molecular function Accession target hits 
catalytic activity  (GO:0003824) 49 
binding  (GO:0005488) 44 
receptor activity  (GO:0004872) 13 
transcription regulator activity  (GO:0030528) 7 
enzyme regulator activity  (GO:0030234) 7 
transporter activity  (GO:0005215) 6 
structural molecule activity  (GO:0005198) 4 
antioxidant activity  (GO:0016209) 2 
translation regulator activity  (GO:0045182) 1 
 
Qing dai: 
Molecular function Accession target hits 
catalytic activity  (GO:0003824) 26 
binding  (GO:0005488) 18 
transcription regulator activity  (GO:0030528) 8 
transporter activity  (GO:0005215) 7 
receptor activity  (GO:0004872) 6 
enzyme regulator activity  (GO:0030234) 3 
structural molecule activity  (GO:0005198) 2 
antioxidant activity  (GO:0016209) 1 
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Etanercept: 
Molecular function Accession target hits 
receptor activity  (GO:0004872) 8 
binding  (GO:0005488) 3 
structural molecule activity  (GO:0005198) 3 
catalytic activity  (GO:0003824) 2 
 
Salicylic acid: 
Molecular function Accession target hits 
transporter activity  (GO:0005215) 9 
catalytic activity  (GO:0003824) 4 
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Appendix 15 List of Molecular Functions identified in PANTHER 
Dan shen: 
Biological Process Accession target hits 
cellular process  (GO:0009987) 62 
metabolic process  (GO:0008152) 59 
cell communication  (GO:0007154) 50 
immune system process  (GO:0002376) 36 
apoptosis  (GO:0006915) 27 
response to stimulus  (GO:0050896) 26 
cell cycle  (GO:0007049) 25 
developmental process  (GO:0032502) 22 
transport  (GO:0006810) 14 
system process  (GO:0003008) 14 
reproduction  (GO:0000003) 9 
cell adhesion  (GO:0007155) 9 
cellular component organization  (GO:0016043) 6 
regulation of biological process  (GO:0050789) 5 
generation of precursor metabolites and energy  (GO:0006091) 5 
homeostatic process  (GO:0042592) 3 
localization  (GO:0051179) 2 
Xi shu: 
Biological Process Accession target hits 
metabolic process  (GO:0008152) 87 
cellular process  (GO:0009987) 85 
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cell communication  (GO:0007154) 68 
immune system process  (GO:0002376) 58 
response to stimulus  (GO:0050896) 48 
developmental process  (GO:0032502) 33 
cell cycle  (GO:0007049) 32 
apoptosis  (GO:0006915) 28 
reproduction  (GO:0000003) 17 
system process  (GO:0003008) 13 
cell adhesion  (GO:0007155) 11 
transport  (GO:0006810) 10 
generation of precursor metabolites and energy  (GO:0006091) 9 
cellular component organization  (GO:0016043) 8 
localization  (GO:0051179) 2 
homeostatic process  (GO:0042592) 2 
Di huang: 
Biological Process Accession target hits 
metabolic process  (GO:0008152) 56 
cellular process  (GO:0009987) 53 
cell communication  (GO:0007154) 48 
immune system process  (GO:0002376) 44 
response to stimulus  (GO:0050896) 33 
apoptosis  (GO:0006915) 21 
developmental process  (GO:0032502) 16 
transport  (GO:0006810) 13 
cell cycle  (GO:0007049) 11 
system process  (GO:0003008) 9 
generation of precursor metabolites and energy  (GO:0006091) 7 
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reproduction  (GO:0000003) 5 
cellular component organization  (GO:0016043) 4 
cell adhesion  (GO:0007155) 4 
homeostatic process  (GO:0042592) 2 
localization  (GO:0051179) 1 
regulation of biological process  (GO:0050789) 1 
Qing dai: 
Biological Process Accession target hits 
metabolic process  (GO:0008152) 31 
cellular process  (GO:0009987) 20 
immune system process  (GO:0002376) 16 
cell communication  (GO:0007154) 15 
apoptosis  (GO:0006915) 12 
response to stimulus  (GO:0050896) 11 
developmental process  (GO:0032502) 10 
cell cycle  (GO:0007049) 8 
system process  (GO:0003008) 6 
transport  (GO:0006810) 4 
reproduction  (GO:0000003) 4 
cell adhesion  (GO:0007155) 3 
localization  (GO:0051179) 2 
cellular component organization  (GO:0016043) 2 
homeostatic process  (GO:0042592) 2 
generation of precursor metabolites and energy  (GO:0006091) 1 
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Etanercept: 
Biological Process Accession target hits 
immune system process  (GO:0002376) 13 
cellular process  (GO:0009987) 12 
response to stimulus  (GO:0050896) 12 
developmental process  (GO:0032502) 6 
cellular component organization or biogenesis  (GO:0071840) 3 
apoptotic process  (GO:0006915) 3 
biological adhesion  (GO:0022610) 3 
metabolic process  (GO:0008152) 2 
reproduction  (GO:0000003) 1 
biological regulation  (GO:0065007) 1 
Salicylic acid: 
Biological Process Accession target hits 
localization  (GO:0051179) 10 
metabolic process  (GO:0008152) 9 
cellular process  (GO:0009987) 6 
multicellular organismal process  (GO:0032501) 5 
immune system process  (GO:0002376) 2 
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Appendix 16 List of Protein Classes identified in PANTHER 
Dan shen: 
Protein Class Accession target hit 
hydrolase  (PC00121) 24 
enzyme modulator  (PC00095) 19 
signaling molecule  (PC00207) 18 
protease  (PC00190) 15 
transferase  (PC00220) 15 
receptor  (PC00197) 15 
kinase  (PC00137) 13 
extracellular matrix protein  (PC00102) 9 
oxidoreductase  (PC00176) 9 
transcription factor  (PC00218) 9 
nucleic acid binding  (PC00171) 8 
cell adhesion molecule  (PC00069) 7 
calcium-binding protein  (PC00060) 7 
defense/immunity protein  (PC00090) 7 
transfer/carrier protein  (PC00219) 7 
phosphatase  (PC00181) 5 
cytoskeletal protein  (PC00085) 3 
transporter  (PC00227) 3 
chaperone  (PC00072) 2 
surfactant  (PC00212) 2 
lyase  (PC00144) 1 
ligase  (PC00142) 1 
structural protein  (PC00211) 1 
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Xi shu: 
Protein Class Accession target hit 
nucleic acid binding  (PC00171) 27 
transcription factor  (PC00218) 26 
signaling molecule (PC00207) 25 
receptor  (PC00197) 24 
transferase  (PC00220) 20 
hydrolase  (PC00121) 20 
enzyme modulator  (PC00095) 18 
oxidoreductase  (PC00176) 16 
kinase  (PC00137) 14 
protease  (PC00190) 13 
extracellular matrix protein  (PC00102) 10 
cell adhesion molecule  (PC00069) 7 
defense/immunity protein  (PC00090) 7 
transporter  (PC00227) 6 
calcium-binding protein  (PC00060) 6 
transfer/carrier protein  (PC00219) 5 
chaperone  (PC00072) 3 
phosphatase  (PC00181) 2 
cell junction protein  (PC00070) 2 
surfactant  (PC00212) 2 
structural protein  (PC00211) 2 
cytoskeletal protein  (PC00085) 1 
transmembrane receptor regulatory/adaptor protein  (PC00226) 1 
lyase  (PC00144) 1 
ligase  (PC00142) 1 
membrane traffic protein  (PC00150) 1 
isomerase  (PC00135) 1 
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Di huang: 
Protein Class Accession target hit 
signaling molecule  (PC00207) 20 
transferase  (PC00220) 17 
oxidoreductase  (PC00176) 15 
hydrolase  (PC00121) 13 
receptor  (PC00197) 12 
enzyme modulator  (PC00095) 9 
nucleic acid binding  (PC00171) 8 
defense/immunity protein  (PC00090) 8 
transfer/carrier protein  (PC00219) 7 
transcription factor  (PC00218) 7 
kinase  (PC00137) 7 
protease  (PC00190) 6 
calcium-binding protein  (PC00060) 5 
transporter  (PC00227) 4 
ligase  (PC00142) 4 
cytoskeletal protein  (PC00085) 3 
cell adhesion molecule  (PC00069) 3 
extracellular matrix protein  (PC00102) 1 
lyase  (PC00144) 1 
membrane traffic protein  (PC00150) 1 
phosphatase  (PC00181) 1 
chaperone  (PC00072) 1 
surfactant  (PC00212) 1 
structural protein  (PC00211) 1 
isomerase  (PC00135) 1 
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Qing dai: 
Protein Class Accession target hit 
hydrolase  (PC00121) 13 
transcription factor  (PC00218) 8 
signaling molecule  (PC00207) 6 
transferase  (PC00220) 5 
nucleic acid binding  (PC00171) 5 
receptor  (PC00197) 5 
protease  (PC00190) 4 
transporter  (PC00227) 4 
ligase  (PC00142) 4 
kinase  (PC00137) 4 
oxidoreductase  (PC00176) 3 
enzyme modulator  (PC00095) 3 
phosphatase  (PC00181) 3 
extracellular matrix protein  (PC00102) 2 
cell adhesion molecule  (PC00069) 2 
defense/immunity protein  (PC00090) 2 
transfer/carrier protein  (PC00219) 2 
surfactant  (PC00212) 2 
lyase  (PC00144) 1 
calcium-binding protein  (PC00060) 1 
Etanercept: 
Protein Class Accession target hit 
defense/immunity protein  (PC00090) 10 
receptor  (PC00197) 6 
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cell adhesion molecule  (PC00069) 5 
extracellular matrix protein  (PC00102) 3 
signaling molecule  (PC00207) 2 
hydrolase  (PC00121) 1 
oxidoreductase  (PC00176) 1 
calcium-binding protein  (PC00060) 1 
protease  (PC00190) 1 
Salicylic acid: 
Protein Class Accession target hit 
transporter  (PC00227) 8 
transfer/carrier protein  (PC00219) 6 
oxidoreductase  (PC00176) 3 
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Appendix 17: List of Celluar Components identified in PANTHER 
Dan shen: 
Cellular component Accession target hit 
extracellular region  (GO:0005576) 10 
intracellular  (GO:0005622) 3 
protein complex  (GO:0043234) 1 
 
Xi shu: 
Cellular component Accession target hit 
extracellular region  (GO:0005576) 11 
plasma membrane  (GO:0005886) 2 
intracellular  (GO:0005622) 1 
 
Di huang: 
Cellular component Accession target hit 
intracellular  (GO:0005622) 3 
extracellular region  (GO:0005576) 1 
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Qing dai: 
Cellular component Accession target hit 
extracellular region  (GO:0005576) 2 
Etanercept: 
Cellular component Accession target hit 
extracellular matrix  (GO:0031012) 3 
extracellular region  (GO:0005576) 3 
Salicylic acid: 
Cellular component Accession target hit 
membrane  (GO:0016020) 1 
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Appendix 18 List of pathways identified in PANTHER 
Dan shen:  
Pathway name Acc. No. %T %P 
Apoptosis signaling pathway  (P00006) 22 21.80% 6.80% 
Angiogenesis  (P00005) 18 17.80% 5.60% 
Gonadotropin releasing hormone receptor pathway  (P06664) 17 16.80% 5.30% 
Inflammation mediated by chemokine and cytokine signaling pathway  (P00031) 15 14.90% 4.60% 
Endothelin signaling pathway  (P00019) 12 11.90% 3.70% 
Huntington disease  (P00029) 11 10.90% 3.40% 
VEGF signaling pathway  (P00056) 11 10.90% 3.40% 
Wnt signaling pathway  (P00057) 10 9.90% 3.10% 
EGF receptor signaling pathway  (P00018) 10 9.90% 3.10% 
Interleukin signaling pathway  (P00036) 9 8.90% 2.80% 
FGF signaling pathway  (P00021) 9 8.90% 2.80% 
B cell activation  (P00010) 9 8.90% 2.80% 
Integrin signalling pathway  (P00034) 8 7.90% 2.50% 
FAS signaling pathway  (P00020) 8 7.90% 2.50% 
PI3 kinase pathway  (P00048) 8 7.90% 2.50% 
Alzheimer disease-amyloid secretase pathway  (P00003) 7 6.90% 2.20% 
Ras Pathway  (P04393) 7 6.90% 2.20% 
T cell activation  (P00053) 7 6.90% 2.20% 
PDGF signaling pathway  (P00047) 7 6.90% 2.20% 
Alzheimer disease-presenilin pathway  (P00004) 6 5.90% 1.90% 
p53 pathway  (P00059) 6 5.90% 1.90% 
Toll receptor signaling pathway  (P00054) 6 5.90% 1.90% 
Plasminogen activating cascade  (P00050) 6 5.90% 1.90% 
Blood coagulation  (P00011) 6 5.90% 1.90% 
A-119 
p53 pathway feedback loops 2  (P04398) 5 5.00% 1.50% 
Oxidative stress response  (P00046) 5 5.00% 1.50% 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway  (P00042) 5 5.00% 1.50% 
5HT2 type receptor mediated signaling pathway  (P04374) 4 4.00% 1.20% 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway  (P00027) 4 4.00% 1.20% 
Thyrotropin-releasing hormone receptor signaling pathway  (P04394) 4 4.00% 1.20% 
TGF-beta signaling pathway  (P00052) 4 4.00% 1.20% 
Oxytocin receptor mediated signaling pathway  (P04391) 4 4.00% 1.20% 
Histamine H1 receptor mediated signaling pathway  (P04385) 4 4.00% 1.20% 
Cadherin signaling pathway  (P00012) 4 4.00% 1.20% 
Interferon-gamma signaling pathway  (P00035) 3 3.00% 0.90% 
Alpha adrenergic receptor signaling pathway  (P00002) 3 3.00% 0.90% 
Insulin/IGF pathway-protein kinase B signaling cascade  (P00033) 3 3.00% 0.90% 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade  (P00032) 3 3.00% 0.90% 
Parkinson disease  (P00049) 3 3.00% 0.90% 
Cytoskeletal regulation by Rho GTPase  (P00016) 3 3.00% 0.90% 
Cell cycle  (P00013) 3 3.00% 0.90% 
Nicotinic acetylcholine receptor signaling pathway  (P00044) 3 3.00% 0.90% 
p53 pathway by glucose deprivation  (P04397) 2 2.00% 0.60% 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway  (P00026) 2 2.00% 0.60% 
p38 MAPK pathway  (P05918) 2 2.00% 0.60% 
Angiotensin II-stimulated signaling through G proteins and beta-arrestin  (P05911) 2 2.00% 0.60% 
Axon guidance mediated by netrin  (P00009) 1 1.00% 0.30% 
Axon guidance mediated by Slit/Robo  (P00008) 1 1.00% 0.30% 
Beta2 adrenergic receptor signaling pathway  (P04378) 1 1.00% 0.30% 
Axon guidance mediated by semaphorins  (P00007) 1 1.00% 0.30% 
Beta1 adrenergic receptor signaling pathway  (P04377) 1 1.00% 0.30% 
JAK/STAT signaling pathway  (P00038) 1 1.00% 0.30% 
Hypoxia response via HIF activation  (P00030) 1 1.00% 0.30% 
Ornithine degradation  (P02758) 1 1.00% 0.30% 
A-120 
Transcription regulation by bZIP transcription factor  (P00055) 1 1.00% 0.30% 
P53 pathway feedback loops 1  (P04392) 1 1.00% 0.30% 
Enkephalin release  (P05913) 1 1.00% 0.30% 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway  (P00043) 1 1.00% 0.30% 
Metabotropic glutamate receptor group I pathway  (P00041) 1 1.00% 0.30% 
Acc. Accession No in PANTHER; No.: Number of target hits in the pathway; %T: target hits/total no. targets (%);%P: target hits/total no. pathway hits (%) 
 
Xi shu: 
Pathway name Acc. No. %T %P 
Gonadotropin releasing hormone receptor pathway  (P06664) 22 16.40% 7.10% 
Angiogenesis  (P00005) 20 14.90% 6.40% 
Apoptosis signaling pathway  (P00006) 18 13.40% 5.80% 
Interleukin signaling pathway  (P00036) 18 13.40% 5.80% 
Inflammation mediated by chemokine and cytokine signaling pathway  (P00031) 16 11.90% 5.10% 
p53 pathway  (P00059) 13 9.70% 4.20% 
VEGF signaling pathway  (P00056) 11 8.20% 3.50% 
EGF receptor signaling pathway  (P00018) 10 7.50% 3.20% 
PDGF signaling pathway  (P00047) 10 7.50% 3.20% 
PI3 kinase pathway  (P00048) 9 6.70% 2.90% 
p53 pathway feedback loops 2  (P04398) 8 6.00% 2.60% 
Wnt signaling pathway  (P00057) 8 6.00% 2.60% 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade  (P00032) 7 5.20% 2.30% 
Huntington disease  (P00029) 7 5.20% 2.30% 
Ras Pathway  (P04393) 7 5.20% 2.30% 
T cell activation  (P00053) 7 5.20% 2.30% 
Endothelin signaling pathway  (P00019) 7 5.20% 2.30% 
B cell activation  (P00010) 7 5.20% 2.30% 
A-121 
Toll receptor signaling pathway  (P00054) 6 4.50% 1.90% 
FGF signaling pathway  (P00021) 6 4.50% 1.90% 
FAS signaling pathway  (P00020) 6 4.50% 1.90% 
Integrin signalling pathway  (P00034) 5 3.70% 1.60% 
Insulin/IGF pathway-protein kinase B signaling cascade  (P00033) 5 3.70% 1.60% 
Plasminogen activating cascade  (P00050) 5 3.70% 1.60% 
Oxidative stress response  (P00046) 5 3.70% 1.60% 
Blood coagulation  (P00011) 5 3.70% 1.60% 
Alzheimer disease-presenilin pathway  (P00004) 4 3.00% 1.30% 
Cell cycle  (P00013) 4 3.00% 1.30% 
Cadherin signaling pathway  (P00012) 4 3.00% 1.30% 
Angiotensin II-stimulated signaling through G proteins and beta-arrestin  (P05911) 4 3.00% 1.30% 
Alzheimer disease-amyloid secretase pathway  (P00003) 3 2.20% 1.00% 
Interferon-gamma signaling pathway  (P00035) 3 2.20% 1.00% 
Hypoxia response via HIF activation  (P00030) 3 2.20% 1.00% 
TGF-beta signaling pathway  (P00052) 3 2.20% 1.00% 
Parkinson disease  (P00049) 3 2.20% 1.00% 
5HT2 type receptor mediated signaling pathway  (P04374) 2 1.50% 0.60% 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway  (P00027) 2 1.50% 0.60% 
p53 pathway by glucose deprivation  (P04397) 2 1.50% 0.60% 
Thyrotropin-releasing hormone receptor signaling pathway  (P04394) 2 1.50% 0.60% 
Oxytocin receptor mediated signaling pathway  (P04391) 2 1.50% 0.60% 
p38 MAPK pathway  (P05918) 2 1.50% 0.60% 
DNA replication  (P00017) 2 1.50% 0.60% 
Histamine H1 receptor mediated signaling pathway  (P04385) 2 1.50% 0.60% 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway  (P00042) 2 1.50% 0.60% 
JAK/STAT signaling pathway  (P00038) 1 0.70% 0.30% 
Purine metabolism  (P02769) 1 0.70% 0.30% 
Alpha adrenergic receptor signaling pathway  (P00002) 1 0.70% 0.30% 
Pentose phosphate pathway  (P02762) 1 0.70% 0.30% 
A-122 
Ubiquitin proteasome pathway  (P00060) 1 0.70% 0.30% 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway  (P00026) 1 0.70% 0.30% 
Vitamin D metabolism and pathway  (P04396) 1 0.70% 0.30% 
Ornithine degradation  (P02758) 1 0.70% 0.30% 
Hedgehog signaling pathway  (P00025) 1 0.70% 0.30% 
Glycolysis  (P00024) 1 0.70% 0.30% 
Adenine and hypoxanthine salvage pathway  (P02723) 1 0.70% 0.30% 
P53 pathway feedback loops 1  (P04392) 1 0.70% 0.30% 
Fructose galactose metabolism  (P02744) 1 0.70% 0.30% 
Metabotropic glutamate receptor group I pathway  (P00041) 1 0.70% 0.30% 
Acc. Accession No in PANTHER; No.: Number of target hits in the pathway; %T: target hits/total no. targets (%);%P: target hits/total no. pathway hits (%) 
 
Di huang: 
Pathway name Acc. No. %T %P 
Inflammation mediated by chemokine and cytokine signaling pathway  (P00031) 18 19.40% 7.40% 
Apoptosis signaling pathway  (P00006) 15 16.10% 6.20% 
Gonadotropin releasing hormone receptor pathway  (P06664) 15 16.10% 6.20% 
Interleukin signaling pathway  (P00036) 13 14.00% 5.30% 
Angiogenesis  (P00005) 11 11.80% 4.50% 
T cell activation  (P00053) 11 11.80% 4.50% 
B cell activation  (P00010) 9 9.70% 3.70% 
Huntington disease  (P00029) 8 8.60% 3.30% 
VEGF signaling pathway  (P00056) 7 7.50% 2.90% 
Toll receptor signaling pathway  (P00054) 7 7.50% 2.90% 
Endothelin signaling pathway  (P00019) 7 7.50% 2.90% 
EGF receptor signaling pathway  (P00018) 7 7.50% 2.90% 
Ras Pathway  (P04393) 6 6.50% 2.50% 
A-123 
FGF signaling pathway  (P00021) 6 6.50% 2.50% 
FAS signaling pathway  (P00020) 6 6.50% 2.50% 
PI3 kinase pathway  (P00048) 6 6.50% 2.50% 
p53 pathway  (P00059) 5 5.40% 2.10% 
Wnt signaling pathway  (P00057) 5 5.40% 2.10% 
PDGF signaling pathway  (P00047) 5 5.40% 2.10% 
Alzheimer disease-amyloid secretase pathway  (P00003) 4 4.30% 1.60% 
Integrin signalling pathway  (P00034) 4 4.30% 1.60% 
p53 pathway feedback loops 2  (P04398) 4 4.30% 1.60% 
TGF-beta signaling pathway  (P00052) 4 4.30% 1.60% 
Oxidative stress response  (P00046) 4 4.30% 1.60% 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway  (P00042) 4 4.30% 1.60% 
Interferon-gamma signaling pathway  (P00035) 3 3.20% 1.20% 
Insulin/IGF pathway-protein kinase B signaling cascade  (P00033) 3 3.20% 1.20% 
Hypoxia response via HIF activation  (P00030) 3 3.20% 1.20% 
Parkinson disease  (P00049) 3 3.20% 1.20% 
Axon guidance mediated by netrin  (P00009) 2 2.20% 0.80% 
5HT2 type receptor mediated signaling pathway  (P04374) 2 2.20% 0.80% 
Alpha adrenergic receptor signaling pathway  (P00002) 2 2.20% 0.80% 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade  (P00032) 2 2.20% 0.80% 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway  (P00027) 2 2.20% 0.80% 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway  (P00026) 2 2.20% 0.80% 
Thyrotropin-releasing hormone receptor signaling pathway  (P04394) 2 2.20% 0.80% 
Oxytocin receptor mediated signaling pathway  (P04391) 2 2.20% 0.80% 
Histamine H1 receptor mediated signaling pathway  (P04385) 2 2.20% 0.80% 
Nicotinic acetylcholine receptor signaling pathway  (P00044) 2 2.20% 0.80% 
Blood coagulation  (P00011) 2 2.20% 0.80% 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway  (P00043) 2 2.20% 0.80% 
Angiotensin II-stimulated signaling through G proteins and beta-arrestin  (P05911) 2 2.20% 0.80% 
Axon guidance mediated by Slit/Robo  (P00008) 1 1.10% 0.40% 
A-124 
Axon guidance mediated by semaphorins  (P00007) 1 1.10% 0.40% 
JAK/STAT signaling pathway  (P00038) 1 1.10% 0.40% 
Purine metabolism  (P02769) 1 1.10% 0.40% 
p53 pathway by glucose deprivation  (P04397) 1 1.10% 0.40% 
Ornithine degradation  (P02758) 1 1.10% 0.40% 
Hedgehog signaling pathway  (P00025) 1 1.10% 0.40% 
Transcription regulation by bZIP transcription factor  (P00055) 1 1.10% 0.40% 
Adenine and hypoxanthine salvage pathway  (P02723) 1 1.10% 0.40% 
p38 MAPK pathway  (P05918) 1 1.10% 0.40% 
Cytoskeletal regulation by Rho GTPase  (P00016) 1 1.10% 0.40% 
Nicotine degradation  (P05914) 1 1.10% 0.40% 
Cell cycle  (P00013) 1 1.10% 0.40% 
Metabotropic glutamate receptor group I pathway  (P00041) 1 1.10% 0.40% 
Acc. Accession No in PANTHER; No.: Number of target hits in the pathway; %T: target hits/total no. targets (%);%P: target hits/total no. pathway hits (%) 
 
Qing dai: 
Pathway name Acc. No. %T %P 
Apoptosis signaling pathway  (P00006) 11 25.60% 9.80% 
Angiogenesis  (P00005) 7 16.30% 6.30% 
Gonadotropin releasing hormone receptor pathway  (P06664) 7 16.30% 6.30% 
Inflammation mediated by chemokine and cytokine signaling pathway  (P00031) 5 11.60% 4.50% 
Huntington disease  (P00029) 5 11.60% 4.50% 
PDGF signaling pathway  (P00047) 5 11.60% 4.50% 
Interleukin signaling pathway  (P00036) 4 9.30% 3.60% 
FAS signaling pathway  (P00020) 4 9.30% 3.60% 
Integrin signalling pathway  (P00034) 3 7.00% 2.70% 
Wnt signaling pathway  (P00057) 3 7.00% 2.70% 
A-125 
VEGF signaling pathway  (P00056) 3 7.00% 2.70% 
Ras Pathway  (P04393) 3 7.00% 2.70% 
T cell activation  (P00053) 3 7.00% 2.70% 
PI3 kinase pathway  (P00048) 3 7.00% 2.70% 
B cell activation  (P00010) 3 7.00% 2.70% 
Alzheimer disease-amyloid secretase pathway  (P00003) 2 4.70% 1.80% 
Interferon-gamma signaling pathway  (P00035) 2 4.70% 1.80% 
Insulin/IGF pathway-protein kinase B signaling cascade  (P00033) 2 4.70% 1.80% 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade  (P00032) 2 4.70% 1.80% 
p53 pathway  (P00059) 2 4.70% 1.80% 
Toll receptor signaling pathway  (P00054) 2 4.70% 1.80% 
FGF signaling pathway  (P00021) 2 4.70% 1.80% 
TGF-beta signaling pathway  (P00052) 2 4.70% 1.80% 
Endothelin signaling pathway  (P00019) 2 4.70% 1.80% 
EGF receptor signaling pathway  (P00018) 2 4.70% 1.80% 
Oxidative stress response  (P00046) 2 4.70% 1.80% 
Angiotensin II-stimulated signaling through G proteins and beta-arrestin  (P05911) 2 4.70% 1.80% 
Alzheimer disease-presenilin pathway  (P00004) 1 2.30% 0.90% 
5HT2 type receptor mediated signaling pathway  (P04374) 1 2.30% 0.90% 
Alpha adrenergic receptor signaling pathway  (P00002) 1 2.30% 0.90% 
Hypoxia response via HIF activation  (P00030) 1 2.30% 0.90% 
Pentose phosphate pathway  (P02762) 1 2.30% 0.90% 
p53 pathway feedback loops 2  (P04398) 1 2.30% 0.90% 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway  (P00027) 1 2.30% 0.90% 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway  (P00026) 1 2.30% 0.90% 
Hedgehog signaling pathway  (P00025) 1 2.30% 0.90% 
Glycolysis  (P00024) 1 2.30% 0.90% 
Thyrotropin-releasing hormone receptor signaling pathway  (P04394) 1 2.30% 0.90% 
Oxytocin receptor mediated signaling pathway  (P04391) 1 2.30% 0.90% 
Parkinson disease  (P00049) 1 2.30% 0.90% 
A-126 
Histamine H1 receptor mediated signaling pathway  (P04385) 1 2.30% 0.90% 
Heme biosynthesis  (P02746) 1 2.30% 0.90% 
Glutamine glutamate conversion  (P02745) 1 2.30% 0.90% 
Cadherin signaling pathway  (P00012) 1 2.30% 0.90% 
Fructose galactose metabolism  (P02744) 1 2.30% 0.90% 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway  (P00042) 1 2.30% 0.90% 
Acc. Accession No in PANTHER; No.: Number of target hits in the pathway; %T: target hits/total no. targets (%);%P: target hits/total no. pathway hits (%) 
Etanercept: 
Pathway name Acc. No. %T %P 
Apoptosis signaling pathway  (P00006) 3 23.10% 42.90% 
Inflammation mediated by chemokine and cytokine signaling pathway  (P00031) 1 7.70% 14.30% 
Wnt signaling pathway  (P00057) 1 7.70% 14.30% 
Endothelin signaling pathway  (P00019) 1 7.70% 14.30% 
Toll receptor signaling pathway  (P00054) 1 7.70% 14.30% 
Acc. Accession No in PANTHER; No.: Number of target hits in the pathway; %T: target hits/total no. targets (%);%P: target hits/total no. pathway hits (%) 
Salicylic acid: 
Pathway name Acc. No. %T %P 
Inflammation mediated by chemokine and cytokine signaling pathway ? (P00031)? 2? 15.40%? 50.00%?
Endothelin signaling pathway ? (P00019)? 1? 7.70%? 25.00%?
Toll receptor signaling pathway ? (P00054)? 1? 7.70%? 25.00%?
Acc. Accession No in PANTHER; No.: Number of target hits in the pathway; %T: target hits/total no. targets (%);%P: target hits/total no. pathway hits 
 
A-127 
Appendix 19. List of protein targets in the top 5 pathways identified in PANTHER 
Target name Panther name Ang Int Inf Gon Apo HIT name 
12-LO Arachidonate 12-lipoxygenase, leukocyte-type    1  NA 
3' FSHbeta Follitropin subunit beta    1  Follitropin subunit beta 
3' LHbeta Luteinizing hormone beta    1  Lutropin subunit beta 
5' FSHbeta 5-hydroxytryptamine receptor 3A    1  5-hydroxytryptamine receptor 3A 
5' LHbeta 5' LHbeta    1  NA 
5-HT3AR 5-HT3AR    1  NA 
A1 Bcl2-related protein A1     1 Bcl-2-related protein A1 
AC Adenylate cyclase    1 1  Adenylate cyclase type 2, 8, 10 
ActRII Activin receptor type-2A    1  NA 
ActRII/IIB Activin receptor type-2A/2B    1  NA 
Adiponectin Adiponectin    1  Adiponectin 
AdipoR1/R2 Adiponectin receptor protein 1/2    1  Adiponectin receptor protein 1/2 
AIF Apoptosis inducing factor      1 NA 
AK006051 AK006051    1  NA 
AKT RAC-alpha serine/threonine-protein kinase 1  1 1 1 RAC-alpha serine/threonine-protein kinase 
Alk4 Activin type I receptor    1  NA 
alpha-beta integrin 
dimer 
Integrin alpha/beta-1    1  Integrin beta-1 
AMPK 5'-AMP-activated protein kinase subunit 
alpha-1/beta-1/beta-2/gamma-1/gamma-2; 45 kDa 
calcium-binding protein 
   1  5'-AMP-activated protein kinase subunit gamma-2 
Ang-1 Angiopoietin-1  1     Angiopoietin-1 
Ang-2 Angiopoietin-2  1     NA 
A-128 
Annexin A5 Annexin A5    1  Annexin A5 
AP-1 activator protein-1    1   Transcription factor AP-1 
Apaf-1 Apoptosis protease activating factor-1      1 Apoptotic protease-activating factor 1 
APC Adenomatous Polyposis of the Colon  1     Adenomatous polyposis coli protein 
AR Androgen receptor    1  Androgen receptor 
Arp2/3 Actin related protein 2/3 complex    1   NA 
ASK1 Apoptosis signal-regulating kinase-1          1 Mitogen-activated protein kinase kinase kinase 5 
ATF Activating transcription factor     1 Cyclic AMP-dependent transcription factor ATF 
ATF2 ATF2    1  NA 
Atf3 Cyclic AMP-dependent transcription factor ATF-3    1  NA 
Axin Axis inhibitor 1 1     NA 
BAD Bcl2 antagonist of cell death 1 1   1 Bcl2 antagonist of cell death 
Bag Bcl-2 associated anthogene-1     1 BAG family molecular chaperone regulator 3 
Bak Bcl-2 antogonist/killer      1 Bcl-2 homologous antagonist/killer 
Bax Bcl-2 associated x protein      1 Apoptosis regulator BAX 
Bcl-2 Bcl-2     1 Apoptosis regulator Bcl-2 
Bcl-w Bcl-w     1 Bcl-2-like protein 2 
Bcl-xL Bcl2-related protein long isoform     1 Bcl-2-like protein 1 
Bcl-xS Bcl2-related protein short isoform     1 Bcl-2-like protein 1 
beta catenin Beta-catenin (beta catenin) 1     Catenin beta-1 
beta-arrestin Beta-arrestin   1   Beta-arrestin 
Bi1 Bax inhibitor-1     1 NA 
Bid BH-3 interacting domain death agonist     1 BH3-interacting domain death agonist 
Bik Bcl-2 interacting killer     1 Bcl-2-interacting killer 
A-129 
Bim Bim     1 Bcl-2-like protein 11 
Blk Bcl-2 interacting killer     1 NA 
BMP2/4/15 Bone morphogenetic protein 2/4/15    1  Bone morphogenetic protein 2/4 
BMP6/7 Bone morphogenetic protein 6/7    1  NA 
BMP7 Bone morphogenetic protein 7    1  NA 
BMPR-IA/IB/II Bone morphogenetic protein receptor type-1A/1B/2    1  Bone morphogenetic protein receptor type-2 
Bok Bcl-2 related ovarian killer     1 Bcl-2-related ovarian killer protein 
Ca/CaMK II Calcium/calmodulin-dependent protein kinase type II 
subunit beta 
   1  NA 
Caln Serine/threonine-protein phosphatase 2B catalytic 
subunit alpha isoform 
   1  Serine/threonine-protein phosphatase 2B catalytic subunit 
alpha isoform 
CaMK Calcium/calModulin-dependent Kinase II, Calcium 
/calmodulin-dependent protein kinase kinase 2 
  1   Calcium/calmodulin-dependent protein kinase kinase 2 
Caspase 10 Caspase 10     1 Caspase-10 
Caspase 3 Caspase 3     1 Caspase-3 
Caspase 7 Caspase 7     1 Caspase-7 
Caspase 8 Caspase 8     1 Caspase-8 
Caspase 9 Caspase 9 1    1 Caspase-9 
Caveolin-1 Caveolin-1    1  Caveolin-1 
CBP CREB-binding protein    1  NA 
Cdc42 Cell division cycle 42 (Cdc42), related to PAK, Cell 
division control protein 42 homolog 
  1 1  Cell division control protein 42 homolog 
c-fos c-Fos Transcription Factor (c-Fos) 1 1  1  Proto-oncogene c-Fos 
CGA Glycoprotein hormones alpha chain    1  NA 
CHK Chemokine (CHK)   1   C-C motif chemokine, C-X-C motif chemokine 
CHKR Chemokine receptor (CHKR)   1   C-C chemokine receptor 
c-IAP1,2 Cellular inhibitor of apoptosis protein 1 and     1 Baculoviral IAP repeat-containing protein 3 
A-130 
2 (c-IAP1,2) 
c-Jun c-Jun Transcription Factor (c-Jun), member of the 
AP-1 (activator protein-1) family 
1    1 Transcription factor AP-1 
CLIM2 LIM domain-binding protein 1    1  NA 
c-Myc Myc proto-oncogene protein  1    Myc proto-oncogene protein 
CNP C-type natriuretic peptide    1  C-type natriuretic peptide 
COX2 Prostaglandin G/H synthase 2    1  Prostaglandin G/H synthase 2 
cPLA2 Cytosolic Phospholipase A2 1     Cytosolic Phospholipase A2 
c-Raf RAF proto-oncogene serine/threonine-protein kinase    1  RAF proto-oncogene serine/threonine-protein kinase 
CREB Cyclic AMP-responsive element-binding protein 1    1  Cyclic AMP-responsive element-binding protein 1 
Crk Crk oncogene 1     NA 
Csda DNA-binding protein A    1  NA 
CSL CBF1, Suppressor of Hairless, Lag-1 Transcription 
Factor Family (CSL) 
1     NA 
CTMP C-terminal modulator protein  1    NA 
CTNNB1 Catenin beta-1    1  Catenin beta-1 
Cyclooxygenase Cyclooxygenase, COX   1   Prostaglandin G/H synthase 
Cytochrome C Cytochrome C     1 Cytochrome c 
Cytokine receptor Cytokine receptor   1   NA 
DAXX Death-associated protein 6     1 Death domain-associated protein 6 
Delta/Serrate Delta 1     NA 
DGK-zeta Diacylglycerol kinase zeta    1  Diacylglycerol kinase theta 
Diva Diva     1 Bcl-2-like protein 10 
Dnm1 Dynamin-1    1  NA 
Dok-R Docking Protein-R 1     Docking protein 2 
A-131 
DRD2 D(2) dopamine receptor    1  D(2) dopamine receptor 
Dsh Dishelvelled 1     NA 
ds-RNA ds-RNA     1 NA 
DUSP1 Dual specificity protein phosphatase 1    1  Dual specificity protein phosphatase 1 
ECM ECM    1  NA 
EGF Pro-epidermal growth factor    1  Pro-epidermal growth factor 
EGFR Epidermal growth factor receptor    1  Epidermal growth factor receptor 
EGR1 Early growth response protein 1    1  Early growth response protein 1 
EIF2A Eukaryotic translation initiation factor 2A    1  Eukaryotic translation initiation factor 2 subunit 1/ alpha 
EIF2AK3 Eukaryotic translation initiation factor 2-alpha kinase 
3 
   1  NA 
ELF2alpha Translation initiation factor 2-alpha      1 Eukaryotic translation initiation factor 2 subunit 1 
ELK NS  1    ETS domain-containing protein Elk-1 
ELK1 ETS domain-containing protein Elk-1    1  ETS domain-containing protein Elk-1 
EMC ExtraCellular matrix protein    1   Collagen alpha 
endoG Endonuclease G     1 NA 
eNOS endothelial nitric oxide synthase 1 1    Nitric oxide synthase, endothelial 
Eph Ephrin  1     NA 
EphR Ephrin Receptor  1     Ephrin type-B receptor 2, Ephrin type-A receptor 2 
ER Steroid hormone receptor ERR1    1  Steroid hormone receptor ERR1 
ERK Extracellular signal-regulated kinase family  1 1    Mitogen-activated protein kinase 1, 3,7,12 
ERK1/2 Mitogen-activated protein kinase 1/3    1  Mitogen-activated protein kinase 1/3 
Ets v-Ets Avian Erythroblastosis Virus E26 Oncogene 
Homolog 1 (Ets) 
1 1    Protein C-ets-1 
F-actin  F-actin   1   Actin, cytoplasmic 1, Alpha-actinin-1, F-actin 
A-132 
cross-linking protein 
FADD Fas associated death domain     1 NA 
FAK Focal Adhesion Kinase 1   1  Focal adhesion kinase 1 
FAS FAS     1 Tumor necrosis factor receptor superfamily member 6 
FAS ligand FAS ligand     1 Tumor necrosis factor ligand superfamily member 6 
FGF Fibroblast Growth Factor 1     Fibroblast Growth Factor 
FGFR-1 Fibroblast Growth Factor Receptor-1  1     Fibroblast Growth Factor Receptor 1  
FKHRL1 Forkhead in Rhabdomyosarcoma-like 1  1    NA 
Flip FLICE inhibitory protein     1 CASP8 and FADD-like apoptosis regulator 
Follistatin Follistatin    1  NA 
Fos Proto-oncogene c-Fos    1 1 Proto-oncogene c-Fos 
Fosb Protein fosB       1   Protein fosB 
FRP Frizzled-Related Protein 1     NA 
FRS-2 Fibroblast Growth Factor Receptor Substrate 2 1     NA 
FSHbeta Follitropin subunit beta    1  Follitropin subunit beta 
FVIIa Factor VIIa 1     Coagulation factor VII 
Fzd Frizzled 1     NA 
Galphai Gi-protein, alpha subunit   1   Guanine nucleotide-binding protein G(i) subunit alpha-1 
Galphai/q Gi/q-protein, alpha subunit   1   Guanine nucleotide-binding protein G(i) subunit alpha 
Galphaq Gq-protein, alpha subunit   1   NA 
GAP GTPase-Activating Protein 1     Ras GTPase-activating protein 1 
GATA2/4 Endothelial transcription factor GATA-2/4      1  Endothelial transcription factor GATA-2 
Gbeta Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 /2/3; Guanine nucleotide-binding 
protein subunit beta-4 /5 
   1  NA 
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Gbetagamma G protein, beta and gamma subunit   1   Guanine nucleotide-binding protein G(s) subunit beta 
GC Guanylate cyclase soluble subunit beta-1; Protein 
Gucy1b2  
   1  Guanylate cyclase soluble subunit beta-1 
GCK Germinal center kinase     1 Mitogen-activated protein kinase kinase kinase kinase 2 
GCKR Germinal center kinase related     1 Mitogen-activated protein kinase kinase kinase kinase 4, 
Mitogen-activated protein kinase kinase kinase kinase 3 
GEF Guanine nucleotide exchange factor   1   Guanine nucleotide exchange factor GEFT 
Ggamma Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-2 
   1  NA 
Glut1 Solute carrier family 2, facilitated glucose transporter 
member 1 
   1  Solute carrier family 2, facilitated glucose transporter 
member 1 
gnai Guanine nucleotide-binding protein G(i) subunit 
alpha-1/2; Guanine nucleotide-binding protein G(k) 
subunit alpha    
   1  Guanine nucleotide-binding protein G(i) subunit alpha-1; 
Guanine nucleotide-binding protein G(k) subunit alpha    
gnai/o Guanine nucleotide-binding protein G(o) subunit 
alpha; Guanine nucleotide-binding protein G(i) 
subunit alpha-1  
   1  NA 
gnaq/11 Guanine nucleotide-binding protein subunit alpha-11; 
Guanine nucleotide-binding protein G(q) subunit 
alpha  
   1  NA 
gnas Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms XLas 
   1  NA 
GnRH Progonadoliberin-1    1  Progonadoliberin-1 
GnRHR Gonadotropin-releasing hormone receptor    1  Gonadotropin-releasing hormone receptor 
GPR147/74 GPR147/74    1  NA 
GPRK G-protein receptor kinase, G protein-coupled receptor 
kinases 
  1   NA 
GR Glucocorticoid receptor    1  Glucocorticoid receptor 
Granzyme B Granzyme B     1 Granzyme B 
Grb Growth factor receptor-bound protein   1   NA 
Grb14 Growth Factor Receptor-Bound Protein 14 1     NA 
Grb2 Growth factor receptor-bound protein 2 1 1  1  NA 
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Grb7 Growth Factor Receptor-Bound Protein 7 1     NA 
GSK3 Glycogen synthase kinase-3 beta   1  1  Glycogen synthase kinase-3 
GSK3beta Glycogen synthase kinase 3-beta 1     Glycogen synthase kinase-3 beta 
GTPase Rho guanosine triphosphatase 1     NA 
HIF-1 Hypoxia Inducible Factor-1 1     Hypoxia-inducible factor 1-alpha 
HSP27 Heat-Shock Protein 27 1     Heat shock protein beta-1 
HSP70 Heat shock protein 70     1 Heat shock 70 kDa protein 1A/1B 
Id2 DNA-binding protein inhibitor ID-2    1  NA 
Id3 DNA-binding protein inhibitor ID-3    1  NA 
IGF-1 Insulin-like growth factor I    1  Insulin-like growth factor IA 
IGF-1R Tyrosine-protein kinase receptor    1  NA 
IGFR2 Insulin-like growth factor II receptor     1 Insulin-like growth factor II receptor 
IkappaB Inhibitor of kappa light chain gene enhancer in B 
cells 
  1  1 NF-kappa-B inhibitor alpha 
Ikk Inhibitor of kappa-B kinase  1 1  1 Inhibitor of nuclear factor kappa-B kinase subunit 
alpha/beta 
IL2 Interleukin-2   1   Interleukin-2 
INFgamma Interferon gamma   1   Interferon gamma 
Inha Inha    1  NA 
Inhba Inhba    1  NA 
Inhba/b Inhba/b    1  NA 
Insulin Insulin    1  Insulin; Insulin B chain; Insulin A chain 
Integrin Integrin beta-3   1   Integrin beta-3  
Interleukin Interleukins  1    Interleukin-XX 
IP3R Inositol 1,4,5-triphosphate receptor   1 1  Inositol 1,4,5-trisphosphate receptor type 1 
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IR Insulin receptor    1  Insulin receptor 
IRS Insulin receptor substrate    1  Insulin receptor substrate 1 
IRS-1 Insulin receptor substrate 1    1  Insulin receptor substrate 1 
IRS1/2 Insulin receptor substrate family  1    Insulin receptor substrate  
Isl-1 Insulin gene enhancer protein ISL-1    1  NA 
JAK Janus kinase, Tyrosine-protein kinase JAK1  1 1   Tyrosine-protein kinase JAK1  
JAK1 Janus Kinase 1 1   1  Tyrosine-protein kinase JAK1; Janus kinase 1 
JNK Jun kinase (JNK), c-Jun NH(2)-terminal kinase     1 Mitogen-activated protein kinase 8, 9, 10 
JNK1 c-Jun N-Terminal Kinase 1 1     Mitogen-activated protein kinase 8 
JNK1/2 Mitogen-activated protein kinase 1/2    1  Mitogen-activated protein kinase 1 
JNKK1 c-Jun N-terminal Kinase Kinase 1 1     Dual specificity mitogen-activated protein kinase kinase 4 
JUN Transcription factor AP-1; Transcription factor jun-B    1  Transcription factor AP-1; Transcription factor jun-B 
Junc Transcription factor AP-1    1  Transcription factor AP-1 
Jund Transcription factor jun-D    1  Transcription factor jun-D 
KSR-1 Kinase suppressor of Ras 1    1  NA 
Lepr Lepr    1  Leptin receptor 
Leptin Leptin    1  Leptin; Obesity factor 
LHbeta Luteinizing hormone beta    1  Lutropin subunit beta; Lutropin beta chain; Luteinizing 
hormone subunit beta 
LHX2 LIM/homeobox protein Lhx2    1  NA 
Lipoxygenase Lipoxygenase    1   Arachidonate 5-lipoxygenase 
L-type Ca2+ Voltage-dependent L-type calcium channel subunit 
alpha-1S/1C/1D; L-type dihydropyridine-sensitive 
calcium channel alpha-1f subunit  
   1  Voltage-dependent L-type calcium channel subunit 
alpha-1C 
MADD Mitogen activated protein kinase activating death 
domain 
    1 MAP kinase-activating death domain protein 
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MAP2K1/2 Dual specificity mitogen-activated protein kinase 
kinase 1/2 
   1  Dual specificity mitogen-activated protein kinase kinase 1 
MAP3Ks Mitogen-activated protein kinase kinase kinase 1-14    1  Mitogen-activated protein kinase kinase kinase 1/4/5 
MAP4Ks Mitogen-activated protein kinase kinase kinase kinase 
1-5 
   1  Mitogen-activated protein kinase kinase kinase kinase 4 
MAPK Mitogen activated protein kinase [1-7, 11 and higher]   1  1 Mitogen-activated protein kinase 1, 3, 5, 7, 8, 10, 12, 13 
MAPKAPK2 Mitogen-activated protein kinase-activated protein 
kinase 2 (MAPKAPK2) 
 1    NA 
MAPKAPK2/3 Mitogen-activated protein kinase-activated protein 
kinase 2 and 3 (MAPKAPK2/3) 
1     NA 
MASH1 Achaete-scute homolog 1    1  NA 
Mcl1 Myeloid cell leukemia 1     1 Induced myeloid leukemia cell differentiation protein 
Mcl-1 
MEK Mitogen-activated protein kinase kinase 1 1 1   Dual specificity mitogen-activated protein kinase kinase 
MEK1/2 Dual specificity mitogen-activated protein kinase 
kinase 1/2 
   1  Dual specificity mitogen-activated protein kinase kinase 1 
MEKK1 Mitogen-activated protein kinase kinase kinase 1 1    1 Mitogen-activated protein kinase kinase kinase 1 
miR-132/212 Heat shock 70 kDa protein 1A    1  Heat shock 70 kDa protein 1A/1B 
MIS Anti-Mullerian hormone    1  NA 
MISRII Anti-Muellerian hormone type-2 receptor    1  NA 
MKK3 Mitogen activated protein kinase kinase 3     1 Dual specificity mitogen-activated protein kinase kinase 3 
MKK3/6 Dual specificity mitogen-activated protein kinase 
kinase 3/6 
   1  NA 
MKK4/7 Dual specificity mitogen-activated protein kinase 
kinase 4/7 
   1  Dual specificity mitogen-activated protein kinase kinase 
4/7 
MKK7 Mitogen activated protein kinase kinase 7     1 Dual specificity mitogen-activated protein kinase kinase 7 
MLCK Myosin light chain kinase   1   NA 
MNK1/2 Mitogen-activated protein kinase-interacting 
serine/threonine kinase1/2  
 1    NA 
mPer1 Period circadian protein homolog 1    1  Period circadian protein homolog 1 
MT1-MMP Matrix metalloproteinase-14    1  Matrix metalloproteinase-14 
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mTOR mammalian target of rapamycin  1    Serine/threonine-protein kinase mTOR 
Myosin Myosin   1   Myosin-7 
NAB NGFI-A-binding protein 1/2    1  NA 
Nck Nck Adaptor Protein 1     NA 
Ncoa3 Nuclear receptor coactivator 3    1  NA 
NFAT Nuclear factor of activated T-cells     1 1   Nuclear factor of activated T-cells 5 
NFkappaB Nuclear factor kappa-B    1  1 Transcription factor p65, Nuclear factor NF-kappa-B p105 
subunit 
NF-Y Nuclear transcription factor Y subunit 
alpha/beta/gamma 
   1  NA 
NIK NF kappa B inducing kinase      1 Mitogen-activated protein kinase kinase kinase kinase 4 
NOSI Inhibition of nitric oxide type I    1  NA 
Notch Notch Receptor 1     Neurogenic locus notch homolog protein 1 
nPKCs Protein kinase C epsilon/delta type    1  Protein kinase C epsilon/delta type 
Npr2 Atrial natriuretic peptide receptor 2    1  NA 
Nur77 Nuclear receptor subfamily 4 group A member 1    1  Nuclear receptor subfamily 4 group A member 1 
OCT-1 POU domain, class 2, transcription factor 1    1  POU domain, class 2, transcription factor 1 
OTX Homeobox protein OTX1    1  NA 
p21CIP1 Cyclin-dependent kinase inhibitor 1A  1    Cyclin-dependent kinase inhibitor 1 
p27KIP1 Cyclin-dependent kinase inhibitor 1B  1    Cyclin-dependent kinase inhibitor 1B 
p300 Histone acetyltransferase p300    1  Histone acetyltransferase p300 
p38 Activator of 90 kDa heat shock protein ATPase 
homolog 1 
   1  Activator of 90 kDa heat shock protein ATPase homolog 1 
p38MAPK p38 Mitogen-Activated Protein Kinase 1     NA 
p53 Tumor protein p53     1 Cellular tumor antigen p53 
p65 NFkappaB    1  Transcription factor p65; Nuclear factor NF-kappa-B p65 
subunit 
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p90RSK Ribosomal protein S6 kinase, 90kD (p90RSK)  1    Ribosomal protein S6 kinase alpha-1 
PAC1R Pituitary adenylate cyclase-activating polypeptide 
type I receptor 
   1  NA 
PAC1-R Pituitary adenylate cyclase-activating polypeptide 
type I receptor 
   1  NA 
PACAP Pituitary adenylate cyclase-activating polypeptide    1  Pituitary adenylate cyclase-activating polypeptide 
PACT Protein activator of interon-induced protein kinase     1 NA 
PAK P21-activated kinase  1  1   Serine/threonine-protein kinase PAK 
PAR Protease Activated Receptor  1     Proteinase-activated receptor 2 
Paxillin Paxillin 1   1  NA 
Pbx1 Pre-B-cell leukemia transcription factor 1    1  NA 
Pcaf Histone acetyltransferase KAT2B    1  NA 
PDGF Platelet-Derived Growth Factor 1     Platelet-derived growth factor subunit A, Platelet-derived 
growth factor subunit B 
PDGFR Platelet-Derived Growth Factor Receptor 1     Beta-type platelet-derived growth factor receptor 
PDK1 3-phosphoinositide-dependent protein kinase 1;  
Phosphoinositide-dependent kinase-1, 
3-phosphoinositide-dependent protein kinase 1 
  1   NA 
PDK1/2 3-phosphoinositide-dependent protein kinase 1 and 2  1    NA 
PEA-15 Astrocytic phosphoprotein PEA-15    1  NA 
PG Rcs Prostacyclin receptor;Prostaglandin E2 receptor 
EP1/2/4 subtype; Prostaglandin E receptor 3 (Subtype 
EP3), isoform CRA_a; Prostaglandin F2-alpha 
receptor  
   1  Prostacyclin receptor;Prostaglandin E2 receptor EP2 
subtype; Prostaglandin E receptor 3 (Subtype EP3), 
isoform CRA_a; Prostaglandin F2-alpha receptor  
PI3K Phosphatidylinositol 3-kinase 1 1 1 1 1 Phosphatidylinositol 3-kinase regulatory subunit alpha 
PITX Pituitary homeobox 1/2    1  NA 
PKA Protein kinase A, cAMP-dependent protein kinase   1 1  NA 
PKB Protein kinase B  1    RAC-alpha serine/threonine-protein kinase 
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PKC Protein kinase C , All types 1  1   Protein kinase C alpha type, Protein kinase C beta type 
PKCe/theta Protein kinase C epsilon/theta type    1  Protein kinase C epsilon/zeta type 
PKCs Protein kinase C; Protein kinase C 
beta/detla/epsilon/zeta type 
   1 1 Protein kinase C; Protein kinase C beta/detla/epsilon/zeta 
type 
PKCs(3) Protein kinase C; Protein kinase C detla/epsilon type    1  Protein kinase C alpha/beta/detla/epsilon/gamma type 
PKCzeta Protein kinase C, zeta   1   Protein kinase C zeta type 
PKR Interferon-inducible double-stranded RNA-activated 
protein kinase (PKR) 
    1 NA 
PLA2 Phospholipase A2 1  1 1  Cytosolic phospholipase A2 
PLCbeta phosphodiesterase beta    1  1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
beta-1/2 
PLCbetagamma Phospholipase C , 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase beta-2 
  1   1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
beta-2, 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-1 
PLC-gamma Phospholipase C-gamma 1     1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
gamma-1 
PLD Phospholipase D 1   1  Phosphatidylinositol-glycan-specific phospholipase D 
PPARalpha/gamma Peroxisome proliferator-activated receptor 
alpha/gamma 
   1  Peroxisome proliferator-activated receptor alpha/gamma 
PPARgamma Peroxisome proliferator-activated receptor gamma    1  Peroxisome proliferator-activated receptor gamma 
PR Progesterone receptor    1  Progesterone receptor 
Prep1 protein PKNOX1    1  NA 
PRLR Prolactin receptor    1  NA 
Pro-inflammatory 
anti-apoptotic genes 
Pro-inflammatory genes   1   NA 
Pro-inflammatory 
genes 
Pro-inflammatory genes   1   NA 
Prolactin Prolactin    1  Prolactin 
Prx2 paired related homeobox 2    1  NA 
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PTEN Phosphatase and tensin homologue   1   Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
and dual-specificity protein phosphatase PTEN 
PYK2 Proline-rich tyrosine kinase 2, Protein-tyrosine kinase 
2-beta 
  1 1  Protein-tyrosine kinase 2-beta 
Rac Ras-related C3 botulinum toxin substrate 1  1   Ras-related C3 botulinum toxin substrate 1 
Rac1 Ras-related C3 botulinum toxin substrate 1    1  Ras-related C3 botulinum toxin substrate 1 
Raf Raf Oncogene 1 1    RAF proto-oncogene serine/threonine-protein kinase 
Raf-1 RAF proto-oncogene serine/threonine-protein kinase   1   RAF proto-oncogene serine/threonine-protein kinase 
RAIDD RIP associated ICH-1/CED homologous protein with 
death domain 
    1 NA 
Rap1b Ras-related protein Rap-1b    1  NA 
Ras Rat Sarcoma GTP-binding protein 1 1 1 1  NA 
RasGAP Ras GTPase-Activating Protein 1 1    Ras GTPase-activating protein 1 
Receptor subunit 
alpha 
Interleukin receptor alpha subunit   1    Interleukin-2 receptor subunit alpha 
Receptor subunit beta Interleukin receptor beta subunit (Receptor subunit 
beta) 
 1    Interleukin-2 receptor subunit beta 
RFRP-1/-3 RFamideRelated Peptide-1/-3    1  NA 
RGS Regulator of G-protein signaling   1   Regulator of G-protein signaling 
Rho Rho   1   Transforming protein RhoA 
RICS Rho GTPase-activating protein 32    1  NA 
RIP Receptor interacting protein (RIP)     1 NA 
ROCK Rho-associated coiled-coil Ser/Thr specific 
kinase (ROCK) 
  1   NA 
Runx2 Runt-related transcription factor 2    1  Runt-related transcription factor 2 
Scg2 Secretogranin-2    1  NA 
Sck Shc-like protein 1     NA 
SEK1 SAPK/ERK kinasae 1     1 Dual specificity mitogen-activated protein kinase kinase 4 
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SF1 Steroidogenic factor 1    1  NA 
Shc SH2 homology domain containing transforming 
protein 
1 1 1   NA 
SHIP SH2 domain-containing inositol 5-phosphatase   1   Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2 
SHP2 Src homology 2 domain-containing tyrosine 
phosphatase 2 
1     NA 
Signaling subunit NS  1    Interleukin-6 receptor subunit beta 
SKIL Ski-like protein    1  NA 
Smac/Diablo Second mitochondria-derived activator of caspase     1 NA 
SMAD1/5/8 Mothers against decapentaplegic homolog 1/5/9    1  Mothers against decapentaplegic homolog 1 
SMAD2-4 Mothers against decapentaplegic homolog 2-4    1  Mothers against decapentaplegic homolog 2-3 
SN SN    1  NA 
SNURF Small nuclear ribonucleoprotein-associated protein N 
upstream reading frame protein 
   1  NA 
SOCS Suppressor of cytokine siganling    1   Suppressor of cytokine signaling 7 
SODD Silencer of death domains     1 BAG family molecular chaperone regulator 3 
SOS Son of sevenless   1 1 1  NA 
SOS-1 Son of Sevenless, Drosophila, Homolog 1 1     NA 
SP1 Transcription factor Sp1    1  Transcription factor Sp1 
SP3 Transcription factor Sp3    1  NA 
SPK Sphingosine Kinase  1     Sphingosine kinase 1 
Src Src tyrosine kinase  1   1  Proto-oncogene tyrosine-protein kinase Src 
Src-like Src-like-adapter 2   1    NA 
SrcPTK Src family tyrosine kinase    1   NA 
SRF Serum response factor   1  1  NA 
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STAT Signal transducer and activator of transcription  1 1   Signal transducer and activator of transcription 
STAT1 Signal transducer and activator of transcription 1 1     Signal transducer and activator of transcription 
1-alpha/beta 
STAT3 Signal transducer and activator of transcription 3 1   1  Signal transducer and activator of transcription 3 
Survivin Baculoviral IAP Repeat-Containing Protein 5  1     Baculoviral IAP repeat-containing protein 5 
Syt IV Synaptotagmin-4    1  NA 
TAK1,  MAP3K7 Mitogen-activated protein kinase kinase kinase 7    1  NA 
TBRIII Transforming growth factor beta receptor type 3    1  NA 
TCF T-Cell Transcription Factor  1   1  Transcription factor 7 
TF Tissue Factor 1     Tissue Factor 
TGFbeta Transforming growth factor beta    1  Transforming growth factor beta 
TGIF1 Homeobox protein TGIF1    1  NA 
Tie2 Tie-2 1     NA 
TNF Tumor necrosis factor      1 Tumor necrosis factor  
TNFR1 Tumor necrosis factor receptor 1     1 Tumor necrosis factor receptor superfamily member 1B 
TNFR2 Tumor necrosis factor receptor 2      1 Tumor necrosis factor receptor superfamily member 1A 
TORC1 transcription coactivator 1     1  NA 
TRADD TNFR1 associated death domain     1 NA 
TRAF2 TNF receptor-associated factor 2      1 TNF receptor-associated factor 2 (TRAF2) 
TRAIL TNF-related apoptosis inducing ligand      1 Tumor necrosis factor ligand superfamily member 10 
TRAIL-R TRAIL-receptor     1 Tumor necrosis factor receptor superfamily member 10 
Tubulin Tubulin    1  Tubulin alpha-1A chain 
Unknown GPCR Unknown G protein-coupled receptor    1  NA 
VEGF Vascular Endothelial Growth Factor  1     Vascular Endothelial Growth Factor A, Vascular 
Endothelial Growth Factor B 
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VEGFR-2 Vascular Endothelial Growth Factor Receptor-2  1     Vascular endothelial growth factor receptor 2 
VE-PTP Vascular Endothelial Protein Tyrosine Phosphatase 1     NA 
Vinculin Vinculin    1  NA 
VRAP VEGFR-Associated Protein  1     NA 
Wnt Wingless-type MMTV integration site family member 1     NA 
XIAP X-linked inhibitor of apoptosis     1 Baculoviral IAP repeat-containing protein 4 
Zeb1 Zinc finger E-box-binding homeobox 1    1  NA 
1: Yes; Ang.: Angiogenesis pathway; Int.: Interleukin signaling pathway; Inf.: Inflammation mediated by chemokine and cytokine signaling pathway; Gon.: Gonadotropin 
releasing hormone receptor pathway; Apo.: Apoptosis pathway 
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Appendix 20 Target name in chapter 7 and the corresponding full name in chapter 8  
Abbreviation Full name in Ch7 Full name in Ch8 
AIF Apoptosis-inducing factor NS 
bak Bcl-2 antogonist/killer  NS 
Bax Bcl-2-associated x protein Apoptosis regulator BAX 
bcl B-cell lymphoma 2 family of apoptosis regulator proteins Apoptosis regulator Bcl-2 
CASP1 Caspase-1 Caspase-1 
CASP3 Caspase-3 Caspase-3 
CASP7 Caspase-7 Caspase-7 
CASP8 Caspase-8 Caspase-8 
CASP9 Caspase-9  Caspase-9  
CAT Catalase Catalase 
CD14 Cluster of differentiation 14 NS 
CDKs Cyclin-dependent kinases NS 
CHK Cultured human keratinocytes C-C motif chemokine 
COX-1 Cyclooxygenase-1 Prostaglandin G/H synthase 1 
COX-2 Cyclooxygenase-2 Prostaglandin G/H synthase 2 
ER Estrogen receptor NS 
ERK Extracellular signal-regulated kinase family Mitogen-activated protein kinase  
GSH Intracellular glutathione NS 
GSH-Px glutathione peroxidase NS 
GSK 3β phosphorylation of glycogen synthase kinase 3β  Glycogen synthase kinase-3 beta 
IFN-γ Interferon-gamma Interferon gamma 
IgE Immunoglobulin E NS 
IgG2a Immunoglobulin G2a NS 
IKK IκBα kinase Inhibitor of nuclear factor kappa-B kinase subunit alpha/beta 
IL- 31 Interleukin 31 NS 
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IL-10 Interleukin 10 Interleukin 10 
IL-17 Interleukin 17 NS 
IL-1β Interleukin 1beta Interleukin 1 
IL-22  Interleukin 22 NS 
IL-4 Interleukin 4 Interleukin 4 
IL-5 Interleukin 5 NS 
IL-6 Interleukin 6 Interleukin 6 
IL-8 Interleukin 8 Interleukin 8 
iNOS Inducible nitric oxide Synthase Nitric oxide synthase, inducible 
IP-10 Interferon gamma-induced protein 10 C-X-C motif chemokine 10 
IκB-α IkappaB kinase NF-kappa-B inhibitor alpha 
JNKs c-Jun N-terminal kinase Mitogen-activated protein kinase 
MCP-1  Monocyte chemotactic protein-1 C-C motif chemokine 2 
mRNA messenger RNA messenger RNA 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells Transcription factor p65 
NF-κB p65 Transcription factor p65 Transcription factor p65 
NIK NF-κB-inducing kinase Mitogen-activated protein kinase kinase kinase kinase 4 
NK-1R Neurokinin-1 receptor NS 
NO  Nitrogen oxide NS 
OMPs Outer-membrane proteins NS 
p21 Cyclin-dependent kinase inhibitor 1 Cyclin-dependent kinase inhibitor 1 
p38 Activator of 90 kDa heat shock protein ATPase homolog 1 Activator of 90 kDa heat shock protein ATPase homolog 1 
p53 Cellular tumor antigen  Cellular tumor antigen p53 
PARP Poly (ADP-ribose) polymerase Poly [ADP-ribose] polymerase 4  
pCDK2 Phospho-Cyclin-dependent kinase 2 NS 
PCNA Proliferating Cell Nuclear Antigen Proliferating Cell Nuclear Antigen 
PGE2 Prostaglandin E2 Prostaglandin E2 
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PPAR-α Peroxisome proliferator-activated receptor Peroxisome proliferator-activated receptors 
PU.1 Transcription factor PU.1 NS 
RAGE  Receptor for advanced glycation end products NS 
RIP2 Receptor interacting protein-2 NS 
RSK2 Ribosomal S6 kinase 2 kinase NS 
SOD Superoxide dismutase Superoxide dismutase 
TARC/CCL17 Thymus and activation regulated chemokine NS 
TLR 4 Toll-like receptor 4 Toll-like receptor 4 
TNF-α Tumour necrosis factor-alpha Tumour necrosis factor-alpha 
α-SMA α-smooth muscle actin NS 
NS: Not stated. 
 
